

GenCore version 5.1.6  
 Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 1, 2004, 08:19:45 ; Search time 55 Seconds  
 (without alignments)  
 462.350 Million cell updates/sec

Title: US-09-989-293A-377  
 Perfect score: 462  
 Sequence: 1 MTFFLSLLLJVCEAIWRSN.....DSRGLILGAEWGRGVKNT 90

Scoring table: BLOSUM62  
 Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0  
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
 Maximum Match 100%  
 Listing first 206 summaries

Database : A.Geneseq 29Jan04:\*

- 1: geneseqp1980s:\*
- 2: geneseqp1990s:\*
- 3: geneseqp2000s:\*
- 4: geneseqp2001s:\*
- 5: geneseqp2002s:\*
- 6: geneseqp2003as:\*
- 7: geneseqp2003bs:\*
- 8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES				Description	
Result No.	Score	Query Match	Length DB ID		
1	462	100.0	90	3	AAY66748 Membrane-
2	462	100.0	90	3	AB33469 Human PRO
3	462	100.0	90	4	AAU12408 Human PRO
4	462	100.0	90	4	AB50922 Human PRO
5	462	100.0	90	4	AB65271 Human PRO
6	462	100.0	90	6	ABU58086 Human PRO
7	462	100.0	90	6	ABU59164 Human PRO
8	462	100.0	90	6	ABU82676 Human PRO
9	462	100.0	90	6	ABU17852 Novel hum
10	462	100.0	90	6	ABU60595 Human PRO
11	462	100.0	90	6	ABU13977 Human PRO
12	462	100.0	90	6	ABU81106 Human PRO
13	462	100.0	90	6	ABU72562 Novel hum
14	462	100.0	90	6	ABU66806 Human PRO
15	462	100.0	90	6	ABU59887 Novel sec
16	462	100.0	90	6	ABU59311 Human PRO
17	462	100.0	90	6	ABO26008 Human PRO
18	462	100.0	90	6	ABO25077 Human PRO
19	462	100.0	90	6	ABU59017 Human PRO
20	462	100.0	90	6	ABU92395 Novel hum
21	462	100.0	90	6	ABU59460 Human PRO
22	462	100.0	90	6	ABU67082 Human PRO
23	462	100.0	90	6	ABU92226 Novel hum
24	462	100.0	90	6	ABU10932 Human PRO
25	462	100.0	90	6	ABU81684 Novel hum

26	462	100.0	90	6	ABU88623 Human PRO
27	462	100.0	90	6	ABO34137 Human PRO
28	462	100.0	90	6	ADA45993 Novel hum
29	462	100.0	90	6	ADA76424 Human PRO
30	462	100.0	90	6	ADA19074 Human PRO
31	462	100.0	90	6	ADA61697 Homo sapi
32	462	100.0	90	6	ADB19482 Novel hum
33	462	100.0	90	6	ADB28023 Human PRO
34	462	100.0	90	6	ADA86502 Novel hum
35	462	100.0	90	6	ADB16066 Human PRO
36	462	100.0	90	6	ADA37888 Human PRO
37	462	100.0	90	6	ADA7852 Human PRO
38	462	100.0	90	6	ADA21574 Human PRO
39	462	100.0	90	6	ADA10361 Human PRO
40	462	100.0	90	6	ADA67647 Human PRO
41	462	100.0	90	6	ADB30654 Human PRO
42	462	100.0	90	6	ADA85950 Novel hum
43	462	100.0	90	6	ADA17905 Human PRO
44	462	100.0	90	6	ADA97162 Human PRO
45	462	100.0	90	6	ADA79466 Human PRO
46	462	100.0	90	6	ADA87605 Novel hum
47	462	100.0	90	6	ADB16807 Human PRO
48	462	100.0	90	6	ADA28013 Human PRO
49	462	100.0	90	6	ADA91899 Novel hum
50	462	100.0	90	6	ADB14962 Human PRO
51	462	100.0	90	6	ADB18923 Novel hum
52	462	100.0	90	6	ADA94138 Human PRO
53	462	100.0	90	6	ADB20034 Novel hum
54	462	100.0	90	6	ADB13346 Human PRO
55	462	100.0	90	6	ABO43385 Novel hum
56	462	100.0	90	6	ADA94593 Human PRO
57	462	100.0	90	6	ADA74600 Human PRO
58	462	100.0	90	6	ADB24833 Human PRO
59	462	100.0	90	6	ADA82357 Human PRO
60	462	100.0	90	6	ADA75320 Human PRO
61	462	100.0	90	6	ADA85398 Human PRO
62	462	100.0	90	6	ADA84846 Novel hum
63	462	100.0	90	6	ADB30102 Human PRO
64	462	100.0	90	6	ADA80630 Human PRO
65	462	100.0	90	6	ADA75872 Human PRO
66	462	100.0	90	6	ADA38818 Human PRO
67	462	100.0	90	6	ADA47097 Human PRO
68	462	100.0	90	6	ADB25393 Human PRO
69	462	100.0	90	6	ADA93569 Human PRO
70	462	100.0	90	6	ADB26919 Human PRO
71	462	100.0	90	6	ADB31206 Human PRO
72	462	100.0	90	6	ADA92939 Human PRO
73	462	100.0	90	6	ADA61134 Homo sapi
74	462	100.0	90	6	ADB24281 Human PRO
75	462	100.0	90	6	ADA96610 Human PRO
76	462	100.0	90	6	ADA81182 Human PRO
77	462	100.0	90	6	ADA96058 Human PRO
78	462	100.0	90	6	ADB26367 Human PRO
79	462	100.0	90	6	ADB21852 Novel hum
80	462	100.0	90	7	ADA77631 Human PRO
81	462	100.0	90	7	ADB18371 Human PRO
82	462	100.0	90	7	ADA87054 Novel hum
83	462	100.0	90	7	ADA88157 Human PRO
84	462	100.0	90	7	ADA46545 Novel hum
85	462	100.0	90	7	ADB28575 Human PRO
86	462	100.0	90	7	ADB29127 Human PRO
87	462	100.0	90	7	ABO53223 Human PRO
88	462	100.0	90	7	ADA77079 Human PRO
89	462	100.0	90	7	ADA22500 Human PRO
90	462	100.0	90	7	ADA88709 Human PRO
91	462	100.0	90	7	ADA97714 Human PRO
92	462	100.0	90	7	ADB27471 Human PRO
93	462	100.0	90	7	ADB22404 Novel hum
94	462	100.0	90	7	ABO22593 Human PRO
95	462	100.0	90	7	ADA06666 Human PRO
96	462	100.0	90	7	ADA39359 Human PRO
97	462	100.0	90	7	ADA67095 Human PRO
98	462	100.0	90	7	ADB22956 Human PRO



PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088730P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088741P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090538P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090691P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091358P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.

PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 10-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 11-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 12-AUG-1998; 98US-0096146P.  
PR 17-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 18-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 19-AUG-1998; 98US-0097022P.  
PR 20-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 26-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097951P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 31-AUG-1998; 98US-0098014P.  
PR 16-SEP-1998; 98US-0098525P.  
PR 12-JAN-1999; 99US-0115565P.  
XX  
PA (GETH ) GENENTECH INC.  
XX Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;  
PI Wood WI, Yuan J;  
XX WPI; 2000-072883/06.  
DR N-PSDB; AAZ65094.  
XX  
DR Membrane-bound proteins and related nucleotide sequences.  
XX Claim 12; Fig 272; 822pp; English.  
XX  
CC The invention provides membrane-bound PRO polypeptides and  
CC polynucleotides encoding them. The PRO sequences of the invention were  
CC identified based on extracellular domain homology screening. The PRO  
CC sequences have homology with proteins including LDL receptors, TIE  
CC ligands and various enzymes. The membrane-bound proteins and receptor  
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor  
CC immunoadhesins, for instance, can be used as therapeutic agents to block  
CC receptor-ligand interactions. The membrane-bound proteins can also be  
CC employed for screening of potential peptide or small molecule inhibitors

CC of the relevant receptor/ligand interaction. The PRO encoding sequences  
 CC are useful as hybridization probes, in chromosome and gene mapping and in  
 CC the generation of antisense RNA and DNA. PRO nucleic acid sequences will  
 CC also be useful for the preparation of PRO polypeptides, especially by  
 CC recombinant techniques  
 CC XX

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 3; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPYKAVKTT 60

Db 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPYKAVKTT 60

Qy 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90

RESULT 2

AAB33469

ID AAB33469 standard; protein; 90 AA.

AC AAB33469;

XX 29-JAN-2001 (first entry)

XX Human PRO1159 protein UNQ589 SEQ ID NO:273.

XX Human; immune related disease; diagnosis; antinflammatory; cardiant;  
 KW dermatological; antiarthritic; antirheumatic; immunosuppressive;  
 KW haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;  
 KW antianemic; hepatotropic; virucide; antiposrotic; antiallergic;  
 KW antiaesthetic; systemic lupus erythematosus; rheumatoid arthritis;  
 KW osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;  
 KW idiopathic inflammatory myopathy; Sjogren's syndrome thyroiditis;  
 KW systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;  
 KW autoimmune thrombocytopaenia; immune-mediated renal disease;  
 KW demyelinating disease; hepatobiliary disease; Whipple's disease;  
 KW inflammatory bowel disease; gluten-sensitive enteropathy;  
 KW autoimmune disease; immune-mediated skin disease; allergic disease;  
 KW immunological disease; transplantation associated disease;  
 KW graft rejection; graft-versus-host-disease.

XX Homo sapiens.

XX WO200053758-A2.

XX 14-SEP-2000.

XX 02-MAR-2000; 2000WO-US005841.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99US-0123618P.

XX 12-MAR-1999; 99US-0123957P.

XX 23-MAR-1999; 99US-0125775P.

XX 12-APR-1999; 99US-0128849P.

XX 20-APR-1999; 99WO-US0008615.

XX 28-APR-1999; 99US-0131445P.

XX 04-MAY-1999; 99US-0132371P.

XX 14-MAY-1999; 99US-0134287P.

XX 02-JUN-1999; 99WO-US012252.

XX 23-JUN-1999; 99US-0141037P.

XX 20-JUL-1999; 99US-0144758P.

XX 28-JUL-1999; 99US-0145698P.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.  
 PR 29-OCT-1999; 99US-0162506P.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 XX XX

(GETH ) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W;  
 PI Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V;  
 PI Stewart TA, Tumas D, Watanabe CK, Wood WI, Yan M;  
 XX XX

WPI; 2000-572271/53.

N-PSDB; AAC58634.

XX Sixty four PRO polypeptides, useful in the diagnosis and treatment of  
 PT immune related disorders, e.g. systemic lupus erythematosus, rheumatoid  
 PT arthritis, osteoarthritis, thyroiditis and diabetes mellitus.

Claim 33; Fig 112; 309pp; English.

CC The present invention describes sixty four human PRO proteins which can  
 CC be used in the treatment of immune related diseases. The human PRO  
 CC proteins, anti-PRO antibodies, agonists and antagonists are useful for  
 CC treating and diagnosing immune related disorders. The disorders are  
 CC selected from systemic lupus erythematosus, rheumatoid arthritis,  
 CC osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,  
 CC systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's  
 CC anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,  
 CC immune-mediated renal disease, demyelinating diseases, inflammatory  
 CC peripheral nervous systems, hepatobiliary diseases, inflammatory bowel  
 CC disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune  
 CC or immune-mediated skin diseases, allergic diseases, immunological  
 CC diseases of the lung, and transplantation associated diseases including  
 CC graft rejection and graft-versus-host-disease. AAC58397 to AAC58578  
 CC represent PCR primers and hybridisation probes used in the isolation of  
 CC human PRO sequences. AAC58579 to AAC58642 and AAB33414 to AAB33477  
 CC represent human PRO polynucleotide and protein sequences given in the  
 CC exemplification of the present invention

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 3; Length 90;

Best Local Similarity 100.0%; Pred. No. 9,8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPYKAVKTT 60

Db 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPYKAVKTT 60

QY 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90

RESULT 3

AAU12408





PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 09-DEC-1999; 99US-0170262P.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 03-MAR-2000; 2000US-0187202P.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.

(GETH ) GENENTECH INC.

PA Ashkenazi AJ, Baker KP, Chan B, Goddard A, Godowski PJ;  
 PI Gurney AL, Hebert C, Henzel W, Kabakoff RC, Shelton DL, Tumas D;  
 PI Watanabe CK, Wood WI;  
 XX N-PSDB; AAC91481.  
 DR WPI: 2001-025253/03.  
 DR N-PSDB; AAC91481.

XX Thirty three nucleic acids encoding PRO polypeptides which are useful in  
 PT the diagnosis and treatment of immune related disorders, e.g. systemic  
 PT lupus erythematosus, rheumatoid arthritis, osteoarthritis, thyroiditis  
 and diabetes mellitus.

Claim 58; Fig 42; 218pp; English.

XX The present sequence is one of thirty three novel PRO polypeptides. The  
 CC PRO polypeptides, anti-PRO antibodies, agonists and antagonists are  
 CC useful for treating and diagnosing immune related disorders such as  
 CC systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis,  
 CC juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis,  
 CC idiopathic inflammatory myopathies, Sjogren's syndrome, systemic  
 CC vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune  
 CC thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal  
 CC disease, demyelinating diseases of the central and peripheral nervous  
 CC systems (such as multiple sclerosis, idiopathic demyelinating  
 CC polynuropathy or Guillain-Barre syndrome, and chronic inflammatory  
 CC demyelinating polynuropathy), hepatobiliary diseases (such as  
 CC infectious, autoimmune chronic active hepatitis, primary biliary  
 CC cirrhosis, granulomatous hepatitis and sclerosing cholangitis),  
 CC inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's  
 CC disease, autoimmune or immune-mediated skin diseases (such as bullous  
 CC skin diseases, erythema multiforme, contact dermatitis, psoriasis),  
 CC allergic diseases such as asthma, allergic rhinitis, atopic dermatitis,  
 CC food hypersensitivity and urticaria), immunological diseases of the lung  
 CC (such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and  
 CC hypersensitivity pneumonitis), transplantation associated diseases  
 CC including graft rejection and graft-versus-host diseases

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 4; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRSSGNTLNGVFLSKNKHNSQPTSSLEDSVTTKAVKTT 60  
 DB 1 MTFPLSLLLLVCEAIWRSSGNTLNGVFLSKNKHNSQPTSSLEDSVTTKAVKTT 60

QY 61 GKGIVKGRNLDRLGILGAZAWGRGVKNT 90

Db 61 GKGIVKGRNLDRLGILGAZAWGRGVKNT 90

## RESULT 5

AAAB65271  
 ID AAB65271 standard; protein; 90 AA.

AC AAB65271;

XX 02-APR-2001 (first entry)

XX Human PRO1159 (UNQ589) protein sequence SEQ ID NO:377.

XX Human; secreted and transmembrane protein; PRO; cytostatic; cell death;  
 KW cancer; chromosomal mapping; gene mapping; tissue typing;  
 KW diagnostic assay.

XX Homo sapiens.

XX WO2000073454-A1.

XX 07-DEC-2000.

XX 30-MAR-2000; 2000WO-US008439.

XX 02-JUN-1999; 99WO-US012252.

XX 23-JUN-1999; 99US-0141037P.

XX 07-JUL-1999; 99US-0143048P.

XX 20-JUL-1999; 99US-0144758P.

XX 26-JUL-1999; 99US-0145698P.

XX 28-JUL-1999; 99US-0146222P.

XX 17-AUG-1999; 99US-0149396P.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 08-OCT-1999; 99US-0158663P.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1999; 99WO-US028301.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000376.

XX 11-FEB-2000; 2000WO-US003565.

XX 18-FEB-2000; 2000WO-US004341.

XX 22-FEB-2000; 2000WO-US004414.

XX 24-FEB-2000; 2000WO-US004914.

XX 24-FEB-2000; 2000WO-US005004.

XX 02-MAR-2000; 2000WO-US005841.

XX 15-MAR-2000; 2000WO-US006884.

XX 20-MAR-2000; 2000WO-US007377.

(GETH ) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Denoyers L, Eaton DL;  
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
 PI Grimaldi CJ, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;  
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
 PI Zhang Z;  
 XX WPI: 2001-032169/04.  
 DR N-PSDB; AAF44240.

XX PRO polynucleotides used to produce polypeptides used to target bioactive  
 PT molecules such as toxins, radiolabels or antibodies, to specific cells,  
 PT to cause targeted cell death.

XX Claim 12; Fig 272; 935pp; English.

XX The present invention describes human secreted and transmembrane PRO  
 CC proteins. The PRO proteins have cytostatic activity. The PRO proteins can  
 CC be used for targeted delivery of bioactive molecules, such as toxins,  
 CC radiolabels or antibodies, that cause cell death. PRO nucleotide  
 CC sequences, and their fragments, can be used as hybridisation probes, in

CC chromosomal and gene mapping, and in the generation of anti-sense RNA and  
 CC DNA. They may also be used to produce transgenic animals which are used  
 CC to develop and screen therapeutically useful reagents. The PRO nucleotide  
 CC and protein sequence can be used for tissue typing and in treating  
 CC cancer. Anti-PRO antibodies can be used in diagnostic assays. AAF44270 to  
 CC AAF44470 represent PCR primers and hybridisation probes used in the  
 CC isolation of human PRO sequences. AAF44087 to AAF44269 and AAB65154 to  
 CC AAB65300 represent human PRO polynucleotide and protein sequences given  
 CC in the exemplification of the present invention  
 XX  
 SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 4; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLSRNKENHQSPTQSSLEDSVTPTKAVKTT 60  
 Db 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLSRNKENHQSPTQSSLEDSVTPTKAVKTT 60  
 QY 61 GKGIKGRNLDLSGLILGAEAWGKVKNT 30  
 Db 61 GKGIKGRNLDLSGLILGAEAWGKVKNT 30

## RESULT 6

ABU58086  
 ID ABU58086 standard; protein; 90 AA.

XX AC ABU58086;

XX DT 14-APR-2003 (first entry)

XX DE Human PRO polypeptide #118.

KW Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;  
 KW horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;  
 KW antibody-dependent enzyme mediated prodruq therapy.

OS Homo sapiens.

XX PN US2003027163-A1.

XX PD 06-FEB-2003.

XX PF 15-NOV-2001; 2001US-00997666.

XX PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 28-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.  
 PR 09-JUN-1998; 98US-0088655P.  
 PR 10-JUN-1998; 98US-0088734P.  
 PR 10-JUN-1998; 98US-0088738P.  
 PR 10-JUN-1998; 98US-0088742P.  
 PR 10-JUN-1998; 98US-0088810P.  
 PR 10-JUN-1998; 98US-0088826P.  
 PR 10-JUN-1998; 98US-0088824P.  
 PR 11-JUN-1998; 98US-0088858P.  
 PR 11-JUN-1998; 98US-0088861P.  
 PR 11-JUN-1998; 98US-0088876P.  
 PR 12-JUN-1998; 98US-0089105P.  
 PR 16-JUN-1998; 98US-0089440P.  
 PR 16-JUN-1998; 98US-0089512P.  
 PR 16-JUN-1998; 98US-0089514P.  
 PR 17-JUN-1998; 98US-0089532P.  
 PR 17-JUN-1998; 98US-0089538P.  
 PR 17-JUN-1998; 98US-0089598P.  
 PR 17-JUN-1998; 98US-0089599P.  
 PR 17-JUN-1998; 98US-0089600P.  
 PR 17-JUN-1998; 98US-0089653P.  
 PR 18-JUN-1998; 98US-0089801P.  
 PR 18-JUN-1998; 98US-0089907P.  
 PR 18-JUN-1998; 98US-0089908P.  
 PR 19-JUN-1998; 98US-0089947P.  
 PR 19-JUN-1998; 98US-0089948P.  
 PR 22-JUN-1998; 98US-0089952P.  
 PR 22-JUN-1998; 98US-0090246P.  
 PR 22-JUN-1998; 98US-0090252P.  
 PR 23-JUN-1998; 98US-0090254P.  
 PR 23-JUN-1998; 98US-0090349P.  
 PR 23-JUN-1998; 98US-0090355P.  
 PR 24-JUN-1998; 98US-0090429P.  
 PR 24-JUN-1998; 98US-0090431P.  
 PR 24-JUN-1998; 98US-0090435P.  
 PR 24-JUN-1998; 98US-0090444P.  
 PR 24-JUN-1998; 98US-0090445P.  
 PR 24-JUN-1998; 98US-0090472P.  
 PR 24-JUN-1998; 98US-0090535P.  
 PR 24-JUN-1998; 98US-0090540P.  
 PR 24-JUN-1998; 98US-0090542P.  
 PR 24-JUN-1998; 98US-0090557P.  
 PR 25-JUN-1998; 98US-0090676P.  
 PR 25-JUN-1998; 98US-0090678P.  
 PR 25-JUN-1998; 98US-0090690P.  
 PR 25-JUN-1998; 98US-0090694P.  
 PR 25-JUN-1998; 98US-0090695P.  
 PR 26-JUN-1998; 98US-0090698P.  
 PR 26-JUN-1998; 98US-0090862P.  
 PR 26-JUN-1998; 98US-0090863P.  
 PR 01-JUL-1998; 98US-0091360P.  
 PR 01-JUL-1998; 98US-0091544P.  
 PR 02-JUL-1998; 98US-0091478P.  
 PR 02-JUL-1998; 98US-0091519P.  
 PR 02-JUL-1998; 98US-0091628P.  
 PR 02-JUL-1998; 98US-0091628P.  
 PR 02-JUL-1998; 98US-0091633P.  
 PR 02-JUL-1998; 98US-0091646P.  
 PR 02-JUL-1998; 98US-0091673P.  
 PR 07-JUL-1998; 98US-0091978P.  
 PR 07-JUL-1998; 98US-0091982P.  
 PR 09-JUL-1998; 98US-0092182P.  
 PR 10-JUL-1998; 98US-0092472P.  
 PR 20-JUL-1998; 98US-0093339P.  
 PR 30-JUL-1998; 98US-0094651P.  
 PR 04-AUG-1998; 98US-0095282P.  
 PR 04-AUG-1998; 98US-0095285P.  
 PR 04-AUG-1998; 98US-0095301P.  
 PR 04-AUG-1998; 98US-0095302P.  
 PR 04-AUG-1998; 98US-0095318P.  
 PR 04-AUG-1998; 98US-0095321P.  
 PR 04-AUG-1998; 98US-0095325P.  
 PR 10-AUG-1998; 98US-0095916P.

```
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0102114P.
PR 01-DEC-1998; 98US-0102510P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-01000106.
PR 08-MAR-1999; 98US-010005028.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98US-0141037P.
PR 23-JUN-1999; 98US-0143048P.
PR 07-JUL-1999; 98US-0144758P.
PR 20-JUL-1999; 98US-0145698P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-01521547.
PR 15-SEP-1999; 98US-0158663P.
PR 30-NOV-1999; 98US-028313.
PR 01-DEC-1999; 98US-028301.
PR 01-DEC-1999; 98US-028634.
PR 16-DEC-1999; 98US-030095.
PR 20-DEC-1999; 98US-030095.
PR 05-JAN-2000; 98US-030219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006884.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred.No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSSGSSNTLENGYFLSRNKNHSOPTQSSLSLDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWRSSGSSNTLENGYFLSRNKNHSOPTQSSLSLDSVTPTKAVKTT 60
QY 61 GKGIYKGRNLDLSRGLILGAEAWGRGVKNT 90
Db 61 GKGIYKGRNLDLSRGLILGAEAWGRGVKNT 90

RESULT 7
ABU59164
ID ABU59164 standard; protein; 90 AA.
XX AC ABU59164;
XX DT 28-APR-2003 (first entry)
XX DE Novel human secreted or transmembrane protein PRO1159.
XX KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
XX KW cardiac insufficiency disorder; cancer; tumour; immune response;
XX KW adrenal cortical capillary endothelial growth; c-fos induction;
XX KW vascular endothelial growth factor inhibition; VEGF inhibition;
XX KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
XX KW retinal neurons cell survival; rod photoreceptor cell survival;
XX KW mammalian kidney mesangial cell proliferation; kidney disorder;
XX KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
XX KW chondrocyte redifferentiation; sports injury; arthritis.
XX OS Homo sapiens.
XX FN US2002132252-A1.
XX PD 19-SEP-2002.
XX PF 14-NOV-2001; 2001US-00990442.
XX PR 16-JUN-1997; 97US-0049787P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 05-NOV-1997; 97WO-US020069.
XX PR 12-NOV-1997; 97US-0065186P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 24-NOV-1997; 97US-0066770P.
XX PR 25-FEB-1998; 98US-0075945P.
XX PR 20-MAR-1998; 98US-0078910P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 07-MAY-1998; 98US-0084600P.
XX PR 28-MAY-1998; 98US-0087106P.
XX PR 02-JUN-1998; 98US-0087607P.
XX PR 02-JUN-1998; 98US-0087609P.
XX PR 02-JUN-1998; 98US-0087759P.
XX PR 03-JUN-1998; 98US-0087827P.
XX PR 04-JUN-1998; 98US-0088021P.
XX PR 04-JUN-1998; 98US-0088025P.
XX PR 04-JUN-1998; 98US-0088026P.
XX PR 04-JUN-1998; 98US-0088028P.
XX PR 04-JUN-1998; 98US-0088029P.
XX PR 04-JUN-1998; 98US-0088030P.
XX PR 04-JUN-1998; 98US-0088033P.
```



KW cardiac insufficiency disorders; angiogenesis; wound healing;  
KW cancerous tumour; immune response; retinal disorder; sight loss;  
KW retinitis pigmentosa; age-related macular degeneration; AMD;  
KW kidney disorder; Berger disease; nephropathy; dermatitis; herpetiformis;  
KW Crohn's disease; sports injury; arthritis.  
OS Homo sapiens.  
XX  
XX  
XX US2003032023-A1.  
XX  
XX 13-FEB-2003.  
XX  
XX 14-NOV-2001; 2001US-00990711.  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088214P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088739P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 19-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 19-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.



PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX

(GETH ) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-341980/32.

N-PSDB; ACD24089.

XX New secreted and transmembrane PRO nucleic acids, for treating  
PT inflammation, organ failure, atherosclerosis, cardiac injury,  
PT infertility, birth defects, premature aging, acquired immunodeficiency  
PT syndrome (AIDS), or cancer.

Claim 12; Fig 474; 660pp; English.

XX The invention describes an isolated nucleic acid (I) comprising, or which  
CC has 80 % sequence identity to, or the full-length coding sequence of, one  
CC of 275 nucleotide sequences, and which encodes a corresponding  
CC polypeptide selected from 275 amino acid sequences, where all sequences  
CC are given in the specification. The polypeptide encoded by (I) is used to  
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a  
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the  
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate the  
CC uptake of glucose or free fatty acid by cells, stimulate or inhibit  
CC the proliferation or differentiation of cells or gene expression.  
CC stimulate the release of proteoglycans, stimulate the release of cytokine  
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide  
CC to factor VIIa, or detect the presence of tumour in a mammal. The nucleic  
CC acid and polypeptide encoded by it, are useful for treating inflammatory  
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,

CC birth defects, premature aging, acquired immunodeficiency syndrome  
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as  
CC hybridisation probes, in chromosome and gene mapping, and in generating  
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,  
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.  
CC This is the amino acid sequence of a novel human secreted and  
CC transmembrane PRO polypeptide

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLVCEAIRWSNCSNTLENGYFLSRKNHNSQPTQSLSLDSVTPPTXAVKTT 60  
|||||  
Db 1 MTFFLSLLLVCEAIRWSNCSNTLENGYFLSRKNHNSQPTQSLSLDSVTPPTXAVKTT 60  
|||||

QY 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90  
|||||  
Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90  
|||||

RESULT 10

ABU60595

ID ABU60595 standard; protein; 90 AA.

XX AC ABU60595;

XX DT 01-MAY-2003 (first entry)

XX DE Human secreted/transmembrane protein, #154.

XX KW Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;  
XX diagnostic; therapeutic; gene therapy.

XX OS Homo sapiens.

XX PN US2002160384-A1.

XX PD 31-OCT-2002.

XX PF 14-NOV-2001; 2001US-00992598.

XX PR 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 24-NOV-1997; 97US-0066770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087106P.

XX PR 02-JUN-1998; 98US-0087607P.

XX PR 02-JUN-1998; 98US-0087609P.

XX PR 02-JUN-1998; 98US-0087759P.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 04-JUN-1998; 98US-0088021P.

XX PR 04-JUN-1998; 98US-0088025P.

XX PR 04-JUN-1998; 98US-0088026P.

XX PR 04-JUN-1998; 98US-0088028P.

XX PR 04-JUN-1998; 98US-0088029P.

XX PR 04-JUN-1998; 98US-0088030P.

XX PR 04-JUN-1998; 98US-0088033P.

XX PR 04-JUN-1998; 98US-0088326P.

XX PR 05-JUN-1998; 98US-0088167P.

XX PR 05-JUN-1998; 98US-0088202P.

XX PR 05-JUN-1998; 98US-0088212P.

XX PR 05-JUN-1998; 98US-0088217P.

XX PR 09-JUN-1998; 98US-0088655P.

XX PR 10-JUN-1998; 98US-0088734P.



PR 10-JUN-1998; 98US-0088738P.  
 PR 10-JUN-1998; 98US-0088742P.  
 PR 10-JUN-1998; 98US-0088810P.  
 PR 10-JUN-1998; 98US-0088824P.  
 PR 10-JUN-1998; 98US-0088826P.  
 PR 10-JUN-1998; 98US-0088858P.  
 PR 11-JUN-1998; 98US-0088861P.  
 PR 11-JUN-1998; 98US-0088876P.  
 PR 12-JUN-1998; 98US-0089105P.  
 PR 16-JUN-1998; 98US-0089440P.  
 PR 16-JUN-1998; 98US-0089512P.  
 PR 16-JUN-1998; 98US-0089514P.  
 PR 17-JUN-1998; 98US-0089532P.  
 PR 17-JUN-1998; 98US-0089538P.  
 PR 17-JUN-1998; 98US-0089598P.  
 PR 17-JUN-1998; 98US-0089599P.  
 PR 17-JUN-1998; 98US-0089600P.  
 PR 17-JUN-1998; 98US-0089653P.  
 PR 18-JUN-1998; 98US-0089801P.  
 PR 18-JUN-1998; 98US-0089907P.  
 PR 18-JUN-1998; 98US-0089908P.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 15-MAY-2000; 2000WO-US013358.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 28-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 28-AUG-2001; 2001US-00941992.

(GETH ) GENENTECH INC.

PA Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;  
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
 PI Grimaldi JC, Gurney AJ, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
 PI Zhang Z;

DR WPI; 2003-288106/28.  
 DR N-P8DB; ABX90341.  
 XX  
 PT New transmembrane polypeptides and nucleic acids encoding the  
 PT polypeptides, useful in gene therapy, in chromosome identification, as  
 PT chromosome markers, or in generating probes.  
 XX  
 PS Claim 12; Fig 272; 650pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC comprising a sequence without signal peptide and the nucleic acid  
 CC encoding them. The polypeptides can be used to raise antibodies that  
 CC specifically bind to the PRO polypeptide, for linking a bioactive  
 CC molecule to a cell expressing a PRO protein and for modulating at least  
 CC one biological activity of a cell. The PRO polypeptides or  
 CC polynucleotides are also useful in gene therapy, in chromosome  
 CC identification, as chromosome markers, or in generating probes. The PRO  
 CC polypeptides are useful as molecular markers for protein electrophoresis,  
 CC and the isolated nucleic acids may be used for recombinantly expressing  
 CC those markers. The PRO polypeptides and nucleic acids may also be used in  
 CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for  
 CC PRO, and in affinity purification of PRO from recombinant cell culture or  
 CC natural sources. The sequences presented in ABU60478-ABU60624 are the PRO  
 CC polynucleotides of the invention. Note: The sequence data for this patent  
 CC is also available in electronic format from USPTO at  
 CC seqdata.uspto.gov/sequence.html  
 XX  
 SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFPLSLLLVCEALWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60  
 DB 1 MTFPLSLLLVCEALWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60  
 QY 61 GKGVKGRNLDGRGLILGAEAWGRGVKKNT 90  
 DB 61 GKGVKGRNLDGRGLILGAEAWGRGVKKNT 90

## RESULT 11

ABU13977  
 ID ABU13977 standard; protein; 90 AA.  
 XX  
 AC ABU13977;  
 XX  
 DT 26-FEB-2003 (first entry)  
 XX  
 DE Human PRO1159 polypeptide.  
 XX  
 KW Human; PRO polypeptide; secreted protein; transmembrane protein;  
 KW genetic disorder; antibacterial; immunosuppressive.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002103125-A1.  
 XX  
 PD 01-AUG-2002.  
 XX  
 PF 20-NOV-2001; 2001US-00989731.  
 XX  
 PR 16-JUN-1997; 97US-0049787P.  
 PR 17-OCT-1997; 97US-0062250P.  
 PR 05-NOV-1997; 97WO-US020069.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 13-NOV-1997; 97US-0065311P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 25-FEB-1998; 98US-0075945P.  
 PR 20-MAR-1998; 98US-0078910P.  
 PR 28-APR-1998; 98US-0083322P.  
 PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087753P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088653P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089901P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX (GETH ) GENENTECH LTD.  
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WJ;  
PI Zhang Z;  
XX WPI; 2003-102117/09.  
DR N-PSDB; ABX64187.  
XX Novel secreted and transmembrane polypeptide for modulating biological  
PT activity of cell expressing the polypeptide, identifying agonists or  
PT antagonists of polypeptide, and as molecular weight markers.  
XX Claim 12; Fig 272; 649pp; English.  
PS The present invention relates to the isolation of novel human PRO  
CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
CC polypeptides are secreted and transmembrane proteins. The PRO  
CC polypeptides are useful for detecting other PRO polypeptides, for linking  
CC bioactive molecules to cells expressing PRO polypeptides, for modulating  
CC biological activities of cells expressing PRO polypeptides, and for  
CC identifying agonists or antagonists. The polynucleotide sequences  
CC encoding PRO polypeptides are useful as hybridisation probes, in  
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
CC in the preparation of PRO polypeptides, for generating transgenic animals  
CC or knockout animals, to construct hybridisation probes for mapping the  
CC gene which encodes the PRO polypeptide, and for the genetic analysis of  
CC individuals with genetic disorders, in gene therapy, for chromosome  
CC identification, as chromosome markers, and for generating probes for PCR,  
CC Northern analysis, Southern analysis and Western analysis. ABU13860-  
CC ABU14006 represent the human PRO polypeptides of the invention. Note: The  
CC sequence data for this patent was obtained in electronic format directly  
CC from the USPTO web site at seqdata.uspto.gov/paidsIDEntry.html  
XX SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSLSLEDSVPTKAVKTT 60  
|||  
DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSLSLEDSVPTKAVKTT 60  
|||  
QY 61 GKGIVKGRNLDRLGILGAEAWGRGVKXNT 90  
|||  
DB 61 GKGIVKGRNLDRLGILGAEAWGRGVKXNT 90  
|||  
RESULT 12  
ABU81106  
ID ABU81106 standard; protein; 90 AA.  
XX AC ABU81106;  
XX DT 23-JUN-2003 (first entry)  
XX DE Human PRO polypeptide #237.  
XX KW Human; PRO polypeptide; secreted and transmembrane protein;

KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;  
 KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;  
 KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;  
 KW hearing loss; coagulation disorder; stroke; heart attack; cardiac;  
 KW antidiabetic; anorectic; vulnery; antiarthritis; osteopathic;  
 KW antirheumatic; auditory; cerebroprotective; angiogenic.  
 XX Homo sapiens.  
 XX US2003004311-A1.  
 XX 02-JAN-2003.  
 XX 19-DEC-2001; 2001US-00028072.  
 XX 18-JUN-1997; 97US-0049911P.  
 XX 26-AUG-1997; 97US-0056974P.  
 XX 17-SEP-1997; 97US-0059113P.  
 XX 17-SEP-1997; 97US-0059115P.  
 XX 17-SEP-1997; 97US-0059117P.  
 XX 17-SEP-1997; 97US-0059122P.  
 XX 17-SEP-1997; 97US-0059184P.  
 XX 18-SEP-1997; 97US-0059263P.  
 XX 19-SEP-1997; 97US-0059352P.  
 XX 19-SEP-1997; 97US-0059588P.  
 XX 24-SEP-1997; 97US-0059836P.  
 XX 17-OCT-1997; 97US-0062250P.  
 XX 17-OCT-1997; 97US-0062285P.  
 XX 17-OCT-1997; 97US-0062287P.  
 XX 17-OCT-1997; 97US-0063755P.  
 XX 24-OCT-1997; 97US-0062814P.  
 XX 24-OCT-1997; 97US-0063045P.  
 XX 24-OCT-1997; 97US-0063045P.  
 XX 24-OCT-1997; 97US-0063082P.  
 XX 24-OCT-1997; 97US-0063127P.  
 XX 27-OCT-1997; 97US-0063327P.  
 XX 27-OCT-1997; 97US-0063329P.  
 XX 28-OCT-1997; 97US-0063550P.  
 XX 28-OCT-1997; 97US-0063561P.  
 XX 29-OCT-1997; 97US-0063704P.  
 XX 29-OCT-1997; 97US-0063733P.  
 XX 29-OCT-1997; 97US-0063735P.  
 XX 29-OCT-1997; 97US-0063738P.  
 XX 03-NOV-1997; 97US-0064248P.  
 XX 07-NOV-1997; 97US-0064809P.  
 XX 12-NOV-1997; 97US-0065186P.  
 XX 17-NOV-1997; 97US-0065846P.  
 XX 21-NOV-1997; 97US-0066364P.  
 XX 24-NOV-1997; 97US-0066453P.  
 XX 24-NOV-1997; 97US-0066511P.  
 XX 24-NOV-1997; 97US-0066770P.  
 XX 11-DEC-1997; 97US-0069212P.  
 XX 11-DEC-1997; 97US-0069278P.  
 XX 11-DEC-1997; 97US-0069334P.  
 XX 16-DEC-1997; 97US-0069694P.  
 XX 23-JAN-1998; 98US-0072320P.  
 XX 04-FEB-1998; 98US-0073612P.  
 XX 09-FEB-1998; 98US-0074086P.  
 XX 09-FEB-1998; 98US-0074092P.  
 XX 12-MAR-1998; 98US-0077791P.  
 XX 20-MAR-1998; 98US-0078910P.  
 XX 25-MAR-1998; 98US-0079294P.  
 XX 27-MAR-1998; 98US-0079663P.  
 XX 27-MAR-1998; 98US-0079728P.  
 XX 31-MAR-1998; 98US-0080165P.  
 XX 12-JUN-1998; 98WO-US012456.  
 XX 14-JUL-1998; 98WO-US014552.  
 XX 28-AUG-1998; 98WO-US017888.  
 XX 10-SEP-1998; 98WO-US018824.  
 XX 14-SEP-1998; 98WO-US019093.  
 XX 14-SEP-1998; 98WO-US019094.  
 XX 14-SEP-1998; 98WO-US019177.  
 XX 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 20-APR-1999; 98WO-US008615.  
 PR 14-MAY-1999; 98WO-US010733.  
 PR 02-JUN-1999; 98WO-US012252.  
 PR 01-SEP-1999; 98WO-US020111.  
 PR 08-SEP-1999; 98WO-US020594.  
 PR 13-SEP-1999; 98WO-US020944.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 05-OCT-1999; 98WO-US023089.  
 PR 29-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 30-NOV-1999; 98WO-US028409.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 02-DEC-1999; 98WO-US028551.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 02-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 16-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 30-DEC-1999; 98WO-US031243.  
 PR 30-DEC-1999; 98WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 11-FEB-2000; 2000WO-US003376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforke L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-352836/33.  
 DR N-PSDB; ACA67230.  
 XX New isolated PRO polypeptide useful for treating diabetes, rheumatoid  
 PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or  
 PT heart attack.  
 XX Claim 12; Fig 474; 643pp; English.  
 CC The present invention relates to the isolation of novel human PRO  
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
 CC polypeptides are secreted and transmembrane proteins. The PRO  
 CC polypeptides and polynucleotides are useful for preparing a medicament  
 CC useful in the treatment of diabetes, bone and/or cartilage disorders  
 CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,  
 CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders  
 CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic  
 CC assays for PRO, by detecting its expression in specific cells, tissues or  
 CC serum, and for affinity purification of PRO from recombinant cell culture  
 CC or natural sources. ABU08070-ABU81144 represent the human PRO  
 CC polypeptides of the invention. Note: The sequence data for this patent  
 CC was obtained in electronic format directly from the USPTO web site at  
 CC seqdata.uspto.gov/psipsDIDEntry.html

```
SQ      Sequence 90 AA;
Query Match      100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MTFFLSLLLLVCEAIWRNSGSLTLENGYFLSRKNKHSQPTQSLSLDSVTPPTKAVKTT 60
      |||||
Db      1 MTFFLSLLLLVCEAIWRNSGSLTLENGYFLSRKNKHSQPTQSLSLDSVTPPTKAVKTT 60
      |||||

QY      61 GKGIIVKGRNLDGRGLILGAEAWGRGVKKNT 90
      |||||
Db      61 GKGIIVKGRNLDGRGLILGAEAWGRGVKKNT 90

RESULT 13
ABU72562
ID      ABU72562 standard; protein; 90 AA.
XX
AC      ABU72562;
DT      17-JUN-2003 (first entry)
DE
DE
DE
KW      Human; secreted and transmembrane protein PRO1159.
KW      Human; secreted and transmembrane protein; cytostatic; anti-HIV;
KW      virucide; hepatotropic; antiinflammatory; neuroprotective; Gene therapy;
KW      PRO; pharmaceutical; diagnostic; biosensor; bioindicator; malignancy;
KW      cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;
KW      lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;
KW      drug screening.
XX
OS      Homo sapiens.
XX
XX      US2003003531-A1.
PN
PD
PD
PD
PF      19-NOV-2001; 2001US-00989734.
XX
XX      16-JUN-1997; 97US-0049787P.
XX      17-OCT-1997; 97US-0062250P.
XX      05-NOV-1997; 97WO-US020069.
XX      12-NOV-1997; 97US-0065186P.
XX      13-NOV-1997; 97US-0065311P.
XX      24-NOV-1997; 97US-0066770P.
XX      25-FEB-1998; 98US-0075945P.
XX      28-MAR-1998; 98US-0078910P.
XX      28-APR-1998; 98US-0083322P.
XX      07-MAY-1998; 98US-0084600P.
XX      28-MAY-1998; 98US-0087106P.
XX      02-JUN-1998; 98US-0087607P.
XX      02-JUN-1998; 98US-0087759P.
XX      02-JUN-1998; 98US-0087827P.
XX      03-JUN-1998; 98US-0088021P.
XX      04-JUN-1998; 98US-0088025P.
XX      04-JUN-1998; 98US-0088026P.
XX      04-JUN-1998; 98US-0088028P.
XX      04-JUN-1998; 98US-0088029P.
XX      04-JUN-1998; 98US-0088030P.
XX      04-JUN-1998; 98US-0088033P.
XX      05-JUN-1998; 98US-0088326P.
XX      05-JUN-1998; 98US-0088167P.
XX      05-JUN-1998; 98US-0088202P.
XX      05-JUN-1998; 98US-0088212P.
XX      05-JUN-1998; 98US-0088217P.
XX      09-JUN-1998; 98US-0088655P.
XX      10-JUN-1998; 98US-0088734P.
XX      10-JUN-1998; 98US-0088738P.
XX      10-JUN-1998; 98US-0088742P.
XX      10-JUN-1998; 98US-0088810P.
XX      10-JUN-1998; 98US-0088824P.

PR      10-JUN-1998; 98US-0088826P.
PR      11-JUN-1998; 98US-0088858P.
PR      11-JUN-1998; 98US-0088861P.
PR      11-JUN-1998; 98US-0088876P.
PR      12-JUN-1998; 98US-0089105P.
PR      16-JUN-1998; 98US-0089440P.
PR      16-JUN-1998; 98US-0089512P.
PR      16-JUN-1998; 98US-0089514P.
PR      17-JUN-1998; 98US-0089532P.
PR      17-JUN-1998; 98US-0089538P.
PR      17-JUN-1998; 98US-0089538P.
PR      17-JUN-1998; 98US-0089538P.
PR      17-JUN-1998; 98US-0089600P.
PR      17-JUN-1998; 98US-0089653P.
PR      18-JUN-1998; 98US-0089801P.
PR      18-JUN-1998; 98US-0089907P.
PR      18-JUN-1998; 98US-0089908P.
PR      16-SEP-1998; 98WO-US019330.
PR      17-SEP-1998; 98WO-US019437.
PR      07-OCT-1998; 98WO-US021141.
PR      01-DEC-1998; 98WO-US025108.
PR      05-JAN-1999; 99WO-US000106.
PR      08-MAR-1999; 99WO-US005028.
PR      02-JUN-1999; 99WO-US012252.
PR      15-SEP-1999; 99WO-US021090.
PR      15-SEP-1999; 99WO-US021547.
PR      30-NOV-1999; 99WO-US028313.
PR      01-DEC-1999; 99WO-US028301.
PR      01-DEC-1999; 99WO-US028634.
PR      16-DEC-1999; 99WO-US030095.
PR      20-DEC-1999; 99WO-US030911.
PR      05-JAN-2000; 2000WO-US000219.
PR      06-JAN-2000; 2000WO-US000376.
PR      11-FEB-2000; 2000WO-US003565.
PR      18-FEB-2000; 2000WO-US004341.
PR      22-FEB-2000; 2000WO-US004414.
PR      24-FEB-2000; 2000WO-US004914.
PR      24-FEB-2000; 2000WO-US005004.
PR      10-MAR-2000; 2000WO-US006319.
PR      15-MAR-2000; 2000WO-US006884.
PR      20-MAR-2000; 2000WO-US007377.
PR      30-MAR-2000; 2000WO-US008439.
PR      15-MAY-2000; 2000WO-US013358.
PR      17-MAY-2000; 2000WO-US013705.
PR      22-MAY-2000; 2000WO-US014042.
PR      30-MAY-2000; 2000WO-US014941.
PR      02-JUN-2000; 2000WO-US015264.
PR      28-JUL-2000; 2000WO-US020710.
PR      11-AUG-2000; 2000WO-US022031.
PR      23-AUG-2000; 2000WO-US023522.
PR      24-AUG-2000; 2000WO-US023328.
PR      08-NOV-2000; 2000WO-US030952.
PR      01-DEC-2000; 2000WO-US032678.
PR      28-FEB-2001; 2001WO-US006520.
PR      01-JUN-2001; 2001WO-US017800.
PR      20-JUN-2001; 2001WO-US019692.
PR      29-JUN-2001; 2001WO-US021066.
PR      09-JUL-2001; 2001WO-US021735.
PR      28-AUG-2001; 2001US-00941992.
XX
XX      (GETH ) GENENTECH INC.
PA
XX      Ashkenazi AJ, Baker KP, Borstein D, Desnoyers L, Eaton DL;
XX      Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
XX      Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
XX      Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
XX      Zhang Z;
XX      WPI; 2003-352829/33.
XX      N-PSDB; ACA64409.
DR
XX      New genes and secreted and transmembrane polypeptides (e.g. PRO183 or
PR
```

PT PRO184}, useful for treating or diagnosing e.g. ovarian cancer, Kaposi's  
PT sarcoma, leukemia, lymphoma, hepatitis B, multiple sclerosis or Crohn's  
PT disease.

XX PS Claim 12; Fig 272; 663pp; English.

XX The invention describes a new isolated nucleic acid molecule comprising  
CC the full length coding sequence of the DNA deposited with the American  
CC Type Culture Collection (e.g. ATCC Deposit No. 209621, 552-PTA, 819-PTA,  
CC 209439, 203135, etc); or a sequence with at least 80% identity to a DNA  
CC encoding a PRO polypeptide. The PRO polypeptides or polynucleotides are  
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These  
CC are particularly useful for detecting or treating e.g. malignancies or  
CC cancers (e.g. ovarian cancer, colorectal cancer, Kaposi's sarcoma,  
CC leukaemia or lymphoma), hepatitis B, multiple sclerosis, or Crohn's  
CC disease in mammals. The PRO polypeptides are useful in drug screening,  
CC particularly as targets for therapeutic intervention in these diseases,  
CC and in the diagnostic determination of the presence of these diseases.  
CC The PRO polypeptides are also useful as molecular weight markers, or for  
CC chromosome identification. The PRO genes are useful as hybridisation  
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.  
CC The PRO genes may also be used in gene therapy, particularly for  
CC replacing a defective gene. This is the amino acid sequence of a novel  
CC human secreted and transmembrane PRO polypeptide

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNKHSQPTQSSLEDSVTPTKAVKIT 60  
Db 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNKHSQPTQSSLEDSVTPTKAVKIT 60  
Qy 61 KGKIVKGRNLSRGLILGAEWGRGVKNT 90  
Db 61 KGKIVKGRNLSRGLILGAEWGRGVKNT 90

## RESULT 14

ABU66806  
ID ABU66806 standard; protein; 90 AA.

XX AC ABU66806;

XX DT 23-MAY-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO polypeptide; secreted and transmembrane protein;  
KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;  
KW differentiation; chondrocyte; tumour; genetic disorder; cytostatic.

XX OS Homo sapiens.

XX PN US2003036180-A1.

XX PD 20-FEB-2003.

XX PF 09-MAY-2002; 2002US-00143114.

XX PP 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US0005028.  
PR 10-MAR-1999; 99WO-US0005190.  
PR 20-APR-1999; 99WO-US0008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030973.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854288.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00862636.  
 PR 19-JUN-2001; 2001US-00863342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-332040/31.  
 DR N-PSDB; ACA03839.  
 XX  
 PT New secreted and transmembrane PRO nucleic acids, useful for gene  
 PT therapy, in chromosome and gene mapping, as chromosome markers, in tissue  
 PT typing, and in chromosome identification.  
 XX  
 PS Claim 12; Fig 474; 660pp; English.  
 XX  
 CC The present invention relates to the isolation of novel human PRO  
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
 CC polypeptides are secreted and transmembrane proteins. The PRO  
 CC polypeptides are useful for detecting other PRO polypeptides, for linking  
 CC bioactive molecules to cells expressing PRO polypeptides, for modulating  
 CC biological activities of cells expressing PRO polypeptides, and for  
 CC identifying agonists or antagonists. The PRO polypeptides are useful for  
 CC for stimulating the release of tumour necrosis factor (TNF)-alpha from  
 CC human blood, for stimulating the proliferation or differentiation of  
 CC chondrocytes, and detecting the presence of tumours. The polynucleotide  
 CC sequences encoding PRO polypeptides are useful as hybridisation probes,  
 CC in chromosome and gene mapping, in the generation of antisense RNA and  
 CC DNA, in the preparation of PRO polypeptides, for generating transgenic  
 CC animals or knockout animals, for the genetic analysis of individuals with  
 CC genetic disorders, and in gene therapy. ABU6570-ABU6684 represent the  
 CC human PRO polypeptides of the invention. Note: The sequence data for this  
 CC patent was obtained in electronic format directly from the USPTO web site  
 CC at seqdata.uspto.gov/psipdIDEntry.html  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 MTFPLSLLLLVCAIRWSNGSNTLNGYFLSRNKENHSOPTQSSLEDVPTPKVKT 60  
 Db 1 MTFPLSLLLLVCAIRWSNGSNTLNGYFLSRNKENHSOPTQSSLEDVPTPKVKT 60  
 Qy 61 KGKIVKGRNLDRLGILGAENAGRGVKNT 90  
 Db 61 KGKIVKGRNLDRLGILGAENAGRGVKNT 90  
 RESULT 15  
 ABUS9887  
 ID ABUS9887 standard; protein; 90 AA.  
 XX  
 AC ABUS9887;  
 XX  
 DT 13-MAY-2003 (first entry)  
 XX

DE Novel secreted and transmembrane protein PRO1159.  
 XX  
 KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;  
 KW cardiac insufficiency disorder; cancer; tumour; immune response;  
 KW adrenal cortical capillary endothelial growth; c-fos induction;  
 KW vascular endothelial growth factor inhibition; VEGF inhibition;  
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;  
 KW retinal neurons cell survival; rod photoreceptor cell survival;  
 KW retinal disorder; retinitis pigmentosa; kidney disease;  
 KW mammalian kidney mesangial cell proliferation; Berger disease;  
 KW dermatitis; herpetic keratitis; Crohn's disease; chondrocyte proliferation;  
 KW chondrocyte redifferentiation; sports injury; arthritis.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003017563-A1.  
 XX  
 XX 23-JAN-2003.  
 PD  
 XX 07-MAY-2002; 2002US-00140808.  
 XX  
 PF 31-MAR-1997; 97WO-US005230.  
 PF 12-JUN-1998; 98WO-US012456.  
 PF 14-JUL-1998; 98WO-US014552.  
 PF 28-AUG-1998; 98WO-US017888.  
 PF 10-SEP-1998; 98WO-US018824.  
 PF 14-SEP-1998; 98WO-US019093.  
 PF 14-SEP-1998; 98WO-US019094.  
 PF 16-SEP-1998; 98WO-US019177.  
 PF 17-SEP-1998; 98WO-US019330.  
 PF 07-OCT-1998; 98WO-US019437.  
 PF 29-OCT-1998; 98WO-US021141.  
 PF 29-OCT-1998; 98WO-US022991.  
 PF 20-NOV-1998; 98WO-US022992.  
 PF 01-DEC-1998; 98WO-US024855.  
 PF 05-JAN-1999; 98WO-US025108.  
 PF 08-MAR-1999; 98WO-US000106.  
 PF 10-MAR-1999; 98WO-US005028.  
 PF 20-APR-1999; 98WO-US005190.  
 PF 14-MAY-1999; 98WO-US008615.  
 PF 02-JUN-1999; 98WO-US010733.  
 PF 01-SEP-1999; 98WO-US012252.  
 PF 08-SEP-1999; 98WO-US020594.  
 PF 13-SEP-1999; 98WO-US020944.  
 PF 15-SEP-1999; 98WO-US021090.  
 PF 05-OCT-1999; 98WO-US021547.  
 PF 29-NOV-1999; 98WO-US023089.  
 PF 30-NOV-1999; 98WO-US028214.  
 PF 01-DEC-1999; 98WO-US028313.  
 PF 01-DEC-1999; 98WO-US028409.  
 PF 02-DEC-1999; 98WO-US028501.  
 PF 02-DEC-1999; 98WO-US028634.  
 PF 02-DEC-1999; 98WO-US028551.  
 PF 02-DEC-1999; 98WO-US028564.  
 PF 16-DEC-1999; 98WO-US028565.  
 PF 20-DEC-1999; 98WO-US030911.  
 PF 22-DEC-1999; 98WO-US030999.  
 PF 30-DEC-1999; 98WO-US030720.  
 PF 30-DEC-1999; 98WO-US031243.  
 PF 30-DEC-1999; 98WO-US031274.  
 PF 03-JAN-2000; 2000WO-US000219.  
 PF 06-JAN-2000; 2000WO-US000277.  
 PF 06-JAN-2000; 2000WO-US000376.  
 PF 11-FEB-2000; 2000WO-US003565.  
 PF 18-FEB-2000; 2000WO-US004341.  
 PF 18-FEB-2000; 2000WO-US004342.  
 PF 22-FEB-2000; 2000WO-US004414.  
 PF 24-FEB-2000; 2000WO-US004914.  
 PF 01-MAR-2000; 2000WO-US005004.  
 PF 02-MAR-2000; 2000WO-US005601.  
 PF 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US0005841.  
PR 10-MAR-2000; 2000WO-US0006319.  
PR 15-MAR-2000; 2000WO-US0006884.  
PR 20-MAR-2000; 2000WO-US0007377.  
PR 21-MAR-2000; 2000WO-US0007532.  
PR 30-MAR-2000; 2000WO-US0008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 01-MAR-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
WPI; 2003-148238/14.  
DR N-PSDB; ABX89377.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
useful for treating pericyte-associated tumors, diabetes and various bone  
and/or cartilage disorders, e.g. arthritis.

Claim 12; Fig 474; 659pp; English.

The invention describes an isolated human PRO polypeptide. The PRO  
polypeptides are useful in detecting PRO polypeptides in a sample, in  
linking a bioactive molecule to a cell expressing a PRO polypeptide, and  
in modulating at least one biological activity of a cell expressing a PRO  
polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus  
useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186  
stimulate adrenal cortical capillary endothelial growth, and PRO536,  
PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,  
PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus  
useful for treating conditions or disorders where angiogenesis would be

CC beneficial, e.g. wound healing and antagonist of this polypeptide are  
CC useful for treating cancerous tumours. PRO812 inhibits vascular  
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial  
CC cells and is thus useful for inhibiting endothelial cell growth in  
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,  
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of  
CC stimulated T-lymphocytes and are therapeutically useful for enhancing  
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of  
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of  
CC rod photoreceptor cells) and therefore are useful for treating retinal  
CC disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813  
CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,  
CC and therefore are useful for treating kidney disorders associated with  
CC decreased mesangial cell function such as Berger disease or other  
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's  
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the  
CC proliferation and/or redifferentiation of chondrocytes in culture and are  
CC thus useful for treating sports injuries, and arthritis. This is the  
CC amino acid sequence of a novel human PRO protein

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTTKAVKTT 60  
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTTKAVKTT 60  
Qy 61 GKGVKGRNLDRLGLILGAEGRGVKKNT 90  
Db 61 GKGVKGRNLDRLGLILGAEGRGVKKNT 90

RESULT 16

ABUS9311  
ID ABUS9311 standard; protein; 90 AA.

XX AC ABUS9311;

XX 22-APR-2003 (first entry)

XX Human secreted/transmembrane protein, #154.

XX Human; PRO; secreted; transmembrane; pharmaceutical; diagnostic;  
XX biosensor; bioreactor; tumour; therapeutic; gene therapy;  
XX tumour-associated antigenic target; TAT; ADEPT;  
XX antibody-dependent enzyme mediated prodrug therapy; cytostatic.

XX Homo sapiens.

XX US2003027162-A1.

XX 06-FEB-2003.

XX 15-NOV-2001; 2001US-00997428.

XX 16-JUN-1997; 97US-0049787P.

XX 17-OCT-1997; 97US-0062250P.

XX 05-NOV-1997; 97WO-US020069.

XX 12-NOV-1997; 97US-0065186P.

XX 13-NOV-1997; 97US-0065311P.

XX 24-NOV-1997; 97US-0066770P.

XX 25-FEB-1998; 98US-0075945P.

XX 20-MAR-1998; 98US-0078910P.

XX 28-APR-1998; 98US-0083322P.

XX 07-MAY-1998; 98US-0084600P.

XX 28-MAY-1998; 98US-0087108P.

XX 02-JUN-1998; 98US-0087607P.

XX 02-JUN-1998; 98US-0087609P.

XX 02-JUN-1998; 98US-0087759P.

XX 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088022P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088328P.  
PR 04-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088121P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089588P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089807P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.

PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095923P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.



```

PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US007377.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

Query Match      100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNKHSQTSQSLDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNKHSQTSQSLDSVTPTKAVKTT 60

QY 61 GKGIVKGRNLDGRLGLGAEAWGRGVKNT 90
Db 61 GKGIVKGRNLDGRLGLGAEAWGRGVKNT 90

RESULT 17
ABO26008
ID ABO26008 standard; protein; 90 AA.
XX
AC ABO26008;
XX
DT 10-SEP-2003 (first entry)
XX
DE Human PRO1159 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive.
XX
OS Homo sapiens.
XX
XX US2002127576-A1.
XX
XX 12-SEP-2002.
XX
XX 14-NOV-2001; 2001US-00991073.
XX
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020069.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX 20-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 07-MAY-1998; 98US-0084600P.
XX 28-MAY-1998; 98US-0087106P.
XX 02-JUN-1998; 98US-0087607P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088021P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088026P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088036P.
PR 05-JUN-1998; 98US-0088126P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088836P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 02-JUN-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US015264.
PR 02-JUN-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUL-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.

```



Wed Jun 2 08:28:01 2004

01-DEC-2000; 2000WO-US032678.  
20-DEC-2000; 2000US-00747259.  
20-DEC-2000; 2000WO-US034956.  
28-FEB-2001; 2001US-00796498.  
28-FEB-2001; 2001WO-US006520.  
01-MAR-2001; 2001WO-US006666.  
09-MAR-2001; 2001US-00802706.  
14-MAR-2001; 2001US-00808689.  
22-MAR-2001; 2001US-00816744.  
05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854280.  
10-MAY-2001; 2001US-00854280.  
18-MAY-2001; 2001US-00860216.  
23-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
25-MAY-2001; 2001WO-US017092.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00882636.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019692.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-466355/44.

N-PSDB; ACD42031.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PRO4978, useful in molecular biology, chromosome and gene mapping, in  
generating antisense RNA and DNA, and in gene therapy.

Claim 12; Fig 474; 659pp; English.

The invention relates to an isolated nucleic acid comprising at least 80%  
sequence identity to a PRO (secreted and transmembrane protein) cDNA  
comprising a nucleic acid (a) encoding a PRO polypeptide, or its  
extracellular domain (with or without its associated signal peptide),  
which comprises any of the 275 120-850 residue amino acid sequences,  
given in the specification; (b) comprising any of the 275 300-3500  
nucleotide sequences, given in the specification; or (c) comprising the  
full-length coding sequence of the nucleotide sequences given in the  
specification, or of the DNA deposited under any of the American Type  
Culture Collection (ATCC) Accession Numbers listed in the specification.  
Also included are a vector comprising the novel nucleic acid, a host cell  
comprising the vector, producing a PRO polypeptide, the isolated PRO  
polypeptides detailed above, a chimeric molecule comprising the PRO  
polypeptide of fused to a heterologous amino acid sequence, an anti-PRO  
antibody, detecting a PRO polypeptide in a sample suspected of containing  
the PRO polypeptide, linking a bioactive molecule to a cell expressing a  
PRO polypeptide, modulating at least one biological activity of a cell  
expressing a PRO polypeptide, stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, (or proteoglycans from  
cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),  
modulating the uptake of glucose or FFA by skeletal muscle cells or  
adipocyte cells, stimulating the proliferation or differentiation of  
chondrocyte cells (or proliferation of or gene expression in pericyte  
cells), stimulating the proliferation of inner ear utricular supporting  
cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the  
binding of A-peptide to factor VIIA, or differentiation of adipocyte

CC cells, detecting the presence of a tumour in a mammal and an  
CC oligonucleotide probe derived from any of the nucleotide sequences given  
CC in the specification. The polynucleotide is useful in molecular biology,  
CC including uses as hybridisation probes, in chromosome and gene mapping,  
CC in generating antisense RNA and DNA, and in gene therapy. The  
CC polynucleotide may also be used in preparing PRO polypeptides by  
CC recombinant techniques, and in generating either transgenic animals or  
CC knock-out animals which, in turn, are useful in the development and  
CC screening of therapeutically useful reagents. The PRO polypeptide or the  
CC antibody is used in preparing a medicament for treating a condition  
CC responsive to the polypeptide or antibody, such as tumours, and in  
CC various diagnostic assays. The present sequence represents a PRO  
CC polypeptide

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQTSLSLDSVTPTKAVKTT 60  
Db 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQTSLSLDSVTPTKAVKTT 60  
Qy 61 KGIVKGRNLDLSRGLILGAENWGRGVKNT 90  
Db 61 KGIVKGRNLDLSRGLILGAENWGRGVKNT 90

RESULT 19

ABUS9017  
ID ABUS9017 standard; protein; 90 AA.

XX AC ABUS9017;

XX DT 16-APR-2003 (first entry)  
XX DE Human secreted/transmembrane protein, #154.

XX KW Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;  
XX KW diagnostic; biosensor; bio-reactor; tumour; therapeutic; colon cancer;  
XX KW lung cancer; breast cancer; cancer; gene therapy.  
XX OS Homo sapiens.

XX PN US2002142961-A1.

XX PD 03-OCT-2002.

XX PF 19-NOV-2001; 2001US-00989721.

XX PR 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 24-NOV-1997; 97US-0068770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087106P.

XX PR 02-JUN-1998; 98US-0087607P.

XX PR 02-JUN-1998; 98US-0087759P.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 04-JUN-1998; 98US-0088021P.

XX PR 04-JUN-1998; 98US-0088025P.

XX PR 04-JUN-1998; 98US-0088026P.

XX PR 04-JUN-1998; 98US-0088028P.

XX PR 04-JUN-1998; 98US-0088029P.

XX PR 04-JUN-1998; 98US-0088030P.

XX PR 04-JUN-1998; 98US-0088033P.



PR	16-JUN-1997;	97US-00493787P.	97US-00906595P.
PR	17-OCT-1997;	97US-0062250P.	98US-0090696P.
PR	05-NOV-1997;	97WO-US020069.	98US-0090862P.
PR	12-NOV-1997;	97US-0065186P.	98US-0090863P.
PR	13-NOV-1997;	97US-0065311P.	98US-0091360P.
PR	24-NOV-1997;	97US-0066770P.	98US-0091544P.
PR	25-FEB-1998;	98US-0075945P.	98US-0091478P.
PR	20-MAR-1998;	98US-0078910P.	98US-0091519P.
PR	28-APR-1998;	98US-0083322P.	98US-0091626P.
PR	07-MAY-1998;	98US-0084600P.	98US-0091628P.
PR	28-MAY-1998;	98US-0087106P.	98US-0091633P.
PR	02-JUN-1998;	98US-0087607P.	98US-0091682P.
PR	02-JUN-1998;	98US-0087609P.	98US-0092182P.
PR	02-JUN-1998;	98US-0087759P.	98US-0092472P.
PR	03-JUN-1998;	98US-0087827P.	98US-0093339P.
PR	04-JUN-1998;	98US-0088021P.	98US-0094651P.
PR	04-JUN-1998;	98US-0088025P.	98US-0095285P.
PR	04-JUN-1998;	98US-0088026P.	98US-0095301P.
PR	04-JUN-1998;	98US-0088028P.	98US-0095302P.
PR	04-JUN-1998;	98US-0088029P.	98US-0095318P.
PR	04-JUN-1998;	98US-0088030P.	98US-0095321P.
PR	04-JUN-1998;	98US-0088033P.	98US-0095325P.
PR	04-JUN-1998;	98US-0088326P.	98US-0095916P.
PR	05-JUN-1998;	98US-0088167P.	98US-0095929P.
PR	05-JUN-1998;	98US-0088202P.	98US-0096012P.
PR	05-JUN-1998;	98US-0088212P.	98US-0096143P.
PR	05-JUN-1998;	98US-0088217P.	98US-0096146P.
PR	09-JUN-1998;	98US-0088555P.	98US-0096773P.
PR	10-JUN-1998;	98US-0088734P.	98US-0096766P.
PR	10-JUN-1998;	98US-0088738P.	98US-0096768P.
PR	10-JUN-1998;	98US-0088742P.	98US-0096771P.
PR	10-JUN-1998;	98US-0088810P.	98US-0096789P.
PR	10-JUN-1998;	98US-0088824P.	98US-0096791P.
PR	11-JUN-1998;	98US-0088826P.	98US-0096867P.
PR	11-JUN-1998;	98US-0088858P.	98US-0096889P.
PR	11-JUN-1998;	98US-0088861P.	98US-0096894P.
PR	11-JUN-1998;	98US-0088876P.	98US-0096895P.
PR	12-JUN-1998;	98US-0089105P.	98US-0096897P.
PR	16-JUN-1998;	98US-0089440P.	98US-0096943P.
PR	16-JUN-1998;	98US-0089512P.	98US-0096950P.
PR	17-JUN-1998;	98US-0089514P.	98US-0096953P.
PR	17-JUN-1998;	98US-0089532P.	98US-0096960P.
PR	17-JUN-1998;	98US-0089538P.	98US-0097022P.
PR	17-JUN-1998;	98US-0089598P.	98US-0097141P.
PR	17-JUN-1998;	98US-0089599P.	98US-0097218P.
PR	17-JUN-1998;	98US-0089600P.	98US-0097661P.
PR	17-JUN-1998;	98US-0089653P.	98US-0097952P.
PR	18-JUN-1998;	98US-0089801P.	98US-0097954P.
PR	18-JUN-1998;	98US-0089907P.	98US-0097955P.
PR	18-JUN-1998;	98US-0089908P.	98US-0097971P.
PR	19-JUN-1998;	98US-0089947P.	98US-0097974P.
PR	19-JUN-1998;	98US-0089952P.	98US-0097978P.
PR	22-JUN-1998;	98US-0090246P.	98US-0097979P.
PR	22-JUN-1998;	98US-0090252P.	98US-0097986P.
PR	22-JUN-1998;	98US-0090254P.	98US-0098014P.
PR	22-JUN-1998;	98US-0090282P.	98US-0098525P.
PR	23-JUN-1998;	98US-0090349P.	98US-0106334P.
PR	23-JUN-1998;	98US-0090355P.	98US-0109330.
PR	23-JUN-1998;	98US-0090472P.	98US-0100858P.
PR	24-JUN-1998;	98US-0090429P.	98US-01019437.
PR	24-JUN-1998;	98US-0090431P.	98US-01021141.
PR	24-JUN-1998;	98US-0090435P.	98US-01025108.
PR	24-JUN-1998;	98US-0090444P.	98US-0113296P.
PR	24-JUN-1998;	98US-0090445P.	98US-0113296P.
PR	24-JUN-1998;	98US-0090472P.	98US-0113296P.
PR	24-JUN-1998;	98US-0090535P.	98US-0113296P.
PR	24-JUN-1998;	98US-0090540P.	98US-0113296P.
PR	24-JUN-1998;	98US-0090542P.	98US-0113296P.
PR	24-JUN-1998;	98US-0090557P.	98US-0113296P.
PR	25-JUN-1998;	98US-0090676P.	98US-0113296P.
PR	25-JUN-1998;	98US-00	

```

PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLIVCAIWRNSGNTLENGYFLSKENHQSPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFPLSLLLIVCAIWRNSGNTLENGYFLSKENHQSPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90
Db 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 21
ABUS9460
ID ABUS9460 standard; protein; 90 AA.
XX AC
XX ABUS9460;
XX DT
XX 22-APR-2003 (first entry)
XX DE
XX Novel human secreted or transmembrane protein PRO1124.
XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
XX cardiac insufficiency disorder; cancer; tumour; immune response;
XX adrenal cortical capillary endothelial growth; c-fos induction;
XX vascular endothelial growth factor inhibition; VEGF inhibition;
XX endothelial cell growth inhibitor; T-lymphocytes stimulation;
XX retinal neurons cell survival; rod photoreceptor cell survival;
XX retinal disorder; retinitis pigmentosa; kidney disorder;
XX mammalian kidney mesangial cell proliferation; Berger disease;
XX dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
XX chondrocyte redifferentiation; sports injury; arthritis.
XX OS
XX Homo sapiens.
XX FN
XX US2003027985-A1.
XX PD
XX 06-FEB-2003.
XX 14-NOV-2001; 2001US-009050562.

```

XX

```

16-JUN-1997; 97US-0049787P.
17-OCT-1997; 97US-0062250P.
05-NOV-1997; 97WO-US020069.
12-NOV-1997; 97US-0065186P.
13-NOV-1997; 97US-0065311P.
24-NOV-1997; 97US-0066770P.
25-FEB-1998; 98US-0075945P.
28-MAR-1998; 98US-0078910P.
28-APR-1998; 98US-0083322P.
07-MAY-1998; 98US-0084600P.
28-MAY-1998; 98US-0087106P.
02-JUN-1998; 98US-0087607P.
02-JUN-1998; 98US-0087609P.
02-JUN-1998; 98US-0087759P.
03-JUN-1998; 98US-0087827P.
04-JUN-1998; 98US-0088021P.
04-JUN-1998; 98US-0088025P.
04-JUN-1998; 98US-0088026P.
04-JUN-1998; 98US-0088028P.
04-JUN-1998; 98US-0088029P.
04-JUN-1998; 98US-0088030P.
04-JUN-1998; 98US-0088033P.
04-JUN-1998; 98US-0088167P.
05-JUN-1998; 98US-0088326P.
05-JUN-1998; 98US-0088202P.
05-JUN-1998; 98US-0088212P.
05-JUN-1998; 98US-0088217P.
09-JUN-1998; 98US-0088655P.
10-JUN-1998; 98US-0088734P.
10-JUN-1998; 98US-0088738P.
10-JUN-1998; 98US-0088742P.
10-JUN-1998; 98US-0088810P.
10-JUN-1998; 98US-0088824P.
10-JUN-1998; 98US-0088826P.
11-JUN-1998; 98US-0088858P.
11-JUN-1998; 98US-0088861P.
11-JUN-1998; 98US-0088876P.
12-JUN-1998; 98US-0089105P.
16-JUN-1998; 98US-0089440P.
16-JUN-1998; 98US-0089512P.
16-JUN-1998; 98US-0089514P.
17-JUN-1998; 98US-0089532P.
17-JUN-1998; 98US-0089538P.
17-JUN-1998; 98US-0089598P.
17-JUN-1998; 98US-0089599P.
17-JUN-1998; 98US-0089600P.
17-JUN-1998; 98US-0089606P.
17-JUN-1998; 98US-0089653P.
18-JUN-1998; 98US-0089801P.
18-JUN-1998; 98US-0089907P.
18-JUN-1998; 98US-0089908P.
19-JUN-1998; 98US-0089947P.
19-JUN-1998; 98US-0089948P.
19-JUN-1998; 98US-0089952P.
22-JUN-1998; 98US-0090246P.
22-JUN-1998; 98US-0090252P.
22-JUN-1998; 98US-0090254P.
23-JUN-1998; 98US-0090349P.
23-JUN-1998; 98US-0090355P.
24-JUN-1998; 98US-0090429P.
24-JUN-1998; 98US-0090431P.
24-JUN-1998; 98US-0090435P.
24-JUN-1998; 98US-0090444P.
24-JUN-1998; 98US-0090445P.
24-JUN-1998; 98US-0090472P.
24-JUN-1998; 98US-0090535P.
24-JUN-1998; 98US-0090540P.
24-JUN-1998; 98US-0090542P.
24-JUN-1998; 98US-0090557P.
25-JUN-1998; 98US-0090676P.
25-JUN-1998; 98US-0090678P.
25-JUN-1998; 98US-0090690P.
25-JUN-1998; 98US-0090694P.

```

PR	25-JUN-1998;	98US-0090695P.	PR	20-JUL-1999;	99US-0144758P.
PR	25-JUN-1998;	98US-0090696P.	PR	26-JUL-1999;	99US-0145698P.
PR	26-JUN-1998;	98US-0090862P.	PR	28-JUL-1999;	99US-0146222P.
PR	26-JUN-1998;	98US-0090863P.	PR	17-AUG-1999;	99US-0149396P.
PR	01-JUL-1998;	98US-0091360P.	PR	15-SEP-1999;	99WO-US021090.
PR	01-JUL-1998;	98US-0091544P.	PR	13-SEP-1999;	99WO-US021547.
PR	02-JUL-1998;	98US-0091478P.	PR	08-OCT-1999;	99US-0158663P.
PR	02-JUL-1998;	98US-0091519P.	PR	30-NOV-1999;	99WO-US028313.
PR	02-JUL-1998;	98US-0091626P.	PR	01-DEC-1999;	99WO-US028301.
PR	02-JUL-1998;	98US-0091628P.	PR	01-DEC-1999;	99WO-US028634.
PR	02-JUL-1998;	98US-0091633P.	PR	16-DEC-1999;	99WO-US030095.
PR	02-JUL-1998;	98US-0091646P.	PR	20-DEC-1999;	99WO-US030911.
PR	02-JUL-1998;	98US-0091673P.	PR	05-JAN-2000;	2000WO-US000219.
PR	07-JUL-1998;	98US-0091978P.	PR	06-JAN-2000;	2000WO-US000376.
PR	09-JUL-1998;	98US-0092182P.	PR	11-FEB-2000;	2000WO-US003565.
PR	10-JUL-1998;	98US-0092472P.	PR	18-FEB-2000;	2000WO-US004341.
PR	20-JUL-1998;	98US-0093339P.	PR	22-FEB-2000;	2000WO-US004414.
PR	30-JUL-1998;	98US-0094651P.	PR	24-FEB-2000;	2000WO-US004914.
PR	04-AUG-1998;	98US-0095282P.	PR	24-FEB-2000;	2000WO-US005004.
PR	04-AUG-1998;	98US-0095285P.	PR	02-MAR-2000;	2000WO-US005841.
PR	04-AUG-1998;	98US-0095302P.	PR	10-MAR-2000;	2000WO-US006319.
PR	04-AUG-1998;	98US-0095318P.	PR	15-MAR-2000;	2000WO-US006884.
PR	04-AUG-1998;	98US-0095321P.	PR	20-MAR-2000;	2000WO-US007377.
PR	04-AUG-1998;	98US-0095325P.	PR	30-MAR-2000;	2000WO-US008439.
PR	10-AUG-1998;	98US-0095913P.	PR	15-MAY-2000;	2000WO-US013358.
PR	10-AUG-1998;	98US-0095923P.	PR	17-MAY-2000;	2000WO-US013705.
PR	10-AUG-1998;	98US-0096012P.	PR	22-MAY-2000;	2000WO-US014042.
PR	11-AUG-1998;	98US-0096143P.	PR	30-MAY-2000;	2000WO-US014941.
PR	11-AUG-1998;	98US-0096146P.			
PR	12-AUG-1998;	98US-0096329P.			
PR	12-AUG-1998;	98US-0096757P.			
PR	17-AUG-1998;	98US-0096766P.			
PR	17-AUG-1998;	98US-0096768P.			
PR	17-AUG-1998;	98US-0096773P.			
PR	17-AUG-1998;	98US-0096791P.			
PR	17-AUG-1998;	98US-0096867P.			
PR	17-AUG-1998;	98US-0096891P.			
PR	17-AUG-1998;	98US-0096894P.			
PR	17-AUG-1998;	98US-0096895P.			
PR	17-AUG-1998;	98US-0096897P.			
PR	18-AUG-1998;	98US-0096949P.			
PR	18-AUG-1998;	98US-0096950P.			
PR	18-AUG-1998;	98US-0096959P.			
PR	18-AUG-1998;	98US-0096960P.			
PR	18-AUG-1998;	98US-0097022P.			
PR	19-AUG-1998;	98US-0097141P.			
PR	20-AUG-1998;	98US-0097218P.			
PR	24-AUG-1998;	98US-0097661P.			
PR	26-AUG-1998;	98US-0097952P.			
PR	26-AUG-1998;	98US-0097954P.			
PR	26-AUG-1998;	98US-0097955P.			
PR	26-AUG-1998;	98US-0097971P.			
PR	26-AUG-1998;	98US-0097974P.			
PR	26-AUG-1998;	98US-0097978P.			
PR	26-AUG-1998;	98US-0097979P.			
PR	26-AUG-1998;	98US-0097986P.			
PR	26-AUG-1998;	98US-0098014P.			
PR	31-AUG-1998;	98US-0098525P.			
PR	16-SEP-1998;	98US-0100634P.			
PR	16-SEP-1998;	98WO-US019330.			
PR	17-SEP-1998;	98US-0100858P.			
PR	17-SEP-1998;	98WO-US019437.			
PR	07-OCT-1998;	98WO-US021141.			
PR	01-DEC-1998;	98WO-US025108.			
PR	22-DEC-1998;	98US-0113296P.			
PR	05-JAN-1999;	99WO-US000106.			
PR	08-MAR-1999;	99WO-US005028.			
PR	12-MAR-1999;	99US-0123957P.			
PR	02-JUN-1999;	99WO-US012252.			
PR	23-JUN-1999;	99US-0141037P.			
PR	07-JUL-1999;	99US-0143048P.			
Query Match Similarity 100.0%; Score 462; DB 6; Length 90;					
Best Local Similarity 100.0%; Pred. No. 9.8e-49;					
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	1	MTFFLSLLILLVCEAIWRSN	QY	1	MTFFLSLLILLVCEAIWRSN
DB	1	MTFFLSLLILLVCEAIWRSN	DB	1	MTFFLSLLILLVCEAIWRSN
QY	61	KGKIVKGRNLDNRGLILGAE	QY	61	KGKIVKGRNLDNRGLILGAE
DB	61	KGKIVKGRNLDNRGLILGAE	DB	61	KGKIVKGRNLDNRGLILGAE
RESULT 22					
ABU67082					
ID ABU67082 standard; protein; 90 AA.					
AC ABU67082;					
XX					
XX					
DT 27-MAY-2003 (first entry)					
XX					
DE Human secreted/transmembrane, PRO, protein SEQ ID 474.					
XX					
KW Human; secreted protein; transmembrane protein; PRO;					
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;					
KW infertility; birth defects; premature aging; AIDS; biosensor;					
KW acquired immunodeficiency syndrome; cancer; diabetic complication;					
KW bioreactor; tumour.					
XX					
OS Homo sapiens.					
XX					
PN US2003032155-A1.					
XX					
PD 13-FEB-2003.					
XX					
PF 03-MAY-2002; 2002US-00137865.					
XX					
PR 31-MAR-1997; 97WO-US005230.					
PR					
PR 12-JUN-1998; 98WO-US012456.					
PR					
PR 14-JUL-1998; 98WO-US014552.					
PR					
PR 28-AUG-1998; 98WO-US017888.					
PR					
PR 10-SEP-1998; 98WO-US018824.					
PR					
PR 14-SEP-1998; 98WO-US019093.					
PR					
PR 14-SEP-1998; 98WO-US019094.					

PR 14-SEP-1998; 98WO-US0191177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 27-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 30-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 20-APR-1999; 98WO-US008615.  
 PR 14-MAY-1999; 98WO-US010733.  
 PR 01-SEP-1999; 98WO-US020111.  
 PR 08-SEP-1999; 98WO-US020594.  
 PR 13-SEP-1999; 98WO-US020944.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 05-OCT-1999; 98WO-US023089.  
 PR 29-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 30-NOV-1999; 98WO-US028409.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 02-DEC-1999; 98WO-US028551.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 02-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 22-DEC-1999; 98WO-US030720.  
 PR 30-DEC-1999; 98WO-US031243.  
 PR 30-DEC-1999; 98WO-US031274.  
 PR 03-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000WO-US034729.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001US-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.

PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-331925/31.  
 N-PSDB; ACA04260.

New secreted and transmembrane nucleic acids and polypeptides, designated as PRO, useful for treating inflammation, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS, or cancer.

Claim 12; Fig 474; 659pp; English.

The invention relates to an isolated nucleic acid comprising, or which is at least 80% identical to, or the full-length coding sequence of, any of the 275 nucleotide sequences, encoding the corresponding PRO polypeptide (one of 275 secreted or transmembrane proteins). The nucleic acid further comprises the full-length coding sequence of the DNA deposited under American Type Culture Collection (ATCC) accession number in a list given in the specification. Also included are vectors and host cells for producing PRO proteins. PRO fusion proteins, anti-PRO antibodies, PRO extracellular domains and mature sequences, methods of detecting PRO proteins, methods for stimulating the release of TNF-alpha (tumour necrosis factor alpha) from human blood, (and the proliferation of, or gene differentiation of chondrocyte cells, the release or proteoglycans from expression in pericyte cells, the release or proliferation of, or gene cartilage, proliferation of inner ear utricular supporting cells, the proliferation of T-lymphocyte cells, the release of a cytokine from peripheral blood mononuclear cells (PBMC), or the proliferation of endothelial cells), a method for modulating the uptake of glucose or free fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the binding of A-peptide to factor VIIA, or the differentiation of adipocyte cells, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the nucleotide sequences cited above. The nucleic acids and polypeptides are useful for treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or diabetic complications. The nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, and in generating antisense RNA or DNA. The polypeptides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both are useful in tissue typing. The present sequence represents a PRO protein of the invention

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. NO. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;



QY	1	MTFFLSILLLLVCEAIWRNSGNTL	ENGYFLSRNKENHSQPTQSSLED	SVTPPKAVKIT	60
Db	1	MTFFLSILLLLVCEAIWRNSGNTL	ENGYFLSRNKENHSQPTQSSLED	SVTPPKAVKIT	60
QY	61	GKGI	VKGRNLD	SRGLILGAEAWGRGVKKNT	90
Db	61	GKGI	VKGRNLD	SRGLILGAEAWGRGVKKNT	90
RESULT 23					
ABU92226					
ID	ABU92226 standard; protein; 90 AA.				
XX	AC	ABU92226;			
XX	DT	16-JUL-2003 (first entry)			
XX	DE	Novel human secreted and transmembrane protein PRO1159.			
XX	KW	Human; secreted and transmembrane protein; PRO; nootropic;			
XX	KW	neuroprotective; antiparkinsonian; cytosstatic; gene therapy;			
XX	KW	chromosome mapping; Gene mapping; transgenic animal; knock-out animal;			
XX	KW	neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.			
XX	OS	Homo sapiens.			
XX	XX	US2003017476-A1.			
XX	PN	23-JAN-2003.			
XX	PD	20-NOV-2001; 2001US-00989724.			
XX	PF	16-JUN-1997; 97US-0049787P.			
XX	PR	17-OCT-1997; 97US-0062250P.			
XX	PR	05-NOV-1997; 97WO-US020069.			
XX	PR	12-NOV-1997; 97US-0085186P.			
XX	PR	13-NOV-1997; 97US-0065311P.			
XX	PR	24-NOV-1997; 97US-0066770P.			
XX	PR	25-FEB-1998; 98US-0075945P.			
XX	PR	20-MAR-1998; 98US-0078910P.			
XX	PR	28-APR-1998; 98US-0083322P.			
XX	PR	07-MAY-1998; 98US-0084600P.			
XX	PR	28-MAY-1998; 98US-0087106P.			
XX	PR	02-JUN-1998; 98US-0087607P.			
XX	PR	02-JUN-1998; 98US-0087609P.			
XX	PR	02-JUN-1998; 98US-0087759P.			
XX	PR	03-JUN-1998; 98US-0087827P.			
XX	PR	04-JUN-1998; 98US-00880021P.			
XX	PR	04-JUN-1998; 98US-00880025P.			
XX	PR	04-JUN-1998; 98US-0088026P.			
XX	PR	04-JUN-1998; 98US-0088028P.			
XX	PR	04-JUN-1998; 98US-0088029P.			
XX	PR	04-JUN-1998; 98US-0088030P.			
XX	PR	04-JUN-1998; 98US-0088033P.			
XX	PR	04-JUN-1998; 98US-0088326P.			
XX	PR	05-JUN-1998; 98US-0088167P.			
XX	PR	05-JUN-1998; 98US-0088202P.			
XX	PR	05-JUN-1998; 98US-0088212P.			
XX	PR	05-JUN-1998; 98US-0088217P.			
XX	PR	09-JUN-1998; 98US-0088653P.			
XX	PR	10-JUN-1998; 98US-0088734P.			
XX	PR	10-JUN-1998; 98US-0088738P.			
XX	PR	10-JUN-1998; 98US-0088742P.			
XX	PR	10-JUN-1998; 98US-0088810P.			
XX	PR	10-JUN-1998; 98US-0088824P.			
XX	PR	10-JUN-1998; 98US-0088826P.			
XX	PR	11-JUN-1998; 98US-0088858P.			
XX	PR	11-JUN-1998; 98US-0088861P.			
XX	PR	11-JUN-1998; 98US-0088876P.			
XX	PR	12-JUN-1998; 98US-0089105P.			
XX	PR	16-JUN-1998; 98US-0089440P.			
XX	PR	16-JUN-1998; 98US-0089512P.			
XX	PR	16-JUN-1998; 98US-0089514P.			

PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 20-AUG-1998; 98US-0097661P.  
PR 24-AUG-1998; 98US-0097952P.  
PR 24-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 07-OCT-1998; 98US-0101141P.  
PR 01-DEC-1998; 98US-0101141P.  
PR 22-DEC-1998; 98US-0112396P.  
PR 05-JAN-1999; 98US-0112396P.  
PR 08-MAR-1999; 98US-0123957P.  
PR 12-MAR-1999; 98US-0123957P.  
PR 02-JUN-1999; 98US-0123957P.  
PR 23-JUN-1999; 98US-0141037P.  
PR 07-JUL-1999; 98US-0143048P.  
PR 20-JUL-1999; 98US-0144758P.  
PR 26-JUL-1999; 98US-0145698P.  
PR 28-JUL-1999; 98US-0146222P.  
PR 17-AUG-1999; 98US-0149386P.  
PR 15-SEP-1999; 98US-0150210P.  
PR 15-SEP-1999; 98US-0150215P.  
PR 08-OCT-1999; 98US-0158663P.  
PR 30-NOV-1999; 98US-028313P.  
PR 01-DEC-1999; 98US-028313P.  
PR 01-DEC-1999; 98US-028313P.  
PR 16-DEC-1999; 98US-0303091P.  
PR 20-DEC-1999; 98US-0303091P.  
PR 05-JAN-2000; 2000US-0000376P.  
PR 06-JAN-2000; 2000US-0000376P.  
PR 11-FEB-2000; 2000US-0003565P.  
PR 18-FEB-2000; 2000US-0004341P.  
PR 22-FEB-2000; 2000US-0004414P.  
PR 24-FEB-2000; 2000US-0004914P.  
PR 02-MAR-2000; 2000US-0005841P.  
PR 10-MAR-2000; 2000US-0006319P.  
PR 15-MAR-2000; 2000US-0006884P.  
PR 20-MAR-2000; 2000US-0007377P.  
PR 30-MAR-2000; 2000US-0008439P.  
PR 15-MAY-2000; 2000US-0013358P.  
PR 17-MAY-2000; 2000US-0013705P.  
PR 22-MAY-2000; 2000US-0014042P.  
PR 30-MAY-2000; 2000US-0014941P.  
PR 02-JUN-2000; 2000US-0015264P.  
PR 23-JUN-2000; 2000US-0015637P.  
PR 28-JUL-2000; 2000US-0020710P.  
PR 11-AUG-2000; 2000US-0022031P.  
PR 23-AUG-2000; 2000US-0023522P.  
PR 24-AUG-2000; 2000US-0023328P.

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
1 MTFLLSLLLVCEAIWRSNCSNTLENGYFLSRKNHNSQPTQSSLESVPTKAVKTT 60  
1 MTFLLSLLLVCEAIWRSNCSNTLENGYFLSRKNHNSQPTQSSLESVPTKAVKTT 60

QY 61 GKGIYKGRNLDNRGLILGAEAWGRGVKXNT 90  
DB 61 GKGIYKGRNLDNRGLILGAEAWGRGVKXNT 90  
RESULT 24  
ABU10932  
ID ABU10932 standard; protein; 90 AA.  
XX AC ABU10932;  
XX DT 04-FEB-2003 (first entry)  
XX DE Human PRO polypeptide #118.  
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide; toxin;  
KW radiolabel; cell death; gene mapping; chromosome mapping;  
KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;  
antibacterial.  
XX OS Homo sapiens.  
XX US2002123463-A1.  
XX PD 05-SEP-2002.  
XX PF 19-NOV-2001; 2001US-00989732.  
XX PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97US-0062250P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088036P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 17-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.  
 PR 17-JUN-1998; 98US-0089600P.  
 PR 17-JUN-1998; 98US-0089653P.  
 PR 18-JUN-1998; 98US-0089801P.  
 PR 18-JUN-1998; 98US-0089907P.  
 PR 18-JUN-1998; 98US-0089908P.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 06-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004414.  
 PR 22-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 15-MAY-2000; 2000WO-US013358.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 29-JUL-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 28-AUG-2001; 2001US-00941992.

(GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
 PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
 PI Zhang Z;

XX WPI: 2003-066810/06.  
 DR N-PSDB; ABX17151.

XX Novel secreted and transmembrane polypeptide for modulating biological  
 PT activity of cell expressing the polypeptide, identifying agonists or  
 PT antagonists of polypeptide, and as molecular weight markers.

XX Claim 12; Fig 272; 655pp; English.

XX The invention relates to a secreted and transmembrane polypeptide, termed  
 CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is  
 CC useful for detecting PRO polypeptides and for linking a bioactive  
 CC molecule to a cell expressing the above polypeptides, where the bioactive  
 CC molecule is a toxin, radiolabel or an antibody. The bioactive material  
 CC causes the death of the cell. The polypeptide is useful for identifying

CC agonists or antagonists of the PRO polypeptide, for preparing variants of  
 CC PRO, as a molecular weight marker for protein electrophoresis purposes  
 CC and the PRO polynucleotide is useful for recombinantly expressing those  
 CC markers. The polynucleotide is also useful as a hybridisation probe, in  
 CC chromosome and gene mapping, in generation of antisense RNA and DNA, in  
 CC the preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, to construct hybridisation  
 CC probes for mapping the gene which encodes PRO and for the genetic  
 CC analysis of individuals with genetic disorders, in gene therapy, for  
 CC chromosome identification, as a chromosome marker and for generating  
 CC probes for PCR, Northern analysis, Southern analysis and Western  
 CC analysis. This sequence represents a human PRO polypeptide of the  
 CC invention

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLGRKNHSGPTOSLSLDSVTPTKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLGRKNHSGPTOSLSLDSVTPTKAVKTT 60

Qy 61 GKGIKGRNLDLSRGLILGAEAWGRGVKNT 90

Db 61 GKGIKGRNLDLSRGLILGAEAWGRGVKNT 90

RESULT 25

ABU81684  
 ID ABU81684 standard; protein; 90 AA.

XX AC ABU81684;

XX DT 24-JUN-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; gene therapy; PRO; PRO943;

XX KW PRO183; PRO184; PRO185; PRO331; PRO1133; PRO363; PRO5723; PRO1387;

XX KW PRO114; PRO3301; PRO9940; PRO1181; PRO170; PRO361; PRO846;

XX KW bioactive molecule; toxin; radiolabel; antibody; cell death; cancer;

XX KW autoimmune disease; chromosome mapping; gene mapping; transgenic animal;

XX KW knockout animal; septic shock.

XX OS Homo sapiens.

XX PN US2002177164-A1.

XX PD 28-NOV-2002.

XX PF 20-NOV-2001; 2001US-00989293.

XX PR 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 24-NOV-1997; 97US-0066770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087106P.

XX PR 02-JUN-1998; 98US-0087607P.

XX PR 02-JUN-1998; 98US-0087609P.

XX PR 02-JUN-1998; 98US-0087759P.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 04-JUN-1998; 98US-0088021P.

XX PR 04-JUN-1998; 98US-0088025P.

XX PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.  
 PR 04-JUN-1998; 98US-0088029P.  
 PR 04-JUN-1998; 98US-0088030P.  
 PR 04-JUN-1998; 98US-0088033P.  
 PR 04-JUN-1998; 98US-0088326P.  
 PR 05-JUN-1998; 98US-0088167P.  
 PR 05-JUN-1998; 98US-0088202P.  
 PR 05-JUN-1998; 98US-0088212P.  
 PR 05-JUN-1998; 98US-0088217P.  
 PR 05-JUN-1998; 98US-0088555P.  
 PR 10-JUN-1998; 98US-0088734P.  
 PR 10-JUN-1998; 98US-0088738P.  
 PR 10-JUN-1998; 98US-0088742P.  
 PR 10-JUN-1998; 98US-0088910P.  
 PR 10-JUN-1998; 98US-0088924P.  
 PR 10-JUN-1998; 98US-0088926P.  
 PR 11-JUN-1998; 98US-0088858P.  
 PR 11-JUN-1998; 98US-0088861P.  
 PR 11-JUN-1998; 98US-0088876P.  
 PR 12-JUN-1998; 98US-0089105P.  
 PR 16-JUN-1998; 98US-0089440P.  
 PR 16-JUN-1998; 98US-0089512P.  
 PR 16-JUN-1998; 98US-0089514P.  
 PR 17-JUN-1998; 98US-0089532P.  
 PR 17-JUN-1998; 98US-0089538P.  
 PR 17-JUN-1998; 98US-0089598P.  
 PR 17-JUN-1998; 98US-0089599P.  
 PR 17-JUN-1998; 98US-0089600P.  
 PR 17-JUN-1998; 98US-0089653P.  
 PR 18-JUN-1998; 98US-0089801P.  
 PR 18-JUN-1998; 98US-0089907P.  
 PR 18-JUN-1998; 98US-0089908P.  
 PR 18-JUN-1998; 98US-00919330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 08-DEC-1998; 98WO-US025108.  
 PR 08-MAR-1999; 99WO-US000106.  
 PR 02-JUN-1999; 99WO-US005028.  
 PR 15-SEP-1999; 99WO-US012252.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 30-NOV-1999; 99WO-US021547.  
 PR 01-DEC-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 16-DEC-1999; 99WO-US028634.  
 PR 20-DEC-1999; 99WO-US030095.  
 PR 05-JAN-2000; 99WO-US030911.  
 PR 06-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US000376.  
 PR 18-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 15-MAY-2000; 2000WO-US013358.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.  
 PR 28-AUG-2001; 2001US-00941992.  
 XX (GETH ) GENENTECH INC.  
 XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
 PI Ferrera N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski EJ;  
 PI Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;  
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
 PI Zhang Z;  
 XX WPI: 2003-328481/31.  
 DR N-PSDB; ACA68006.  
 XX  
 PT New secreted and transmembrane polypeptide, useful for modulating  
 PT biological activity of cell expressing the polypeptide, for identifying  
 PT agonists or antagonists of polypeptide, and as molecular weight markers.  
 XX  
 PS Claim 12; Fig 272; 654pp; English.  
 XX  
 CC The invention describes an isolated, secreted and transmembrane  
 CC polypeptide (I), termed PRO polypeptide. (I) is useful for detecting  
 CC PRO943, PRO183, PRO184, PRO185, PRO331, PRO1133, PRO363, PRO5723,  
 CC PRO1387, PRO1114, PRO3301, PRO9940, PRO1181, PRO71170, PRO361 or PRO846  
 CC polypeptide comprising contacting the sample with the polypeptide and  
 CC determining formation of a polypeptide conjugate. (I) is also useful for  
 CC linking a bioactive molecule e.g. toxin, radiolabel or antibody, to a  
 CC cell expressing the above polypeptides to cause cell death. (I) is also  
 CC useful as a therapeutic agent e.g. for treating cancer and autoimmune  
 CC disease. PRO is useful in assays to identify other proteins or molecules  
 CC involved in binding interactions. The polynucleotide (II) encoding (I) is  
 CC useful in chromosome and gene mapping, for generating transgenic animals  
 CC or knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, for the genetic analysis of  
 CC individuals with genetic disorders, in gene therapy, for chromosome  
 CC identification, and as a chromosome marker. An anti-(I)-antibody is  
 CC useful in diagnostic assays for PRO, e.g. detecting its expression in  
 CC specific cells, tissues or serum, for affinity purification of PRO, and  
 CC for treating septic shock. This is the amino acid sequence of a novel  
 CC human secreted and transmembrane PRO polypeptide  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. NO. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFPLSLLLLVCEAIWRNSGNTLLENGYFLSRNKHHSQPTQSSLEDSVTPTKAVKTT 60  
 DB 1 MTFPLSLLLLVCEAIWRNSGNTLLENGYFLSRNKHHSQPTQSSLEDSVTPTKAVKTT 60  
 QY 61 GKGVKGRNLDRLGLILGAEGAWGRVKKNT 90  
 DB 61 GKGVKGRNLDRLGLILGAEGAWGRVKKNT 90  
 RESULT 26  
 ABUS8623  
 ID ABUS8623 standard; protein; 90 AA.  
 XX AC ABUS8623;  
 XX  
 DT 11-AUG-2003 (first entry)  
 XX  
 DE Human secreted and transmembrane polypeptide PRO1159.  
 XX Human; gene therapy; cancer; retinal disorder; wound healing;  
 KW kidney disorder.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002197615-A1.  
 XX

```
PD 26-DEC-2002.
XX 16-NOV-2001; 2001US-00991181.
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US000431.
PR 22-FEB-2000; 2000WO-US000414.

PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX (GETH ) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gertsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Garney AL, Kljavin IJ, Napier MA, Pan J, Paoni NP;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX WPI; 2003-370792/35.
DR N-PSDB; ACA88455.
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for the preparation of a medicament for treating a
PT condition that is responsive to the PRO polypeptide. e.g., cancer.
XX Claim 12; Fig 272; 647pp; English.
XX The invention relates to an isolated nucleic acid encoding a PRO
XX polypeptide. The polypeptide, agonist, antagonist and antibody are useful
CC for the preparation of a medicament for treating a condition that is
CC responsive to the PRO polypeptide. The nucleotide sequence is useful in
CC molecular biology including being used as hybridisation probes, in
CC chromosome and gene mapping and in the generation of anti-sense RNA and
CC DNA. The PRO polypeptides can also be used in the treatment of e.g.
CC cancer, retinal disorders, wound healing and kidney disorders. The
CC present sequence represents the amino acid sequence of a human secreted
CC and transmembrane PRO polypeptide of the present invention. Note: The
CC sequence data for this patent did not form part of the printed
CC specification but was obtained in electronic format directly from USPTO
CC at seqdata.uspto.gov/sequence.html?DocID=20020197615
XX Sequence 90 AA;
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLLVCEAIWRSNCSGNTLENGYFYSRNKENHSQPTQSLSDESVPTKAVKTT 60
DB 1 MTFFLSLLLLLVCEAIWRSNCSGNTLENGYFYSRNKENHSQPTQSLSDESVPTKAVKTT 60
QY 61 GKGIYKGRNLDGRGLILGAEAWGRGVKNT 90
DB 61 GKGIYKGRNLDGRGLILGAEAWGRGVKNT 90
RESULT 27
AB034137
```

ID ABO34137 standard; protein; 90 AA.  
XX AC ABO34137;  
XX DT 19-SEP-2003 (first entry)  
XX DE Human PRO1159 polypeptide.  
XX DE Human; PRO polypeptide; secreted protein; transmembrane protein;  
KW biosensor; bioindicator; tumour; cancer; diabetes; ALS; ulcer;  
KW rheumatoid arthritis; amyotrophic lateral sclerosis; cytostatic;  
KW antidiabetic; antiarthritic; antirheumatic; antiulcer.  
XX OS Homo sapiens.  
XX PN US2003017981-A1.  
XX PD 23-JAN-2003.  
XX PF 20-NOV-2001; 2001US-00989728.  
XX PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 10-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 12-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089593P.  
PR 17-JUN-1998; 98US-0089593P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089949P.  
PR 19-JUN-1998; 98US-0089950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-009057P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 30-JUL-1998; 98US-009339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 12-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.

RESULT 28  
ADA45993  
ID ADA45993 standard; protein; 90 AA.  
XX  
AC ADA45993;

PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006566.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-0086028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 03-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 18-JUL-2001; 2001WO-US021735.  
 PR 06-AUG-2001; 2001US-00908827.  
 PR 16-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 DR WPI; 2003-584997/55.  
 DR N-PSDB; ADA5992.

XX Novel secreted and transmembrane polypeptide for modulating biological  
 PT activity of cell expressing the polypeptide, identifying agonists or  
 PT antagonists of polypeptide, and as molecular weight markers.

XX Claim 12; Fig 474; 659pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from PBMC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This is the amino  
 CC acid sequence of a novel human secreted and transmembrane PRO  
 CC polypeptide.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNCSNTLENGYFLSRNKNHNSQPTQSLSDSVPTTKAVKT 60

Db 1 MTFFLSLLLLVCEAIWRSNCSNTLENGYFLSRNKNHNSQPTQSLSDSVPTTKAVKT 60

QY 61 GKGIYKGRNLDGRLLILGAEAWGRGVKNT 90

Db 61 GKGIYKGRNLDGRLLILGAEAWGRGVKNT 90

RESULT 29

ADA76424

ID ADA76424 standard; protein; 90 AA.

XX ADA76424;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; FFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; T-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

XX Homo sapiens.

OS US2003073212-A1.

XX 17-APR-2003.

XX 16-APR-2002; 2002US-00123903.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.



PR 15-SEP-1998; 98WO-US013330.  
PR 17-SEP-1998; 98WO-US013437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 28-OCT-1998; 98WO-US022991.  
PR 28-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 22-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006894.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015244.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001WO-US007066.  
PR 14-MAR-2001; 2001US-00808689.  
PR 14-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 23-JUN-2001; 2001WO-US021066.  
PR 03-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-687639/65.  
DR N-PSDB; ADA76423.  
XX  
XX New isolated nucleic acid encoding a secreted and transmembrane  
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and  
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.  
XX  
PS Claim 12; Fig 474; 659pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear uricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MTFFLSLLLLVCEAIWRSGNSNTLENGYFLSRKNKHNHSTOSSLEDSVTPTKAVKTT	60
Db	1	MTFFLSLLLLVCEAIWRSGNSNTLENGYFLSRKNKHNHSTOSSLEDSVTPTKAVKTT	60
Qy	61	GKGIYKGRNLDNRGLILGAERAGRGVKNT	90
Db	61	GKGIYKGRNLDNRGLILGAERAGRGVKNT	90
RESULT 30			
ADAL9074			
ID	ADAL9074	standard; protein; 90 AA.	
AC	ADAL9074;		
XX			
XX			
DT	20-NOV-2003	(first entry)	
DE		Human PRO polypeptide #237.	
XX			
KW		Human; PRO; secreted polypeptide; transmembrane polypeptide;	
KW		tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;	
KW		colon; breast; prostate; rectum; cervix; liver; tumour; cancer;	
KW		glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;	
KW		cartilage; inner ear utricular supporting cell; cytokine; A-peptide;	
KW		factor VIIA; endothelial cell.	
OS		Homo sapiens.	
XX			
PN	US2003054517-A1.		
PD			
PD	20-MAR-2003.		
XX			
PF	08-MAY-2002; 2002US-00141755.		
XX			
PR	31-MAR-1997;	97WO-US005230.	
PR	12-JUN-1998;	98WO-US012456.	
PR	14-JUL-1998;	98WO-US014552.	
PR	28-AUG-1998;	98WO-US017888.	
PR	10-SEP-1998;	98WO-US018824.	
PR	14-SEP-1998;	98WO-US019093.	
PR	14-SEP-1998;	98WO-US019094.	
PR	16-SEP-1998;	98WO-US019177.	
PR	17-SEP-1998;	98WO-US019330.	
PR	07-OCT-1998;	98WO-US019437.	
PR	29-OCT-1998;	98WO-US022991.	
PR	29-OCT-1998;	98WO-US022992.	
PR	20-NOV-1998;	98WO-US024855.	
PR	01-DEC-1998;	98WO-US025108.	
PR	05-JAN-1999;	99WO-US000106.	
PR	08-MAR-1999;	99WO-US005028.	
PR	20-APR-1999;	99WO-US008615.	
PR	14-MAY-1999;	99WO-US010733.	
PR	02-JUN-1999;	99WO-US012252.	
PR	01-SEP-1999;	99WO-US020111.	
PR	08-SEP-1999;	99WO-US020594.	
PR	13-SEP-1999;	99WO-US020944.	
PR	15-SEP-1999;	99WO-US021090.	
PR	15-SEP-1999;	99WO-US021547.	
PR	05-OCT-1999;	99WO-US023089.	
PR	29-NOV-1999;	99WO-US028214.	
PR	30-NOV-1999;	99WO-US028313.	
PR	30-NOV-1999;	99WO-US028409.	
PR	01-DEC-1999;	99WO-US028401.	
PR	01-DEC-1999;	99WO-US028634.	
PR	02-DEC-1999;	99WO-US028551.	
PR	02-DEC-1999;	99WO-US028551.	
PR	02-DEC-1999;	99WO-US028564.	
PR	16-DEC-1999;	99WO-US028565.	
PR	16-DEC-1999;	99WO-US030095.	
PR	20-DEC-1999;	99WO-US030911.	
PR	20-DEC-1999;	99WO-US030999.	

PR	22-DEC-1999;	99WO-US030720.
PR	30-DEC-1999;	99WO-US031243.
PR	30-DEC-1999;	99WO-US031274.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000277.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	18-FEB-2000;	2000WO-US004342.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005746.
PR	10-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001US-00796498.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	09-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00808689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00866028.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001WO-US019692.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00938827.
PR	06-AUG-2001;	2001US-00924419.
PR	09-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00028072.
XX		(GETH ) GENENTECH INC.
PA		
XX		
PI		Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI		Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI		Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX		WPI; 2003-521854/49.
DR		N-PSDB; ADAL9073.
XX		
XX		New PRO nucleic acid, useful for preparing a composition for treating
PT		e.g., tumors.

XX PS Claim 12; Fig 474; 660pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and

XX CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC CC invention also relates to an antibody which specifically binds to a PRO

CC CC polypeptide, a method for stimulating the release of tumour necrosis

CC CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC CC proliferation or differentiation of chondrocyte cells and a method for

CC CC detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,

CC CC prostate, rectal, cervical and liver tumours). The polynucleotides are

CC CC useful in molecular biology, including uses as hybridisation probes, in

CC CC chromosome and gene mapping, in generating antisense RNA and DNA and in

CC CC gene therapy. The polynucleotides may also be used in preparing PRO

CC CC polypeptides by recombinant techniques and in generating either

CC CC transgenic animals or knock-out animals which are useful in the

CC CC development and screening of therapeutically useful reagents. The PRO

CC CC polypeptides or antibodies are used in preparing a medicament for

CC CC treating a condition responsive to the polypeptides or antibodies, such

CC CC as tumours, for modulating the uptake of glucose or FFA by adipocyte

CC CC cells, for stimulating the proliferation of or gene expression in

CC CC pericyte cells, for stimulating the release of proteoglycans from

CC CC cartilage, for stimulating the proliferation of inner ear utricular

CC CC supporting cells, for stimulating the release of cytokines from PMEC

CC CC cells, for inhibiting the binding of A-peptide to factor VIIa, for

CC CC inhibiting the differentiation of adipocyte cells and for stimulating the

CC CC proliferation of endothelial cells. This sequence represents a human PRO

CC CC polypeptide of the invention. Note: The sequence data for this patent is

CC CC also available in electronic format from USFTO at

CC CC seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCAIWRNSGNTLENGYFLSRKNHNSQPTSSLEDSVTPTKAVKTT 60

Db 1 MTFPLSLLLLVCAIWRNSGNTLENGYFLSRKNHNSQPTSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90

RESULT 31

ADA61697

ID ADA61697 standard; protein; 90 AA.

XX AC ADA61697;

XX DT 20-NOV-2003 (first entry)

XX DE Homo sapiens.

XX KW Human; secreted and transmembrane protein; PRO;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; PFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX OS Novel.

OS human.

OS secreted.

OS and.

OS transmembrane.

OS protein.

OS PRO1159.

XX

PN XX US2003049816-A1.

XX PD 13-MAR-2003.

XX 15-APR-2002; 2002US-00123262..

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 23-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US0223089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.

PR 15-MAR-2000; 2000WO-US006894.

PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00806689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 03-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GENTH ) GENENTECH INC.

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-695892/66.

XX N-PSDB; ADA61696.

XX New PRO nucleic acid and encode polypeptides, are useful for  
PT manufacturing a medicament for diagnosing or treating cancer.

XX Claim 12; Fig 474; 660pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PMBC cells, for inhibiting the binding of  
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This is the amino  
CC acid sequence of a novel human secreted and transmembrane PRO  
CC polypeptide.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEALWRSNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Db 1 MTFFLSLLLLVCEALWRSNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90

Db 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 32

ADB19482

ID ADB19482 standard; protein; 90 AA.

XX AC ADB19482;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; PRO;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW Glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine releas.

XX OS Homo sapiens.

XX PN US2003069796-A1.

XX PD 10-APR-2003.

XX PF 15-APR-2002; 2002US-00123261.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 29-OCT-1998; 98WO-US022992.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 99WO-US000106.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 10-MAR-1999; 99WO-US005190.

XX PR 20-APR-1999; 99WO-US008615.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 08-SEP-1999; 99WO-US020594.

XX PR 13-SEP-1999; 99WO-US020944.

XX PR 15-SEP-1999; 99WO-US021090.

XX PR 15-SEP-1999; 99WO-US021547.

XX PR 05-OCT-1999; 99WO-US023089.

XX PR 29-NOV-1999; 99WO-US028214.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 30-NOV-1999; 99WO-US028409.

```

PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00815744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00892636.
PR 19-JUN-2001; 2001US-00896342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-765415/72.
DR N-PSDB; ADB28022.

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-695927/66.
DR N-PSDB; ADB19481.
XX Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX Claim 12; Fig 474; 660pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte
XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTOSSLEDSVTPKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTOSSLEDSVTPKAVKTT 60
QY 61 GKGIKGRNLDLSRGLILGAEAWGRGVKNT 90
DB 61 GKGIKGRNLDLSRGLILGAEAWGRGVKNT 90

RESULT 33
ADE28023
ID ADB28023 standard; protein; 90 AA.
XX AC ADB28023;
XX 20-NOV-2003 (first entry)
XX Human PRO polypeptide #237.
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003082704-A1.
XX 01-MAY-2003.
XX 24-APR-2002; 2002US-00131819.
XX 09-DEC-1999; 99US-01702622.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-765415/72.
DR N-PSDB; ADB28022.

```

XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.  
XX  
XX  
PS Claim 12; Fig 474; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.  
XX  
XX  
SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFLLSLLLLVCEATWRNSGNTLENGVFLSRNKNHNSQPTQSSLEDSVTPTKAVKTT 60  
DB 1 MTFLLSLLLLVCEATWRNSGNTLENGVFLSRNKNHNSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 GKGIKVRNLDRLGLILGAEGWGVKNT 90  
DB 61 GKGIKVRNLDRLGLILGAEGWGVKNT 90  
RESULT 34  
ADA86502  
ID ADA86502 standard; protein; 90 AA.  
XX  
XX ADA86502;  
XX  
XX 20-NOV-2003 (first entry)  
XX  
XX Novel human secreted and transmembrane protein PRO1159.  
XX  
XX Human; secreted and transmembrane protein; PRO;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.  
OS  
XX US2003082711-A1.  
PN  
XX  
XX  
PD 01-MAY-2003.  
XX  
XX 16-MAY-2002; 2002US-00147508.  
XX  
XX 02-JUL-1998; 98US-0091519P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 07-JUL-1999; 99US-0143048P.  
PR 25-AUG-1999; 99US-00380437.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI: 2003-786914/74.  
XX N-PSDB; ADA86501.  
XX  
XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.  
XX  
XX Claim 12; Fig 474; 637pp; English.  
XX  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PBM cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This is the amino  
CC acid sequence of a novel human secreted and transmembrane PRO  
CC polypeptide.  
XX  
XX Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFLLSLLLLVCEATWRNSGNTLENGVFLSRNKNHNSQPTQSSLEDSVTPTKAVKTT 60  
DB 1 MTFLLSLLLLVCEATWRNSGNTLENGVFLSRNKNHNSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 GKGIKVRNLDRLGLILGAEGWGVKNT 90

Db 61 GKGIVKGRNLDRLGLGAEAWGRGVKNT 90

RESULT 35  
ADBI6066  
ID ADBI6066 standard; protein; 90 AA.  
XX  
AC ADBI6066;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003087350-A1.  
XX  
PD 08-MAY-2003.  
XX  
PF 22-APR-2002; 2002US-00127821.  
XX  
PR 04-AUG-1998; 98US-0095301P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 25-AUG-1999; 99US-00380137.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CX, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-786941/74.  
DR N-PSDB; ADBI6065.  
XX  
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,  
PT and for manufacturing a medicament for diagnosing or treating tumor.  
XX  
PS Claim 12; Fig 474; 637pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems. PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFFLSLLLLLVCEAIWRNSGNTLNGYFLSRKNKHHSQPTQSSLEDSVTPKAVKTT 60  
DB 1 MTFFLSLLLLLVCEAIWRNSGNTLNGYFLSRKNKHHSQPTQSSLEDSVTPKAVKTT 60  
QY 61 GKGIVKGRNLDRLGLGAEAWGRGVKNT 90  
DB 61 GKGIVKGRNLDRLGLGAEAWGRGVKNT 90  
RESULT 36  
ADA37888  
ID ADA37888 standard; protein; 90 AA.  
XX  
AC ADA37888;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein PRO1159.  
XX  
KW PRO; secreted protein; transmembrane protein;  
KW hypertrophy of neonatal heart; angiogenesis;  
KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
KW c-fos induction; adipocyte cell; chondrocyte differentiation;  
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;  
KW cancer; human; colon cancer; lung cancer; breast cancer;  
KW rod photoreceptor cell.  
XX  
OS Homo sapiens.  
XX  
PN US2003008297-A1.  
XX  
PD 09-JAN-2003.  
XX  
PF 15-NOV-2001; 2001US-00997653.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0086770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087593P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.  
 PR 04-JUN-1998; 98US-0088028P.  
 PR 04-JUN-1998; 98US-0088029P.  
 PR 04-JUN-1998; 98US-0088030P.  
 PR 04-JUN-1998; 98US-0088033P.  
 PR 04-JUN-1998; 98US-0088326P.  
 PR 05-JUN-1998; 98US-0088167P.  
 PR 05-JUN-1998; 98US-0088202P.  
 PR 05-JUN-1998; 98US-0088212P.  
 PR 05-JUN-1998; 98US-0088217P.  
 PR 09-JUN-1998; 98US-0088655P.  
 PR 10-JUN-1998; 98US-0088734P.  
 PR 10-JUN-1998; 98US-0088738P.  
 PR 10-JUN-1998; 98US-0088742P.  
 PR 10-JUN-1998; 98US-0089810P.  
 PR 10-JUN-1998; 98US-00888224P.  
 PR 10-JUN-1998; 98US-0088826P.  
 PR 11-JUN-1998; 98US-0088858P.  
 PR 11-JUN-1998; 98US-0088861P.  
 PR 11-JUN-1998; 98US-0088876P.  
 PR 12-JUN-1998; 98US-0089105P.  
 PR 16-JUN-1998; 98US-0089440P.  
 PR 16-JUN-1998; 98US-0089512P.  
 PR 16-JUN-1998; 98US-0089514P.  
 PR 17-JUN-1998; 98US-0089532P.  
 PR 17-JUN-1998; 98US-0089538P.  
 PR 17-JUN-1998; 98US-0089588P.  
 PR 17-JUN-1998; 98US-0089599P.  
 PR 17-JUN-1998; 98US-0089600P.  
 PR 17-JUN-1998; 98US-0089653P.  
 PR 18-JUN-1998; 98US-0089801P.  
 PR 18-JUN-1998; 98US-0089807P.  
 PR 18-JUN-1998; 98US-0089908P.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 17-OCT-1998; 98WO-US021141.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 28-DEC-1999; 99WO-US030911.  
 PR 03-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 15-MAY-2000; 2000WO-US013358.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 20-JUN-2001; 2001WO-US019692.

PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 28-AUG-2001; 2001US-00941992.  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
 PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WT;  
 PI Zhang Z;  
 XX  
 XX WPI; 2003-531419/50.  
 DR DR N-PSDB; ADA37887.  
 XX  
 PT New isolated PRO183, PRO184, PRO361 or PRO846 nucleic acid and secreted  
 PT transmembrane polypeptides, useful as targets for the diagnosis and  
 PT treatment of cancers, such as lung and breast cancers.  
 XX  
 PS Claim 12; Fig 272; 660pp; English.

CC The invention relates to an isolated nucleic acid molecule comprising the  
 CC full-length coding sequence of the DNA ATCC Accession Numbers given in  
 CC the specification, or comprising a sequence with at least 80% identity  
 CC to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an  
 CC extracellular domain of the polypeptide; or (b) any of 147 nucleotide  
 CC sequences fully defined in the specification. Also included are the PRO  
 CC proteins (or their extracellular domains) with or without their associated  
 CC extracellular domains), expression vectors, host cells, PRO chimaeric  
 CC proteins, anti-PRO antibodies, methods of detecting polypeptide in a  
 CC sample, methods of linking a bioactive molecule to a cell expressing a  
 CC polypeptide and methods of modulating at least one biological activity of  
 CC a cell expressing the polypeptide. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, promoting angiogenesis, inhibiting vascular endothelial growth  
 CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating  
 CC the proliferation of stimulated T-lymphocytes, enhancing the survival or  
 CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-  
 CC fos in endothelial cells, modulating glucose or FFA uptake by adipocyte  
 CC cells, inducing proliferation and/or re-differentiation of chondrocytes,  
 CC or inducing pancreatic beta-cell precursor differentiation. In  
 CC particular, these are useful for detecting or treating tumours and  
 CC certain cancers (colon, lung or breast cancers) in mammals, e.g. humans,  
 CC dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes  
 CC may also be used in gene therapy, particularly for replacing a defective  
 CC gene. The present sequence represents a PRO protein.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. NO. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLILLVCEATWRSGSNTLENGYFSLRNKENHSQPTOSLSDSVTPKAVKTT 60  
 DB 1 MTFELSLILLVCEATWRSGSNTLENGYFSLRNKENHSQPTOSLSDSVTPKAVKTT 60  
 QY 61 GKGVKGRNLDRLGLILGAEWGRGVKKNT 90  
 DB 61 GKGVKGRNLDRLGLILGAEWGRGVKKNT 90

RESULT 37  
 ADA47852

ID ADA47852 standard; protein; 90 AA.

XX ADA47852;

XX 20-NOV-2003 (first entry)

DE Human PRO polypeptide #237.

XX



KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
FN US2003073215-A1.  
XX  
PD 17-APR-2003.  
XX  
PF 07-MAY-2002; 2002US-00140925.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022992.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98WO-US005190.  
PR 20-APR-1999; 98WO-US008615.  
PR 14-MAY-1999; 98WO-US010733.  
PR 02-JUN-1999; 98WO-US012252.  
PR 01-SEP-1999; 98WO-US020111.  
PR 08-SEP-1999; 98WO-US020594.  
PR 13-SEP-1999; 98WO-US020944.  
PR 15-SEP-1999; 98WO-US021090.  
PR 15-SEP-1999; 98WO-US021547.  
PR 05-OCT-1999; 98WO-US023089.  
PR 29-NOV-1999; 98WO-US028214.  
PR 30-NOV-1999; 98WO-US028313.  
PR 30-NOV-1999; 98WO-US028409.  
PR 01-DEC-1999; 98WO-US028301.  
PR 01-DEC-1999; 98WO-US028634.  
PR 02-DEC-1999; 98WO-US028551.  
PR 02-DEC-1999; 98WO-US028564.  
PR 02-DEC-1999; 98WO-US028565.  
PR 16-DEC-1999; 98WO-US030095.  
PR 20-DEC-1999; 98WO-US030911.  
PR 20-DEC-1999; 98WO-US030999.  
PR 22-DEC-1999; 98WO-US030720.  
PR 30-DEC-1999; 98WO-US031243.  
PR 30-DEC-1999; 98WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-644801/61.  
XX N-PSDB; ADA47851.  
DR  
XX  
XX  
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
PT in gene therapy, detecting the presence of tumor in a mammal, or  
PT modulating the uptake of glucose or free fatty acid by skeletal muscle  
XX cells or adipocyte cells.  
PS Claim 12; Fig 474; 659pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQTSLEDVPTKAVKTT 60

Db 1 MTFSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQTSLEDVPTKAVKTT 60

QY 61 GKGVGRNLDRLGLGAEAWGRGVKKNT 90

Db 61 GKGVGRNLDRLGLGAEAWGRGVKKNT 90

RESULT 38

ADA21574

ID ADA21574 standard; protein; 90 AA.

XX ADA21574;

AC ADA21574;

XX 20-NOV-2003 (first entry)

DT 20-NOV-2003 (first entry)

XX Human secreted/transmembrane polypeptide PRO1159.

XX human; tumour; cancer; colorectal cancer; gene therapy;

KW chondrocyte differentiation; VEGF inhibition;

KW vascular endothelial growth factor; Alzheimer's disease;

KW Parkinson's disease; atherosclerosis; cystic fibrosis;

KW multiple sclerosis; ovarian cancer; tissue typing.

XX Homo sapiens.

OS Homo sapiens.

XX US2003054404-A1.

PN 20-MAR-2003.

XX 15-NOV-2001; 2001US-00997601.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065166P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 28-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089632P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 18-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.

02-JUL-1998; 98US-0091673P.  
07-JUL-1998; 98US-0091978P.  
07-JUL-1998; 98US-0091982P.  
09-JUL-1998; 98US-0092182P.  
10-JUL-1998; 98US-0092472P.  
20-JUL-1998; 98US-0093339P.  
30-JUL-1998; 98US-0094651P.  
04-AUG-1998; 98US-0095282P.  
04-AUG-1998; 98US-0095285P.  
04-AUG-1998; 98US-0095301P.  
04-AUG-1998; 98US-0095302P.  
04-AUG-1998; 98US-0095318P.  
04-AUG-1998; 98US-0095321P.  
04-AUG-1998; 98US-0095325P.  
10-AUG-1998; 98US-0095916P.  
10-AUG-1998; 98US-0095929P.  
10-AUG-1998; 98US-0096012P.  
11-AUG-1998; 98US-0096143P.  
11-AUG-1998; 98US-0096146P.  
12-AUG-1998; 98US-0096329P.  
17-AUG-1998; 98US-0096575P.  
17-AUG-1998; 98US-0096766P.  
17-AUG-1998; 98US-0096769P.  
17-AUG-1998; 98US-0096773P.  
17-AUG-1998; 98US-0096791P.  
17-AUG-1998; 98US-0096867P.  
17-AUG-1998; 98US-0096891P.  
17-AUG-1998; 98US-0096894P.  
17-AUG-1998; 98US-0096895P.  
17-AUG-1998; 98US-0096897P.  
18-AUG-1998; 98US-0096949P.  
18-AUG-1998; 98US-0096950P.  
18-AUG-1998; 98US-0096959P.  
18-AUG-1998; 98US-0096960P.  
18-AUG-1998; 98US-0097022P.  
19-AUG-1998; 98US-0097141P.  
20-AUG-1998; 98US-0097218P.  
24-AUG-1998; 98US-0097661P.  
26-AUG-1998; 98US-0097952P.  
26-AUG-1998; 98US-0097954P.  
26-AUG-1998; 98US-0097955P.  
26-AUG-1998; 98US-0097971P.  
26-AUG-1998; 98US-0097974P.  
26-AUG-1998; 98US-0097978P.  
26-AUG-1998; 98US-0097979P.  
26-AUG-1998; 98US-0097986P.  
26-AUG-1998; 98US-0098014P.  
31-AUG-1998; 98US-0098525P.  
16-SEP-1998; 98US-0100634P.  
16-SEP-1998; 98WO-US019330.  
17-SEP-1998; 98US-0100858P.  
17-SEP-1998; 98WO-US019437.  
01-OCT-1998; 98WO-US021141.  
01-DEC-1998; 98WO-US025108.  
22-DEC-1998; 98US-0113296P.  
05-JAN-1999; 98WO-US000106.  
08-MAR-1999; 98WO-US005028.  
12-MAR-1999; 98US-0123957P.  
02-JUN-1999; 98WO-US012252.  
23-JUN-1999; 98US-0141037P.  
07-JUL-1999; 98US-0143048P.  
20-JUL-1999; 98US-0144758P.  
26-JUL-1999; 98US-0145698P.  
28-JUL-1999; 98US-0146222P.  
17-AUG-1999; 98US-0149396P.  
15-SEP-1999; 98WO-US021090.  
15-SEP-1999; 98WO-US021547.  
08-OCT-1999; 98US-0158663P.  
30-NOV-1999; 98WO-US028313.  
01-DEC-1999; 98WO-US028301.  
01-DEC-1999; 98WO-US028634.  
16-DEC-1999; 98WO-US030095.  
20-DEC-1999; 98WO-US030911.

05-JAN-2000; 2000WO-US000219.  
06-JAN-2000; 2000WO-US000376.  
11-FEB-2000; 2000WO-US003565.  
18-FEB-2000; 2000WO-US004341.  
22-FEB-2000; 2000WO-US004414.  
24-FEB-2000; 2000WO-US004914.  
24-FEB-2000; 2000WO-US005004.  
02-MAR-2000; 2000WO-US005841.  
10-MAR-2000; 2000WO-US006319.  
15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
30-MAR-2000; 2000WO-US008439.  
15-MAY-2000; 2000WO-US013358.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015264.  
23-JUN-2000; 2000US-0213637P.  
28-JUL-2000; 2000WO-US020710.  
11-AUG-2000; 2000WO-US022031.  
23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNCSNTLENGYFLSRKNHNSOPTQSSLEDSVTPTKAVKTT 60  
|||||  
DB 1 MTFFLSLLLLVCEAIWRSNCSNTLENGYFLSRKNHNSOPTQSSLEDSVTPTKAVKTT 60  
|||||

QY 61 GKGVKGRNLDNRGLILGAEAMRGVKKNT 90  
|||||  
DB 61 GKGVKGRNLDNRGLILGAEAMRGVKKNT 90  
|||||

RESULT 39  
ADA10361  
ID ADA10361 standard; protein; 90 AA.  
XX  
AC ADA10361;  
XX  
XX  
DT 06-NOV-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein, Prol159.  
XX PRO; secreted protein; transmembrane protein; human; septic shock;  
KW immunogen.  
KW  
XX  
XX Homo sapiens.  
XX  
PN US2003059831-A1.  
XX  
XX  
PD 27-MAR-2003.  
XX  
XX 19-NOV-2001; 2001US-00989729.  
XX  
XX 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.

02-JUL-1998; 98US-0091673P.  
07-JUL-1998; 98US-0091978P.  
07-JUL-1998; 98US-0091982P.  
09-JUL-1998; 98US-0092182P.  
10-JUL-1998; 98US-0092472P.  
20-JUL-1998; 98US-0093339P.  
30-JUL-1998; 98US-0094651P.  
04-AUG-1998; 98US-0095282P.  
04-AUG-1998; 98US-0095285P.  
04-AUG-1998; 98US-0095301P.  
04-AUG-1998; 98US-0095302P.  
04-AUG-1998; 98US-0095318P.  
04-AUG-1998; 98US-0095321P.  
04-AUG-1998; 98US-0095325P.  
10-AUG-1998; 98US-0095916P.  
10-AUG-1998; 98US-0095929P.  
10-AUG-1998; 98US-0096012P.  
11-AUG-1998; 98US-0096143P.  
11-AUG-1998; 98US-0096146P.  
12-AUG-1998; 98US-0096329P.  
17-AUG-1998; 98US-0096575P.  
17-AUG-1998; 98US-0096766P.  
17-AUG-1998; 98US-0096769P.  
17-AUG-1998; 98US-0096773P.  
17-AUG-1998; 98US-0096791P.  
17-AUG-1998; 98US-0096867P.  
17-AUG-1998; 98US-0096891P.  
17-AUG-1998; 98US-0096894P.  
17-AUG-1998; 98US-0096895P.  
17-AUG-1998; 98US-0096897P.  
18-AUG-1998; 98US-0096949P.  
18-AUG-1998; 98US-0096950P.  
18-AUG-1998; 98US-0096959P.  
18-AUG-1998; 98US-0096960P.  
18-AUG-1998; 98US-0097022P.  
19-AUG-1998; 98US-0097141P.  
20-AUG-1998; 98US-0097218P.  
24-AUG-1998; 98US-0097661P.  
26-AUG-1998; 98US-0097952P.  
26-AUG-1998; 98US-0097954P.  
26-AUG-1998; 98US-0097955P.  
26-AUG-1998; 98US-0097971P.  
26-AUG-1998; 98US-0097974P.  
26-AUG-1998; 98US-0097978P.  
26-AUG-1998; 98US-0097979P.  
26-AUG-1998; 98US-0097986P.  
26-AUG-1998; 98US-0098014P.  
31-AUG-1998; 98US-0098525P.  
16-SEP-1998; 98US-0100634P.  
16-SEP-1998; 98WO-US019330.  
17-SEP-1998; 98US-0100858P.  
17-SEP-1998; 98WO-US019437.  
01-OCT-1998; 98WO-US021141.  
01-DEC-1998; 98WO-US025108.  
22-DEC-1998; 98US-0113296P.  
05-JAN-1999; 98WO-US000106.  
08-MAR-1999; 98WO-US005028.  
12-MAR-1999; 98US-0123957P.  
02-JUN-1999; 98WO-US012252.  
23-JUN-1999; 98US-0141037P.  
07-JUL-1999; 98US-0143048P.  
20-JUL-1999; 98US-0144758P.  
26-JUL-1999; 98US-0145698P.  
28-JUL-1999; 98US-0146222P.  
17-AUG-1999; 98US-0149396P.  
15-SEP-1999; 98WO-US021090.  
15-SEP-1999; 98WO-US021547.  
08-OCT-1999; 98US-0158663P.  
30-NOV-1999; 98WO-US028313.  
01-DEC-1999; 98WO-US028301.  
01-DEC-1999; 98WO-US028634.  
16-DEC-1999; 98WO-US030095.  
20-DEC-1999; 98WO-US030911.

05-JAN-2000; 2000WO-US000219.  
06-JAN-2000; 2000WO-US000376.  
11-FEB-2000; 2000WO-US003565.  
18-FEB-2000; 2000WO-US004341.  
22-FEB-2000; 2000WO-US004414.  
24-FEB-2000; 2000WO-US004914.  
24-FEB-2000; 2000WO-US005004.  
02-MAR-2000; 2000WO-US005841.  
10-MAR-2000; 2000WO-US006319.  
15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
30-MAR-2000; 2000WO-US008439.  
15-MAY-2000; 2000WO-US013358.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015264.  
23-JUN-2000; 2000US-0213637P.  
28-JUL-2000; 2000WO-US020710.  
11-AUG-2000; 2000WO-US022031.  
23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSOPTQSSLEDSVTPTKAVKTT 60  
|||||  
DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSOPTQSSLEDSVTPTKAVKTT 60  
|||||

QY 61 GKGIKGRNLDNRGLILGAEAMRGVKKNT 90  
|||||  
DB 61 GKGIKGRNLDNRGLILGAEAMRGVKKNT 90  
|||||

RESULT 39  
ADA10361  
ID ADA10361 standard; protein; 90 AA.  
XX  
AC ADA10361;  
XX  
XX  
DT 06-NOV-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein, Prol159.  
XX PRO; secreted protein; transmembrane protein; human; septic shock;  
KW immunogen.  
KW  
XX  
XX Homo sapiens.  
XX  
PN US2003059831-A1.  
XX  
PD 27-MAR-2003.  
XX  
XX 19-NOV-2001; 2001US-00989729.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.



```
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFELSLLLLVCEAIWRNSGSGNTLENGYFLSRNKHNSQPTOSSLEDVTPTKAVKTT 60
Db 1 MTFELSLLLLVCEAIWRNSGSGNTLENGYFLSRNKHNSQPTOSSLEDVTPTKAVKTT 60

Qy 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90
Db 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90

RESULT 40
ADA67647
ID ADA67647 standard; protein; 90 AA.
AC AC
XX AC
XX ADA67647;
DT 20-NOV-2003 (first entry)
DE Human PRO polypeptide #237.
DE Human; PRO: secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS
XX Homo sapiens.
XX US2003068795-A1.
XX PN
XX 10-APR-2003.
XX FD
XX 15-APR-2002; 2002US-00123236.
XX PF
XX 31-MAR-1997; 97WO-US005030.
XX PR 12-JUN-1998; 98WO-US012456.
XX PR 14-JUL-1998; 98WO-US014552.
XX PR 28-AUG-1998; 98WO-US017888.
XX PR 10-SEP-1998; 98WO-US018824.
XX PR 14-SEP-1998; 98WO-US019093.
XX PR 14-SEP-1998; 98WO-US019094.
XX PR 14-SEP-1998; 98WO-US019177.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 17-SEP-1998; 98WO-US019437.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022392.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020344.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
```

PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX

DR WPI; 2003-695926/66.

DR N-PSDB; ADA67646.

XX Novel isolated PRO secreted and transmembrane polypeptides useful for  
 PT stimulating the release of tumor necrosis factor-alpha from human blood  
 PT and detecting the presence of a tumor in a mammal.

XX Claim 12; Fig 474; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumor necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLILVCAIWRNSGSGTLENGYFLSRNKENHSQPTSSLEDSVTPTKAVKTT 60  
 Db 1 MTFPLSLLLILVCAIWRNSGSGTLENGYFLSRNKENHSQPTSSLEDSVTPTKAVKTT 60

Qy 61 GKGIKVRNLDLSRGLILGAEAWGKVKONT 90  
 Db 61 GKGIKVRNLDLSRGLILGAEAWGKVKONT 90

# RESULT 41

ADB30654  
 ID ADB30654 standard; protein; 90 AA.

XX AC ADB30654;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX Human PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

OS Homo sapiens.

XX US2003068794-A1.

XX PD 10-APR-2003.

XX PF 15-APR-2002; 2002US-00123155.

XX PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 16-SEP-1998; 98WO-US019177.  
 PR 17-SEP-1998; 98WO-US019330.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 08-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 23-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028401.  
 PR 02-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 11-FEB-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US020231.  
 PR 23-AUG-2000; 2000WO-US023528.  
 PR 24-AUG-2000; 2000WO-US023322.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00806889.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017032.  
 PR 01-JUN-2001; 2001WO-US017032.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019632.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 PA (GETH) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood MT, Zhang Z;  
 XX WPI; 2003-708391/67.  
 DR N-PSDB; ADB30653.  
 XX New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the  
 PT preparation of a medicament for treating a condition responsive to PRO

PT polypeptide, and as therapeutic agents e.g. vaccines.  
 XX Claim 12; Fig 474; 660pp; English.  
 FS The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC the proliferation of or gene expression in pericyte cells, for stimulating  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC the USPTO website at seqdata.uspto.gov.  
 XX Sequence 90 AA;  
 SQ

Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPSLLILLVCEAIWRNSGSGNTLENGFLSRKNHNSOPTOSLSDSVTPKAVKTT 60  
 DB 1 MTFPSLLILLVCEAIWRNSGSGNTLENGFLSRKNHNSOPTOSLSDSVTPKAVKTT 60  
 QY 61 GKGIVKGRNLDNRGLIIGAEAWGRGVKNT 90  
 DB 61 GKGIVKGRNLDNRGLIIGAEAWGRGVKNT 90

RESULT 42  
 ADA85950  
 ID ADA85950 standard; protein; 90 AA.  
 XX ADA85950;  
 AC ADA85950;  
 XX 20-NOV-2003 (first entry)  
 DT 20-NOV-2003 (first entry)  
 XX Novel human secreted and transmembrane protein PRO1159.  
 DE Human; secreted and transmembrane protein; PRO;  
 XX Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX Homo sapiens.

XX US2003082693-A1.  
 XX PD 01-MAY-2003.  
 XX PF 22-APR-2002; 2002US-00127843.  
 XX PR 05-JUN-2000; 2000US-0209832P.  
 XX PR 01-DEC-2000; 2000WO-US032678.  
 XX PR 19-DEC-2001; 2001US-00028072.  
 XX PA (GETH ) GENENTECH INC.  
 XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX DR WPI; 2003-786907/74.  
 XX DR N-PSDB; ADA85949.  
 XX PT New PRO nucleic acid, useful for preparing a composition for treating  
 PT e.g., tumor or for tissue typing.  
 XX PS Claim 12; Fig 474; 637pp; English.  
 XX CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of or gene expression in pericyte  
 CC cells, for stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from PMMC cells, for inhibiting the binding of  
 CC A-peptide to factor VITR, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This is the amino  
 CC acid sequence of a novel human secreted and transmembrane PRO  
 XX polypeptide.  
 XX SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLGRNKNHSPQTSSEDSVTTKAVKTT 60  
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLGRNKNHSPQTSSEDSVTTKAVKTT 60  
 QY 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90  
 Db 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90  
 RESULT 43  
 ADA17905  
 ID ADA17905 standard; protein; 90 AA.

XX AC ADA17905;  
 XX DT 20-NOV-2003 (first entry)  
 XX DE Human PRO1159 polypeptide.  
 XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;  
 XX KW transgenic; tumour; cytosstatic.  
 XX OS Homo sapiens.  
 XX EN US2003054987-A1.  
 XX PD 20-MAR-2003.  
 XX PF 14-NOV-2001; 2001US-00990443.  
 XX PR 16-JUN-1997; 97US-0049787P.  
 PR 17-OCT-1997; 97US-0062250P.  
 PR 05-NOV-1997; 97WO-US020069.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 13-NOV-1997; 97US-0065311P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 25-FEB-1998; 98US-0075945P.  
 PR 20-MAR-1998; 98US-0078910P.  
 PR 28-APR-1998; 98US-0083322P.  
 PR 07-MAY-1998; 98US-0084600P.  
 PR 28-MAY-1998; 98US-0087106P.  
 PR 02-JUN-1998; 98US-0087607P.  
 PR 02-JUN-1998; 98US-0087609P.  
 PR 03-JUN-1998; 98US-0087759P.  
 PR 03-JUN-1998; 98US-0087827P.  
 PR 04-JUN-1998; 98US-0088021P.  
 PR 04-JUN-1998; 98US-0088025P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 04-JUN-1998; 98US-0088028P.  
 PR 04-JUN-1998; 98US-0088029P.  
 PR 04-JUN-1998; 98US-0088030P.  
 PR 04-JUN-1998; 98US-0088033P.  
 PR 04-JUN-1998; 98US-0088126P.  
 PR 05-JUN-1998; 98US-0088167P.  
 PR 05-JUN-1998; 98US-0088202P.  
 PR 05-JUN-1998; 98US-0088212P.  
 PR 05-JUN-1998; 98US-0088217P.  
 PR 08-JUN-1998; 98US-0088655P.  
 PR 10-JUN-1998; 98US-0088734P.  
 PR 10-JUN-1998; 98US-0088738P.  
 PR 10-JUN-1998; 98US-0088742P.  
 PR 10-JUN-1998; 98US-0088810P.  
 PR 10-JUN-1998; 98US-0088824P.  
 PR 10-JUN-1998; 98US-0088826P.  
 PR 11-JUN-1998; 98US-0088858P.  
 PR 11-JUN-1998; 98US-0088861P.  
 PR 11-JUN-1998; 98US-0088876P.  
 PR 12-JUN-1998; 98US-0089105P.  
 PR 16-JUN-1998; 98US-0089440P.  
 PR 16-JUN-1998; 98US-0089512P.  
 PR 16-JUN-1998; 98US-0089514P.  
 PR 17-JUN-1998; 98US-0089532P.  
 PR 17-JUN-1998; 98US-0089538P.  
 PR 17-JUN-1998; 98US-0089598P.  
 PR 17-JUN-1998; 98US-0089599P.  
 PR 17-JUN-1998; 98US-0089600P.  
 PR 17-JUN-1998; 98US-0089653P.  
 PR 18-JUN-1998; 98US-0089801P.  
 PR 18-JUN-1998; 98US-0089907P.  
 PR 18-JUN-1998; 98US-0089908P.  
 PR 19-JUN-1998; 98US-0089947P.  
 PR 19-JUN-1998; 98US-0089948P.  
 PR 19-JUN-1998; 98US-0089952P.  
 PR 22-JUN-1998; 98US-0090246P.  
 PR 22-JUN-1998; 98US-0090252P.



PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 24-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 01-JUL-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 02-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0096929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 12-AUG-1998; 98US-0096146P.  
PR 17-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.

PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021050.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US028634.  
PR 20-DEC-1999; 99WO-US030095.  
PR 05-JAN-2000; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004514.  
PR 02-MAR-2000; 2000WO-US005004.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 30-MAR-2000; 2000WO-US007377.  
PR 15-MAY-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013358.  
PR 22-MAY-2000; 2000WO-US013705.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 07-SEP-2000; 2000US-0230978P.  
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60  
Db 1 MTFFLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60  
Qy 61 GKGIKGRNLDLSRGLILGAFAWGRGVKNT 90  
Db 61 GKGIKGRNLDLSRGLILGAFAWGRGVKNT 90

RESULT 44  
ADA97162  
ID ADA97162 standard; protein; 90 AA.  
XX  
AC ADA97162;  
XX

20-NOV-2003 (first entry)

Human PRO polypeptide #237.

Human; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

Homo sapiens.

US2003082705-A1.

01-MAY-2003.

24-APR-2002; 2002US-00131829.

09-DEC-1999; 99US-0170262P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GENTH ) GENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755112/71.

N-PSDB; ADA97161.

New PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.

Claim 12; Fig 474; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from

CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Db 1 MTFELSLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKIVKGRNLDRLGLGAEAWGRGVKNT 90

Db 61 GKIVKGRNLDRLGLGAEAWGRGVKNT 90

RESULT 45

ADA79466

ID ADA79466 standard; protein; 90 AA.

XX AC ADA79466;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082763-A1.

XX PD 01-MAY-2003.

XX PF 17-APR-2002; 2002US-00124818.

XX PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US019437.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 22-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US005819.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US020231.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030878.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001US-00065320.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001US-00887879.  
 PR 29-JUN-2001; 2001WO-US020116.  
 PR 09-JUL-2001; 2001WO-US021066.  
 PR 18-JUL-2001; 2001WO-US021735.  
 PR 06-AUG-2001; 2001US-00908827.  
 PR 09-AUG-2001; 2001US-00924419.  
 PR 16-AUG-2001; 2001US-00927796.  
 PR 19-DEC-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 PR XX

PA (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-755116/71.  
 DR N-PSDB; ADA79465.  
 XX  
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
 in detection and treatment of cancer and in modulating the uptake of  
 glucose or free fatty acid by skeletal muscle cells or adipocyte cells.  
 PT  
 XX  
 PS Claim 12; Fig 474; 659pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 transmembrane polypeptides) and the polynucleotides encoding them. The  
 invention also relates to an antibody which specifically binds to a PRO  
 polypeptide, a method for stimulating the release of tumour necrosis  
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 proliferation or differentiation of chondrocyte cells and a method for  
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 polynucleotides are useful in molecular biology, including uses as  
 hybridisation probes, in chromosome and gene mapping, in generating  
 antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 be used in preparing PRO polypeptides by recombinant techniques and in  
 generating either transgenic animals or knock-out animals which are  
 useful in the development and screening of therapeutically useful  
 reagents. The PRO polypeptides or antibodies are used in preparing a  
 medicament for treating a condition responsive to the polypeptides or  
 antibodies, such as tumours, for stimulating and inhibiting proliferation  
 of human microvascular endothelial cells, for modulating the uptake of  
 glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 stimulating differentiation of adipocyte cells, for stimulating  
 proliferation of or gene expression in pericyte cells, for stimulating  
 the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 cells, for inducing endothelial cell tube formation and for treating  
 various bone and/or cartilage disorders such as sports injuries and  
 arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 from cartilage are useful for treating sports-related joint problems,  
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 polypeptides are also useful for treating various mammalian haemoglobin-  
 associated disorders such as various thalassaemias and conditions which  
 may benefit from enhanced local immune system cell infiltration. This  
 sequence represents a human PRO polypeptide of the invention. Note: The  
 sequence data for this patent is also available in electronic format from  
 CC USPTO at seqdata.uspto.gov/sequence.html.  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLSRNKHNSQPTOSLSDSVTPKAVKTT 60  
 Db 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLSRNKHNSQPTOSLSDSVTPKAVKTT 60  
 QY 61 KGKIVKGNLDSRGLILGAEGWGRVKNT 90  
 Db 61 KGKIVKGNLDSRGLILGAEGWGRVKNT 90  
 RESULT 46  
 ADA87605  
 ID ADA87605 standard; protein; 90 AA.  
 XX  
 AC ADA87605;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003087345-A1.  
 XX  
 XX 08-MAY-2003.  
 XX  
 XX 16-APR-2002; 2002US-001233907.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 10-MAR-1999; 2000WO-US006319.  
 PR 20-APR-1999; 99WO-US0008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 20-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 03-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski R, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-786937/74.  
 DR N-PSDB; ADA87604.  
 XX  
 XX New PRO nucleic acid, useful for manufacturing a medicament for  
 PT diagnosing or treating tumor.  
 PT  
 XX  
 PS Claim 12; Fig 474; 638pp; English.  
 CC  
 CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60  
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60  
QY 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90  
Db 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90

## RESULT 47

ADA16807  
ID ADA16807 standard; protein; 90 AA.

XX AC ADA16807;

XX 20-NOV-2003 (first entry)

DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003087349-A1.

XX 08-MAY-2003.

XX 19-APR-2002; 2002US-00125928.

XX 19-JUN-1998; 98US-0089947P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-00380137.

XX 02-MAR-2000; 2000WO-US005841.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-786940/74.  
XX N-PSDB; ADB16806.

PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,  
PT and for manufacturing a medicament for diagnosing or treating tumor.  
XX

PS Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis.  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60  
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60  
QY 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90  
Db 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90

## RESULT 48

ADA28013

ID ADA28013 standard; protein; 90 AA.

XX AC ADA28013;

XX 20-NOV-2003 (first entry)

DE Human secreted/transmembrane protein PRO1159.

XX PRO; secreted protein; transmembrane protein;  
KW hypertrophy of neonatal heart; angiogenesis;  
KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
KW rod photoreceptor cell; c-fos induction; adipocyte cell;  
KW chondrocyte differentiation;

KW pancreatic beta-cell precursor differentiation;  
KW cardiac insufficiency disorder; wound; cancerous tumour;  
KW retinal disorders; loss of sight; retinitis pigmentosum; kidney disorder;  
KW obesity; diabetes; hyperinsulinaemia; hypoinsulinaemia; bone disorder;  
KW cartilage disorder; sports injury; arthritis; cancer; human.  
XX Homo sapiens.  
OS  
XX  
XX US2003054359-A1.  
XX PD  
XX PD 20-MAR-2003.  
XX  
XX 14-NOV-2001; 2001US-00990726.  
XX  
XX 16-JUN-1997; 97US-0049787P.  
XX 17-OCT-1997; 97US-0062250P.  
XX 05-NOV-1997; 97WO-US020069.  
XX 12-NOV-1997; 97US-0065186P.  
XX 13-NOV-1997; 97US-0065311P.  
XX 24-NOV-1997; 97US-0066770P.  
XX 25-FEB-1998; 98US-0075945P.  
XX 20-MAR-1998; 98US-0078910P.  
XX 28-APR-1998; 98US-0083322P.  
XX 07-MAY-1998; 98US-0084600P.  
XX 28-MAY-1998; 98US-0087106P.  
XX 02-JUN-1998; 98US-0087607P.  
XX 02-JUN-1998; 98US-0087609P.  
XX 02-JUN-1998; 98US-0087759P.  
XX 03-JUN-1998; 98US-0087827P.  
XX 04-JUN-1998; 98US-0088021P.  
XX 04-JUN-1998; 98US-0088025P.  
XX 04-JUN-1998; 98US-0088026P.  
XX 04-JUN-1998; 98US-0088028P.  
XX 04-JUN-1998; 98US-0088029P.  
XX 04-JUN-1998; 98US-0088030P.  
XX 04-JUN-1998; 98US-0088033P.  
XX 05-JUN-1998; 98US-0088167P.  
XX 05-JUN-1998; 98US-0088202P.  
XX 05-JUN-1998; 98US-0088212P.  
XX 05-JUN-1998; 98US-0088217P.  
XX 09-JUN-1998; 98US-0088655P.  
XX 10-JUN-1998; 98US-0088734P.  
XX 10-JUN-1998; 98US-0088738P.  
XX 10-JUN-1998; 98US-0088742P.  
XX 10-JUN-1998; 98US-0088810P.  
XX 10-JUN-1998; 98US-0088824P.  
XX 10-JUN-1998; 98US-0088826P.  
XX 11-JUN-1998; 98US-0088858P.  
XX 11-JUN-1998; 98US-0088861P.  
XX 11-JUN-1998; 98US-0088876P.  
XX 12-JUN-1998; 98US-0089105P.  
XX 16-JUN-1998; 98US-0089440P.  
XX 16-JUN-1998; 98US-0089512P.  
XX 16-JUN-1998; 98US-0089514P.  
XX 17-JUN-1998; 98US-0089532P.  
XX 17-JUN-1998; 98US-0089538P.  
XX 17-JUN-1998; 98US-0089598P.  
XX 17-JUN-1998; 98US-0089599P.  
XX 17-JUN-1998; 98US-0089600P.  
XX 17-JUN-1998; 98US-0089653P.  
XX 18-JUN-1998; 98US-0089801P.  
XX 18-JUN-1998; 98US-0089907P.  
XX 18-JUN-1998; 98US-0089908P.  
XX 19-JUN-1998; 98US-0089947P.  
XX 19-JUN-1998; 98US-0089948P.  
XX 19-JUN-1998; 98US-0089952P.  
XX 22-JUN-1998; 98US-0090246P.  
XX 22-JUN-1998; 98US-0090252P.  
XX 22-JUN-1998; 98US-0090254P.  
XX 23-JUN-1998; 98US-0090349P.  
XX 23-JUN-1998; 98US-0090355P.  
XX 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 25-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 02-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 30-JUL-1998; 98US-0093339P.  
PR 04-AUG-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 11-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.

```
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60
QY 61 GKGVKGRNLDGRGLILGAEMGRGVKNT 90
DB 61 GKGVKGRNLDGRGLILGAEMGRGVKNT 90

RESULT 49
ADA91899
ID ADA91899 standard; protein; 90 AA.
XX
AC ADA91899;
XX
XX 20-NOV-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1159.
XX
XX Human; secreted and transmembrane protein; PRO;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX Glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX
```

```
OS Homo sapiens.
XX US2003082694-A1.
XX
XX 01-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127845.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786908/74.
XX N-ESDB; ADA91898.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
XX or a composition for treating e.g., tumor or for tissue typing.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from BMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This is the amino
XX acid sequence of a novel human secreted and transmembrane PRO
XX polypeptide.
XX
XX Sequence 90 AA;
XX
XX Query Match 100.0%; Score 462; DB 6; Length 90;
XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;
XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60
XX DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60
XX QY 61 GKGVKGRNLDGRGLILGAEMGRGVKNT 90
XX DB 61 GKGVKGRNLDGRGLILGAEMGRGVKNT 90
XX
XX RESULT 50
XX ADA914962
```

ID ADB14962 standard; protein; 90 AA.  
XX ADB14962;  
AC ADB14962;  
XX 20-NOV-2003 (first entry)  
XX Human PRO polypeptide #237.  
XX  
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; r-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
XX Homo sapiens.  
XX US2003087351-A1.  
XX  
XX 08-MAY-2003.  
XX  
XX 22-APR-2002; 2002US-00127822.  
XX  
XX 17-JUN-1998; 98US-0089532P.  
XX 02-JUN-1999; 99WO-US012252.  
XX 25-AUG-1999; 99US-00380137.  
XX 30-NOV-1999; 99WO-US028313.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-786942/74.  
XX N-PSDB; ADB14961.  
XX  
XX New PRO nucleic acid, useful for manufacturing a medicament for  
XX diagnosing or treating tumor.  
XX  
XX Claim 12; Fig 474; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX the proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or r-lymphocyte  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTOSSLEDSVTPTKAVKTT 60  
DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTOSSLEDSVTPTKAVKTT 60  
QY 61 KGIVKGRNLDRLGLILGAEAWGRGVKNT 90  
DB 61 KGIVKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 51

ID ADB18923  
ADBI8923  
ID ADB18923 standard; protein; 90 AA.

AC ADB18923;

XX 20-NOV-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO1159.

KW Human; secreted and transmembrane protein; PRO;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release.  
XX  
XX Homo sapiens.

PN US2003073211-A1.

XX 17-APR-2003.

XX 15-APR-2002; 2002US-00123292.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 10-MAR-1999; 99WO-US005028.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.



PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US000355.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034356.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00806889.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 08-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 28-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 08-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-695954/66.  
 DR N-PSDB; ADB18922.  
 XX  
 XX New isolated nucleic acid and encoded PRO polypeptide, are useful in the  
 PI diagnosis and treatment of cancer.  
 XX  
 XX Claim 12; Fig 474; 638pp; English.  
 XX  
 CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Oy 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRKKNHSGPTOSSLEDSVTPTKAVKTT 60  
 Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRKKNHSGPTOSSLEDSVTPTKAVKTT 60  
 Oy 61 GKGIKGRNLDRLGLILGAEGWGRGVKNT 90  
 Db 61 GKGIKGRNLDRLGLILGAEGWGRGVKNT 90  
 RESULT 52  
 ADA94138  
 ID ADA94138 standard; protein; 90 AA.  
 XX AC ADA94138;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PRO polypeptide #237.  
 XX  
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003077722-A1.  
 XX  
 PD 24-APR-2003.  
 XX  
 XX 03-MAY-2002; 2002US-00137872.  
 XX  
 XX 03-MAR-2000; 2000US-0187202P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-755077/71.  
 DR N-PSDB; ADA94137.  
 XX  
 PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the  
 PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,  
 PT breast, prostate, rectal, cervical and/or liver tumors.  
 XX  
 PS Claim 12; Fig 474; 637pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human macrovascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at seqdata.uspto.gov/sequence.html.  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFEFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQTSLSLEDSVPTKAVKTT 60  
 Db 1 MTFEFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQTSLSLEDSVPTKAVKTT 60  
 QY 61 GKGIKGRNLDGRGLTGAFAEAGRGVKNT 90  
 Db 61 GKGIKGRNLDGRGLTGAFAEAGRGVKNT 90  
 RESULT 53  
 ADB20034  
 ID ADB20034 standard; protein; 90 AA.  
 XX  
 AC ADB20034;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO1159.  
 XX  
 KW Human; secreted and transmembrane protein; PRO;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 OS Homo sapiens.  
 XX  
 PN US2003082691-A1.  
 XX  
 XX 01-MAY-2003.  
 PD  
 XX  
 PF 22-APR-2002; 2002US-00127838.  
 XX  
 PR 17-NOV-1998; 98US-0108802P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 18-OCT-1999; 99US-00403297.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 DR WPI; 2003-755108/71.  
 XX N-PSDB; ADB20033.  
 DR  
 XX PRO nucleic acid, useful for preparing a composition for treating e.g.,  
 PT tumor or for tissue typing.  
 PT  
 Claim 12; Fig 474; 637pp; English.  
 XX  
 CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping. In generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This is the amino  
 CC acid sequence of a novel human secreted and transmembrane PRO  
 CC polypeptide.  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSPQTSSLEDSVTPTKAVKTT 60  
 DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSPQTSSLEDSVTPTKAVKTT 60  
 QY 61 GKGIVKGRNLDNRGLILGAEAAGRGVKNT 90  
 DB 61 GKGIVKGRNLDNRGLILGAEAAGRGVKNT 90

RESULT 54  
 ADB13346  
 ID ADB13346 standard; protein; 90 AA.  
 XX  
 AC ADB13346;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PRO polypeptide #237.  
 XX  
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; PFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003082710-A1.  
 XX  
 PD 01-MAY-2003.  
 XX  
 PF 16-MAY-2002; 2002US-00147484.  
 XX  
 PP 09-DEC-1999; 99US-0170262P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-786913/74.  
 DR N-PSDB; ADB13345.  
 XX  
 PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,  
 PT preparing a composition for treating e.g., tumor, or for tissue typing.  
 XX  
 PS Claim 12; Fig 474; 637pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or PFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSPQTSSLEDSVTPTKAVKTT 60  
 DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSPQTSSLEDSVTPTKAVKTT 60  
 QY 61 GKGIVKGRNLDNRGLILGAEAAGRGVKNT 90  
 DB 61 GKGIVKGRNLDNRGLILGAEAAGRGVKNT 90

RESULT 55

ABO43385  
 ID ABO43385 standard; protein; 90 AA.  
 XX  
 AC ABO43385;  
 XX  
 DT 26-SEP-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO1159.  
 XX  
 KW Human; secreted and transmembrane protein; PRO; gene therapy;  
 KW chromosome identification; tissue typing.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003044945-A1.  
 XX  
 PD 06-MAR-2003.  
 XX  
 PF 10-MAY-2002; 2002US-00142419.  
 XX  
 PP 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 16-SEP-1998; 98WO-US019177.  
 PR 17-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.

```
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020844.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 05-JAN-2000; 2000WO-US000277.
PR 08-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005941.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006684.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 03-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00887879.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.

PA (GETH ) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-492275/46.
XX N-PSDB; ACD98660.
XX New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX Claim 12; Fig 474; 660pp; English.
XX The invention describes an isolated nucleic acid encoding a PRO (secreted
CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
CC used to generate either transgenic animals or knock-out animals useful in
CC developing and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy, in chromosome identification, as
CC chromosome markers, or in generating probes. The PRO polypeptides are
CC useful as molecular markers for protein electrophoresis, and the isolated
CC nucleic acids may be used for recombinantly expressing those markers. The
CC PRO polypeptides and nucleic acids may also be used in tissue typing.
CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTFKAVKT 60
Db 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTFKAVKT 60
QY 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90
Db 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90
RESULT 56
IDA94593
ID ADA94593 standard; protein; 90 AA.
XX ADA94593;
AC ADA94593;
XX
DT 20-NOV-2003 (first entry)
XX Human secreted/transmembrane protein PRO1159.
XX PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
XX rod photoreceptor cell.
OS Homo sapiens.
XX US2003059832-A1.
PN
```

XX  
PD  
XX  
PF  
XX  
27-MAR-2003.  
15-NOV-2001; 2001US-00997349.  
16-JUN-1997; 97US-0049787P.  
17-OCT-1997; 97US-0062250P.  
05-NOV-1997; 97MO-US020069.  
12-NOV-1997; 97US-0055186P.  
13-NOV-1997; 97US-0065311P.  
24-NOV-1997; 97US-0066770P.  
25-FEB-1998; 98US-0075945P.  
20-MAR-1998; 98US-0078910P.  
28-APR-1998; 98US-0083322P.  
07-MAY-1998; 98US-0084600P.  
28-MAY-1998; 98US-0087106P.  
02-JUN-1998; 98US-0087607P.  
02-JUN-1998; 98US-0087609P.  
02-JUN-1998; 98US-0087759P.  
03-JUN-1998; 98US-0088021P.  
04-JUN-1998; 98US-0088025P.  
04-JUN-1998; 98US-0088026P.  
04-JUN-1998; 98US-0088028P.  
04-JUN-1998; 98US-0088029P.  
04-JUN-1998; 98US-0088030P.  
04-JUN-1998; 98US-0088033P.  
04-JUN-1998; 98US-0088032P.  
05-JUN-1998; 98US-0088167P.  
05-JUN-1998; 98US-0088202P.  
05-JUN-1998; 98US-0088212P.  
05-JUN-1998; 98US-0088217P.  
09-JUN-1998; 98US-0088655P.  
10-JUN-1998; 98US-0088734P.  
10-JUN-1998; 98US-0088738P.  
10-JUN-1998; 98US-0088742P.  
10-JUN-1998; 98US-0088810P.  
10-JUN-1998; 98US-0088824P.  
10-JUN-1998; 98US-0088826P.  
11-JUN-1998; 98US-0088858P.  
11-JUN-1998; 98US-0088861P.  
11-JUN-1998; 98US-0088876P.  
12-JUN-1998; 98US-0089105P.  
16-JUN-1998; 98US-0089440P.  
16-JUN-1998; 98US-0089512P.  
16-JUN-1998; 98US-0089514P.  
17-JUN-1998; 98US-0089532P.  
17-JUN-1998; 98US-0089538P.  
17-JUN-1998; 98US-0089588P.  
17-JUN-1998; 98US-0089599P.  
17-JUN-1998; 98US-0089600P.  
17-JUN-1998; 98US-0089653P.  
18-JUN-1998; 98US-0089801P.  
18-JUN-1998; 98US-0089907P.  
18-JUN-1998; 98US-0089908P.  
19-JUN-1998; 98US-0089947P.  
19-JUN-1998; 98US-0089948P.  
19-JUN-1998; 98US-0089952P.  
22-JUN-1998; 98US-0090246P.  
22-JUN-1998; 98US-0090252P.  
22-JUN-1998; 98US-0090254P.  
23-JUN-1998; 98US-0090349P.  
23-JUN-1998; 98US-0090355P.  
24-JUN-1998; 98US-0090429P.  
24-JUN-1998; 98US-0090431P.  
24-JUN-1998; 98US-0090435P.  
24-JUN-1998; 98US-0090444P.  
24-JUN-1998; 98US-0090445P.  
24-JUN-1998; 98US-0090472P.  
24-JUN-1998; 98US-0090535P.  
24-JUN-1998; 98US-0090540P.  
24-JUN-1998; 98US-0090542P.  
24-JUN-1998; 98US-0090557P.  
25-JUN-1998; 98US-0090676P.  
25-JUN-1998; 98US-0090678P.  
25-JUN-1998; 98US-0090690P.  
25-JUN-1998; 98US-0090694P.  
25-JUN-1998; 98US-0090695P.  
25-JUN-1998; 98US-0090696P.  
26-JUN-1998; 98US-0090862P.  
26-JUN-1998; 98US-0090863P.  
01-JUL-1998; 98US-0091360P.  
01-JUL-1998; 98US-0091544P.  
02-JUL-1998; 98US-0091478P.  
02-JUL-1998; 98US-0091519P.  
02-JUL-1998; 98US-0091626P.  
02-JUL-1998; 98US-0091628P.  
02-JUL-1998; 98US-0091633P.  
02-JUL-1998; 98US-0091646P.  
02-JUL-1998; 98US-0091673P.  
07-JUL-1998; 98US-0091978P.  
07-JUL-1998; 98US-0091982P.  
09-JUL-1998; 98US-0092182P.  
10-JUL-1998; 98US-0092472P.  
20-JUL-1998; 98US-0093339P.  
30-JUL-1998; 98US-0094651P.  
04-AUG-1998; 98US-0095282P.  
04-AUG-1998; 98US-0095285P.  
04-AUG-1998; 98US-0095301P.  
04-AUG-1998; 98US-0095302P.  
04-AUG-1998; 98US-0095318P.  
04-AUG-1998; 98US-0095321P.  
04-AUG-1998; 98US-0095325P.  
10-AUG-1998; 98US-0095916P.  
10-AUG-1998; 98US-0095929P.  
10-AUG-1998; 98US-0096012P.  
11-AUG-1998; 98US-0096143P.  
11-AUG-1998; 98US-0096146P.  
12-AUG-1998; 98US-0096329P.  
17-AUG-1998; 98US-0096757P.  
17-AUG-1998; 98US-0096766P.  
17-AUG-1998; 98US-0096768P.  
17-AUG-1998; 98US-0096773P.  
17-AUG-1998; 98US-0096791P.  
17-AUG-1998; 98US-0096867P.  
17-AUG-1998; 98US-0096889P.  
17-AUG-1998; 98US-0096894P.  
17-AUG-1998; 98US-0096895P.  
17-AUG-1998; 98US-0096897P.  
18-AUG-1998; 98US-0096949P.  
18-AUG-1998; 98US-0096950P.  
18-AUG-1998; 98US-0096953P.  
18-AUG-1998; 98US-0096960P.  
18-AUG-1998; 98US-0097022P.  
19-AUG-1998; 98US-0097141P.  
20-AUG-1998; 98US-0097218P.  
24-AUG-1998; 98US-0097661P.  
26-AUG-1998; 98US-0097952P.  
26-AUG-1998; 98US-0097954P.  
26-AUG-1998; 98US-0097955P.  
26-AUG-1998; 98US-0097974P.  
26-AUG-1998; 98US-0097978P.  
26-AUG-1998; 98US-0097979P.  
26-AUG-1998; 98US-0097986P.  
26-AUG-1998; 98US-0098014P.  
31-AUG-1998; 98US-0098525P.  
16-SEP-1998; 98US-0100634P.  
16-SEP-1998; 98MO-US019330.  
17-SEP-1998; 98US-0100858P.  
17-SEP-1998; 98MO-US019437.  
17-OCT-1998; 98MO-US021141.  
01-DEC-1998; 98MO-US025108.  
22-DEC-1998; 98US-0113296P.  
05-JAN-1999; 99MO-US000106.  
08-MAR-1999; 99MO-US005028.

```
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000376.
PR 06-JAN-2000; 2000WO-US003565.
PR 11-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCAIWRNSGNTLENGVFLSRNKHNSHPTOSSLEDSVTPKAVKTT 60
Db 1 MTFPLSLLLLVCAIWRNSGNTLENGVFLSRNKHNSHPTOSSLEDSVTPKAVKTT 60

Qy 61 GKGIVKGNLDSRGLILGAEWGRGVKNT 90
Db 61 GKGIVKGNLDSRGLILGAEWGRGVKNT 90

RESULT 57
ADA74600
ID ADA74600 standard; protein; 90 AA.
XX AC ADA74600;
XX DT 20-NOV-2003 (first entry)
XX DE Human PRO polypeptide #237.
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003068798-A1.
XX
```

```
PD 10-APR-2003.
XX 07-MAY-2002; 2002US-00140928.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 01-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 03-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
```

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 90 AA;  
  
Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRKKNHSQPTOSSEDSVTPKAVKIT 60  
DB 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRKKNHSQPTOSSEDSVTPKAVKIT 60  
  
QY 61 CGKIVKGRNLDRLGILGAEAWGRGVKNT 90  
DB 61 CGKIVKGRNLDRLGILGAEAWGRGVKNT 90  
  
RESULT 58  
ADB24833  
ID ADB24833 standard; protein; 90 AA.  
XX  
AC ADB24833;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polypeptide SEQ ID NO 474.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003077713-AL.  
XX  
PD 24-APR-2003.  
XX  
PF 22-APR-2002; 2002US-00127839.  
XX  
PR 05-JUN-2000; 2000US-0209832P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WI; 2003-755068/71.  
DR N-PSDB; ADB24833.  
XX  
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic  
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,  
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
PT tumors.  
XX  
PS Claim 12; Fig 474; 637pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and

PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WI; 2003-625490/59.  
XX N-PSDB; ADA74599.  
XX  
XX Novel secreted and transmembrane PRO polypeptides and polynucleotides  
PT encoding them, useful for treating bone disorders, arthritis, heart  
PT attack, injuries, tumors, and stimulating release of Tumor Necrosis  
PT Factor-alpha from human blood.  
XX  
XX Claim 12; Fig 474; 659pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,

transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLLVCEAIWRSNSGNTLENGYFUSRNKENHSQPTQSSLEDSVPTKAVKTT 60  
DB 1 MTFFLSLLLLLVCEAIWRSNSGNTLENGYFUSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

DB 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 59

ID ADA82357 standard; protein; 90 AA.

AC ADA82357;

DT 20-NOV-2003 (first entry)

DE Human PRO polypeptide #237.

Human; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.

Homo sapiens.

OS US2003082701-A1.

XX

PD 01-MAY-2003.

XX 23-APR-2002; 2002US-00128686.

XX 31-AUG-1998; 98US-0098525P.

XX 16-SEP-1998; 98US-0100634P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 02-JUN-2000; 2000WO-US015264.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755110/71.

XX N-PSDB; ADA82356.

XX PRO nucleic acid, useful for preparing a composition for treating e.g.,

XX tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX antibodies, such as tumours, for stimulating and inhibiting proliferation

XX of human microvascular endothelial cells, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating

XX the proliferation of inner ear utricular supporting cells or T-lymphocyte

XX cells, for inducing endothelial cell tube formation and for treating

XX various bone and/or cartilage disorders such as sports injuries and

XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

PD 01-MAY-2003.

XX 23-APR-2002; 2002US-00128686.

XX 31-AUG-1998; 98US-0098525P.

XX 16-SEP-1998; 98US-0100634P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 02-JUN-2000; 2000WO-US015264.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755110/71.

XX N-PSDB; ADA82356.

XX PRO nucleic acid, useful for preparing a composition for treating e.g.,

XX tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX antibodies, such as tumours, for stimulating and inhibiting proliferation

XX of human microvascular endothelial cells, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating

XX the proliferation of inner ear utricular supporting cells or T-lymphocyte

XX cells, for inducing endothelial cell tube formation and for treating

XX various bone and/or cartilage disorders such as sports injuries and

XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLLVCEAIWRSNSGNTLENGYFUSRNKENHSQPTQSSLEDSVPTKAVKTT 60

DB 1 MTFFLSLLLLLVCEAIWRSNSGNTLENGYFUSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90



us-09-989-293a-377.jun1.rag

Wed Jun 2 08:28:01 2004

61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

Db	61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90	05-JAN-2000; 2000WO-US000219.	PR
RESULT 60		06-JAN-2000; 2000WO-US000277.	PR
ADA75320		06-JAN-2000; 2000WO-US000376.	PR
ID ADA75320 standard; protein; 90 AA.		11-FEB-2000; 2000WO-US003565.	PR
XX		18-FEB-2000; 2000WO-US004341.	PR
AC ADA75320;		18-FEB-2000; 2000WO-US004342.	PR
XX		22-FEB-2000; 2000WO-US004414.	PR
DT		24-FEB-2000; 2000WO-US004914.	PR
XX		01-MAR-2000; 2000WO-US005601.	PR
XX		02-MAR-2000; 2000WO-US005746.	PR
DE		10-MAR-2000; 2000WO-US006319.	PR
XX		15-MAR-2000; 2000WO-US006884.	PR
KW	Human; PRO; secreted polypeptide; transmembrane polypeptide;	20-MAR-2000; 2000WO-US007377.	PR
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	21-MAR-2000; 2000WO-US007532.	PR
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	30-MAR-2000; 2000WO-US008439.	PR
KW	liver; microvascular endothelial cell; glucose; FFA;	17-MAY-2000; 2000WO-US013705.	PR
KW	skeletal muscle cell; adipocyte cell; pericyte cell;	22-MAY-2000; 2000WO-US014042.	PR
KW	inner ear utricular supporting cell; T-lymphocyte cell;	30-MAY-2000; 2000WO-US014941.	PR
KW	endothelial cell tube formation; bone disorder; cartilage disorder;	02-JUN-2000; 2000WO-US015264.	PR
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	28-JUL-2000; 2000WO-US020710.	PR
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	11-AUG-2000; 2000WO-US022031.	PR
KW	immune system cell infiltration.	23-AUG-2000; 2000WO-US023522.	PR
XX		24-AUG-2000; 2000WO-US023328.	PR
OS	Homo sapiens.	08-NOV-2000; 2000WO-US030952.	PR
XX		10-NOV-2000; 2000WO-US030873.	PR
PN	US2003073216-A1.	01-DEC-2000; 2000WO-US032678.	PR
XX		20-DEC-2000; 2000US-00747259.	PR
PD	17-APR-2003.	20-DEC-2000; 2000WO-US034956.	PR
XX		28-FEB-2001; 2001US-00796498.	PR
PF		28-FEB-2001; 2001WO-US006520.	PR
XX		01-MAR-2001; 2001WO-US006666.	PR
PR		09-MAR-2001; 2001US-00802706.	PR
PR		14-MAR-2001; 2001US-00808689.	PR
PR		22-MAR-2001; 2001US-00816744.	PR
PR		05-APR-2001; 2001US-00828366.	PR
PR		10-MAY-2001; 2001US-00854208.	PR
PR		10-MAY-2001; 2001US-00864280.	PR
PR		18-MAY-2001; 2001US-008660216.	PR
PR		25-MAY-2001; 2001US-00866034.	PR
PR		25-MAY-2001; 2001US-00866028.	PR
PR		25-MAY-2001; 2001WO-US017092.	PR
PR		01-JUN-2001; 2001US-00872035.	PR
PR		01-JUN-2001; 2001WO-US017803.	PR
PR		05-JUN-2001; 2001US-00874503.	PR
PR		14-JUN-2001; 2001US-00882636.	PR
PR		19-JUN-2001; 2001US-00886342.	PR
PR		20-JUN-2001; 2001WO-US019692.	PR
PR		21-JUN-2001; 2001US-00887879.	PR
PR		22-JUN-2001; 2001WO-US020116.	PR
PR		29-JUN-2001; 2001WO-US021066.	PR
PR		18-JUL-2001; 2001WO-US021735.	PR
PR		09-AUG-2001; 2001US-00908827.	PR
PR		06-AUG-2001; 2001US-00924419.	PR
PR		09-AUG-2001; 2001US-00927796.	PR
PR		16-AUG-2001; 2001US-00931836.	PR
PR		19-DEC-2001; 2001US-00028072.	PR
XX		(GETH ) GENENTECH INC.	XX
PA		Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	XX
PI		Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	PI
PI		Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	PI
XX		WPI; 2003-765392/72.	XX
DR		N-PSDB; ADA75319.	DR
XX		New secreted and transmembrane PRO polypeptides useful for stimulating	XX
PT		the release of tumor necrosis factor alpha in human blood and detecting	PT
PT		the presence of tumor in a mammal.	PT
XX		Claim 12; Fig 474; 638pp; English.	XX
PS			PS

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSVTPTKAVKTT 60  
Db 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90  
Db 61 KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 61  
ADA85398  
ID ADA85398 standard; protein; 90 AA.

XX ADA85398;

XX 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003082695-A1.

XX

PD 01-MAY-2003.

XX 22-APR-2002; 2002US-00127846.

XX 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-786909/74.

DR N-PSDB; ADA85397.

XX New nucleic acid encoding a PRO polypeptide, useful for preparing a  
PT composition for treating e.g. tumor by gene therapy, or for tissue  
PT typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This is the amino  
CC acid sequence of a novel human secreted and transmembrane PRO  
CC polypeptide.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSVTPTKAVKTT 60  
Db 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSVTPTKAVKTT 60

QY 61 KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90

Db 61 KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 62

ADA84846

ID ADA84846 standard; protein; 90 AA.

XX

XX ADA84846;

XX AC

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; PRO;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW Glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003082708-A1.

XX PD 01-MAY-2003.

XX PF 15-MAY-2002; 2002US-00145729.

XX PR 05-JUN-2000; 2000US-0209832P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH ) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI: 2003-786911/74.

XX DR N-PSDB; ADA64845.

XX PT New PRO nucleic acid, useful for preparing a composition for treating

XX PT e.g. tumor or for tissue typing.

XX PS Claim 12; Fig 474; 637pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and

CC transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte

CC cells, for stimulating the release of proteoglycans from cartilage, for

CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from PMBC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

CC cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,

CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or

CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in binding

CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome

CC and gene mapping, in generation of antisense RNA and DNA, in the

CC preparation of PRO polypeptide, for generating transgenic animals or

CC knockout animals which in turn are useful in the development and

CC screening of therapeutically useful reagents, in gene therapy, for

CC chromosome identification, as chromosome marker, and for generating

CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

CC detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This is the amino

CC acid sequence of a novel human secreted and transmembrane PRO

XX CC polypeptide.

XX SQ Sequence 90 AA;

Query Match

100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49; Mismatches 0; Indels 0; Gaps 0;

Matches 90; Conservative 0;

QY 1 MTFPLSLILLVCEAIWRNSNGSNTLENGYFLSRNKENHQSPTQSSLEDSVPTKAVKTT 60

DB 1 MTFPLSLILLVCEAIWRNSNGSNTLENGYFLSRNKENHQSPTQSSLEDSVPTKAVKTT 60

QY 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90

DB 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90

## RESULT 63

ADB30102

ID ADB30102 standard; protein; 90 AA.

XX AC ADB30102;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003073214-A1.

XX PD 17-APR-2003.

XX PF 17-APR-2002; 2002US-00124822.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 99WO-US000106.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 10-MAR-1999; 99WO-US005190.

XX PR 20-APR-1999; 99WO-US008615.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 08-SEP-1999; 99WO-US020111.

XX PR 13-SEP-1999; 99WO-US020594.

XX PR 15-SEP-1999; 99WO-US020944.

XX PR 15-SEP-1999; 99WO-US021547.

XX PR 05-OCT-1999; 99WO-US023089.

XX PR 29-NOV-1999; 99WO-US028214.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 01-DEC-1999; 99WO-US028409.

XX PR 01-DEC-1999; 99WO-US028301.

XX PR 01-DEC-1999; 99WO-US028634.





CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60  
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60  
QY 61 KGKIVKGRNLDRLGLILGAEAWGKVKNT 90  
DB 61 KGKIVKGRNLDRLGLILGAEAWGKVKNT 90

## RESULT 65

ADAV5872  
ID ADA75872 standard; protein; 90 AA.

XX ADA75872;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
XX liver; microvascular endothelial cell; glucose; FFA;  
XX skeletal muscle cell; adipocyte cell; pericyte cell;  
XX inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
XX immune system cell infiltration.

XX Homo sapiens.

XX US2003082703-A1.

XX 01-MAY-2003.

XX 23-APR-2002; 2002US-00128691.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KF, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-765414/72.

DR N-PSDB; ADA75871.

XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX from cartilage are useful for treating sports-related joint problems, PRO  
XX polypeptides are also useful for treating various mammalian haemoglobin-  
XX associated disorders such as various thalassaemias and conditions which  
XX may benefit from enhanced local immune system cell infiltration. This  
XX sequence represents a human PRO polypeptide of the invention. Note: The  
XX USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60  
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

QY 61 KGKIVKGRNLDRLGLILGAEAWGKVKNT 90  
DB 61 KGKIVKGRNLDRLGLILGAEAWGKVKNT 90

## RESULT 66

ADA38818  
ID ADA38818 standard; protein; 90 AA.

XX ADA38818;

XX 20-NOV-2003 (first entry)

XX Human secreted/transmembrane protein PRO1159.

XX PRO; secreted protein; transmembrane protein; gene therapy; tumour;  
XX cancer; human; colon cancer; lung cancer; breast cancer.

XX Homo sapiens.

XX US2003059780-A1.

XX

PR	25-JUN-1998	98US-0030678P
PR	25-JUN-1998	98US-0030679P
PR	25-JUN-1998	98US-0030680P
PR	25-JUN-1998	98US-0030681P
PR	25-JUN-1998	98US-0030682P
PR	25-JUN-1998	98US-0030683P
PR	25-JUN-1998	98US-0030684P
PR	25-JUN-1998	98US-0030685P
PR	25-JUN-1998	98US-0030686P
PR	26-JUN-1998	98US-0030687P
PR	26-JUN-1998	98US-0030688P
PR	01-JUL-1998	98US-0031340P
PR	01-JUL-1998	98US-0031341P
PR	02-JUL-1998	98US-0031447P
PR	02-JUL-1998	98US-0031478P
PR	02-JUL-1998	98US-0031519P
PR	02-JUL-1998	98US-0031626P
PR	02-JUL-1998	98US-0031628P
PR	02-JUL-1998	98US-0031633P
PR	02-JUL-1998	98US-0031634P
PR	02-JUL-1998	98US-0031673P
PR	07-JUL-1998	98US-0031978P
PR	07-JUL-1998	98US-0031982P
PR	09-JUL-1998	98US-0032182P
PR	10-JUL-1998	98US-0032472P
PR	20-JUL-1998	98US-0093339P
PR	30-JUL-1998	98US-0094651P
PR	04-AUG-1998	98US-0094528P
PR	04-AUG-1998	98US-0095301P
PR	04-AUG-1998	98US-0095302P
PR	04-AUG-1998	98US-0095318P
PR	04-AUG-1998	98US-00953321P
PR	04-AUG-1998	98US-0095325P
PR	10-AUG-1998	98US-0095591P
PR	10-AUG-1998	98US-0095923P
PR	11-AUG-1998	98US-00961012P
PR	11-AUG-1998	98US-0096143P
PR	11-AUG-1998	98US-0096146P
PR	12-AUG-1998	98US-0096329P
PR	17-AUG-1998	98US-0096575P
PR	17-AUG-1998	98US-0096766P
PR	17-AUG-1998	98US-0096768P
PR	17-AUG-1998	98US-0096773P
PR	17-AUG-1998	98US-0096791P
PR	17-AUG-1998	98US-0096867P
PR	17-AUG-1998	98US-0096891P
PR	18-AUG-1998	98US-0096936P
PR	18-AUG-1998	98US-0096950P
PR	18-AUG-1998	98US-0096959P
PR	18-AUG-1998	98US-0096960P
PR	19-AUG-1998	98US-0097022P
PR	19-AUG-1998	98US-0097141P
PR	20-AUG-1998	98US-0097218P
PR	24-AUG-1998	98US-0097661P
PR	25-AUG-1998	98US-0097952P
PR	26-AUG-1998	98US-0097986P
PR	26-AUG-1998	98US-0097954P
PR	26-AUG-1998	98US-0097955P
PR	26-AUG-1998	98US-0097971P
PR	26-AUG-1998	98US-0097974P
PR	26-AUG-1998	98US-0097978P
PR	26-AUG-1998	98US-0097979P
PR	26-AUG-1998	98US-0097986P
PR	26-AUG-1998	98US-0098014P
PR	31-AUG-1998	98US-0098255P
PR	16-SEP-1998	98US-0100634P
PR	17-SEP-1998	98WO-US0119330
PR	17-SEP-1998	98WO-US0119330
PR	17-SEP-1998	98WO-US0119437
PR	07-OCT-1998	98WO-US021141
PR	01-DEC-1998	98WO-US025108
PR	22-DEC-1998	98US-0113296P
PR	05-JAN-1999	99WO-US000106
PR	08-MAR-1999	99WO-US005028
PR	12-MAR-1999	99US-013357P

PR	02-JUN-1999;	99WO-US012252.	XX	OS	Homo sapiens.
PR	23-JUN-1999;	99US-0141037P.	XX	XX	US2003073210-A1.
PR	07-JUL-1999;	99US-0143048P.	PN	XX	
PR	20-JUL-1999;	99US-0144758P.	XX	XX	
PR	26-JUL-1999;	99US-0145698P.	PD	XX	17-APR-2003.
PR	28-JUL-1999;	99US-0146222P.	XX	XX	11-APR-2002; 2002US-00121045.
PR	17-AUG-1999;	99US-0149396P.	XX	XX	
PR	15-SEP-1999;	99WO-US021090.	XX	XX	
PR	18-SEP-1999;	99WO-US021547.	PR	31-MAR-1997;	97WO-US005230.
PR	08-OCT-1999;	99US-0158663P.	PR	12-JUN-1998;	98WO-US012456.
PR	30-NOV-1999;	99WO-US028313.	PR	14-JUL-1998;	98WO-US014552.
PR	01-DEC-1999;	99WO-US028301.	PR	28-AUG-1998;	98WO-US017888.
PR	16-DEC-1999;	99WO-US030095.	PR	10-SEP-1998;	98WO-US018824.
PR	20-DEC-1999;	99WO-US030911.	PR	14-SEP-1998;	98WO-US019093.
PR	05-JAN-2000;	2000WO-US000219.	PR	14-SEP-1998;	98WO-US019094.
PR	06-JAN-2000;	2000WO-US000376.	PR	16-SEP-1998;	98WO-US019177.
PR	11-FEB-2000;	2000WO-US003565.	PR	17-SEP-1998;	98WO-US019330.
PR	18-FEB-2000;	2000WO-US004341.	PR	17-SEP-1998;	98WO-US019437.
PR	24-FEB-2000;	2000WO-US004914.	PR	07-OCT-1998;	98WO-US021141.
PR	01-MAR-2000;	2000WO-US005601.	PR	29-OCT-1998;	98WO-US022991.
PR	02-MAR-2000;	2000WO-US005746.	PR	29-OCT-1998;	98WO-US024855.
PR	10-MAR-2000;	2000WO-US006319.	PR	01-DEC-1998;	98WO-US025108.
PR	15-MAR-2000;	2000WO-US006884.	PR	05-JAN-1999;	99WO-US000106.
PR	21-MAR-2000;	2000WO-US007377.	PR	08-MAR-1999;	99WO-US005028.
PR	30-MAR-2000;	2000WO-US008439.	PR	10-MAR-1999;	99WO-US005190.
PR	17-MAY-2000;	2000WO-US013705.	PR	20-APR-1999;	99WO-US008615.
PR	22-MAY-2000;	2000WO-US014042.	PR	14-MAY-1999;	99WO-US010733.
PR	30-MAY-2000;	2000WO-US014941.	PR	02-JUN-1999;	99WO-US012252.
PR	02-JUN-2000;	2000WO-US015264.	PR	01-SEP-1999;	99WO-US020111.
PR	28-JUL-2000;	2000WO-US020710.	PR	08-SEP-1999;	99WO-US020594.
PR	11-AUG-2000;	2000WO-US022031.	PR	13-SEP-1999;	99WO-US020944.
PR	23-AUG-2000;	2000WO-US023522.	PR	15-SEP-1999;	99WO-US021090.
PR	24-AUG-2000;	2000WO-US023328.	PR	05-OCT-1999;	99WO-US023089.
PR	07-SEP-2000;	2000US-0230978P.	PR	23-NOV-1999;	99WO-US028214.
PR	08-NOV-2000;	2000WO-US030952.	PR	30-NOV-1999;	99WO-US028313.
Query Match 100.0%; Score 462; DB 6; Length 90;			PR	01-DEC-1999;	99WO-US028634.
Best Local Similarity 100.0%; Pred. No. 9.8e-49;			PR	02-DEC-1999;	99WO-US028551.
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			PR	02-DEC-1999;	99WO-US028564.
			PR	02-DEC-1999;	99WO-US028565.
Qy	1	MTFSLLLLLLVCEAIWRNSGNTLENGYFLSRNKENHSHQPTQSSLEDSVTPTKAVKTT 60	PR	16-DEC-1999;	99WO-US030095.
Db	1	MTFSLLLLLLVCEAIWRNSGNTLENGYFLSRNKENHSHQPTQSSLEDSVTPTKAVKTT 60	PR	20-DEC-1999;	99WO-US030911.
Qy	61	GKGVKGRNLDNRGLILGAEAWGVRKNT 90	PR	22-DEC-1999;	99WO-US030720.
Db	61	GKGVKGRNLDNRGLILGAEAWGVRKNT 90	PR	30-DEC-1999;	99WO-US031243.
RESULT 67			PR	03-DEC-1999;	99WO-US031274.
ADA47097			PR	05-JAN-2000;	2000WO-US000219.
ID	ADA47097	standard; protein; 90 AA.	PR	06-JAN-2000;	2000WO-US000277.
XX	ADA47097;		PR	11-FEB-2000;	2000WO-US000376.
XX	20-NOV-2003	(first entry)	PR	18-FEB-2000;	2000WO-US003565.
DT	Human PRO polypeptide #237.		PR	22-FEB-2000;	2000WO-US004341.
XX	Human; PRO; secreted polypeptide; transmembrane polypeptide;		PR	24-FEB-2000;	2000WO-US004914.
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		PR	01-MAR-2000;	2000WO-US005601.
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		PR	02-MAR-2000;	2000WO-US005746.
KW	liver; microvascular endothelial cell; glucose; FFA;		PR	10-MAR-2000;	2000WO-US006319.
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		PR	15-MAR-2000;	2000WO-US006884.
KW	inner ear utricular supporting cell; T-lymphocyte cell;		PR	21-MAR-2000;	2000WO-US007377.
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		PR	30-MAR-2000;	2000WO-US008439.
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		PR	17-MAY-2000;	2000WO-US013705.
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		PR	22-MAY-2000;	2000WO-US014042.
KW	immune system cell infiltration.		PR	30-MAY-2000;	2000WO-US014941.



PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874593.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-644800/61.  
XX N-PSDB; ADA47096.

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.

XX Claim 12; Fig 474; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems. PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSKENHSGPTOSSLEDSVTPKAVKTT 60  
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSKENHSGPTOSSLEDSVTPKAVKTT 60

Qy 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90

Db 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 68

ADB25393

ID ADB25393 standard; protein; 90 AA.

XX AC ADB25393;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide SEQ ID NO 474.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX XX US2003077715-A1.

XX XX 24-APR-2003.

XX XX 23-APR-2002; 2002US-00128693.

XX XX 31-AUG-1998; 98US-0098525P.

XX XX 16-SEP-1998; 98US-0100634P.

XX XX 02-JUN-1999; 99WO-US012252.

XX XX 25-AUG-1999; 99US-00380137.

XX XX 30-MAR-2000; 2000WO-US008439.

XX XX 02-JUN-2000; 2000WO-US015264.

XX XX 01-DEC-2000; 2000WO-US032678.

XX XX 19-DEC-2001; 2001US-00028072.

XX XX (GETH ) GENENTECH INC.

XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX XX WPI; 2003-755070/71.

XX XX N-PSDB; ADB25392.

XX New isolated, secreted and transmembrane PRO nucleic acids, useful for  
 PT the diagnosis, prevention and/or treatment of tumors, such as lung,  
 PT colon, breast, prostate, rectal, cervical and/or liver tumors.  
 XX  
 PS Claim 12; Fig 474; 637pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
 XX  
 SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLILLVCEATWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

DB 1 MTFPLSLILLVCEATWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGVKGRNLDLSGLIIGAEAWGRGVKNT 90

DB 61 GKGVKGRNLDLSGLIIGAEAWGRGVKNT 90

RESULT 69

ADA93569

ID ADA93569 standard; protein; 90 AA.

AC ADA93569;

XX 20-NOV-2003 (first entry)

DT Human PRO polypeptide #237.

DE Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

OS Homo sapiens.

PN US2003077721-A1.

PD 24-APR-2003.

PF 24-APR-2002; 2002US-00131837.

XX 09-DEC-1999; 93US-0170262P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-755076/71.

DR N-PSDB; ADA93568.

XX New PRO nucleic acid, useful for recombinantly producing a PRO  
 PT polypeptide and for manufacturing a medicament for diagnosing or treating  
 PT tumor.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC the proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLILLVCEATWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

Db 1 MTFFLSILLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60  
QY 61 KGKIVGRNLDRLGLGAEAWGKVKNT 90  
Db 61 KGKIVGRNLDRLGLGAEAWGKVKNT 90  
RESULT 70  
ADB26919  
ID ADB26919 standard; protein; 90 AA.  
AC ADB26919;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polypeptide #37.  
XX  
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
XX  
XX US2003092147-A1.  
PN  
XX  
PD 15-MAY-2003.  
XX  
XX 11-APR-2002; 2002US-00121051.  
XX  
PR 31-MAR-1997; 99WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 01-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 21-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001US-00796498.  
PR 01-MAR-2001; 2001WO-US006520.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 23-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GENTH ) GENENTECH INC.  
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-777249/73.  
DR N-PSDE; ADB26918.  
XX  
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper-

PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
PT attack, various coagulation disorders, tumors.  
XX Claim 12; Fig 474; 660pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).  
XX  
SQ Sequence 90 AA;  
  
Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTTKAVKTT 60  
Dd |||||  
1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTTKAVKTT 60  
QY 61 GKGIKGRNLDRLGLILGAAGRGVKKNT 90  
Dd |||||  
61 GKGIKGRNLDRLGLILGAAGRGVKKNT 90  
  
RESULT 71  
ADB31206  
ID ADB31206 standard; protein; 90 AA.  
XX  
AC ADB31206;  
XX  
DT 20-NOV-2003 (first entry)  
DE  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003096386-A1.  
XX  
PD 22-MAY-2003.  
XX  
PF 11-APR-2002; 2002US-00121042.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98WO-US005190.  
PR 20-APR-1999; 98WO-US008615.  
PR 14-MAY-1999; 98WO-US010733.  
PR 02-JUN-1999; 98WO-US012252.  
PR 01-SEP-1999; 98WO-US020111.  
PR 08-SEP-1999; 98WO-US020594.  
PR 13-SEP-1999; 98WO-US020944.  
PR 15-SEP-1999; 98WO-US021090.  
PR 05-OCT-1999; 98WO-US021547.  
PR 15-SEP-1999; 98WO-US023089.  
PR 29-NOV-1999; 98WO-US028214.  
PR 30-NOV-1999; 98WO-US028313.  
PR 30-NOV-1999; 98WO-US028409.  
PR 01-DEC-1999; 98WO-US028301.  
PR 01-DEC-1999; 98WO-US028634.  
PR 02-DEC-1999; 98WO-US028551.  
PR 02-DEC-1999; 98WO-US028564.  
PR 02-DEC-1999; 98WO-US028565.  
PR 16-DEC-1999; 98WO-US030095.  
PR 20-DEC-1999; 98WO-US030911.  
PR 20-DEC-1999; 98WO-US030999.  
PR 22-DEC-1999; 98WO-US030720.  
PR 30-DEC-1999; 98WO-US031243.  
PR 30-DEC-1999; 98WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032878.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854280.  
PR 10-MAY-2001; 2001US-00860216.  
PR 18-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786990/74.  
DR N-PSDB; ADB31205.  
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or  
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
PT attack, various coagulation disorders, tumors.  
XX Claim 12; Fig 474; 638pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.  
XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQPTOSSLEDSVTPTKAVKTT 60  
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQPTOSSLEDSVTPTKAVKTT 60  
Qy 61 GKGVKGRNLDNRGLILGAEGWGVKKNT 90  
Db 61 GKGVKGRNLDNRGLILGAEGWGVKKNT 90

## RESULT 72

ADA92939  
ID ADA92939 standard; protein; 90 AA.  
XX  
AC ADA92939;  
DT 20-NOV-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein PRO1159.  
XX

KW PRO; secreted protein; transmembrane protein;  
KW hypertrophy of neonatal heart; angiogenesis;  
KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
KW c-fos induction; adipocyte cell; chondrocyte differentiation;  
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;  
KW cancer; human; colon cancer; lung cancer; breast cancer;  
KW rod photoreceptor cell.

XX Homo sapiens.  
XX OS  
XX US2003060407-A1.  
XX  
XX 27-MAR-2003.  
XX  
XX 14-NOV-2001; 2001US-00990440.  
XX  
XX 16-JUN-1997; 97US-0049797P.  
XX 17-OCT-1997; 97US-0062250P.  
XX 05-NOV-1997; 97WO-US020069.  
XX 12-NOV-1997; 97US-0065186P.  
XX 13-NOV-1997; 97US-0065311P.  
XX 24-NOV-1997; 97US-0066770P.  
XX 25-FEB-1998; 98US-0075945P.  
XX 20-MAR-1998; 98US-0078910P.  
XX 28-APR-1998; 98US-0083322P.  
XX 07-MAY-1998; 98US-0084600P.  
XX 28-MAY-1998; 98US-0087106P.  
XX 02-JUN-1998; 98US-0087607P.  
XX 02-JUN-1998; 98US-0087609P.  
XX 02-JUN-1998; 98US-0087759P.  
XX 03-JUN-1998; 98US-0087827P.  
XX 04-JUN-1998; 98US-0088021P.  
XX 04-JUN-1998; 98US-0088025P.  
XX 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 18-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090826P.  
PR 26-JUN-1998; 98US-0090829P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100834P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 01-DEC-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-011326P.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 12-MAR-1999; 98US-0123957P.  
PR 02-JUN-1999; 98WO-US012252.  
PR 23-JUN-1999; 98US-0141037P.  
PR 07-JUL-1999; 98US-0143048P.  
PR 20-JUL-1999; 98US-0144758P.  
PR 26-JUL-1999; 98US-0145698P.  
PR 28-JUL-1999; 98US-0146222P.  
PR 17-AUG-1999; 98US-0149396P.  
PR 15-SEP-1999; 98WO-US021090.  
PR 15-SEP-1999; 98WO-US021547.  
PR 08-OCT-1999; 98US-0158663P.  
PR 30-NOV-1999; 98WO-US028313.  
PR 01-DEC-1999; 98WO-US028301.  
PR 16-DEC-1999; 98WO-US028634.  
PR 20-DEC-1999; 98WO-US030095.  
PR 05-JAN-2000; 98WO-US030911.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.

```

PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match      100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9. Be-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSILLILLCVCAIWRNSGNTLENGYFLSRNKENHNSOPTOSSLEDSVTPTKAVKTT 60
Db 1 MTFPLSILLILLCVCAIWRNSGNTLENGYFLSRNKENHNSOPTOSSLEDSVTPTKAVKTT 60

Qy 61 GKGIKVGKGNLDSRGLILCAEAWGRGVKQNT 90
Db 61 GKGIKVGKGNLDSRGLILCAEAWGRGVKQNT 90

RESULT 73
ID ADA61134 standard; protein; 90 AA.
AC ADA61134;
XX
XX
XX 20-NOV-2003 (first entry)
XX Homo sapiens.
XX Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO1159.
XX
XX US2003049817-A1.
XX
XX 13-MAR-2003.
XX
XX 10-MAY-2002; 2002US-00142423.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018834.
XX 14-SEP-1998; 98WO-US019033.
XX 14-SEP-1998; 98WO-US019094.
XX 16-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.

```

20-JUN-2001; 2001WO-US019692.  
 21-JUN-2001; 2001US-00887879.  
 22-JUN-2001; 2001WO-US020116.  
 29-JUN-2001; 2001WO-US021066.  
 09-JUL-2001; 2001WO-US021735.  
 18-JUL-2001; 2001US-00908827.  
 06-AUG-2001; 2001US-00924419.  
 09-AUG-2001; 2001US-00927796.  
 16-AUG-2001; 2001US-00931836.  
 19-DEC-2001; 2001US-00028072.  
 10-MAR-2009; 2000WO-US006319.  
 (GETH ) GENENTECH INC.  
 Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI; 2003-695993/66.  
 N-PSDB; ADA61133.  
 New secreted and transmembrane PRO polypeptide and nucleic acid, useful  
 for manufacturing a medicament for diagnosing or treating tumor.  
 Claim 12; Fig 474; 659pp; English.  
 The invention describes 305 nucleic acids encoding PRO (secreted and  
 transmembrane) polypeptides (I). (I) is useful for stimulating the  
 release of TNF-alpha from human blood, for modulating the uptake of  
 glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 stimulating the proliferation or differentiation of chondrocyte cells,  
 for stimulating the proliferation of or gene expression in pericyte  
 cells, for stimulating the release of proteoglycans from cartilage, for  
 stimulating the proliferation of inner ear utricular supporting cells,  
 for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 the release of a cytokine from PBMC cells, for inhibiting the binding of  
 a peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 cells, for stimulating proliferation of endothelial cells, for detecting  
 the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 are useful for isolating genomic and cDNA nucleotide sequences or  
 antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 in assays to identify other proteins or molecules involved in binding  
 interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 and gene mapping, in generation of antisense RNA and DNA, in the  
 preparation of PRO polypeptide, for generating transgenic animals or  
 knockout animals which in turn are useful in the development and  
 screening of therapeutically useful reagents, in gene therapy, for  
 chromosome identification, as chromosome marker, and for generating  
 probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 detecting its expression in specific cells, tissues or serum, and for  
 affinity purification of PRO from recombinant cell culture or natural  
 sources. (I) and (II) are useful for tissue typing. This is the amino  
 acid sequence of a novel human secreted and transmembrane PRO  
 polypeptide.  
 Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFPLSLLLLLVCEAIWRNSGNTLENGYFLSRKNENHSQPTQSSLEDSVTPTKAVKTT 60  
 Db 1 MTFPLSLLLLLVCEAIWRNSGNTLENGYFLSRKNENHSQPTQSSLEDSVTPTKAVKTT 60  
 QY 61 GKGVKGRNLDRLGLIIGAGWGRGVKNT 90  
 Db 61 GKGVKGRNLDRLGLIIGAGWGRGVKNT 90  
 RESULT 74  
 ADB24281

ID ADB24281 standard; protein; 90 AA.  
 AC ADB24281;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PRO polypeptide SEQ ID NO 474.  
 XX  
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003077714-A1.  
 XX  
 PD 24-APR-2003.  
 XX  
 XX 22-APR-2002; 2002US-00127901.  
 XX  
 PR 17-JUN-1998; 98US-0089599P.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 25-AUG-1999; 99US-00380137.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 (GETH ) GENENTECH INC.  
 Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI; 2003-755069/71.  
 N-PSDB; ADB24280.  
 New isolated, secreted and transmembrane PRO polypeptides and nucleic  
 acids, useful for the diagnosis, prevention and/or treatment of tumors,  
 such as lung, colon, breast, prostate, rectal, cervical and/or liver  
 tumors.  
 Claim 12; Fig 474; 637pp; English.  
 The invention relates to isolated human PRO polypeptides (secreted and  
 transmembrane polypeptides) and the polynucleotides encoding them. The  
 invention also relates to an antibody which specifically binds to a PRO  
 polypeptide, a method for stimulating the release of tumour necrosis  
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 proliferation or differentiation of chondrocyte cells and a method for  
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 polynucleotides are useful in molecular biology, including uses as  
 hybridisation probes, in chromosome and gene mapping, in generating  
 antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 be used in preparing PRO polypeptides by recombinant techniques and in  
 generating either transgenic animals or knock-out animals which are  
 useful in the development and screening of therapeutically useful  
 reagents. The PRO polypeptides or antibodies are used in preparing a  
 medicament for treating a condition responsive to the polypeptides or  
 antibodies, such as tumours, for stimulating and inhibiting proliferation  
 of human microvascular endothelial cells, for modulating the uptake of  
 glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 stimulating differentiation of adipocyte cells, for stimulating  
 proliferation of or gene expression in pericyte cells, for stimulating  
 the proliferation of inner ear utricular supporting cells or T-lymphocyte



CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60  
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60

QY 61 KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90

Db 61 KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 75

ADA96610  
ID ADA96610 standard; protein; 90 AA.

XX AC ADA96610;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
XX liver; microvascular endothelial cell; glucose; FFA;  
XX skeletal muscle cell; adipocyte cell; pericyte cell;  
XX inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
XX immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082690-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127837.

XX PR 01-SEP-1998; 98US-0098750P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 08-NOV-2000; 2000WO-US030952.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff B, Gao W;

XX Gerbitzen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;

XX WPI; 2003-755107/71.

XX DR N-PSDB; ADA96609.

PT PRO nucleic acid, useful for preparing a composition for treating e.g.,  
PT tumor or for tissue typing.

PS Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60

QY 61 KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90

Db 61 KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 76

ADA81182  
ID ADA81182 standard; protein; 90 AA.

XX AC ADA81182;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; FFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; T-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082702-A1.

XX 01-MAY-2003.

XX 23-APR-2002; 2002US-00128690.

XX 02-MAR-2000; 2000WO-US005841.

XX 30-MAY-2000; 2000WO-US014941.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerlitsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755111/71.

XX N-PSDB; ADA81181.

XX New PRO nucleic acid, useful for preparing a composition for treating

XX e.g., tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

XX Query Match 100.0%; Score 462; DB 6; Length 90;

XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;

XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGTLENGVFLSRNKENHSQPTQSSLEDSTVPTKAVKTT 60

DB 1 MTFPLSLLLLVCEAIWRNSGSGTLENGVFLSRNKENHSQPTQSSLEDSTVPTKAVKTT 60

QY 61 GKGIVKGNLDSRGLILGAEAWGRGVKKNT 90

DB 61 GKGIVKGNLDSRGLILGAEAWGRGVKKNT 90

RESULT 77

ADA96058

ID ADA96058 standard; protein; 90 AA.

XX AC ADA96058;

XX 20-NOV-2003 (first entry)

DE Human PRO polypeptide #237.

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

OS US2003082759-A1.

XX 01-MAY-2003.

XX 11-APR-2002; 2002US-00121040.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 05-OCT-1999; 99WO-US021547.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 02-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 02-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

XX 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015254.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021056.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Matanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-755114/71.  
DR N-PSDB; ADA96057.  
XX New isolated PRO polypeptides, useful for treating diabetes, hyper- or  
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
PT attack, various coagulation disorders and tumors.

XX

Claim 12; Fig 474; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX from cartilage are useful for treating sports-related joint problems,  
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
XX polypeptides are also useful for treating various mammalian haemoglobin-  
XX associated disorders such as various thalassaemias and conditions which  
XX may benefit from enhanced local immune system cell infiltration. This  
XX sequence represents a human PRO polypeptide of the invention. Note: The  
XX sequence data for this patent is also available in electronic format from  
XX USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLLLLVCEAIWFSNGSNTLENGYFLSRKNKHSQPTOSSLEDSVPTKAVKTT 60

Db 1 MTFELSLLLLVCEAIWFSNGSNTLENGYFLSRKNKHSQPTOSSLEDSVPTKAVKTT 60

QY 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 78

ID ADB26367 standard; protein; 90 AA.

XX ADB26367;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
XX liver; microvascular endothelial cell; glucose; FFA;  
XX skeletal muscle cell; adipocyte cell; pericyte cell;  
XX inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
XX immune system cell infiltration.

OS	Homo sapiens.	PR	24-AUG-2000;	2000WO-US033328.
XX		PR	08-NOV-2000;	2000WO-US0310952.
XX		PR	10-NOV-2000;	2000WO-US030873.
XX	US2003082760-A1.	PR	01-DEC-2000;	2000WO-US032678.
PD		PR	20-DEC-2000;	2000US-00747259.
PD	01-MAY-2003.	PR	28-DEC-2000;	2000WO-US034956.
XX		PR	28-FEB-2001;	2001US-00796498.
XX		PR	01-MAR-2001;	2001WO-US006520.
XX		PR	09-MAR-2001;	2001US-00802706.
PR	31-MAR-1997;	PR	14-MAR-2001;	2001US-00808689.
PR	12-JUN-1998;	PR	22-MAR-2001;	2001US-00816744.
PR	14-JUL-1998;	PR	05-APR-2001;	2001US-00828366.
PR	28-AUG-1998;	PR	10-MAY-2001;	2001US-00854208.
PR	10-SEP-1998;	PR	18-MAY-2001;	2001US-00860216.
PR	14-SEP-1998;	PR	25-MAY-2001;	2001US-00866028.
PR	14-SEP-1998;	PR	25-MAY-2001;	2001US-00866034.
PR	16-SEP-1998;	PR	01-JUN-2001;	2001US-00872035.
PR	17-SEP-1998;	PR	01-JUN-2001;	2001WO-US017800.
PR	07-OCT-1998;	PR	05-JUN-2001;	2001US-00874503.
PR	29-OCT-1998;	PR	14-JUN-2001;	2001US-00882636.
PR	29-OCT-1998;	PR	19-JUN-2001;	2001US-00886342.
PR	20-NOV-1998;	PR	20-JUN-2001;	2001WO-US019692.
PR	01-DEC-1998;	PR	21-JUN-2001;	2001US-00887879.
PR	05-JAN-1999;	PR	22-JUN-2001;	2001WO-US020116.
PR	08-MAR-1999;	PR	29-JUN-2001;	2001WO-US021066.
PR	10-MAR-1999;	PR	09-JUL-2001;	2001WO-US021735.
PR	20-APR-1999;	PR	18-JUL-2001;	2001US-00908827.
PR	14-MAY-1999;	PR	06-AUG-2001;	2001US-00924419.
PR	02-JUN-1999;	PR	09-AUG-2001;	2001US-00927796.
PR	01-SEP-1999;	PR	16-AUG-2001;	2001US-00931836.
PR	08-SEP-1999;	PR	19-DEC-2001;	2001US-00028072.
PR	13-SEP-1999;	XX		
PR	15-SEP-1999;	XX	(GETH ) GENENTECH INC.	
PR	15-SEP-1999;	XX		
PR	05-OCT-1999;	PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,	
PR	29-NOV-1999;	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PR	30-NOV-1999;	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
PR	30-NOV-1999;	XX	WPI: 2003-777204/73.	
PR	30-NOV-1999;	DR	N-PSDB; ADB26366.	
PR	06-JAN-2000;	XX		
PR	11-FEB-2000;	PT	New secreted and transmembrane PRO polypeptides and nucleic acids, useful	
PR	18-FEB-2000;	PT	in gene therapy, detecting the presence of tumor in a mammal, or	
PR	18-FEB-2000;	PT	modulating the uptake of glucose or free fatty acid by skeletal muscle	
PR	18-FEB-2000;	PT	cells or adipocyte cells.	
PR	22-FEB-2000;	XX	Claim 12; Fig 474; 659pp; English.	
PR	24-FEB-2000;	XX		
PR	24-FEB-2000;	CC	The invention relates to isolated human PRO polypeptides (secreted and	
PR	01-MAR-2000;	CC	transmembrane polypeptides) and the polynucleotides encoding them. The	
PR	02-MAR-2000;	CC	invention also relates to an antibody which specifically binds to a PRO	
PR	02-MAR-2000;	CC	polypeptide, a method for stimulating the release of tumour necrosis	
PR	02-MAR-2000;	CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the	
PR	10-MAR-2000;	CC	proliferation or differentiation of chondrocyte cells and a method for	
PR	15-MAR-2000;	CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,	
PR	15-MAR-2000;	CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The	
PR	21-MAR-2000;	CC	polynucleotides are useful in molecular biology, including uses as	
PR	30-MAR-2000;	CC	hybridisation probes, in chromosome and gene mapping, in generating	
PR	17-MAY-2000;	CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also	
PR	22-MAY-2000;	CC	be used in preparing PRO polypeptides by recombinant techniques and in	
PR	30-MAY-2000;	CC	generating either transgenic animals or knock-out animals which are	
PR	02-JUN-2000;	CC	useful in the development and screening of therapeutically useful	
PR	28-JUL-2000;	CC	reagents. The PRO polypeptides or antibodies are used in preparing a	
PR	11-AUG-2000;	CC	medicament for treating a condition responsive to the polypeptides or	
PR	23-AUG-2000;	CC	antibodies, such as tumours, for stimulating and inhibiting proliferation	
PR		CC	of human microvascular endothelial cells, for modulating the uptake of	
PR		CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	
PR		CC	stimulating differentiation of adipocyte cells, for stimulating	
PR		CC	proliferation of or gene expression in pericyte cells, for stimulating	
PR		CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte	
PR		CC	cells	

PR	14-MAY-1999;	99WO-US010733;
PR	02-JUN-1999;	99WO-US012252;
PR	01-SEP-1999;	99WO-US020111;
PR	08-SEP-1999;	99WO-US020944;
PR	13-SEP-1999;	99WO-US020944;
PR	15-SEP-1999;	99WO-US021090;
PR	15-SEP-1999;	99WO-US021547;
PR	05-OCT-1999;	99WO-US020889;
PR	29-NOV-1999;	99WO-US022814;
PR	30-NOV-1999;	99WO-US028313;
PR	30-NOV-1999;	99WO-US028409;
PR	01-DEC-1999;	99WO-US028301;
PR	01-DEC-1999;	99WO-US028634;
PR	02-DEC-1999;	99WO-US028551;
PR	02-DEC-1999;	99WO-US028564;
PR	02-DEC-1999;	99WO-US028565;
PR	16-DEC-1999;	99WO-US030095;
PR	20-DEC-1999;	99WO-US030959;
PR	20-DEC-1999;	99WO-US030720;
PR	22-DEC-1999;	99WO-US031243;
PR	30-DEC-1999;	99WO-US031274;
PR	05-JAN-2000;	2000WO-US000219;
PR	06-JAN-2000;	2000WO-US000277;
PR	06-JAN-2000;	2000WO-US000376;
PR	11-FEB-2000;	2000WO-US003565;
PR	18-FEB-2000;	2000WO-US004341;
PR	18-FEB-2000;	2000WO-US004342;
PR	22-FEB-2000;	2000WO-US004414;
PR	24-FEB-2000;	2000WO-US004504;
PR	24-FEB-2000;	2000WO-US005914;
PR	01-MAR-2000;	2000WO-US005601;
PR	02-MAR-2000;	2000WO-US005746;
PR	02-MAR-2000;	2000WO-US005841;
PR	15-MAR-2000;	2000WO-US006319;
PR	20-MAR-2000;	2000WO-US007332;
PR	21-MAR-2000;	2000WO-US007537;
PR	30-MAR-2000;	2000WO-US008439;
PR	17-MAY-2000;	2000WO-US013705;
PR	20-MAY-2000;	2000WO-US014042;
PR	30-MAY-2000;	2000WO-US014941;
PR	02-JUN-2000;	2000WO-US015264;
PR	18-JUL-2000;	2000WO-US020710;
PR	11-AUG-2000;	2000WO-US020311;
PR	23-AUG-2000;	2000WO-US023522;
PR	24-AUG-2000;	2000WO-US023328;
PR	08-NOV-2000;	2000WO-US030952;
PR	10-NOV-2000;	2000WO-US030873;
PR	01-DEC-2000;	2000WO-US032678;
PR	20-DEC-2000;	2000US-00747259;
PR	20-DEC-2000;	2000WO-US034956;
PR	28-FEB-2001;	2001US-00796498;
PR	28-FEB-2001;	2001WO-US006520;
PR	01-MAR-2001;	2001WO-US006666;
PR	09-MAR-2001;	2001US-00802706;
PR	14-MAR-2001;	2001US-00808689;
PR	02-APR-2001;	2001US-00816744;
PR	25-APR-2001;	2001US-00828366;
PR	10-MAY-2001;	2001US-00854208;
PR	18-MAY-2001;	2001US-00860216;
PR	23-MAY-2001;	2001US-00866028;
PR	25-MAY-2001;	2001US-00866034;
PR	25-MAY-2001;	2001WO-US017092;
PR	01-JUN-2001;	2001US-00872035;
PR	01-JUN-2001;	2001WO-US017800;
PR	05-JUN-2001;	2001US-00874503;
PR	14-JUN-2001;	2001US-00882636;
PR	19-JUN-2001;	2001US-00886342;
PR	20-JUN-2001;	2001WO-US019692;
PR	22-JUN-2001;	2001US-00887879;
PR	22-JUN-2001;	2001WO-US020116;

Query Match	100.0%;	Score 462;	DB 6;	Length 90;
Best Local Similarity	100.0%;	Pred. No. 9.8e-49;		
Matches 90; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy 1 MTFFLSLILLVCEAIWRNSGSNTILENGYFLSRNKENHSQPTQSSLEDSTVTPKAVKTT 60

61 GKGVKGRNLD SRGLIIGAEAWGRGVKKNT 90

61 GKGLVKGRLNDSRGITIGAEAWGRGVKKNT 90

RESULT 79  
ADB21852  
ID ADB21852 standard: protein: 90 AA.

AC ADB21852;

DT 20-NOV-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO1159.

Human; secreted and transmembrane protein; PRO;  
tumour necrosis factor alpha release; TNF-alpha release;  
glucose uptake modulator; FFA uptake modulator;  
cell proliferation stimulator; cell differentiation stimulator;  
cell differentiation inhibitor; cytokine release stimulator;  
lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
cervical tumour; liver tumour; chromosome mapping; gene mapping;  
gene therapy; chromosome identification; chromosome marker

OS Homo sapiens.

PN US2003082765-A1.

01-MAY-2003.

17-MAY-2002: 2002US-00147492.

31-MAR-1997: 97WO-US005230.

PR 12-JUN-1998: 98WO-USUI2436:  
PR 14-JUL-1998: 98WO-USO14552:

FR 28-AUG-1998; 98WC-US011888;  
PP 10-SEP-1998; 98WC-US018824

PR 14-SEP-1998: 98WQ-US019093.  
PR 14-SEP-1998: 98WQ-US019094.

PR 14-SEP-1998; 98WC-US019171.  
PR 16-SEP-1998; 98WC-US019330

PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141

PR 29-OCT-1998; 98W0-US0229991.  
PR 29-OCT-1998; 98W0-US0229992.  
PR 29-OCT-1998; 98W0-US0229993.

PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108

PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US0005038

PR 10-MAR-1999; 99WO-US005190-  
PR 20-APR-1999; 99WO-US008615

PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen MF, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-786920/74.  
 DR N-PSDB; ADB21851.  
 XX  
 XX New secreted and transmembrane PRO polypeptide useful for detecting the  
 PT presence of tumor in a mammal, or modulating the uptake of glucose or  
 PT free fatty acid by skeletal muscle cells or adipocyte cells.  
 XX  
 XX Claim 12; Fig 474; 639pp; English.  
 XX  
 XX The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from BMC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumor in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This is the amino  
 CC acid sequence of a novel human secreted and transmembrane PRO  
 XX polypeptide.  
 XX  
 XX Sequence 90 AA;  
 SQ  
 Query Match 100.0%; Score 462; DB 6; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Oy 1 MTFLLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTSSLEDSVTPKAVKTT 60  
 Db 1 MTFLLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTSSLEDSVTPKAVKTT 60  
 Oy 61 KGKIVKGRNLSRGLILGAEGWGRGVKNT 90  
 Db 61 KGKIVKGRNLSRGLILGAEGWGRGVKNT 90  
 RESULT 80  
 ADA77631  
 ID ADA77631 standard; protein; 90 AA.  
 XX  
 AC ADA77631;

XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PRO polypeptide #237.  
 XX  
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 XX Homo sapiens.  
 OS  
 XX US2003068797-A1.  
 PN  
 XX  
 XX 10-APR-2003.  
 PD  
 XX  
 XX 07-MAY-2002; 2002US-00140921.  
 PF  
 XX 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030311.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US007532.  
PR 21-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2000WO-US0796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
PA  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen WE, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-625489/59.  
DR N-PSDB; ADA77630.  
XX  
XX Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801  
PT and PRO114, useful in the preparation of a medicament for treating a  
PT condition responsive to PRO polypeptide, and as therapeutic agents e.g.  
PT vaccines.  
XX  
XX Claim 12; Fig 474; 659pp; English.  
PS  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNKHSQTSQSLDSVPTTKAVKTT 60  
Db 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNKHSQTSQSLDSVPTTKAVKTT 60  
QY 61 GKGIVKGRNLDGRGLILGAEAWGRGVKKNT 90  
Db 61 GKGIVKGRNLDGRGLILGAEAWGRGVKKNT 90  
RESULT 81  
ADB18371  
ID ADB18371 standard; protein; 90 AA.  
XX ADB18371;  
AC ADB18371;  
XX 20-NOV-2003 (first entry)  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
XX US2003077710-A1.  
PN  
XX 24-APR-2003.  
PD  
XX 22-APR-2002; 2002US-00127825.  
PF  
XX 22-OCT-1998; 98US-0105169P.  
PR

PR 01-SEP-1999; 99WO-US020111.  
 PR 18-OCT-1999; 99US-00403297.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 PA  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 DR WPI; 2003-755065/71.  
 DR N-PSDB; ADB18370.  
 XX  
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
 PT in gene therapy, in chromosome and gene mapping, as chromosome markers,  
 PT in tissue typing, and in identifying chromosomes.  
 XX  
 PS Claim 12; Fig 474; 637pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC the USPTO website at seqdata.uspto.gov.  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 MTFLLSLLLLVCEAIWRNSGNSLTENGYPFLSRNKHNSPTQSSLEDSVTPKAVKTT 60  
 Db 1 MTFLLSLLLLVCEAIWRNSGNSLTENGYPFLSRNKHNSPTQSSLEDSVTPKAVKTT 60  
 Qy 61 GKGIVKGRNLDRLGLLGAEGWGRVKKNT 90  
 Db 61 GKGIVKGRNLDRLGLLGAEGWGRVKKNT 90

RESULT 82  
 ADA87054

ID ADA87054 standard; protein; 90 AA.  
 XX  
 AC ADA87054;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO1159.  
 XX  
 KW Human; secreted and transmembrane protein; PRO;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003082709-A1.  
 XX  
 PD 01-MAY-2003.  
 XX  
 PF 15-MAY-2002; 2002US-00146791.  
 XX  
 PR 17-AUG-1998; 98US-0096895P.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 25-AUG-1999; 99US-00380137.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 DR WPI; 2003-786912/74.  
 DR N-PSDB; ADA87053.  
 XX  
 PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,  
 PT for preparing a composition for treating e.g., tumor, or for tissue  
 PT typing.  
 PS Claim 12; Fig 474; 637pp; English.  
 XX  
 CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from FBM cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (i) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (ii) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(i)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural



CC sources. (I) and (II) are useful for tissue typing. This is the amino  
CC acid sequence of a novel human secreted and transmembrane PRO  
CC polypeptide.  
XX  
SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTOSLSLDSVTPTKAVKTT 60  
Db 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTOSLSLDSVTPTKAVKTT 60  
Qy 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90  
Db 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90  
RESULT 83  
ADA88157  
ID ADA88157 standard; protein; 90 AA.  
XX  
AC ADA88157;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1159.  
XX  
KW Human; secreted and transmembrane protein; PRO;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW Gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
PN US2003082700-A1.  
XX  
PD 01-MAY-2003.  
XX  
PF 23-APR-2002; 2002US-00128684.  
XX  
PR 05-JUN-2000; 2000US-0209832P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;  
XX  
WPI; 2003-786910/74.  
DR N-PSDB; ADA88156.  
XX  
New PRO nucleic acid, useful for preparing a composition for treating  
e.g., tumor or for tissue typing.  
XX  
Claim 12; Fig 474; 637pp; English.  
XX  
The invention describes 305 nucleic acids encoding PRO (secreted and  
transmembrane) polypeptides (I). (I) is useful for stimulating the  
release of TNF-alpha from human blood, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating the proliferation or differentiation of chondrocyte cells,  
for stimulating the proliferation of or gene expression in pericyte  
cells, for stimulating the release of proteoglycans from cartilage, for  
stimulating the proliferation of inner ear utricular supporting cells,  
for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from BMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This is the amino  
CC acid sequence of a novel human secreted and transmembrane PRO  
CC polypeptide.  
XX  
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTOSLSLDSVTPTKAVKTT 60  
Db 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTOSLSLDSVTPTKAVKTT 60

Qy 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90  
Db 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

## RESULT 84

ADA46545  
ID ADA46545 standard; protein; 90 AA.

XX  
AC ADA46545;

XX  
DT 20-NOV-2003 (first entry)

XX  
DE Novel human secreted and transmembrane protein PRO1159.

XX  
KW Human; secreted and transmembrane protein; PRO;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.

XX  
OS Homo sapiens.

XX  
PN US2003054516-A1.

XX  
PD 20-MAR-2003.

XX  
PF 12-APR-2002; 2002US-00121050.

XX  
PR 31-MAR-1997; 97WO-US005230.

XX  
PR 12-JUN-1998; 98WO-US012456.

XX  
PR 14-JUL-1998; 98WO-US014552.

XX  
PR 28-AUG-1998; 98WO-US017888.

XX  
PR 10-SEP-1998; 98WO-US018824.

XX  
PR 14-SEP-1998; 98WO-US019093.

XX  
PR 14-SEP-1998; 98WO-US019094.

XX  
PR 16-SEP-1998; 98WO-US019177.

XX  
PR 17-SEP-1998; 98WO-US019330.

XX  
PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 29-OCT-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US0005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 14-MAY-1999; 99WO-US010733.  
PR 01-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 03-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005501.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006319.  
PR 20-MAR-2000; 2000WO-US006884.  
PR 21-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US007532.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 23-AUG-2000; 2000WO-US023528.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-521853/49.

N-PSDB; ADA46544.

New pro nucleic acid, useful for preparing a composition for treating  
e.g., tumor.

Claim 12; Fig 474; 200pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumor in a mammal. The tumor is lung, colon, breast, prostate, rectal, cervical or liver tumor. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTOSSLEDSVTPKAVKTT 60  
Db 1 MTFPLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTOSSLEDSVTPKAVKTT 60  
Qy 61 GKGIKGRNLDNRGLILGAEWGRGVKNT 90  
|||||

61 GKGIVKGRNLDRLGLLGAEGAWGRGVKNT 90

CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRKNHNSQPTQSSLEDSVTPPKAVKTT 60  
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRKNHNSQPTQSSLEDSVTPPKAVKTT 60  
QY 61 GKGIVKGRNLDRLGLLGAEGAWGRGVKNT 90  
DB 61 GKGIVKGRNLDRLGLLGAEGAWGRGVKNT 90

RESULT 86

ADB29127

ID ADB29127 standard; protein; 90 AA.

XX AC ADB29127;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082706-A1.

XX PD 01-MAY-2003.

XX PF 24-APR-2002; 2002US-00131836.

XX PR 09-DEC-1999; 9SUS-0170262P.

XX PR 10-NOV-2000; 2000WO-US030873.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH ) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforgre L, Desnoyers L, Filvaroff E;

XX PI Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-777202/73.

XX DR N-PSDB; ADB29126.

XX

DB

RESULT 85

ID ADB28575

XX AD ADB28575 standard; protein; 90 AA.

XX AC ADB28575;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082699-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127851.

XX PR 17-JUN-1998; 9SUS-0089599P.

XX PR 02-JUN-1998; 9SUS-0012252.

XX PR 25-AUG-1999; 9SUS-00380137.

XX PR 30-NOV-1999; 9SUS-00283113.

XX PR 30-MAR-2000; 2000WO-US008439.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH ) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforgre L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-777202/73.

XX DR N-PSDB; ADB28574.

XX PT New PRO nucleic acid, useful for preparing a composition for treating

XX PT e.g., tumor or for tissue typing.

XX PS Claim 12; Fig 474; 637pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and  
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The  
XX CC invention also relates to an antibody which specifically binds to a PRO  
XX CC polypeptide, a method for stimulating the release of tumour necrosis  
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX CC proliferation or differentiation of chondrocyte cells and a method for  
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX CC polynucleotides are useful in molecular biology, including uses as  
XX CC hybridisation probes, in chromosome and gene mapping, in generating  
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX CC be used in preparing PRO polypeptides by recombinant techniques and in  
XX CC generating either transgenic animals or knock-out animals which are  
XX CC useful in the development and screening of therapeutically useful  
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a  
XX CC medicament for treating a condition responsive to the polypeptides or  
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX CC of human microvascular endothelial cells, for modulating the uptake of  
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

Human; secreted protein; transmembrane protein; PRO;  
adrenal cortical capillary endothelial cell; angiogenesis; wound healing;  
diabetes; obesity; hyper-insulinaemia; hypo-insulinaemia;  
chondrocyte redifferentiation; bone disorder; cartilage disorder;  
sports injury; arthritis; kidney mesangial cell proliferation;  
kidney disorder; Berger disease; neuropathy; coeliac disease;  
dermatitis herpetiformis; Crohn's disease; tumour; cancer.  
Homo sapiens.

PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093333P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095313P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0096011P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096323P.  
PR 13-AUG-1998; 98US-0096413P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 20-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 31-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 17-SEP-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.

PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US0005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US028634.  
PR 20-DEC-1999; 99WO-US030095.  
PR 05-JAN-2000; 99WO-US030911.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 02-MAR-2000; 2000WO-US005004.  
PR 10-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006319.  
PR 20-MAR-2000; 2000WO-US006884.  
PR 30-MAR-2000; 2000WO-US007377.  
PR 15-MAY-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013358.  
PR 22-MAY-2000; 2000WO-US013705.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.  
PR 28-JUL-2000; 2000WO-US020710.

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFELSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSOPTOSSEDSVTPKAVKTT 60

Db 1 MTFELSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSOPTOSSEDSVTPKAVKTT 60

Qy 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

Db 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 88

ADA77079

ID ADA77079 standard; protein; 90 AA.

XX ADA77079;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

OS Homo sapiens.

XX US2003059909-A1.  
PN 27-MAR-2003.  
XX 10-MAY-2002; 2002US-00143032.  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 16-SEP-1998; 98WO-US019177.  
PR 14-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 13-SEP-1999; 99WO-US020594.  
PR 15-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 05-OCT-1999; 99WO-US021547.  
PR 29-NOV-1999; 99WO-US023089.  
PR 30-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 01-MAR-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006319.  
PR 20-MAR-2000; 2000WO-US006884.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030973.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021086.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tomas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-540684/51.  
DR N-PSDB; ADA77078.

XX New secreted and transmembrane nucleic acids and polypeptides, designated  
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
PT cancer.

XX Claim 12; Fig 474; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLLVCAIWRNSGNTLENGYPLSRNKHNSQPTOSLSLDSVPTPKAVKTT 60  
Db 1 MTFPLSLLLLLVCAIWRNSGNTLENGYPLSRNKHNSQPTOSLSLDSVPTPKAVKTT 60  
Qy 61 GKGIVKGNLDSRGLILGAEGWGRGVKNT 90  
Db 61 GKGIVKGNLDSRGLILGAEGWGRGVKNT 90

## RESULT 89

ADA22500

ID ADA22500 standard; protein; 90 AA.

XX AC ADA22500;

XX DT 20-NOV-2003 (first entry)

XX DE Human secreted/transmembrane polypeptide PRO1159.

XX human; tumour; cancer; colorectal cancer; gene therapy;  
KW chondrocyte differentiation; VEGF inhibition;  
KW vascular endothelial growth factor; Alzheimer's disease;  
KW Parkinson's disease; atherosclerosis; cystic fibrosis;  
XX multiple sclerosis; ovarian cancer; tissue typing.

XX OS Homo sapiens.

XX PN US2003040473-A1.

XX PD 27-FEB-2003.

XX PF 19-NOV-2001; 2001US-00989726.

XX 16-JUN-1997; 97US-0049787P.

XX 17-OCT-1997; 97US-0062250P.

XX 05-NOV-1997; 97WO-US020069.

XX 12-NOV-1997; 97US-0065186P.

XX 13-NOV-1997; 97US-0065311P.

XX 24-NOV-1997; 97US-0066770P.

XX 25-FEB-1998; 98US-0075945P.

XX 20-MAR-1998; 98US-0078910P.

XX 28-APR-1998; 98US-0083322P.

XX 07-MAY-1998; 98US-0084600P.

XX 28-MAY-1998; 98US-0087106P.

XX 02-JUN-1998; 98US-0087607P.

XX 02-JUN-1998; 98US-0087609P.

XX 02-JUN-1998; 98US-0087759P.

XX 03-JUN-1998; 98US-0087827P.

XX 04-JUN-1998; 98US-0088021P.

XX 04-JUN-1998; 98US-0088025P.

XX 04-JUN-1998; 98US-0088026P.

XX 04-JUN-1998; 98US-0088028P.

XX 04-JUN-1998; 98US-0088030P.

XX 04-JUN-1998; 98US-0088032P.

XX 04-JUN-1998; 98US-0088033P.

XX 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.

```
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149339P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.

PR 15-MAY-2000; 2000WO-US013359.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60
DB 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60

QY 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90
DB 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 90
ADA88709
ID ADA88709 standard; protein; 90 AA.
AC ADA88709;
XX
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumor necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003073213-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124819.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
```



PR	13-SEP-1999,	99WO-US020944.
PR	15-SEP-1999,	99WO-US021090.
PR	15-SEP-1999,	99WO-US021547.
PR	05-OCT-1999,	99WO-US023089.
PR	29-NOV-1999,	99WO-US028214.
PR	30-NOV-1999,	99WO-US028313.
PR	30-NOV-1999,	99WO-US028409.
PR	01-DEC-1999,	99WO-US028301.
PR	01-DEC-1999,	99WO-US028634.
PR	02-DEC-1999,	99WO-US028551.
PR	02-DEC-1999,	99WO-US028564.
PR	02-DEC-1999,	99WO-US028565.
PR	16-DEC-1999,	99WO-US030095.
PR	20-DEC-1999,	99WO-US030911.
PR	20-DEC-1999,	99WO-US030999.
PR	22-DEC-1999,	99WO-US030720.
PR	30-DEC-1999,	99WO-US031243.
PR	30-DEC-1999,	99WO-US031274.
PR	05-JAN-2000,	2000WO-US000219.
PR	05-JAN-2000,	2000WO-US000277.
PR	05-JAN-2000,	2000WO-US000326.
PR	11-FEB-2000,	2000WO-US003565.
PR	18-FEB-2000,	2000WO-US004341.
PR	18-FEB-2000,	2000WO-US004342.
PR	22-FEB-2000,	2000WO-US004414.
PR	24-FEB-2000,	2000WO-US004914.
PR	24-FEB-2000,	2000WO-US005004.
PR	01-MAR-2000,	2000WO-US005061.
PR	02-MAR-2000,	2000WO-US005746.
PR	02-MAR-2000,	2000WO-US005841.
PR	10-MAR-2000,	2000WO-US006319.
PR	15-MAR-2000,	2000WO-US006884.
PR	20-MAR-2000,	2000WO-US007377.
PR	21-MAR-2000,	2000WO-US007532.
PR	30-MAR-2000,	2000WO-US008439.
PR	17-MAY-2000,	2000WO-US013705.
PR	22-MAY-2000,	2000WO-US014042.
PR	30-MAY-2000,	2000WO-US014941.
PR	02-JUN-2000,	2000WO-US015264.
PR	28-JUL-2000,	2000WO-US020710.
PR	11-AUG-2000,	2000WO-US022031.
PR	23-AUG-2000,	2000WO-US023522.
PR	24-AUG-2000,	2000WO-US023328.
PR	08-NOV-2000,	2000WO-US030952.
PR	10-NOV-2000,	2000WO-US030873.
PR	01-DEC-2000,	2000WO-US032678.
PR	20-DEC-2000,	2000US-U0747259.
PR	20-DEC-2000,	2000US-U034956.
PR	28-DEC-2000,	2000US-U036498.
PR	28-FEB-2001,	2001WO-US006520.
PR	01-MAR-2001,	2001WO-US002766.
PR	09-MAR-2001,	2001US-U0802706.
PR	14-MAR-2001,	2001US-U080989.
PR	22-MAR-2001,	2001US-U0816744.
PR	05-APR-2001,	2001US-U0828366.
PR	10-MAY-2001,	2001US-U0854208.
PR	10-MAY-2001,	2001US-U0854280.
PR	18-MAY-2001,	2001US-U0860216.
PR	25-MAY-2001,	2001US-U08606028.
PR	25-MAY-2001,	2001US-U0866034.
PR	25-MAY-2001,	2001WO-US017092.
PR	01-JUN-2001,	2001US-U0872035.
PR	01-JUN-2001,	2001WO-US020116.
PR	05-JUN-2001,	2001US-U0874503.
PR	14-JUN-2001,	2001US-U0882636.
PR	19-JUN-2001,	2001US-U0886342.
PR	20-JUN-2001,	2001WO-US019692.
PR	21-JUN-2001,	2001US-U0887879.
PR	22-JUN-2001,	2001WO-US020116.
PR	09-JUL-2001,	2001WO-US021066.
PR	09-JUL-2001,	2001WO-US021735.
PR	18-JUL-2001,	2001US-U0908699.
PR	06-AUG-2001,	2001US-U0924419.

PR	09-AUG-2001; 2001US-009277796.	
PR	16-AUG-2001; 2001US-00931836.	
PR	19-DEC-2001; 2001US-00028072.	
XX		
PA	(GETH ) GENENTECH INC.	
XX		
PI	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX		
DR	WPI; 2003-743816/70.	
DR	N-PSDB; ADA88708.	
XX		
XX	New secreted and transmembrane PRO polypeptides and nucleic acids, useful	
PT	in gene therapy, detecting the presence of tumor in a mammal, or	
PT	modulating the uptake of glucose or free fatty acid by skeletal muscle	
PT	cells or adipocyte cells.	
XX		
PS	Claim 12; fig 474; 659pp; English.	
XX		
CC	The invention describes 305 nucleic acids encoding PRO (secreted and	
CC	transmembrane) polypeptides (I). (I) is useful for stimulating the	
CC	release of TNF-alpha from human blood, for modulating the uptake of	
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	
CC	stimulating the proliferation or differentiation of chondrocyte cells,	
CC	for stimulating the proliferation of or gene expression in pericyte	
CC	cells, for stimulating the release of proteoglycans from cartilage, for	
CC	stimulating the proliferation of inner ear utricular supporting cells,	
CC	for stimulating the proliferation of T-lymphocyte cells, for stimulating	
CC	the release of a cytokine from PMBC cells, for inhibiting the binding of	
CC	A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte	
CC	cells, for stimulating proliferation of endothelial cells, for detecting	
CC	the presence of tumour in a mammal. The tumour is lung, colon, breast,	
CC	prostate, rectal, cervical or liver tumour. The oligonucleotide probes	
CC	are useful for isolating genomic and cDNA nucleotide sequences or	
CC	antisense probes. (I) is also useful as therapeutic agent. PRO is useful	
CC	in assays to identify other proteins or molecules involved in binding	
CC	interaction. A polynucleotide (II) encoding (I) is useful in chromosome	
CC	and gene mapping, in generation of antisense RNA and DNA, in the	
CC	preparation of PRO polypeptide, for generating transgenic animals or	
CC	knockout animals which in turn are useful in the development and	
CC	screening of therapeutically useful reagents, in gene therapy, for	
CC	chromosome identification, as chromosome marker, and for generating	
CC	probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g	
CC	detecting its expression in specific cells, tissues or serum, and for	
CC	affinity purification of PRO from recombinant cell culture or natural	
CC	sources. (I) and (II) are useful for tissue typing. This is the amino	
CC	acid sequence of a novel human secreted and transmembrane PRO	
CC	polypeptide.	
XX		
SQ	Sequence 90 AA;	
	Query Match 100.0%; Score 462; DB 7; Length 90;	
	Best Local Similarity 100.0%; Pred. No. 9.8e-43;	
	Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps	
Qy	1 MTFELSLILLVCEAIWRNSGNTLNGYFLFSRNKENHSQFTSSLSDSVTPPKAVKTT 60	
Db	1 MTFELSLILLVCEAIWRNSGNTLNGYFLFSRNKENHSQFTSSLSDSVTPPKAVKTT 60	
Qy	61 GKGIKVGKRLNDSRGLILGAEAWGRGVKNT 90	
Db	61 GKGIKVGKRLNDSRGLILGAEAWGRGVKNT 90	
RESULT 91		
ADA97714		
ID	ADA97714 standard; protein; 90 AA.	
XX	ADA97714;	
AC	ADA97714;	
XX		
DT	20-NOV-2003 (first entry)	

Human PRO polypeptide #237.

Human; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.

Homo sapiens.

US2003082686-A1.

01-MAY-2003.

19-APR-2002; 2002US-00125926.

05-JUN-2000; 2000US-0209832P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WFI; 2003-755106/71.

N-PSDB; ADA97713.

Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

PRO4978, useful in molecular biology, chromosome and gene mapping, in

generating antisense RNA and DNA, and in gene therapy.

Claim 12; Fig 474; 665pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIRWSNGSNTLENGYFLSRNKHNSQTSLSLDSVTPTKAVKTT 60  
|||||  
Db 1 MTFFLSLLLLVCEAIRWSNGSNTLENGYFLSRNKHNSQTSLSLDSVTPTKAVKTT 60  
|||||

QY 61 GGIIVKGRNLDNRGLILGAEAWGRGVKKNT 90  
|||||

Db 61 GGIIVKGRNLDNRGLILGAEAWGRGVKKNT 90  
|||||

RESULT 92

ADB27471  
ID ADB27471 standard; protein; 90 AA.

XX AC ADB27471;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003022239-A1.

XX PD 30-JAN-2003.

XX PF 12-APR-2002; 2002US-00121049.

XX PR 18-JUN-1997; 97US-0049911P.

XX PR 26-AUG-1997; 97US-0056974P.

XX PR 17-SEP-1997; 97US-0059113P.

XX PR 17-SEP-1997; 97US-0059115P.

XX PR 17-SEP-1997; 97US-0059117P.

XX PR 17-SEP-1997; 97US-0059122P.

XX PR 18-SEP-1997; 97US-0059184P.

XX PR 19-SEP-1997; 97US-0059263P.

XX PR 19-SEP-1997; 97US-0059352P.

XX PR 19-SEP-1997; 97US-0059588P.

XX PR 24-SEP-1997; 97US-0059836P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 17-OCT-1997; 97US-0062287P.

XX PR 17-OCT-1997; 97US-0063755P.

XX PR 24-OCT-1997; 97US-0062814P.

XX PR 24-OCT-1997; 97US-0062816P.

XX PR 24-OCT-1997; 97US-0063045P.

XX PR 24-OCT-1997; 97US-0063082P.

XX PR 24-OCT-1997; 97US-0063127P.

XX PR 27-OCT-1997; 97US-0063327P.

XX PR 27-OCT-1997; 97US-0063329P.

XX PR 28-OCT-1997; 97US-0063550P.

XX PR 28-OCT-1997; 97US-0063561P.

XX PR 29-OCT-1997; 97US-0063704P.

XX PR 29-OCT-1997; 97US-0063733P.

XX PR 29-OCT-1997; 97US-0063735P.

XX PR 29-OCT-1997; 97US-0063738P.



Query Match	100.0%;	Score 462;	DB 7;	Length 90;	
Best Local Similarity	100.0%;	Pred. No. 9.8e-49;			
Matches	90;	Conservative	0;	Mismatches	0;
				Indels	0;
				Gaps	0;
QY	1	MTFFLSLLLLVCEATWRSNGSNTLNGYFSLRNKENHSQPTQSSLEDVPTKAVKTT	60		
DB	1	MTFFLSLLLLVCEATWRSNGSNTLNGYFSLRNKENHSQPTQSSLEDVPTKAVKTT	60		
QY	61	GKGIKGRNLDNRGLILGAEWGRGVKKNT	90		
DB	61	GKGIKGRNLDNRGLILGAEWGRGVKKNT	90		
RESULT 93					
ADB22404					
ID	ADB22404	standard; protein; 90 AA.			
XX					
AC	ADB22404;				
XX					
DT	20-NOV-2003	(first entry)			
DE					
DE		Novel human secreted and transmembrane protein PRO1159.			
XX					
KW		Human; secreted and transmembrane protein; PRO;			
KW		Tumour necrosis factor alpha release; TNF-alpha release;			
KW		glucose uptake modulator; FFA uptake modulator;			
KW		cell proliferation stimulator; cell differentiation stimulator;			
KW		cell differentiation inhibitor; cytokine release stimulator; tumour;			
KW		lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;			
KW		cervical tumour; liver tumour; chromosome mapping; gene mapping;			
KW		gene therapy; chromosome identification; chromosome marker.			
XX					
OS		Homo sapiens.			
PN					
EN		US2003087344-A1.			
XX					
PD		08-MAY-2003.			
XX					
FF	16-APR-2002;	2002US-00123905.			
XX					
PR	18-JUN-1997;	97US-0049911P.			
PR	26-AUG-1997;	97US-0056974P.			
PR	17-SEP-1997;	97US-0059113P.			
PR	17-SEP-1997;	97US-0059115P.			
PR	17-SEP-1997;	97US-0059117P.			
PR	17-SEP-1997;	97US-0059122P.			
PR	17-SEP-1997;	97US-0059184P.			
PR	18-SEP-1997;	97US-0059263P.			
PR	19-SEP-1997;	97US-0059352P.			
PR	19-SEP-1997;	97US-0059588P.			
PR	24-SEP-1997;	97US-0059836P.			
PR	17-OCT-1997;	97US-0062250P.			
PR	17-OCT-1997;	97US-0062285P.			
PR	17-OCT-1997;	97US-0062287P.			
PR	17-OCT-1997;	97US-0063755P.			
PR	24-OCT-1997;	97US-0062814P.			
PR	24-OCT-1997;	97US-0062816P.			
PR	24-OCT-1997;	97US-0063045P.			
PR	24-OCT-1997;	97US-0063082P.			
PR	24-OCT-1997;	97US-0063127P.			
PR	27-OCT-1997;	97US-0063327P.			
PR	27-OCT-1997;	97US-0063329P.			
PR	28-OCT-1997;	97US-0063550P.			
PR	28-OCT-1997;	97US-0063561P.			
PR	29-OCT-1997;	97US-0063704P.			
PR	29-OCT-1997;	97US-0063733P.			
PR	29-OCT-1997;	97US-0063735P.			
PR	29-OCT-1997;	97US-0063738P.			
PR	03-NOV-1997;	97US-0064248P.			
PR	07-NOV-1997;	97US-0064809P.			
PR	12-NOV-1997;	97US-0065186P.			
PR	17-NOV-1997;	97US-0065846P.			
PR	21-NOV-1997;	97US-0066364P.			
PR					
PR	24-NOV-1997;	97US-0066453P.			
PR	24-NOV-1997;	97US-0066511P.			
PR	24-NOV-1997;	97US-0066706P.			
PR	11-DEC-1997;	97US-0069212P.			
PR	11-DEC-1997;	97US-0069278P.			
PR	11-DEC-1997;	97US-0069334P.			
PR	16-DEC-1997;	97US-0069694P.			
PR	23-JAN-1998;	98US-0072320P.			
PR	04-FEB-1998;	98US-0073612P.			
PR	09-FEB-1998;	98US-0074086P.			
PR	09-FEB-1998;	98US-0074092P.			
PR	12-MAR-1998;	98US-0077791P.			
PR	20-MAR-1998;	98US-0078910P.			
PR	25-MAR-1998;	98US-0079294P.			
PR	27-MAR-1998;	98US-0079663P.			
PR	31-MAR-1998;	98US-0079728P.			
PR	09-APR-1998;	98US-0080165P.			
PR	14-APR-1998;	98US-0081229P.			
PR	15-APR-1998;	98US-0081695P.			
PR	15-APR-1998;	98US-0081817P.			
PR	24-APR-1998;	98US-0082999P.			
PR	28-APR-1998;	98US-0083322P.			
PR	29-APR-1998;	98US-0083545P.			
PR	07-MAY-1998;	98US-0084600P.			
PR	07-MAY-1998;	98US-0084627P.			
PR	12-MAY-1998;	98US-0084637P.			
PR	13-MAY-1998;	98US-0085149P.			
PR	13-MAY-1998;	98US-0085323P.			
PR	13-MAY-1998;	98US-0085338P.			
PR	15-MAY-1998;	98US-0085339P.			
PR	15-MAY-1998;	98US-0085579P.			
PR	15-MAY-1998;	98US-0085697P.			
PR	22-MAY-1998;	98US-0085704P.			
PR	22-MAY-1998;	98US-0086414P.			
PR	26-MAY-1998;	98US-0086430P.			
PR	04-JUN-1998;	98US-0087106P.			
PR	10-JUN-1998;	98US-0088026P.			
PR	10-JUN-1998;	98US-0088730P.			
PR	11-JUN-1998;	98US-0088741P.			
PR	11-JUN-1998;	98US-0088810P.			
PR	12-JUN-1998;	98US-0088858P.			
PR	17-JUN-1998;	98US-008912455.			
PR	17-JUN-1998;	98US-0089532P.			
PR	18-JUN-1998;	98US-0089599P.			
PR	19-JUN-1998;	98US-0089907P.			
PR	23-JUN-1998;	98US-0089947P.			
PR	24-JUN-1998;	98US-0090429P.			
PR	24-JUN-1998;	98US-0090455P.			
PR	26-JUN-1998;	98US-0090538P.			
PR	01-JUL-1998;	98US-0090863P.			
PR	02-JUL-1998;	98US-0091360P.			
PR	07-JUL-1998;	98US-0091519P.			
PR	14-JUL-1998;	98US-0091982P.			
PR	20-JUL-1998;	98US-0093339P.			
PR	30-JUL-1998;	98US-0094651P.			
PR	04-AUG-1998;	98US-0095285P.			
PR	04-AUG-1998;	98US-0095301P.			
PR	04-AUG-1998;	98US-0095302P.			
PR	11-AUG-1998;	98US-0095325P.			
PR	11-AUG-1998;	98US-0096143P.			
PR	12-AUG-1998;	98US-0096146P.			
PR	17-AUG-1998;	98US-0096329P.			
PR	17-AUG-1998;	98US-0096768P.			
PR	17-AUG-1998;	98US-0096773P.			
PR	17-AUG-1998;	98US-0096791P.			
PR	17-AUG-1998;	98US-0096891P.			
PR	18-AUG-1998;	98US-0096895P.			
PR	19-AUG-1998;	98US-0096960P.			
PR	20-AUG-1998;	98US-0097141P.			
PR	20-AUG-1998;	98US-0097218P.			

```
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106858P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113298P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 12-JAN-1999; 98US-0115549P.
PR 12-JAN-1999; 98US-0115557P.
PR 12-JAN-1999; 98US-0115560P.
PR 12-JAN-1999; 98US-0115562P.
PR 12-JAN-1999; 98US-0115564P.
PR 12-JAN-1999; 98US-0115630P.
PR 12-JAN-1999; 98US-0115705P.
PR 12-JAN-1999; 98US-0115733P.
PR 20-JAN-1999; 98US-0116533P.
PR 01-FEB-1999; 98US-0116210P.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

26-AUG-1998; 98US-0097951P.
26-AUG-1998; 98US-0097986P.
28-AUG-1998; 98WO-US017888.
31-AUG-1998; 98US-0098525P.
01-SEP-1998; 98US-0098750P.
09-SEP-1998; 98US-0099536P.
09-SEP-1998; 98US-0099598P.
09-SEP-1998; 98US-0099601P.
10-SEP-1998; 98US-0099792P.
10-SEP-1998; 98US-0099803P.
10-SEP-1998; 98US-0099816P.
10-SEP-1998; 98WO-US018824.
14-SEP-1998; 98US-0100263P.
14-SEP-1998; 98US-0100263P.
14-SEP-1998; 98WO-US019093.
14-SEP-1998; 98WO-US019094.
14-SEP-1998; 98WO-US019177.
15-SEP-1998; 98US-0100390P.
16-SEP-1998; 98US-0100634P.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98US-0100710P.
17-SEP-1998; 98US-0100858P.
17-SEP-1998; 98WO-US019437.
23-SEP-1998; 98US-0101474P.
23-SEP-1998; 98US-0101477P.
24-SEP-1998; 98US-0101741P.
07-OCT-1998; 98US-0103315P.
07-OCT-1998; 98US-0103328P.
07-OCT-1998; 98WO-US021141.
13-OCT-1998; 98US-0104080P.
20-OCT-1998; 98US-0104987P.
22-OCT-1998; 98US-0105169P.
28-OCT-1998; 98US-0106030P.
29-OCT-1998; 98WO-US022991.
29-OCT-1998; 98WO-US022992.
30-OCT-1998; 98US-0106464P.
03-NOV-1998; 98US-0106858P.
03-NOV-1998; 98US-0106934P.
10-NOV-1998; 98US-0107783P.
17-NOV-1998; 98US-0108775P.
17-NOV-1998; 98US-0108801P.
17-NOV-1998; 98US-0108802P.
17-NOV-1998; 98US-0108925P.
20-NOV-1998; 98US-0109304P.
20-NOV-1998; 98WO-US024855.
01-DEC-1998; 98WO-US025108.
15-DEC-1998; 98US-0112743P.
16-DEC-1998; 98US-0112850P.
22-DEC-1998; 98US-0113298P.
22-DEC-1998; 98US-0113299P.
22-DEC-1998; 98US-0113300P.
22-DEC-1998; 98US-0113313P.
22-DEC-1998; 98US-0113314P.
22-DEC-1998; 98US-0113315P.
22-DEC-1998; 98US-0113510P.
22-DEC-1998; 98US-0113511P.
23-DEC-1998; 98US-0113605P.
23-DEC-1998; 98US-0113621P.
05-JAN-1999; 98WO-US000106.
12-JAN-1999; 98US-0115549P.
12-JAN-1999; 98US-0115557P.
12-JAN-1999; 98US-0115560P.
12-JAN-1999; 98US-0115562P.
12-JAN-1999; 98US-0115564P.
12-JAN-1999; 98US-0115630P.
12-JAN-1999; 98US-0115705P.
12-JAN-1999; 98US-0115733P.
20-JAN-1999; 98US-0116533P.
01-FEB-1999; 98US-0116210P.

QY 1 MTFFLSLLLLLVCEAIWRNSNGSNTLENGYFLSRKNKHNSQPTQSSLEDSVTPTKAVKTT 60
DB 1 MTFFLSLLLLLVCEAIWRNSNGSNTLENGYFLSRKNKHNSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKKN 90
DB 61 GKGIKGRNLDNRGLILGAEAWGRGVKKN 90

RESULT 94
ABO22593
ID ABO22593 standard; protein; 90 AA.
XX AC ABO22593;
XX DT 04-SEP-2003 (first entry)
XX DE Human secreted/transmembrane protein PRO1159.
XX KW Human; PRO; secreted protein; transmembrane protein; antidiabetic;
KW cytosolic; antirheumatic; antiarthritic; antitumor; neuroprotective;
KW antiinflammatory; antibacterial; immunosuppressive; gene therapy;
KW diabetes; cancer; rheumatoid arthritis; ulcers;
KW amyotrophic lateral sclerosis; inflammatory condition; septic shock.
XX OS Homo sapiens.
XX PN US2003017982-A1.
XX PD 23-JAN-2003.
XX PF 16-NOV-2001; 2001US-00990441.
XX PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
```



Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 GKGIKGRNLDRLGLLGAAGRGVKKNT 90  
Db 61 GKGIKGRNLDRLGLLGAAGRGVKKNT 90

RESULT 95  
ADA06666  
ID ADA06666 standard; protein; 90 AA.  
XX ADA06666;  
XX  
DT 29-JAN-2004 (revised)  
DT 06-NOV-2003 (first entry)  
XX  
XX Human secreted/transmembrane PRO polypeptide #118.  
XX  
KW human; tissue typing; cardiac insufficiency disorder; angiogenesis;  
KW wound healing; tumour; immune response; retinal disorder; retinal injury;  
KW sight loss; age-related macular degeneration; AMD; kidney disorder;  
KW mesangial cell function; Berger disease; nephropathy; dermatitis;  
KW herpiform; Crohn's disease; sports injury; arthritis.  
XX  
OS Homo sapiens.  
XX  
XX US2003049638-A1.  
PN 13-MAR-2003.  
PD  
XX  
PF 16-NOV-2001; 2001US-00991157.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088867P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 11-AUG-1998; 98US-0096012P.  
PR 12-AUG-1998; 98US-0096146P.  
PR 13-AUG-1998; 98US-0096413P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.







## RESULT 97

ADA67095

ID ADA67095 standard; protein; 90 AA.

XX ADA67095;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; INF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

XX Homo sapiens.

XX US2003068793-A1.

XX 10-APR-2003.

XX 15-APR-2002; 2002US-00123108.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021114.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 02-JUN-1999; 99WO-US010733.

XX 01-SEP-1999; 99WO-US012252.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015284.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI; 2003-695925/66.

XX N-PSDB; ADA67094.

XX Novel secreted and transmembrane PRO polypeptides useful for stimulating  
 PT release of tumor necrosis factor-alpha from human blood and detecting the  
 PT presence of a tumor in a mammal.

XX Claim 12; Fig 474; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

OS Homo sapiens.  
XX  
PN US2003077711-A1.

QY	1	MTFFLSLLLLLVCEAIWRNSGNTLENGFYLSRNKENHSPTQSSLEDVTPTKAVKTT	60
Db	1	MTFFLSLLLLLVCEAIWRNSGNTLENGFYLSRNKENHSPTQSSLEDVTPTKAVKTT	60
QY	61	KGKIVKGRNLDGRGLILGAEAWGRGVKNT	90

||||| 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

Db

RESULT 99

ADB23729

ID ADB23729 standard; protein; 90 AA.

XX

AC ADB23729;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human PRO polypeptide SEQ ID NO 474.

XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW

KW cancer; adrenal; lung; colon; breast; prostate; restum; kidney; cervix;

KW

KW liver; microvascular endothelial cell; glucose; FFA;

KW

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW

KW immune system cell infiltration.

XX

OS Homo sapiens.

XX

PN US2003077712-A1.

XX

PD 24-APR-2003.

XX

PF 22-APR-2002; 2002US-00127835.

XX

PR 20-OCT-1998; 98US-0104987P.

XX

PR 01-SEP-1999; 99WO-US020111.

PR

PR 18-OCT-1999; 99US-00403297.

PR

PR 18-FEB-2000; 2000WO-US004342.

PR

PR 01-DEC-2000; 2000WO-US032678.

PR

PR 19-DEC-2001; 2001US-00028072.

XX

PA (GETH ) GENENTECH INC.

XX

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-755067/71.

XX

DR N-PSDB; ADB23728.

XX

XX New isolated, secreted and transmembrane PRO nucleic acid, useful for the

PT

PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,

PT

PT breast, prostate, rectal, cervical and/or liver tumors.

XX

XX Claim 12; Fig 474; 637pp; English.

XX

XX The invention relates to isolated human PRO polypeptides (secreted and

CC

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC

CC invention also relates to an antibody which specifically binds to a PRO

CC

CC polypeptide, a method for stimulating the release of tumour necrosis

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, PRO

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polypeptide of the invention. Note: The

CC sequence data for this patent is also available in electronic format from

CC USPTO at seqdata.uspto.gov/sequence.html.

XX

XX Sequence 90 AA;

SQ

Query Match

100.0%; Score 462; DB 7; Length 90;

Best Local Similarity

100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MTFFLSLLILLVCEAIWRSNGSNTLENGYFLSRNKNHSQPTQSSLEDVTPTKAVKTT 60

1 MTFFLSLLILLVCEAIWRSNGSNTLENGYFLSRNKNHSQPTQSSLEDVTPTKAVKTT 60

61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 100

ADA92451

ID ADA92451 standard; protein; 90 AA.

XX AC ADA92451;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO;

XX Tumour necrosis factor alpha release; TNF-alpha release;

XX glucose uptake modulator; FFA uptake modulator;

XX cell proliferation stimulator; cell differentiation stimulator;

XX cell differentiation inhibitor; cytokine release stimulator; tumour;

XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003082712-A1.

XX 01-MAY-2003.

XX 16-MAY-2002; 2002US-00147512.

XX 15-MAY-1998; 98US-0085697P.

XX 08-MAR-1999; 99WO-US005028.

XX 25-AUG-1999; 99US-00380138.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786915/74.

XX DR N-PSDB; ADA92450.

PT New PRO nucleic acid, useful for preparing a composition for treating  
 PT e.g., tumor or for tissue typing.  
 XX  
 PS Claim 12; Fig 474; 637pp; English.  
 XX  
 CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from BMC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumor in a mammal. The tumor is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This is the amino  
 CC acid sequence of a novel human secreted and transmembrane PRO  
 CC polypeptide.  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFPLSLLLLVCEAIWRSNGSGNTLENGYFLSRNKENHSQPTOSLSDSVTPKAVKTT 60  
 DB 1 MTFPLSLLLLVCEAIWRSNGSGNTLENGYFLSRNKENHSQPTOSLSDSVTPKAVKTT 60  
 QY 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90  
 DB 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90  
 RESULT 101  
 ADB15514  
 ID ADB15514 standard; protein; 90 AA.  
 XX  
 AC ADB15514;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PRO polypeptide #237.  
 XX  
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX

US2003087352-A1.  
 08-MAY-2003.  
 22-APR-2002; 2002US-00127824.

17-AUG-1998; 98US-0096891P.  
 02-JUN-1999; 99WO-US012252.  
 25-AUG-1999; 99US-00380137.  
 30-MAR-2000; 2000WO-US008439.  
 30-MAY-2000; 2000WO-US014941.  
 01-DEC-2000; 2000WO-US032678.  
 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-786943/74.  
 N-PSDB; ADB15513.

New PRO nucleic acid, useful for producing a recombinant PRO polypeptide  
 and for manufacturing a medicament for diagnosing or treating tumor.

Claim 12; Fig 474; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumor necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRSNGSGNTLENGYFLSRNKENHSQPTOSLSDSVTPKAVKTT 60  
 DB 1 MTFPLSLLLLVCEAIWRSNGSGNTLENGYFLSRNKENHSQPTOSLSDSVTPKAVKTT 60  
 QY 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

DB 61 GKGIKGRNLDGRGLLGAENRGVKKNT 90  
RESULT 102  
ADB38766  
ID ADB38766 standard; protein; 90 AA.  
XX AC ADB38766;  
XX DT 04-DEC-2003 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO1159.  
XX KW Human; secreted and transmembrane protein; PRO;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW Cell proliferation stimulator; cell differentiation stimulator;  
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW Lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW Cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX OS Homo sapiens.  
XX PN US2003082766-A1.  
XX PD 01-MAY-2003.  
XX PF 30-MAY-2002; 2002US-00158782.  
XX PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019130.  
PR 17-SEP-1998; 98WO-US019437.  
PR 27-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 28-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001US-00796498.  
PR 01-MAR-2001; 2001WO-US006520.  
PR 09-MAR-2001; 2001WO-US006666.  
PR 14-MAR-2001; 2001US-00802706.  
PR 22-MAR-2001; 2001US-00808689.  
PR 05-APR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX PA (GETH ) GENENTECH INC.  
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786921/74.  
DR N-PSDB; ADB38765.  
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
PT in gene therapy, detecting the presence of tumor in a mammal, or  
PT modulating the uptake of glucose or free fatty acid by skeletal muscle  
XX cells or adipocyte cells.  
PR Claim 12; Fig 474; 660pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from BMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as a therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This is the amino  
CC acid sequence of a novel human secreted and transmembrane PRO  
CC polypeptide.

XX  
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-43;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSGPTQSSLEDVTPPKAVKTT 60  
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSGPTQSSLEDVTPPKAVKTT 60  
  
QY 61 KGKIVGRNLDRLGILGAEWGRVKNT 90  
Db 61 KGKIVGRNLDRLGILGAEWGRVKNT 90

RESULT 103

ADB96385  
ID ADB96385 standard; protein; 90 AA.

XX ADB96385;

XX 04-DEC-2003 (first entry)

DT Human PRO polypeptide #118.

DE

XX Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;

XX insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;

XX thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;

XX polycystic kidney disease; renal tumour; antidiabetic; antianemic;

XX cytostatic; cardiac; vulnery; antinflammatory; anorectic.

XX Homo sapiens.

OS

XX US2003054403-A1.

EN

PD 20-MAR-2003.

XX 15-NOV-2001; 2001US-00997559.

PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 12-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 25-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.

```
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094551P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 18-AUG-1998; 98US-0097026P.
PR 20-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0101943P.
PR 01-DEC-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149356P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-OCT-1999; 99US-0158663P.
PR 08-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNCSNTLENGYFLSRKNHSQPTQSSLEDVPTTKAVKIT 60
DB 1 MTFFLSLLLLVCEAIWRSNCSNTLENGYFLSRKNHSQPTQSSLEDVPTTKAVKIT 60

QY 61 GKGVKGRNLDNRGLILGAEWGRGVKNT 90
DB 61 GKGVKGRNLDNRGLILGAEWGRGVKNT 90

RESULT 104
ADB38214
ID ADB38214 standard; protein; 90 AA.
XX
AC ADB38214;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
US2003087347-A1.
XX
PN
XX
PD 08-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125921.
XX
PR 17-AUG-1998; 98US-0096791P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR
```



PR 30-MAR-2000; 2000WO-US008439.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH) GENENTECH INC.  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-786938/74.  
 DR N-ESDB; ADB38213.  
 XX  
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide  
 PT and for manufacturing a medicament for diagnosing or treating tumor.  
 XX  
 XX Claim 12; Fig 47a; 637pp; English.  
 XX  
 XX The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of  
 CC A-peptide to factor VITA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumor in a mammal. The tumor is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This is the amino  
 CC acid sequence of a novel human secreted and transmembrane PRO  
 CC polypeptide.  
 XX  
 XX Sequence 90 AA;  
 SQ  
 Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFFLSLILLVCEAIWRSNSGNTLENGYFUSRNKENHSQPTQSSLEDVPTTKAVKTT 60  
 Db 1 MTFFLSLILLVCEAIWRSNSGNTLENGYFUSRNKENHSQPTQSSLEDVPTTKAVKTT 60  
 QY 61 GKGIVKGRNLDGRGLILGAEWGRGVKNT 90  
 Db 61 GKGIVKGRNLDGRGLILGAEWGRGVKNT 90  
 RESULT 105  
 ADB66686  
 ID ADB66686 standard; protein; 90 AA.  
 XX  
 AC ADB66686;  
 XX  
 DT 04-DEC-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO1159.  
 XX

KW Human; secreted and transmembrane protein; PRO;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX  
 OS Homo sapiens.  
 XX  
 DN US2003082689-A1.  
 XX  
 PD 01-MAY-2003.  
 XX  
 XX 22-APR-2002; 2002US-00127831.  
 XX  
 XX 31-MAR-1997; 97WO-US005230.  
 XX 12-JUN-1998; 98WO-US012456.  
 XX 14-JUL-1998; 98WO-US014552.  
 XX 28-AUG-1998; 98WO-US017888.  
 XX 10-SEP-1998; 98WO-US018824.  
 XX 14-SEP-1998; 98WO-US019093.  
 XX 14-SEP-1998; 98WO-US019094.  
 XX 14-SEP-1998; 98WO-US019177.  
 XX 16-SEP-1998; 98WO-US019330.  
 XX 17-SEP-1998; 98WO-US019437.  
 XX 07-OCT-1998; 98WO-US021141.  
 XX 29-OCT-1998; 98WO-US022991.  
 XX 29-OCT-1998; 98WO-US022992.  
 XX 20-NOV-1998; 98WO-US024855.  
 XX 01-DEC-1998; 98WO-US025108.  
 XX 05-JAN-1999; 99WO-US000106.  
 XX 08-MAR-1999; 99WO-US005028.  
 XX 10-MAR-1999; 99WO-US005190.  
 XX 20-APR-1999; 99WO-US008615.  
 XX 14-MAY-1999; 99WO-US010733.  
 XX 02-JUN-1999; 99WO-US012252.  
 XX 01-SEP-1999; 99WO-US020111.  
 XX 08-SEP-1999; 99WO-US020594.  
 XX 13-SEP-1999; 99WO-US020944.  
 XX 15-SEP-1999; 99WO-US021090.  
 XX 15-SEP-1999; 99WO-US021547.  
 XX 05-OCT-1999; 99WO-US023089.  
 XX 29-NOV-1999; 99WO-US028214.  
 XX 30-NOV-1999; 99WO-US028313.  
 XX 30-NOV-1999; 99WO-US028409.  
 XX 01-DEC-1999; 99WO-US028301.  
 XX 01-DEC-1999; 99WO-US028634.  
 XX 02-DEC-1999; 99WO-US028551.  
 XX 02-DEC-1999; 99WO-US028564.  
 XX 02-DEC-1999; 99WO-US028565.  
 XX 16-DEC-1999; 99WO-US030095.  
 XX 20-DEC-1999; 99WO-US030911.  
 XX 20-DEC-1999; 99WO-US030999.  
 XX 22-DEC-1999; 99WO-US030720.  
 XX 30-DEC-1999; 99WO-US031243.  
 XX 30-DEC-1999; 99WO-US031274.  
 XX 05-JAN-2000; 2000WO-US000219.  
 XX 06-JAN-2000; 2000WO-US000277.  
 XX 06-JAN-2000; 2000WO-US000376.  
 XX 11-FEB-2000; 2000WO-US003565.  
 XX 18-FEB-2000; 2000WO-US004341.  
 XX 22-FEB-2000; 2000WO-US004342.  
 XX 24-FEB-2000; 2000WO-US004914.  
 XX 24-FEB-2000; 2000WO-US005004.  
 XX 01-MAR-2000; 2000WO-US005601.  
 XX 02-MAR-2000; 2000WO-US005746.  
 XX 02-MAR-2000; 2000WO-US005841.  
 XX 10-MAR-2000; 2000WO-US006319.  
 XX 15-MAR-2000; 2000WO-US006884.  
 XX 20-MAR-2000; 2000WO-US007377.

YY

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF- $\alpha$  from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or



PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908927.  
 PR 08-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-743899/70.  
 N-PSDB; ADB90497.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
 in gene therapy, and in the detection and treatment of tumor in a mammal.

Claim 12; Fig 474; 649pp; English.

The invention relates to isolated human PRO polypeptides (secreted and  
 transmembrane polypeptides) and the polynucleotides encoding them. The  
 invention also relates to an antibody which specifically binds to a PRO  
 polypeptide, a method for stimulating the release of tumor necrosis  
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 proliferation or differentiation of chondrocyte cells and a method for  
 detecting the presence of a tumor in a mammal (e.g. adrenal, lung,  
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 polynucleotides are useful in molecular biology, including uses as  
 hybridisation probes, in chromosome and gene mapping, in generating  
 antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 be used in preparing PRO polypeptides by recombinant techniques and in  
 generating either transgenic animals or knock-out animals which are  
 useful in the development and screening of therapeutically useful  
 reagents. The PRO polypeptides or antibodies are used in preparing a  
 medicament for treating a condition responsive to the polypeptides or  
 antibodies, such as tumours, for stimulating and inhibiting proliferation  
 of human microvascular endothelial cells, for modulating the uptake of  
 glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Fred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEALWRSNSGNTLENGYFLSRNKNHSQPTQSSLESVPTKAVKTT 60  
 Db 1 MTFFLSLLLLVCEALWRSNSGNTLENGYFLSRNKNHSQPTQSSLESVPTKAVKTT 60  
 QY 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90  
 Db 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 108

ADB39599

ID ADB39599 standard; protein; 90 AA.

XX AC ADB39599;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; PRO;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW Glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

XX PN US2003082764-A1.

XX PD 01-MAY-2003.

XX PF 03-MAY-2002; 2002US-00137868.

XX PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US000356.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-786919/74.

DR N-FSDB; ADB39598.

XX New secreted and transmembrane PRO polypeptide useful for detecting the  
presence of tumor in a mammal, or modulating the uptake of glucose or  
free fatty acid by skeletal muscle cells or adipocyte cells.

XX Claim 12; Fig 474; 659pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
transmembrane) polypeptides (I). (I) is useful for stimulating the  
release of TNF-alpha from human blood, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating the proliferation or differentiation of chondrocyte cells,  
for stimulating the proliferation of or gene expression in pericyte  
cells, for stimulating the release of proteoglycans from cartilage, for  
stimulating the proliferation of inner ear utricular supporting cells,  
stimulating the proliferation of T-lymphocyte cells, for stimulating  
the release of a cytokine from BMC cells, for inhibiting the binding of  
A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
cells, for stimulating proliferation of endothelial cells, for detecting  
the presence of tumour in a mammal. The tumour is lung, colon, breast,  
prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
are useful for isolating genomic and cDNA nucleotide sequences or  
in assays to identify other proteins or molecules involved in binding  
interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
and gene mapping, in generation of antisense RNA and DNA, in the  
preparation of PRO polypeptide, for generating transgenic animals or  
knockout animals which in turn are useful in the development and  
screening of therapeutically useful reagents, in gene therapy, for  
chromosome identification, as chromosome marker, and for generating  
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
detecting its expression in specific cells, tissues or serum, and for  
affinity purification of PRO from recombinant cell culture or natural  
sources. (I) and (II) are useful for tissue typing. This is the amino  
acid sequence of a novel human secreted and transmembrane PRO  
polypeptide.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRSNGSNTLENGYFLSRKNKHSHQPTQSSLEDSVTPTKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRSNGSNTLENGYFLSRKNKHSHQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 109

ADB47222

ID AD47222 standard; protein; 90 AA.  
XX  
AC AD47222;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1159.  
XX  
KW Human; secreted and transmembrane protein; PRO;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
PN US2003082687-A1.  
XX  
PD 01-MAY-2003.  
XX  
PF 19-APR-2002; 2002US-00125930.  
XX  
PR 05-JUN-2000; 2000US-0209832P.  
PR 01-DEC-2000; 2000MO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-786904/74.  
DR N-PSDB; ADB47221.  
XX  
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
XX  
PS Claim 12; Fig 474; 627pp; English.  
XX  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PMBC cells, for inhibiting the binding of  
CC A-peptide to factor VITA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This is the amino  
CC acid sequence of a novel human secreted and transmembrane PRO  
CC polypeptide.

XX Sequence 90 AA;  
XX  
XX Query Match 100.0%; Score 462; DB 7; Length 90;  
XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
QY 1 MTFFLSLILLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60  
DB 1 MTFFLSLILLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60  
QY 61 GKGIKGRNLDGRGLILGAEAMGRGVKKNT 90  
DB 61 GKGIKGRNLDGRGLILGAEAMGRGVKKNT 90  
XX  
RESULT 110  
ADB86829  
ID ADB86829 standard; protein; 90 AA.  
XX  
AC ADB86829;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX  
XX Homo sapiens.  
XX  
XX US2003082697-A1.  
XX  
XX 01-MAY-2003.  
XX  
XX 22-APR-2002; 2002US-00127849.  
XX  
XX 20-OCT-1998; 98US-0104987P.  
XX 01-SEP-1999; 99MO-US020111.  
XX 18-OCT-1999; 99US-00403297.  
XX 18-FEB-2000; 2000MO-US004342.  
XX 01-DEC-2000; 2000MO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-743895/70.  
DR N-PSDB; ADB86828.  
XX  
XX New secreted and transmembrane PRO polypeptides, useful in the diagnosis  
PT and treatment of cancer.  
XX  
XX Claim 12; Fig 474; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or PFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRKNKHSPTQSSLEDSVTPTKAVKTT 60  
Db 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRKNKHSPTQSSLEDSVTPTKAVKTT 60

Qy 61 KGKIVKGNLDSRGLILGAEGWGRGVKNT 90  
Db 61 KGKIVKGNLDSRGLILGAEGWGRGVKNT 90

RESULT 111

ADB77434

ID ADB77434 standard; protein; 90 AA.

XX AC ADB77434;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRL159.

XX KW Human; secreted and transmembrane protein; PRO;  
XX KW Tumour necrosis factor alpha release; TNF-alpha release;  
XX KW Glucose uptake modulator; PFA uptake modulator;  
XX KW cell proliferation stimulator; cell differentiation stimulator;  
XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003082696-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127848.

XX PR 03-NOV-1998; 98US-0106934P.

XX PR 26-JUL-1999; 99US-0145698P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

PR 05-JAN-2000; 2000WO-US000219.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX PA (GETH ) GENENTECH INC.  
XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI: 2003-755109/71.  
XX DR N-PSDB; ADB77433.

XX PRO nucleic acid, useful for preparing a composition for treating e.g.,  
XX tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or PFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRKNKHSPTQSSLEDSVTPTKAVKTT 60  
Db 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRKNKHSPTQSSLEDSVTPTKAVKTT 60

Qy 61 KGKIVKGNLDSRGLILGAEGWGRGVKNT 90

Db 61 KGKIVKGNLDSRGLILGAEGWGRGVKNT 90

RESULT 112

ADB34591

ID ADB34591 standard; protein; 90 AA.

XX AC ADB34591;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polypeptide SEQ ID NO 474.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX Homo sapiens.  
 XX US200307717-17-A1.  
 XX 24-APR-2003.  
 XX 24-APR-2002; 2002US-00131818.  
 XX 07-OCT-1998; 98US-0103328P.  
 XX 01-SEP-1999; 99WO-US020111.  
 XX 18-OCT-1999; 99WO-00403297.  
 XX 30-NOV-1999; 99WO-US028313.  
 XX 18-FEB-2000; 2000WO-US004342.  
 XX 01-DEC-2000; 2000WO-US032678.  
 XX 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX Gerritsen MB, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-755072/71.  
 XX N-PSDB; ADB34590.  
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic  
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,  
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
 PT tumors.  
 XX Claim 12; Fig 474; 637pp; English.  
 XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at seqdata.uspto.gov/sequence.html.  
 XX USPTO at seqdata.uspto.gov/sequence.html.  
 XX Sequence 90 AA;  
 XX Query Match 100.0%; Score 462; DB 7; Length 90;  
 XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFPLSLLLLVCEAIWFSNCSNTLENGYFLSRNKNHSQPTQSSLSDSVTPTRAVKIT 60  
 Db 1 MTFPLSLLLLVCEAIWFSNCSNTLENGYFLSRNKNHSQPTQSSLSDSVTPTRAVKIT 60  
 QY 61 GKGIKGRNLDLSRGLILGAEAWGRGVKNT 90  
 Db 61 GKGIKGRNLDLSRGLILGAEAWGRGVKNT 90  
 RESULT 113  
 ADB35695  
 ID ADB35695 standard; protein; 90 AA.  
 XX ADB35695;  
 AC ADB35695;  
 XX 04-DEC-2003 (first entry)  
 DT Human PRO polypeptide SEQ ID NO 474.  
 XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX Homo sapiens.  
 XX OS  
 XX US200307719-A1.  
 XX 24-APR-2003.  
 XX 24-APR-2002; 2002US-00131824.  
 XX 09-FEB-1999; 99US-0119341P.  
 XX 01-DEC-1999; 99WO-US028634.  
 XX 01-DEC-2000; 2000WO-US032678.  
 XX 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX Gerritsen MB, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-755074/71.  
 XX N-PSDB; ADB35694.  
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic  
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,  
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
 PT tumors.  
 XX Claim 12; Fig 474; 637pp; English.  
 XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which



CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHNSQPTQSSLEDSVTPKAVKTT 60  
Db 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHNSQPTQSSLEDSVTPKAVKTT 60  
Qy 61 GKGVKGRNLDRLGLILGAFAWGRGVKNT 90  
Db 61 GKGVKGRNLDRLGLILGAFAWGRGVKNT 90

RESULT 114  
ADB34039  
ID ADB34039 standard; protein; 90 AA.  
AC ADB34039;  
XX  
XX  
XX 04-DEC-2003 (first entry)  
XX  
XX Human PRO polypeptide SEQ ID NO 474.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
XX liver; microvascular endothelial cell; glucose; FFA;  
XX skeletal muscle cell; adipocyte cell; pericyte cell;  
XX inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
XX immune system cell infiltration.

XX Homo sapiens.  
XX  
XX US2003077716-A1.  
XX  
XX  
XX 24-APR-2003.

PF 24-APR-2002; 2002US-00131813.  
XX  
XX 07-OCT-1998; 98US-0103315P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 18-OCT-1999; 99US-00403297.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI: 2003-755071/71.  
XX  
XX N-PSDB; ADB34038.  
XX  
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
XX in gene therapy, in chromosome and gene mapping, as chromosome markers,  
XX in tissue typing, and in identifying chromosomes.  
XX  
XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX the proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX from cartilage are useful for treating sports-related joint problems,  
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
XX polypeptides are also useful for treating various mammalian haemoglobin-  
XX associated disorders such as various thalassaemias and conditions which  
XX may benefit from enhanced local immune system cell infiltration. This  
XX sequence represents a human PRO polypeptide of the invention. Note: The  
XX sequence data for this patent is also available in electronic format from  
XX USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHNSQPTQSSLEDSVTPKAVKTT 60  
Db 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHNSQPTQSSLEDSVTPKAVKTT 60  
Qy 61 GKGVKGRNLDRLGLILGAFAWGRGVKNT 90  
Db 61 GKGVKGRNLDRLGLILGAFAWGRGVKNT 90

## RESULT 115

ADB35143

ID ADB35143 standard; protein; 90 AA.

XX ADB35143;

XX ADB35143;

XX 04-DEC-2003 (first entry)

XX Human PRO polypeptide SEQ ID NO 474.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

XX Homo sapiens.

XX OS

XX PN

XX US2003077718-A1.

XX PD

XX 24-APR-2003.

XX 24-APR-2002; 2002US-00131823.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022391.

XX 29-OCT-1998; 98WO-US022392.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 16-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

XX 22-DEC-1999; 99WO-US030720.

XX 30-DEC-1999; 99WO-US031243.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808699.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 03-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755073/71.  
 N-PSDB; ADB35142.

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 12; Fig 474; 638pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSTPTKAVKTT 60  
DB 1 MTFLLSLLLVCCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSTPTKAVKTT 60  
QY 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90  
DB 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 116

ADB36247

XX ADB36247

XX ADB36247;

DT 04-DEC-2003 (first entry)

XX Human PRO polypeptide SEQ ID NO 474.

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003077720-A1.

FN

XX 24-APR-2003.  
PD 24-APR-2002; 2002US-00131830.  
XX 09-DEC-1999; 99US-0170262P.  
XX 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755075/71.  
XX N-PSDB; ADB36246.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic  
XX acids, useful for the diagnosis, prevention and/or treatment of tumours,  
XX such as lung, colon, breast, prostate, rectal, cervical and/or liver  
XX tumours.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX from cartilage are useful for treating sports-related joint problems,  
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
XX polypeptides are also useful for treating various mammalian haemoglobin-  
XX associated disorders such as various thalassaemias and conditions which  
XX may benefit from enhanced local immune system cell infiltration. This  
XX sequence represents a human PRO polypeptide of the invention. Note: The  
XX sequence data for this patent is also available in electronic format from  
XX USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSTPTKAVKTT 60  
DB 1 MTFLLSLLLVCCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSTPTKAVKTT 60  
QY 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90  
DB 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 117  
ADB46642  
ID ADB46642 standard; protein; 90 AA.  
XX  
AC ADB46642;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1159.  
XX  
KW Human; secreted and transmembrane protein; PRO;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW Cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
PN US2003082692-A1.  
XX  
PD 01-MAY-2003.  
XX  
PF 22-APR-2002; 2002US-00127842.  
XX  
PR 03-MAR-2000; 2000US-0187202P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR NPI; 2003-786906/74.  
DR N-PSDB; ADB46641.  
XX  
PT New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.  
XX  
PS Claim 12; Fig 474; 637pp; English.  
XX  
CC The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PMc cells, for inhibiting the binding of  
CC A-peptide to factor viiRa, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This is the amino

CC acid sequence of a novel human secreted and transmembrane PRO  
CC polypeptide.  
XX  
SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49; Mismatches 0; Indels 0; Gaps 0;  
Matches 90; Conservative 0;  
QY 1 MTFFLSLLLLVCEAIRWSNGSNTLENGYFLSRNKENHSQPTQSSLEDVTPTKAVKIT 60  
DB 1 MTFFLSLLLLVCEAIRWSNGSNTLENGYFLSRNKENHSQPTQSSLEDVTPTKAVKIT 60  
QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKXNT 90  
DB 61 GKGIVKGRNLDNRGLILGAEAWGRGVKXNT 90  
RESULT 118  
ADC57857  
ID ADC57857 standard; protein; 90 AA.  
XX  
AC ADC57857;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human PRO polypeptide #118.  
XX  
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;  
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;  
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;  
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;  
KW cytostatic; cardiant; vulnarary; antinflammatory; anorectic.  
XX  
OS Homo sapiens.  
XX  
PN US2003027754-A1.  
XX  
PD 06-FEB-2003.  
XX  
PF 14-NOV-2001; 2001US-00990438.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.



```
PR 23-AUG-2000; 2000WO-US023522.
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKIT 60
Db 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKIT 60
QY 61 GKGIVKGRNLDGRGLILGAENGGRVKKNT 90
Db 61 GKGIVKGRNLDGRGLILGAENGGRVKKNT 90

RESULT 119
ADC55221
ID ADC55221 standard; protein; 90 AA.
XX AC ADC55221;
XX DT 18-DEC-2003 (first entry)
XX DE Human PRO polypeptide #118.
XX KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalasassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnery; antiinflammatory; anorectic.
XX OS Homo sapiens.
XX PN US2003045463-A1.
XX PD 06-MAR-2003.
XX PF 16-NOV-2001; 2001US-00990437.
XX PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-009057P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 09-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
```

[illegible]







Qy	61	KGKIVKRNLD	SRGLILGAEAWGRGVKNT	90
Db	61	KGKIVKRNLD	SRGLILGAEAWGRGVKNT	90
RESULT 122				
AD	C07565			
ID	ADC07565	standard; protein; 90	AA.	
XX	XX			
AC	ADC07565;			
XX	XX			
DT	18-DEC-2003	(first entry)		
XX	XX			
DE	Human secreted/transmembrane protein	PRO1159.		
XX	XX			
KW	PRO; secreted protein; transmembrane protein;			
KW	hypertrophy of neonatal heart; angiogenesis;			
KW	vascular endothelial growth factor; VEGF-stimulated proliferation;			
KW	endothelial cell; T-lymphocyte proliferation; retinal neuron;			
KW	c-fos induction; adipocyte cell; chondrocyte differentiation;			
KW	pancreatic beta-cell precursor differentiation; gene therapy; tumour;			
KW	cancer; human; colon cancer; lung cancer; breast cancer;			
KW	rod photoreceptor cell.			
XX	XX			
OS	Homo sapiens.			
XX	XX			
EN	US2003068647-A1.			
XX	XX			
PD	10-APR-2003.			
XX	XX			
PF	15-NOV-2001; 2001US-00997542.			
XX	XX			
PR	16-JUN-1997; 97US-0049787P.			
PR	17-OCT-1997; 97US-0062250P.			
PR	05-NOV-1997; 97WO-US020069.			
PR	12-NOV-1997; 97US-0065186P.			
PR	13-NOV-1997; 97US-0065311P.			
PR	24-NOV-1997; 97US-0066770P.			
PR	25-FEB-1998; 98US-0075945P.			
PR	20-MAR-1998; 98US-0078310P.			
PR	28-APR-1998; 98US-0083322P.			
PR	07-MAY-1998; 98US-0084600P.			
PR	28-MAY-1998; 98US-0087106P.			
PR	02-JUN-1998; 98US-0087607P.			
PR	02-JUN-1998; 98US-0087609P.			
PR	02-JUN-1998; 98US-0087759P.			
PR	03-JUN-1998; 98US-0087827P.			
PR	04-JUN-1998; 98US-0088021P.			
PR	04-JUN-1998; 98US-0088025P.			
PR	04-JUN-1998; 98US-0088026P.			
PR	04-JUN-1998; 98US-0088028P.			
PR	04-JUN-1998; 98US-0088029P.			
PR	04-JUN-1998; 98US-0088030P.			
PR	04-JUN-1998; 98US-0088033P.			
PR	04-JUN-1998; 98US-0088326P.			
PR	05-JUN-1998; 98US-0088167P.			
PR	05-JUN-1998; 98US-0088202P.			
PR	05-JUN-1998; 98US-0088212P.			
PR	05-JUN-1998; 98US-0088217P.			
PR	09-JUN-1998; 98US-0088655P.			
PR	10-JUN-1998; 98US-0088724P.			
PR	10-JUN-1998; 98US-0088738P.			
PR	10-JUN-1998; 98US-0088742P.			
PR	10-JUN-1998; 98US-0088810P.			
PR	10-JUN-1998; 98US-0088824P.			
PR	10-JUN-1998; 98US-0088826P.			
PR	11-JUN-1998; 98US-0088858P.			
PR	11-JUN-1998; 98US-0088861P.			
PR	11-JUN-1998; 98US-0088876P.			
PR	12-JUN-1998; 98US-0089105P.			
PR	16-JUN-1998; 98US-0089440P.			
PR	16-JUN-1998; 98US-0089512P.			

PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089603P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 02-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091789P.  
PR 02-JUL-1998; 98US-0091978P.  
PR 02-JUL-1998; 98US-0091982P.  
PR 02-JUL-1998; 98US-0091986P.  
PR 02-JUL-1998; 98US-0092182P.  
PR 02-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.

PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 31-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9,8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKT 60  
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKT 60  
QY 61 GKGVKGRNLDNRGLILGAEWGRGVKNT 90  
|||||

Db 61 GKGVKGRNLSRGLILGAENGRGVKKNT 90

RESULT 123  
ADCL1555  
ID ADCL1555 standard; protein; 90 AA.  
XX  
AC ADCL1555;  
DT 18-DEC-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein PRO159.  
XX  
KW PRO; secreted protein; transmembrane protein;  
KW hypertrophy of neonatal heart; angiogenesis;  
KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
KW c-fos induction; adipocyte cell; chondrocyte differentiation;  
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;  
KW cancer; human; colon cancer; lung cancer; breast cancer;  
KW rod photoreceptor cell.  
OS Homo sapiens.  
XX  
XX US2003069403-A1.  
XX  
XX 10-APR-2003.  
XX  
XX 14-NOV-2001; 2001US-00993748.  
XX  
XX 16-JUN-1997; 97US-0049787P.  
XX 17-OCT-1997; 97US-0062250P.  
XX 05-NOV-1997; 97WO-US020069.  
XX 12-NOV-1997; 97US-0065186P.  
XX 13-NOV-1997; 97US-0065311P.  
XX 24-NOV-1997; 97US-0066770P.  
XX 25-FEB-1998; 98US-0075945P.  
XX 20-MAR-1998; 98US-0078910P.  
XX 28-APR-1998; 98US-0083322P.  
XX 07-MAY-1998; 98US-0084600P.  
XX 28-MAY-1998; 98US-0087106P.  
XX 02-JUN-1998; 98US-0087607P.  
XX 02-JUN-1998; 98US-0087609P.  
XX 02-JUN-1998; 98US-0087759P.  
XX 03-JUN-1998; 98US-0087827P.  
XX 04-JUN-1998; 98US-0088021P.  
XX 04-JUN-1998; 98US-0088025P.  
XX 04-JUN-1998; 98US-0088026P.  
XX 04-JUN-1998; 98US-0088028P.  
XX 04-JUN-1998; 98US-0088029P.  
XX 04-JUN-1998; 98US-0088030P.  
XX 04-JUN-1998; 98US-0088033P.  
XX 04-JUN-1998; 98US-0088326P.  
XX 05-JUN-1998; 98US-0088167P.  
XX 05-JUN-1998; 98US-0088202P.  
XX 05-JUN-1998; 98US-0088212P.  
XX 05-JUN-1998; 98US-0088217P.  
XX 09-JUN-1998; 98US-0088655P.  
XX 10-JUN-1998; 98US-0088734P.  
XX 10-JUN-1998; 98US-0088738P.  
XX 10-JUN-1998; 98US-0088742P.  
XX 10-JUN-1998; 98US-0088810P.  
XX 10-JUN-1998; 98US-0088824P.  
XX 10-JUN-1998; 98US-0088826P.  
XX 11-JUN-1998; 98US-0088858P.  
XX 11-JUN-1998; 98US-0088861P.  
XX 11-JUN-1998; 98US-0088976P.  
XX 12-JUN-1998; 98US-0089105P.  
XX 16-JUN-1998; 98US-0089440P.  
XX 16-JUN-1998; 98US-0089512P.  
XX 16-JUN-1998; 98US-0089514P.  
XX 17-JUN-1998; 98US-0089532P.  
XX 17-JUN-1998; 98US-0089538P.  
17-JUN-1998; 98US-0089598P.  
17-JUN-1998; 98US-0089599P.  
17-JUN-1998; 98US-0089600P.  
17-JUN-1998; 98US-0089653P.  
18-JUN-1998; 98US-0089801P.  
18-JUN-1998; 98US-0089907P.  
18-JUN-1998; 98US-0089908P.  
19-JUN-1998; 98US-0089947P.  
19-JUN-1998; 98US-0089948P.  
19-JUN-1998; 98US-0089952P.  
22-JUN-1998; 98US-0090246P.  
22-JUN-1998; 98US-0090252P.  
22-JUN-1998; 98US-0090254P.  
23-JUN-1998; 98US-0090349P.  
23-JUN-1998; 98US-0090355P.  
24-JUN-1998; 98US-0090429P.  
24-JUN-1998; 98US-0090431P.  
24-JUN-1998; 98US-0090435P.  
24-JUN-1998; 98US-0090444P.  
24-JUN-1998; 98US-0090445P.  
24-JUN-1998; 98US-0090472P.  
24-JUN-1998; 98US-0090535P.  
24-JUN-1998; 98US-0090540P.  
24-JUN-1998; 98US-0090542P.  
24-JUN-1998; 98US-0090557P.  
25-JUN-1998; 98US-0090676P.  
25-JUN-1998; 98US-0090679P.  
25-JUN-1998; 98US-0090690P.  
25-JUN-1998; 98US-0090694P.  
25-JUN-1998; 98US-0090695P.  
25-JUN-1998; 98US-0090696P.  
26-JUN-1998; 98US-0090862P.  
26-JUN-1998; 98US-0090863P.  
01-JUL-1998; 98US-0091360P.  
01-JUL-1998; 98US-0091544P.  
02-JUL-1998; 98US-0091478P.  
02-JUL-1998; 98US-0091519P.  
02-JUL-1998; 98US-0091626P.  
02-JUL-1998; 98US-0091628P.  
02-JUL-1998; 98US-0091633P.  
02-JUL-1998; 98US-0091646P.  
02-JUL-1998; 98US-0091673P.  
07-JUL-1998; 98US-0091978P.  
07-JUL-1998; 98US-0091982P.  
09-JUL-1998; 98US-0092182P.  
10-JUL-1998; 98US-0092472P.  
20-JUL-1998; 98US-0093339P.  
30-JUL-1998; 98US-0094651P.  
04-AUG-1998; 98US-0095282P.  
04-AUG-1998; 98US-0095285P.  
04-AUG-1998; 98US-0095301P.  
04-AUG-1998; 98US-0095302P.  
04-AUG-1998; 98US-0095310P.  
04-AUG-1998; 98US-0095321P.  
04-AUG-1998; 98US-0095325P.  
10-AUG-1998; 98US-0095916P.  
10-AUG-1998; 98US-0095929P.  
10-AUG-1998; 98US-0096012P.  
11-AUG-1998; 98US-0096143P.  
11-AUG-1998; 98US-0096146P.  
12-AUG-1998; 98US-0096329P.  
17-AUG-1998; 98US-0096757P.  
17-AUG-1998; 98US-0096766P.  
17-AUG-1998; 98US-0096768P.  
17-AUG-1998; 98US-0096773P.  
17-AUG-1998; 98US-0096791P.  
17-AUG-1998; 98US-0096867P.  
17-AUG-1998; 98US-0096891P.  
17-AUG-1998; 98US-0096894P.  
17-AUG-1998; 98US-0096895P.  
17-AUG-1998; 98US-0096897P.  
18-AUG-1998; 98US-0096949P.  
18-AUG-1998; 98US-0096950P.

```
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0100858P.
PR 05-JAN-1999; 98US-0100858P.
PR 05-JAN-1999; 98US-0100858P.
PR 08-MAR-1999; 98US-0100858P.
PR 12-MAR-1999; 98US-0100858P.
PR 12-MAR-1999; 98US-0100858P.
PR 02-JUN-1999; 98US-0100858P.
PR 23-JUN-1999; 98US-0100858P.
PR 07-JUL-1999; 98US-0100858P.
PR 20-JUL-1999; 98US-0100858P.
PR 26-JUL-1999; 98US-0100858P.
PR 28-JUL-1999; 98US-0100858P.
PR 17-AUG-1999; 98US-0100858P.
PR 15-SEP-1999; 98US-0100858P.
PR 15-SEP-1999; 98US-0100858P.
PR 15-SEP-1999; 98US-0100858P.
PR 08-OCT-1999; 98US-0100858P.
PR 30-NOV-1999; 98US-0100858P.
PR 01-DEC-1999; 98US-0100858P.
PR 01-DEC-1999; 98US-0100858P.
PR 01-DEC-1999; 98US-0100858P.
PR 20-DEC-1999; 98US-0100858P.
PR 05-JAN-2000; 98US-0100858P.
PR 06-JAN-2000; 98US-0100858P.
PR 11-FEB-2000; 98US-0100858P.
PR 18-FEB-2000; 98US-0100858P.
PR 22-FEB-2000; 98US-0100858P.
PR 24-FEB-2000; 98US-0100858P.
PR 02-MAR-2000; 98US-0100858P.
PR 10-MAR-2000; 98US-0100858P.
PR 15-MAR-2000; 98US-0100858P.
PR 20-MAR-2000; 98US-0100858P.
PR 30-MAR-2000; 98US-0100858P.
PR 17-MAY-2000; 98US-0100858P.
PR 22-MAY-2000; 98US-0100858P.
PR 30-MAY-2000; 98US-0100858P.
PR 02-JUN-2000; 98US-0100858P.
PR 23-JUN-2000; 98US-0100858P.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFSLSLLLLVCAIWRNSGSGTLENGYFLSRNKENHSGPTOSLSLDSVPTKAVKTT 60
DB 1 MTFSLSLLLLVCAIWRNSGSGTLENGYFLSRNKENHSGPTOSLSLDSVPTKAVKTT 60
QY 61 GKGIKVGKRLNDSRLILGAEAWGRGVKNT 90
DB 61 GKGIKVGKRLNDSRLILGAEAWGRGVKNT 90
```

## RESULT 124

```
ADCS0515
ID ADCS0515 standard; protein; 90 AA.
XX
AC ADCS0515;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
US2003092106-A1.
XX
15-MAY-2003.
XX
24-APR-2002; 2002US-00131822.
XX
19-AUG-1998; 98US-0097141P.
PR 02-JUN-1999; 99US-0012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000US-0008439.
PR 01-DEC-2000; 2000US-0032678.
PR 19-DEC-2001; 2001US-00028072.
XX
( GETH ) GENENTECH INC.
XX
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-801171/75.
DR N-PSDB; ADCS0514.
XX
New secreted and transmembrane nucleic acid useful for treating
inflammation, organ failure, atherosclerosis, cardiac injury,
infertility, birth defects, premature aging, acquired immunodeficiency
syndrome or cancer.
XX
Claim 12; Fig 474; 637pp; English.
XX
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
```

CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, for  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassaemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polypeptide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEALWRNSGNTLENGYFLSRNKENHSQPTQSSLEDVSPTKAVKTT 60  
DB 1 MTFFLSLLLLVCEALWRNSGNTLENGYFLSRNKENHSQPTQSSLEDVSPTKAVKTT 60  
QY 61 GKGVKGRNLDNRGLILGAEAWGRGVKNT 90  
DB 61 GKGVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 125  
ADC72062  
ID ADC72062 standard; protein; 90 AA.

AC ADC72062;

DT 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
KW cell differentiation; skeletal muscle cell; adipocyte cell;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003092107-A1.

XX 15-MAY-2003.

XX 24-APR-2002; 2002US-00131828.

XX 07-OCT-1998; 98US-0103315P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 18-FEB-2000; 2000WO-US004342.

XX 10-NOV-2000; 2000WO-US030873.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI: 2003-801172/75.  
DR N-PSDB; ADC72061.

XX New secreted and transmembrane nucleic acids and polypeptides, designated  
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
PT cancer.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, for  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassaemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polypeptide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEALWRNSGNTLENGYFLSRNKENHSQPTQSSLEDVSPTKAVKTT 60  
DB 1 MTFFLSLLLLVCEALWRNSGNTLENGYFLSRNKENHSQPTQSSLEDVSPTKAVKTT 60  
QY 61 GKGVKGRNLDNRGLILGAEAWGRGVKNT 90  
DB 61 GKGVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 126  
ADC60041  
ID ADC60041 standard; protein; 90 AA.

XX AC ADC60041;

XX DT 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
KW cell differentiation; skeletal muscle cell; adipocyte cell;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
XX Homo sapiens.  
XX US2003092105-A1.  
XX  
XX 15-MAY-2003.  
XX 24-APR-2002; 2002US-00131821.  
XX  
XX 09-DEC-1999; 99US-0170262P.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH.) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI: 2003-801170/75.  
XX N-PSDB; ADC60040.  
XX  
XX New secreted and transmembrane nucleic acids and polypeptides, designated  
XX as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
XX cardiac injury, infertility, birth defects, premature aging, AIDS, or  
XX cancer.  
XX  
XX Claim 12; Fig 474; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
XX cells, for stimulating differentiation of adipocyte cells, for  
XX stimulating proliferation of or gene expression in pericyte cells, for  
XX stimulating the proliferation of inner ear utricular supporting cells or  
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for  
XX treating various bone and/or cartilage disorders such as sports injuries  
XX and arthritis. PRO polypeptides which stimulate the release of  
XX proteoglycans from cartilage are useful for treating sports-related joint  
XX problems, articular cartilage defects, osteoarthritis and rheumatoid  
XX arthritis. PRO polypeptides are also useful for treating various  
XX mammalian haemoglobin-associated disorders such as various thalassaemias  
XX and conditions which may benefit from enhanced local immune system cell  
XX infiltration. This sequence represents a human PRO polypeptide of the  
XX invention. Note: The sequence data for this patent is also available in  
XX electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
Db 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
Qy 61 GKGIIVGRNLDLSRGLILGAEAWGRGVKNT 90  
Db 61 GKGIIVGRNLDLSRGLILGAEAWGRGVKNT 90  
RESULT 127  
ID ADC53048  
AC ADC53048 standard; protein; 90 AA.  
XX  
AC ADC53048;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein Seq ID474.  
XX  
KW human; PRO; membrane bound protein; membrane bound receptor;  
KW cell proliferation; cell migration; cell differentiation;  
KW mitogenic factor; survival factor; cytotoxic factor;  
KW differentiation factor; neuropeptide; hormone; cell receptor;  
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.  
XX  
OS Homo sapiens.  
XX  
XX US2003087365-A1.  
XX  
PD 08-MAY-2003.  
XX  
PF 23-APR-2002; 2002US-00128689.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
XX 28-AUG-1998; 98WO-US017888.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98WO-US019093.  
XX 14-SEP-1998; 98WO-US019094.  
XX 14-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.  
XX 17-SEP-1998; 98WO-US019437.  
XX 07-OCT-1998; 98WO-US021141.  
XX 29-OCT-1998; 98WO-US022991.  
XX 29-OCT-1998; 98WO-US022992.  
XX 20-NOV-1998; 98WO-US024855.  
XX 01-DEC-1998; 98WO-US025108.  
XX 05-JAN-1999; 99WO-US000106.  
XX 08-MAR-1999; 99WO-US005028.  
XX 10-MAR-1999; 99WO-US005190.  
XX 20-MAR-1999; 2000WO-US006319.  
XX 20-APR-1999; 99WO-US008615.  
XX 14-MAY-1999; 99WO-US010733.  
XX 02-JUN-1999; 99WO-US012252.  
XX 01-SEP-1999; 99WO-US020111.  
XX 08-SEP-1999; 99WO-US020594.  
XX 13-SEP-1999; 99WO-US020944.  
XX 15-SEP-1999; 99WO-US021090.  
XX 15-SEP-1999; 99WO-US021547.  
XX 05-OCT-1999; 99WO-US023089.  
XX 29-NOV-1999; 99WO-US028214.  
XX 30-NOV-1999; 99WO-US028313.  
XX 30-NOV-1999; 99WO-US028409.  
XX 01-DEC-1999; 99WO-US028301.  
XX 01-DEC-1999; 99WO-US028634.  
XX 02-DEC-1999; 99WO-US028551.

```

PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 03-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US032678.
PR 01-DEC-2000; 2000WO-US030873.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US008520.
PR 01-MAR-2001; 2001WO-US008666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godwoski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801150/75.

```

DR N-PSDB; ADC53047.

XX New PRO nucleic acid, useful for manufacturing a medicament for diagnosing or treating tumor.

PS Claim 1; SEQ ID NO 474; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted and transmembrane proteins. Extracellular proteins play important roles in the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells (for example proliferation, migration or differentiation) is typically governed by information received from other cells and the immediate environment. The information is often transmitted by secreted polypeptides (for example mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neurotrophic factors and hormones) which are received and interpreted by diverse cell receptors or membrane bound proteins. These membrane bound proteins as in the blocking of receptor-ligand interactions. The current invention provides the amino acid sequences of novel human membrane bound receptors and proteins, along with the cDNA sequences encoding them. The novel proteins of the invention may have cytostatic activities through the stimulation of chondrocytes. The nucleic acids of the invention may be useful for the manufacture of a medicament for diagnosing or treating a tumour in a mammal. In addition, they may be useful for measuring or detecting the expression of a tumour associated gene. The present invention is the amino acid sequence of a human PRO protein of the

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEALWRSNGSNTLENGYFLSRNKENHSQPTQSLSLDSVPTKAVKTT 60  
Db 1 MTFFLSLLLLVCEALWRSNGSNTLENGYFLSRNKENHSQPTQSLSLDSVPTKAVKTT 60

QY 61 GKGVKGRNLDGRGLILGAAGRGVKKNT 90  
Db 61 GKGVKGRNLDGRGLILGAAGRGVKKNT 90

RESULT 128  
ADC57402  
ID ADC57402 standard; protein; 90 AA.  
XX  
AC ADC57402;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein Seq ID474.  
XX human; PRO; membrane bound protein; membrane bound receptor;  
KW cell proliferation; cell migration; cell differentiation;  
KW mitogenic factor; survival factor; cytotoxic factor;  
KW differentiation factor; neurotrophic; hormone; cell receptor;  
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.  
XX Homo sapiens.  
OS  
XX US2003087366-A1.  
PN  
XX 08-MAY-2003.  
PD  
XX 23-APR-2002; 2002US-00128694.  
PF  
XX 02-MAR-2000; 2000WO-US005841.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX



PA (GETH) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-801151/75.  
DR N-PSDB; ADC57401.  
XX  
XX New PRO nucleic acid, useful for manufacturing a medicament for  
PT diagnosing or treating tumor.  
XX  
XX Claim 1; SEQ ID NO 474; 637pp; English.  
XX  
XX This invention relates to novel nucleic acids encoding human PRO secreted  
CC and transmembrane proteins. Extracellular proteins play important roles  
CC in the formation, differentiation and maintenance of multicellular  
CC organisms. The fate of many individual cells (for example proliferation,  
CC migration or differentiation) is typically governed by information  
CC received from other cells and the immediate environment. The information  
CC is often transmitted by secreted polypeptides (for example mitogenic  
CC factors, survival factors, cytotoxic factors, differentiation factors,  
CC neurotrophins and hormones) which are received and interpreted by diverse  
CC cell receptors or membrane bound proteins. These membrane bound proteins  
CC and receptors may be of use as pharmaceutical and diagnostic agents, such  
CC as in the blocking of receptor-ligand interactions. The current invention  
CC provides the amino acid sequences of novel human membrane bound receptors  
CC and proteins, along with the cDNA sequences encoding them. The novel  
CC proteins of the invention may have cytostatic activities through the  
CC stimulation of chondrocytes. The nucleic acids of the invention may be  
CC useful for the manufacture of a medicament for diagnosing or treating a  
CC tumour in a mammal. In addition, they may be useful for measuring or  
CC detecting the expression of a tumour associated gene. The present  
CC sequence is the amino acid sequence of a human PRO protein of the  
CC invention.  
XX  
XX Sequence 90 AA;  
SQ  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MTFPLSLLLLVCAIWFNSGNSGTLENGYFLSRNKENHSQTSLSLDSVTPKAVKTT 60  
Db 1 MTFPLSLLLLVCAIWFNSGNSGTLENGYFLSRNKENHSQTSLSLDSVTPKAVKTT 60  
Qy 61 KGIVKGNLDSRGLILGAEGWGRVKNT 90  
Db 61 KGIVKGNLDSRGLILGAEGWGRVKNT 90  
RESULT 129  
ID ADC60593 standard; protein; 90 AA.  
XX  
XX AC ADC60593;  
XX  
XX 18-DEC-2003 (first entry)  
XX  
XX Novel human secreted and transmembrane protein PRO1159.  
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
KW glucose uptake modulator; RFA uptake modulator; cell proliferation;  
KW cell differentiation; skeletal muscle cell; adipocyte cell;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.  
OS  
XX US2003087367-A1.  
PN  
XX 08-MAY-2003.  
PD  
XX 24-APR-2002; 2002US-00131825.  
PF  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 2000WO-US006319.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 28-DEC-2000; 2000WO-US034956.  
 PR 20-FEB-2001; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 01-MAR-2001; 2001WO-US006520.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00806889.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 18-MAY-2001; 2001US-00854208.  
 PR 25-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 01-JUN-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001US-00887879.  
 PR 21-JUN-2001; 2001WO-US019692.  
 PR 22-JUN-2001; 2001US-00887879.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908927.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX N-PSDB; ADC60592.  
 DR WPI; 2003-801152/75.  
 DR N-PSDB; ADC60592.

PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide  
 PT and for manufacturing a medicament for diagnosing or treating tumor.

PS Claim 12; Fig 474; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumor necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
 CC cells, for stimulating differentiation of adipocyte cells, for  
 CC stimulating proliferation of or gene expression in pericyte cells, for  
 CC stimulating the proliferation of inner ear utricular supporting cells or  
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for

CC treating various bone and/or cartilage disorders such as sports injuries  
 CC and arthritis. PRO polypeptides which stimulate the release of  
 CC proteoglycans from cartilage are useful for treating sports-related joint  
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
 CC arthritis. PRO polypeptides are also useful for treating various  
 CC mammalian haemoglobin-associated disorders such as various thalassaemias  
 CC and conditions which may benefit from enhanced local immune system cell  
 CC infiltration. This sequence represents a human PRO polypeptide of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLILLVCEAIWRNSGNTLENGYFLSRNKHSHSQTSSELSVTPTKAVKT 60  
 DB 1 MTFELSLILLVCEAIWRNSGNTLENGYFLSRNKHSHSQTSSELSVTPTKAVKT 60  
 QY 61 GKGIKGRNLDNRGLILGAEWGRGVKNT 90  
 DB 61 GKGIKGRNLDNRGLILGAEWGRGVKNT 90

RESULT 130

ADC51068  
 ID ADC51068 standard; protein; 90 AA.

XX AC ADC51068;

XX 18-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
 KW cell differentiation; skeletal muscle cell; adipocyte cell;  
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
 KW immune system cell infiltration; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003087361-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127841.

XX 09-SEP-1998; 98US-0099536P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 18-FEB-2000; 2000WO-US004342.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801146/75.

XX N-PSDB; ADC51067.

PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide  
 PT and for manufacturing a medicament for diagnosing or treating tumor.

PS Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
 CC cells, for stimulating differentiation of adipocyte cells, for  
 CC stimulating proliferation of or gene expression in pericyte cells, for  
 CC stimulating the proliferation of inner ear utricular supporting cells or  
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
 CC treating various bone and/or cartilage disorders such as sports injuries  
 CC and arthritis. PRO polypeptides which stimulate the release of  
 CC proteoglycans from cartilage are useful for treating sports-related joint  
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
 CC arthritis. PRO polypeptides are also useful for treating various  
 CC mammalian haemoglobin-associated disorders such as various thalassaemias  
 CC and conditions which may benefit from enhanced local immune system cell  
 CC infiltration. This sequence represents a human PRO polypeptide of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

Db 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

Qy 61 GKGIVKGNLDSRGLILGAEGWGRVKNT 90

Db 61 GKGIVKGNLDSRGLILGAEGWGRVKNT 90

RESULT 131

ID ADC65595

XX ADC65595 standard; protein; 90 AA.

AC ADC65595;

DT 18-DEC-2003 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

XX US2003087362-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127844.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801147/75.

XX N-PSDB; ADC65594.

XX New PRO nucleic acid, useful for manufacturing a medicament for  
 PT diagnosing or treating tumor.

XX Claim 12; Fig 474; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC the proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

Db 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

Qy 61 GKGIVKGNLDSRGLILGAEGWGRVKNT 90

Db 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90  
|||||

## RESULT 132

ADCS3654  
ID ADCS3654 standard; protein; 90 AA.

XX AC ADCS3654;

DT 18-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein Seq ID474.

XX human; PRO; membrane bound protein; membrane bound receptor;  
KW cell proliferation; cell migration; cell differentiation;  
KW mitogenic factor; survival factor; cytotoxic factor;  
KW differentiation factor; neurotrophic factor; hormone; cell receptor;  
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.

OS Homo sapiens.

PN US2003087363-A1.

XX 08-MAY-2003.

PF 23-APR-2002; 2002US-00128687.

XX 10-SEP-1998; 98US-0099816P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 18-FEB-2000; 2000WO-US004342.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801148/75.

DR N-PSDB; ADCS3654.

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide  
PT and for manufacturing a medicament for diagnosing or treating tumor.

PS Claim 1; SEQ ID NO 474; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted  
CC and transmembrane proteins. Extracellular proteins play important roles  
CC in the formation, differentiation and maintenance of multicellular  
CC organisms. The fate of many individual cells (for example proliferation,  
CC migration or differentiation) is typically governed by information  
CC received from other cells and the immediate environment. The information  
CC is often transmitted by secreted polypeptides (for example mitogenic  
CC factors, survival factors, cytotoxic factors, differentiation factors,  
CC neuropeptides and hormones) which are received and interpreted by diverse  
CC cell receptors or membrane bound proteins. These membrane bound proteins  
CC and receptors may be of use as pharmaceutical and diagnostic agents, such  
CC as in the blocking of receptor-ligand interactions. The current invention  
CC provides the amino acid sequences of novel human membrane bound receptors  
CC and proteins, along with the cDNA sequences encoding them. The novel  
CC proteins of the invention may have cytostatic activities through the  
CC stimulation of chondrocytes. The nucleic acids of the invention may be  
CC useful for the manufacture of a medicament for diagnosing or treating a  
CC tumour in a mammal. In addition, they may be useful for measuring or  
CC detecting the expression of a tumour associated gene. The present  
CC sequence is the amino acid sequence of a human PRO protein of the  
CC invention.

XX Sequence 90 AA;

SQ

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLILLVCEAIWRSNCSNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60  
Db 1 MTFFLSLLILLVCEAIWRSNCSNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

Db 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

## RESULT 133

ADCS3654

ID ADCS3654 standard; protein; 90 AA.

XX AC ADCS3654;

DT 18-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein Seq ID474.

XX human; PRO; membrane bound protein; membrane bound receptor;  
KW cell proliferation; cell migration; cell differentiation;  
KW mitogenic factor; survival factor; cytotoxic factor;  
KW differentiation factor; neurotrophic factor; hormone; cell receptor;  
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.

OS Homo sapiens.

PN US2003087363-A1.

XX 08-MAY-2003.

PF 23-APR-2002; 2002US-00128688.

XX 09-FEB-1999; 99US-0119341P.

PR 01-DEC-1999; 99WO-US028634.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801149/75.

DR N-PSDB; ADCS3653.

XX New PRO nucleic acid, useful for manufacturing a medicament for  
PT diagnosing or treating tumor.

PS Claim 1; SEQ ID NO 474; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted  
CC and transmembrane proteins. Extracellular proteins play important roles  
CC in the formation, differentiation and maintenance of multicellular  
CC organisms. The fate of many individual cells (for example proliferation,  
CC migration or differentiation) is typically governed by information  
CC received from other cells and the immediate environment. The information  
CC is often transmitted by secreted polypeptides (for example mitogenic  
CC factors, survival factors, cytotoxic factors, differentiation factors,  
CC neuropeptides and hormones) which are received and interpreted by diverse  
CC cell receptors or membrane bound proteins. These membrane bound proteins  
CC and receptors may be of use as pharmaceutical and diagnostic agents, such  
CC as in the blocking of receptor-ligand interactions. The current invention  
CC provides the amino acid sequences of novel human membrane bound receptors  
CC and proteins, along with the cDNA sequences encoding them. The novel  
CC proteins of the invention may have cytostatic activities through the  
CC stimulation of chondrocytes. The nucleic acids of the invention may be  
CC useful for the manufacture of a medicament for diagnosing or treating a

CC tumour in a mammal. In addition, they may be useful for measuring or  
 CC detecting the expression of a tumour associated gene. The present  
 CC sequence is the amino acid sequence of a human PRO protein of the  
 CC invention.  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60  
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60  
 QY 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90  
 Db 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90  
 RESULT 134  
 ID ADC59177 standard; protein; 90 AA.  
 XX  
 AC ADC59177;  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein Seq ID474.  
 XX  
 KW human; PRO; membrane bound protein; membrane bound receptor;  
 KW cell proliferation; cell migration; cell differentiation;  
 KW mitogenic factor; survival factor; cytotoxic factor;  
 KW differentiation factor; neuropeptide; hormone; cell receptor;  
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003087359-A1.  
 XX  
 PD 08-MAY-2003.  
 XX  
 PF 22-APR-2002; 2002US-00127834.  
 XX  
 PR 17-SEP-1998; 98US-0100710P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 18-OCT-1999; 99US-00403297.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI: 2003-801144/75.  
 DR N-PSDB; ADC59176.  
 XX  
 PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide  
 PT and for manufacturing a medicament for diagnosing or treating tumor.  
 XX  
 PS Claim 1; SEQ ID NO 474; 637pp; English.  
 XX  
 CC This invention relates to novel nucleic acids encoding human PRO secreted  
 CC and transmembrane proteins. Extracellular proteins play important roles  
 CC in the formation, differentiation and maintenance of multicellular  
 CC organisms. The fate of many individual cells (for example proliferation,  
 CC migration or differentiation) is typically governed by information  
 CC received from other cells and the immediate environment. The information  
 CC is often transmitted by secreted polypeptides (for example mitogenic  
 CC factors, survival factors, cytotoxic factors, differentiation factors,

CC neuropeptides and hormones) which are received and interpreted by diverse  
 CC cell receptors or membrane bound proteins. These membrane bound proteins  
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such  
 CC as in the blocking of receptor-ligand interactions. The current invention  
 CC provides the amino acid sequences of novel human membrane bound receptors  
 CC and proteins, along with the cDNA sequences encoding them. The novel  
 CC proteins of the invention may have cytostatic activities through the  
 CC stimulation of chondrocytes. The nucleic acids of the invention may be  
 CC useful for the manufacture of a medicament for diagnosing or treating a  
 CC tumour in a mammal. In addition, they may be useful for measuring or  
 CC detecting the expression of a tumour associated gene. The present  
 CC sequence is the amino acid sequence of a human PRO protein of the  
 CC invention.  
 XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60

Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90

RESULT 135

ADC56055

ID ADC56055 standard; protein; 90 AA.

XX

AC ADC56055;

XX

DT 18-DEC-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein Seq ID474.

XX

KW human; PRO; membrane bound protein; membrane bound receptor;  
 KW cell proliferation; cell migration; cell differentiation;  
 KW mitogenic factor; survival factor; cytotoxic factor;  
 KW differentiation factor; neuropeptide; hormone; cell receptor;  
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.

XX

OS Homo sapiens.

XX

PN US2003087360-A1.

XX

PD 08-MAY-2003.

XX

PF 22-APR-2002; 2002US-00127836.

XX

PR 17-NOV-1998; 98US-0108802P.

XX

PR 01-SEP-1999; 99WO-US020111.

XX

PR 18-OCT-1999; 99US-00403297.

XX

PR 18-FEB-2000; 2000WO-US004342.

XX

PR 02-JUN-2000; 2000WO-US015264.

XX

PR 23-AUG-2000; 2000WO-US023522.

XX

PR 01-DEC-2000; 2000WO-US032678.

XX

PR 19-DEC-2001; 2001US-00028072.

XX

PA (GETH ) GENENTECH INC.

XX

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI: 2003-801145/75.  
 DR N-PSDB; ADC56054.  
 XX  
 PT New PRO nucleic acid, useful for manufacturing a medicament for  
 PT diagnosing or treating tumor.

```
XX PS Claim 1; SEQ ID NO 474; 637pp; English.
XX CC This invention relates to novel nucleic acids encoding human PRO secreted
XX CC and transmembrane proteins. Extracellular proteins play important roles
XX CC in the formation, differentiation and maintenance of multicellular
XX CC organisms. The fate of many individual cells (for example proliferation,
XX CC migration or differentiation) is typically governed by information
XX CC received from other cells and the immediate environment. The information
XX CC is often transmitted by secreted polypeptides (for example mitogenic
XX CC factors, survival factors, cytotoxic factors, differentiation factors,
XX CC neurotrophic factors and hormones) which are received and interpreted by diverse
XX CC cell receptors or membrane bound proteins. These membrane bound proteins
XX CC as in the blocking of receptor-ligand interactions. The current invention
XX CC provides the amino acid sequences of novel human membrane bound receptors
XX CC and proteins, along with the cDNA sequences encoding them. The novel
XX CC proteins of the invention may have cytostatic activities through the
XX CC stimulation of chondrocytes. The nucleic acids of the invention may be
XX CC useful for the manufacture of a medicament for diagnosing or treating a
XX CC tumour in a mammal. In addition, they may be useful for measuring or
XX CC detecting the expression of a tumour associated gene. The present
XX CC sequence is the amino acid sequence of a human PRO protein of the
XX CC invention.
XX SQ Sequence 90 AA;
XX
XX Query Match 100.0%; Score 462; DB 7; Length 90;
XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;
XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
XX Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
XX
XX QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90
XX Db 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90
XX
XX RESULT 136
XX AD58625
XX ID ADC58625 standard; protein; 90 AA.
XX AC ADC58625;
XX XX
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein Seq ID474.
XX KW human; PRO; membrane bound protein; membrane bound receptor;
XX KW cell proliferation; cell migration; cell differentiation;
XX KW mitogenic factor; survival factor; cytotoxic factor;
XX KW differentiation factor; neurotrophic factor; hormone; cell receptor;
XX KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX OS Homo sapiens.
XX XX
XX PN US2003087346-A1.
XX XX
XX PD 08-MAY-2003.
XX XX
XX PF 17-APR-2002; 2002US-00124815.
XX XX
XX PR 09-DEC-1999; 99US-0170262P.
XX PR 01-DEC-2000; 2000MO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX XX
XX PA (GETH ) GENENTECH INC.
XX XX
XX PI Baker KP, Beresini M, Deforge L, Deanoyers L, Filvaroff E, Gao W;
XX PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
```

PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97US-00965056.  
PR 12-NOV-1997; 97WO-US020069.  
PR 13-NOV-1997; 97US-0065186P.  
PR 24-NOV-1997; 97US-0065311P.  
PR 25-FEB-1998; 97US-0066770P.  
PR 28-MAR-1998; 98US-0075945P.  
PR 28-APR-1998; 98US-0078910P.  
PR 28-MAY-1998; 98US-0083322P.  
PR 28-MAY-1998; 98US-0084600P.  
PR 02-JUN-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 03-JUN-1998; 98US-0087753P.  
PR 04-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088023P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 05-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 23-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 24-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091344P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 09-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 18-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 31-AUG-1998; 98US-0098014P.  
PR 16-SEP-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 17-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US019437.  
PR 06-NOV-1998; 98US-00187368.  
PR 01-DEC-1998; 98WO-US025108.  
PR 07-DEC-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 20-FEB-1999; 99WO-US030911.

```

PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 09-MAR-1999; 99US-00254460.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 12-APR-1999; 99US-00284291.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 18-OCT-1999; 99US-00403296.
PR 12-NOV-1999; 99US-00423844.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 05-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPSLLLLVCEAWRNSGNTLENGYFLSRNKNHSQPTOSLSDSVPTKAVKTT 60
Db |||||
QY 61 GKGIKGRNLDRLGLILGAEGWGVKKNT 90
Db |||||
QY 61 GKGIKGRNLDRLGLILGAEGWGVKKNT 90
Db |||||

RESULT 138
ADD08209
ID ADD08209 standard; protein; 90 AA.
AC
XX
XX
DT
DT
XX
XX
DE 01-JAN-2004 (first entry)
XX
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; neurotropic; neuroprotective;
KW antiparkinsonian.
XX
OS Homo sapiens.
XX
XX
FN US2003068623-A1.
XX

```

```

PD 10-APR-2003.
XX
XX
XX
XX
PR 15-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 18-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.

```



```
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 25-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096323P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 17-SEP-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 12-MAR-1999; 98US-0123957P.

PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTTKAVKTT 60
DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTTKAVKTT 60
QY 61 KGKIVKRNLDNRGLILGAEAWGKVKNT 90
DB 61 KGKIVKRNLDNRGLILGAEAWGKVKNT 90

RESULT 139
ADD03299
ID ADD03299 standard; protein; 90 AA.
XX
AC ADD03299;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
US2003092104-A1.
PN
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131817.
XX
PR 31-MAR-1997; 97WO-US005230.
```

PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 27-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US0005028.  
PR 10-MAR-1999; 99WO-US0005190.  
PR 20-APR-1999; 99WO-US0008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 28-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 11-JUL-2000; 2000WO-US020710.  
PR 28-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, GoCowski PU, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-801169/75.

N-PSDB; ADD03298.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PRO4978, useful in molecular biology, chromosome and gene mapping, in  
generating antisense RNA and DNA, and in gene therapy.

Claim 12; Fig 474; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of  
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
cells, for stimulating differentiation of adipocyte cells, for  
stimulating proliferation of or gene expression in pericyte cells, for  
stimulating the proliferation of inner ear utricular supporting cells or  
T-lymphocyte cells, for inducing endothelial cell tube formation and for  
treating various bone and/or cartilage disorders such as sports injuries  
and arthritis. PRO polypeptides which stimulate the release of  
proteoglycans from cartilage are useful for treating sports-related joint  
problems, articular cartilage defects, osteoarthritis and rheumatoid  
arthritis. PRO polypeptides are also useful for treating various  
mammalian haemoglobin-associated disorders such as various thalassaemias  
and conditions which may benefit from enhanced local immune system cell  
infiltration. This sequence represents a human PRO polypeptide of the  
invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

SQ

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNNGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60

Db 1 MTFFLSLLLLVCEAIWRSNNGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60

QY 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 140

ID ADC90291 standard; protein; 90 AA.

XX ADC90291;

DT 01-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO1159.

KW Human; secreted and transmembrane protein; PRO;

KW tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS US2003087348-A1.

PN 08-MAY-2003.

PD 19-APR-2002; 2002US-00125923.

PF 05-JUN-2000; 2000US-0209832P.

PR 01-DEC-2000; 2000MO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786939/74.

DR N-PSDB; ADC90290.

XX New PRO nucleic acid, useful for manufacturing a medicament for  
diagnosing or treating tumor.

PT Claim 12; SEQ ID NO 474; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
transmembrane) polypeptides (I). (I) is useful for stimulating the  
release of TNF alpha from human blood, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating the proliferation or differentiation of chondrocyte cells,  
for stimulating the proliferation or gene expression in pericyte  
cells, for stimulating the release of or gene expression in pericyte  
cells, for stimulating the proliferation of inner ear utricular supporting cells,  
for stimulating the proliferation of T-lymphocyte cells, for stimulating  
the release of a cytokine from PBMC cells, for inhibiting the binding of  
A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

CC cells, for stimulating proliferation of endothelial cells, for detecting  
the presence of tumour in a mammal. The tumour is lung, colon, breast,  
prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
are useful for isolating genomic and cDNA nucleotide sequences or  
antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
in assays to identify other proteins or molecules involved in binding  
interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
and gene mapping, in generation of antisense RNA and DNA, in the  
preparation of PRO polypeptide, for generating transgenic animals or  
knockout animals which in turn are useful in the development and  
screening of therapeutically useful reagents, in gene therapy, for  
chromosome identification, as chromosome marker, and for generating  
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
detecting its expression in specific cells, tissues or serum, and for  
affinity purification of PRO from recombinant cell culture or natural  
sources. (I) and (II) are useful for tissue typing. This is the amino  
acid sequence of a novel human secreted and transmembrane PRO  
polypeptide.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNNGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60

Db 1 MTFFLSLLLLVCEAIWRSNNGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60

QY 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 141

ID ADC82034

XX ADC82034 standard; protein; 90 AA.

XX ADC82034;

DT 01-JAN-2004 (first entry)

DE Human PRO polypeptide #118.

XX Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;  
insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;  
thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;  
polycystic kidney disease; renal tumour; antidiabetic; antianemic;  
cytostatic; cardiant; vulnery; antiinflammatory; anorectic.

OS Homo sapiens.

XX US2003083461-A1.

XX 01-MAY-2003.

PF 14-NOV-2001; 2001US-00992521.

PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 24-NOV-1997; 97US-0065311P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088856P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089544P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090432P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUN-1998; 98US-0088021P.  
PR 10-JUN-1998; 98US-0088025P.  
PR 10-JUN-1998; 98US-0088026P.  
PR 10-JUN-1998; 98US-0088028P.  
PR 10-JUN-1998; 98US-0088029P.  
PR 10-JUN-1998; 98US-0088030P.  
PR 10-JUN-1998; 98US-0088033P.  
PR 10-JUN-1998; 98US-0088326P.  
PR 10-JUN-1998; 98US-0088167P.  
PR 10-JUN-1998; 98US-0088202P.  
PR 10-JUN-1998; 98US-0088212P.  
PR 10-JUN-1998; 98US-0088217P.  
PR 10-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088856P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089544P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090432P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 10-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095316P.  
PR 10-AUG-1998; 98US-0095329P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 31-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 18-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.

```
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004314.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006984.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013358.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match      100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTQSSLEDSVTPKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTQSSLEDSVTPKAVKTT 60

QY 61 GKGIVKGRNLDRLGLILGAEGWGRVKNT 90
DB 61 GKGIVKGRNLDRLGLILGAEGWGRVKNT 90

RESULT 142
ADC69710
ID ADC69710 standard; protein; 90 AA.
XX
AC ADC69710;
XX
DT 01-JAN-2004 (first entry)
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX OS
XX US2003194770-A1.
XX PN
XX 16-OCT-2003.
XX PD
XX
XX 21-MAY-2002; 2002US-00152375.
XX PF
XX
XX 03-MAR-2000; 2000US-0187202P.
XX PR
XX 30-MAY-2000; 2000WO-US014941.
XX PR
XX 01-DEC-2000; 2000WO-US032678.
XX PR
XX 19-DEC-2001; 2001US-00028072.
XX PR
XX
XX (GETH ) GENENTECH INC.
XX PA
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-844453/78.
XX DR
XX N-PSDB; ADC69709.
XX
```

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 12; Fig 474; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTQSSLEDSVTPKAVKTT 60  
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTQSSLEDSVTPKAVKTT 60

QY 61 GKGIVKGRNLDRLGLILGAEGWGRVKNT 90  
DB 61 GKGIVKGRNLDRLGLILGAEGWGRVKNT 90

RESULT 143  
ADC48599  
ID ADC48599 standard; protein; 90 AA.  
XX  
AC ADC48599;  
XX  
DT 01-JAN-2004 (first entry)  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003194773-A1.  
XX  
PD 16-OCT-2003.  
XX  
PF 21-MAY-2002; 2002US-00152391.  
XX  
PR 09-DEC-1999; 99US-0170262P.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-844455/78.  
DR N-PSDB; ADC48598.  
XX  
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful  
PT for detecting a tumor, stimulating the release of tumor necrosis factor  
PT alpha and stimulating the proliferation of endothelial cells.  
XX  
PS Claim 12; Fig 474; 637pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumor necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting the proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. NO. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLYCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSVPTTKAVKTT 60  
Db |||||  
1 MTFFLSLLLLYCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSVPTTKAVKTT 60  
QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKKNT 90  
Db |||||  
61 GKGIVKGRNLDNRGLILGAEAWGRGVKKNT 90  
RESULT 144  
ADD10128  
ID ADD10128 standard; protein; 90 AA.  
XX  
AC ADD10128;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX US2003194776-A1.  
XX  
PD 16-OCT-2003.  
XX  
PF 29-MAY-2002; 2002US-00157785.  
XX  
PR 05-JUN-2000; 2000US-0209832P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-852596/79.  
DR N-PSDB; ADD10127.  
XX  
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful  
PT for detecting a tumor, stimulating the release of proteoglycans from  
PT cartilage and inhibiting the differentiation of adipocyte cells.  
XX  
PS Claim 12; Fig 474; 637pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumor necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting the proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
SQ Sequence 90 AA;

CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 MTFLLSLLLLVCEAIWNSGNSNLENGYFLSRKNENHSQTSLEDSVTPKAVKTT 60  
 Db 1 MTFLLSLLLLVCEAIWNSGNSNLENGYFLSRKNENHSQTSLEDSVTPKAVKTT 60  
 Qy 61 KGKIVKGNLDSRGLILGAEAWGRCVKNT 90  
 Db 61 KGKIVKGNLDSRGLILGAEAWGRCVKNT 90

RESULT 145

ADD07676

ID ADD07676 standard; protein; 90 AA.

AC ADD07676;

DT 01-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO1159.

KW Human; secreted protein; transmembrane protein; PRO;

KW neonatal heart hypertrophy; angiogenesis;

KW vascular endothelial growth factor; VEGF-stimulated proliferation;

KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

KW rod photoreceptor cell; c-fos induction; adipocyte;

KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;

KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;

KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;

KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;

KW polycystic kidney disease; renal tumour; neurodegenerative disorder;

KW Parkinson's disease; Alzheimer's disease; gene therapy;

KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;

KW antidiabetic; antianaemic; cytostatic; neurotropic; neuroprotective;

KW antiparkinsonian.

OS Homo sapiens.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

PR 20-MAR-1998; 98US-0078910P.  
 PR 28-APR-1998; 98US-0083322P.  
 PR 07-MAY-1998; 98US-0084600P.  
 PR 28-MAY-1998; 98US-0087106P.  
 PR 02-JUN-1998; 98US-0087607P.  
 PR 02-JUN-1998; 98US-0087609P.  
 PR 02-JUN-1998; 98US-0087759P.  
 PR 03-JUN-1998; 98US-0087827P.  
 PR 04-JUN-1998; 98US-0088021P.  
 PR 04-JUN-1998; 98US-0088025P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 04-JUN-1998; 98US-0088028P.  
 PR 04-JUN-1998; 98US-0088029P.  
 PR 04-JUN-1998; 98US-0088030P.  
 PR 04-JUN-1998; 98US-0088033P.  
 PR 04-JUN-1998; 98US-0088326P.  
 PR 05-JUN-1998; 98US-0088167P.  
 PR 05-JUN-1998; 98US-0088202P.  
 PR 05-JUN-1998; 98US-0088212P.  
 PR 05-JUN-1998; 98US-0088217P.  
 PR 09-JUN-1998; 98US-0088655P.  
 PR 10-JUN-1998; 98US-0088734P.  
 PR 10-JUN-1998; 98US-0088738P.  
 PR 10-JUN-1998; 98US-0088742P.  
 PR 10-JUN-1998; 98US-0088810P.  
 PR 10-JUN-1998; 98US-0088824P.  
 PR 10-JUN-1998; 98US-0088826P.  
 PR 11-JUN-1998; 98US-0088858P.  
 PR 11-JUN-1998; 98US-0088861P.  
 PR 11-JUN-1998; 98US-0088876P.  
 PR 12-JUN-1998; 98US-0089105P.  
 PR 16-JUN-1998; 98US-0089440P.  
 PR 16-JUN-1998; 98US-0089512P.  
 PR 16-JUN-1998; 98US-0089514P.  
 PR 17-JUN-1998; 98US-0089532P.  
 PR 17-JUN-1998; 98US-0089538P.  
 PR 17-JUN-1998; 98US-0089598P.  
 PR 17-JUN-1998; 98US-0089599P.  
 PR 17-JUN-1998; 98US-0089600P.  
 PR 17-JUN-1998; 98US-0089653P.  
 PR 18-JUN-1998; 98US-0089801P.  
 PR 18-JUN-1998; 98US-0089907P.  
 PR 18-JUN-1998; 98US-0089908P.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 02-JUN-1999; 98WO-US012252.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 02-MAR-2000; 2000WO-US005004.  
 PR 10-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006319.  
 PR 20-MAR-2000; 2000WO-US006884.  
 PR 30-MAR-2000; 2000WO-US007377.  
 PR 15-MAY-2000; 2000WO-US013358.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
XX WPI; 2003-657230/62.  
XX N-PSDB; ADD07675.  
XX  
XX Isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and  
PT PRO1375, which stimulate proliferation of stimulated T-lymphocytes and  
PT are thus therapeutically useful e.g. for enhancing immune response.  
XX  
XX Claim 12; SEQ ID NO 377; 659pp; English.  
XX  
XX The invention relates to human secreted and transmembrane PRO  
CC polypeptides and the polynucleotides encoding them. The PRO polypeptides  
CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors  
CC or bioreactors. They are useful for stimulating hypertrophy of neonatal  
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth  
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating  
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or  
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-  
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,  
CC inducing proliferation and/or re-differentiation of chondrocytes, or  
CC inducing pancreatic beta-cell precursor differentiation into mature  
CC pancreatic beta-cells. They may therefore be useful in the treatment of  
CC various insulin deficient states in mammals, including diabetes mellitus,  
CC and in treating undesired endothelial cell growth, e.g., inhibiting  
CC tumour growth. The sequences are also useful for treating mammalian  
CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic  
CC renal dysplasia, polycystic kidney disease, renal tumours, and other  
CC cancers such as those of the colon, lung and breast. PRO polypeptides or  
CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in  
CC a sample; to link a bioactive molecule to a cell; to modulate a  
CC biological activity of a cell; as molecular weight markers for protein  
CC electrophoresis purposes; for tissue typing; to prepare a medicament for  
CC treating a condition responsive to the polypeptide or antibody, such as  
CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's  
CC disease); and in various diagnostic assays. The PRO polynucleotides can  
CC be used as hybridisation probes, in chromosome and gene mapping, in  
CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide  
CC may also be used in preparing PRO polypeptides by recombinant techniques,  
CC and in generating either transgenic animals or knock-out animals which,  
CC in turn, are useful in the development and screening of therapeutically  
CC useful reagents. This sequence represents a human PRO polypeptide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
XX Sequence 90 AA;  
SQ

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60  
QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKKNT 90  
|||||  
Db 61 GKGIKGRNLDNRGLILGAEAWGRGVKKNT 90  
|||||  
RESULT 146  
ADD04703  
ID ADD04703 standard; protein; 90 AA.  
XX  
AC ADD04703;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
XX Novel human secreted and transmembrane protein PRO1159.  
XX  
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
KW cell differentiation; skeletal muscle cell; adipocyte cell;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
XX Homo sapiens.  
OS  
XX US2003087354-A1.  
XX  
PD 08-MAY-2003.  
XX  
XX 22-APR-2002; 2002US-00127827.  
XX  
XX 17-AUG-1998; 98US-0096891P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 25-AUG-1999; 99US-00380137.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-801139/75.  
XX N-PSDB; ADD04702.  
XX  
XX New PRO nucleic acid, useful for manufacturing a medicament for  
PT diagnosing or treating tumor.  
XX  
XX Claim 12; Fig 474; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are



CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, for  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassaemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polypeptide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFEFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
Db 1 MTFEFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 GKGIKGRNLDRLGLIIGAEAWGRGVKNT 90  
Db 61 GKGIKGRNLDRLGLIIGAEAWGRGVKNT 90

RESULT 147

IDC82567

ID ADC82567 standard; protein; 90 AA.

XX

AC ADC82567;

XX

DT 01-JAN-2004 (first entry)

XX

DE Human PRO polypeptide #118.

XX

KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;  
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;  
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;  
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;  
KW cytostatic; cardiatic; vulnerary; antiinflammatory; anorectic.

XX

OS Homo sapiens.

XX

PN US2003059833-A1.

XX

PD 27-MAR-2003.

XX

PF 15-NOV-2001; 2001US-00997440.

XX

PR 16-JUN-1997; 97US-0049787E.

PR

PR 17-OCT-1997; 97US-0062250P.

PR

PR 05-NOV-1997; 97WO-US020069.

PR

PR 12-NOV-1997; 97US-0065186P.

PR

PR 13-NOV-1997; 97US-0065311P.

PR

PR 24-NOV-1997; 97US-0066770P.

PR

PR 25-FEB-1998; 98US-0075945P.

PR

PR 20-MAR-1998; 98US-0078910P.

PR

PR 28-APR-1998; 98US-0083322P.

PR

PR 07-MAY-1998; 98US-0084600P.

PR

PR 28-MAY-1998; 98US-0087106P.

PR

PR 02-JUN-1998; 98US-0087607P.

PR

PR 02-JUN-1998; 98US-0087609P.

PR

PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088032P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090679P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 26-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.

```
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095918P.
PR 10-AUG-1998; 98US-0095923P.
PR 10-AUG-1998; 98US-0095926P.
PR 11-AUG-1998; 98US-0096011P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100859P.
PR 07-OCT-1998; 98WO-US019437.
PR 01-DEC-1998; 98WO-US021141.
PR 22-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US013296P.
PR 20-FEB-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US030911.
PR 12-MAR-1999; 98WO-US005028.
PR 02-JUN-1999; 98US-0123957P.
PR 23-JUN-1999; 98WO-US012252.
PR 07-JUL-1999; 98US-0141037P.
PR 20-JUL-1999; 98US-0143048P.
PR 26-JUL-1999; 98US-0144758P.
PR 28-JUL-1999; 98US-0145698P.
PR 17-AUG-1999; 98US-0146222P.
PR 15-SEP-1999; 98US-0149386P.
PR 15-SEP-1999; 98WO-US021090.
PR 30-OCT-1999; 98WO-US021547.
PR 30-NOV-1999; 98US-0158663P.
PR 01-DEC-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028301.
PR 16-DEC-1999; 98WO-US028634.
PR 05-JAN-2000; 98WO-US030095.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004514.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013358.
PR 22-MAY-2000; 2000WO-US013705.
PR 30-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTOSLSDSVTPTKAVKTT 60
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTOSLSDSVTPTKAVKTT 60
QY 61 GKGIKGRNLDRLILGAEAWGRGVKNT 90
Db 61 GKGIKGRNLDRLILGAEAWGRGVKNT 90
RESULT 148
ADC80659
ID ADC80659 standard; protein; 90 AA.
AC ADC80659;
XX
DT 01-JAN-2004 (first entry)
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;
KW sports injury; proteoglycan; articular cartilage defect; thalassaemia;
KW rheumatoid arthritis; haemoglobin-associated disorder; gene mapping;
KW immune system cell infiltration; chromosome mapping; chromosome marker.
XX
OS Homo sapiens.
XX
FN US2003092103-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131815.
XX
PR 22-DEC-1998; 98US-0113511P.
PR 01-DEC-1999; 98WO-US028634.
PR 22-FEB-2000; 2000WO-US004414.
PR 19-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
```



Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49; Indels 0; Gaps 0;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
 DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIVKGRNLDRLGLILGAEAWGRGVKKN 90  
 DB 61 GKGIVKGRNLDRLGLILGAEAWGRGVKKN 90

RESULT 150  
 ADC48047  
 ID ADC48047 standard; protein; 90 AA.  
 AC ADC48047;  
 XX  
 DT 01-JAN-2004 (first entry)  
 XX  
 DE Human PRO polypeptide #237.  
 XX  
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003194771-A1.  
 XX  
 PD 16-OCT-2003.  
 XX  
 PF 21-MAY-2002; 2002US-00152377.  
 XX  
 PR 09-DEC-1999; 99US-0170262P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Gurney SL, Smith V;  
 PI Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-844454/78.  
 DR N-PSDB; ADC48046.  
 XX  
 PT New secreted and transmembrane PRO polypeptides and nucleic acids useful  
 PT for detecting a tumor, stimulating the release of proteoglycans from  
 PT cartilage and stimulating the proliferation of endothelial cells.  
 XX  
 PS Claim 12; Fig 474; 637pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumors, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49; Indels 0; Gaps 0;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
 DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIVKGRNLDRLGLILGAEAWGRGVKKN 90  
 DB 61 GKGIVKGRNLDRLGLILGAEAWGRGVKKN 90

RESULT 151

ADD08747  
 ID ADD08747 standard; protein; 90 AA.

AC ADD08747;

DT 01-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO1159.

XX  
 KW Human; secreted protein; transmembrane protein; PRO;  
 KW neonatal heart hypertrophy; angiogenesis;  
 KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
 KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
 KW rod photoreceptor cell; c-fos induction; adipocyte;  
 KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;  
 KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;  
 KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;  
 KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;  
 KW polycystic kidney disease; renal tumour; neurodegenerative disorder;  
 KW Parkinson's disease; Alzheimer's disease; gene therapy;  
 KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;  
 KW antidiabetic; antianaemic; cytostatic; neurotropic; neuroprotective;  
 KW antiparkinsonian.

XX Homo sapiens.

OS US2003073090-A1.

PN 17-APR-2003.

PF 16-NOV-2001; 2001US-00990439.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.



PR 15-SEP-1999; 99WO-US021547.  
 PR 08-OCT-1999; 99US-0158663P.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 08-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 15-MAY-2000; 2000WO-US013358.

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
 |||||  
 DB 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
 |||||

QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90  
 |||||  
 DB 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90  
 |||||

RESULT 152  
 ADC80107  
 ID ADC80107 standard; protein; 90 AA.  
 XX  
 AC ADC80107;  
 XX  
 DT 01-JAN-2004 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO1159.  
 XX  
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
 KW cell differentiation; skeletal muscle cell; adipocyte cell;  
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
 KW immune system cell infiltration; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003087358-A1.  
 XX  
 PD 08-MAY-2003.  
 XX  
 XX 22-APR-2002; 2002US-00127833.  
 XX  
 PF 01-SEP-1998; 98US-0098750P.  
 XX  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 18-OCT-1999; 99US-00403297.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 08-NOV-2000; 2000WO-US010952.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX

PA (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-801143/75.  
 DR N-PSDB; ADC80106.  
 XX  
 XX New PRO nucleic acid, useful for manufacturing a medicament for  
 PT diagnosing or treating tumor.  
 PT  
 PS Claim 12; Fig 474; 637pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
 CC cells, for stimulating differentiation of adipocyte cells, for  
 CC stimulating proliferation of or gene expression in pericyte cells, for  
 CC stimulating the proliferation of inner ear utricular supporting cells or  
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
 CC treating various bone and/or cartilage disorders such as sports injuries  
 CC and arthritis. PRO polypeptides which stimulate the release of  
 CC proteoglycans from cartilage are useful for treating sports-related joint  
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
 CC arthritis. PRO polypeptides are also useful for treating various  
 CC mammalian haemoglobin-associated disorders such as various thalassemias  
 CC and conditions which may benefit from enhanced local immune system cell  
 CC infiltration. This sequence represents a human PRO polypeptide of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
 |||||  
 DB 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
 |||||

QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90  
 |||||  
 DB 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90  
 |||||

RESULT 153  
 ADD06996  
 ID ADD06996 standard; protein; 90 AA.  
 XX  
 AC ADD06996;  
 XX  
 DT 01-JAN-2004 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO1159.  
 XX

KW Human; secreted protein; transmembrane protein; PRO;  
KW neonatal heart hypertrophy; angiogenesis;  
KW vascular endothelial growth factor; VEGF-stimulated proliferation;  
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;  
KW rod photoreceptor cell; c-fos induction; adipocyte;  
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;  
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;  
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;  
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;  
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;  
KW Parkinson's disease; Alzheimer's disease; gene therapy;  
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;  
KW antidiabetic; antianaemic; cytostatic; neurotropic; neuroprotective;  
KW antiparkinsonian.  
XX  
OS Homo sapiens.  
XX  
XX US2002193300-A1.  
XX  
XX 19-DEC-2002.  
XX  
XX 14-NOV-2001; 2001US-00950444.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 28-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 05-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088320P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 18-JUN-1998; 98US-0089909P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030895.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
XX WPI; 2003-657231/62.  
DR N-PSDB; ADD06995.  
XX  
XX Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346  
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes  
PT and are thus therapeutically useful for enhancing immune response.  
XX  
XX Claim 12; SEQ ID NO 377; 653pp; English.  
XX  
XX The invention relates to human secreted and transmembrane PRO  
CC polypeptides and the polynucleotides encoding them. The PRO polypeptides  
CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors  
CC or bioreactors. They are useful for stimulating hypertrophy of neonatal  
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth  
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating  
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or  
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-  
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,  
CC inducing proliferation and/or re-differentiation of chondrocytes, or  
CC inducing pancreatic beta-cell precursor differentiation into mature  
CC pancreatic beta-cells. They may therefore be useful in the treatment of

CC various insulin deficient states in mammals, including diabetes mellitus,  
CC and in treating undesired endothelial cell growth, e.g., inhibiting  
CC tumour growth. The sequences are also useful for treating mammalian  
CC renal dysplasia, polycystic kidney disease, renal tumours, and other  
CC cancers such as those of the colon, lung and breast. PRO polypeptides or  
CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in  
CC a sample; to link a bioactive molecule to a cell; to modulate a  
CC biological activity of a cell; as molecular weight markers for protein  
CC electrophoresis purposes; for tissue typing; to prepare a medicament for  
CC treating a condition responsive to the polypeptide or antibody, such as  
CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's  
CC disease); and in various diagnostic assays. The PRO polynucleotides can  
CC be used as hybridisation probes, in chromosome and gene mapping, in  
CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide  
CC may also be used in preparing PRO polypeptides by recombinant techniques,  
CC and in generating either transgenic animals or knock-out animals which,  
CC in turn, are useful in the development and screening of therapeutically  
CC useful reagents. This sequence represents a human PRO polypeptide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60  
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60  
QY 61 GKGIKVRNLDNRGLILGAEGAWGRGVKNT 90  
DB 61 GKGIKVRNLDNRGLILGAEGAWGRGVKNT 90

RESULT 154

ID ADD09576 standard; protein; 90 AA.

AC ADD09576;

XX 01-JAN-2004 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX Homo sapiens.

OS US2003194775-A1.

XX 16-OCT-2003.

XX 28-MAY-2002; 2002US-00156848.

XX 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI: 2003-852595/79.  
DR N-PSDB; ADD09575.

XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful  
PT for detecting a tumor, stimulating the release of tumor necrosis factor  
PT alpha from blood and stimulating the release of proteoglycans from  
PT cartilage.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60  
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60  
QY 61 GKGIKVRNLDNRGLILGAEGAWGRGVKNT 90  
DB 61 GKGIKVRNLDNRGLILGAEGAWGRGVKNT 90

RESULT 155

ADC83243

ID ADC83243 standard; protein; 90 AA.

XX ADC83243;

XX 01-JAN-2004 (first entry)

XX Human PRO polypeptide #118.

XX Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;







of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSLSDSVTPTKAVKT 60  
61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90  
61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 157  
ADD52428  
ID ADD52428 standard; protein; 90 AA.  
AC  
AC ADD52428;  
XX  
DT 15-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003194769-A1.  
XX  
PD 16-OCT-2003.  
XX  
XX 21-MAY-2002; 2002US-00152374.  
XX  
XX 09-DEC-1999; 99US-0170262P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CX, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-852593/79.  
DR N-PSDB; ADD52427.  
XX  
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic acids useful for detection of tumors, modulating the uptake of glucose or free fatty acids and stimulating the release of proteoglycans from cartilage.  
XX  
XX Claim 12; Fig 474; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSLSDSVTPTKAVKT 60  
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSLSDSVTPTKAVKT 60  
QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90  
Db 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 158  
ADD53168  
ID ADD53168 standard; protein; 90 AA.  
XX  
AC ADD53168;  
XX  
DT 15-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003194792-A1.  
XX  
PD 16-OCT-2003.  
XX  
XX 15-APR-2002; 2002US-00123156.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
XX 28-AUG-1998; 98WO-US017888.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98WO-US019093.  
XX 14-SEP-1998; 98WO-US019094.  
XX 14-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.  
XX 17-SEP-1998; 98WO-US019437.  
XX 07-OCT-1998; 98WO-US021141.  
XX 29-OCT-1998; 98WO-US022991.

```
PR 29-OCT-1998; 98WO-US022992.
PR 30-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005139.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 15-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US020311.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.
PR 03-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-852599/79.
DR N-PSDB; ADD53167.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in chromosome and gene mapping, in generating antisense
PT RNA and DNA, and in the treatment of cancer.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 MTFFLSLLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60
```

preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWESNGSNTLENGYFLSRNKNHSQPTQSSLEDSVTPTKAVKTT 60  
Db 1 MTFFLSLLLLVCEAIWESNGSNTLENGYFLSRNKNHSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90  
Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 160  
ADD53350  
ID ADD53350 standard; protein; 90 AA.  
XX  
AC ADD53350;  
XX  
DT 15-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #118.  
XX  
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;  
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;  
KW thalassemia; endothelial cell growth; cancer; cystic renal dysplasia;  
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;  
KW cytotatic; cardiac; vulnarary; antiinflammatory; anorectic.  
XX  
OS Homo sapiens.  
XX  
PN US2003077593-A1.  
XX  
PD 24-APR-2003.  
XX  
PF 19-NOV-2001; 2001US-00989328.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087105P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.

61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90  
61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 159  
ADD53720  
ID ADD53720 standard; protein; 90 AA.  
XX  
AC ADD53720;  
XX  
DT 15-JAN-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1159.  
XX  
KW Human; secreted and transmembrane protein; PRO;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; PFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
PN US2003203437-A1.  
XX  
PD 30-OCT-2003.  
XX  
PF 15-MAY-2002; 2002US-00146728.  
XX  
PR 01-JUL-1998; 98US-0091360P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-DEC-2000; 2000US-00380137.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
DR WPI; 2003-875644/81.  
DR N-PSDB; ADD53719.  
XX  
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.  
XX  
FS Claim 12; SEQ ID NO 474; 659pp; English.  
XX  
XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or PFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the proliferation of BMC cells, for inhibiting the binding of the release of a cytokine from BMC cells, for inhibiting the differentiation of adipocyte A-peptide to factor VIIA, for inhibiting the differentiation of endothelial cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the



```
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000WO-US0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLILLVCEAIWRNSGNTLENGYFLSRNKENHSOQTQSLEDVSTPKAVKTT 60
Db 1 MTFELSLILLVCEAIWRNSGNTLENGYFLSRNKENHSOQTQSLEDVSTPKAVKTT 60

QY 61 GKGIKGRNLDNRGLILGAEWGRGVKKNT 90
Db 61 GKGIKGRNLDNRGLILGAEWGRGVKKNT 90

RESULT 161
ADD56308
ID ADD56308 standard; protein; 90 AA.
XX AC ADD56308;
XX DT 15-JAN-2004 (first entry)
XX DE Human PRO polypeptide #118.
XX KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytosstatic; cardiant; vulnery; antiinflammatory; anorectic.
XX OS Homo sapiens.
XX PN US2003077594-A1.
XX PD 24-APR-2003.
XX PF 14-NOV-2001; 2001US-009393593.
XX PR 16-JUN-1997; 97US-0049787P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 05-NOV-1997; 97WO-US020069.
XX PR 12-NOV-1997; 97US-0065186P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 24-NOV-1997; 97US-0066770P.
XX PR 25-FEB-1998; 98US-0075945P.
XX PR 20-MAR-1998; 98US-0078910P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 07-MAY-1998; 98US-0084600P.
XX PR 28-MAY-1998; 98US-0087106P.
XX PR 02-JUN-1998; 98US-0087607P.
XX PR 02-JUN-1998; 98US-0087609P.
XX PR 02-JUN-1998; 98US-0087759P.
XX PR 03-JUN-1998; 98US-0087827P.
XX PR 04-JUN-1998; 98US-0088021P.
XX PR 04-JUN-1998; 98US-0088025P.
XX PR 04-JUN-1998; 98US-0088026P.
XX PR 04-JUN-1998; 98US-0088028P.
XX PR 04-JUN-1998; 98US-0088029P.
XX PR 04-JUN-1998; 98US-0088030P.
XX PR 04-JUN-1998; 98US-0088033P.
XX PR 04-JUN-1998; 98US-0088326P.
XX PR 05-JUN-1998; 98US-0088167P.
XX PR 05-JUN-1998; 98US-0088202P.
XX PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088653P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 17-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 18-JUN-1998; 98US-0089946P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 23-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0092182P.
PR 09-JUL-1998; 98US-0092472P.
PR 10-JUL-1998; 98US-0093339P.
PR 20-JUL-1998; 98US-0094651P.
PR 30-JUL-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
```

```
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 01-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023323.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLILLVCEAIWFSNGSNTLENGYFLSRNKENHSOPTQSSLEDSVTPTKAVKTT 60
|||
DB 1 MTFFLSLILLVCEAIWFSNGSNTLENGYFLSRNKENHSOPTQSSLEDSVTPTKAVKTT 60
|||
QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90
|||
DB 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 162
ADD51876
ID ADD51876 standard; protein; 90 AA.
XX AC ADD51876;
XX DT 15-JAN-2004 (first entry)
XX DE Human PRO polypeptide #237.
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; Glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003194779-A1.
XX PD 16-OCT-2003.
XX PF 30-MAY-2002; 2002US-00160500.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2003-852597/79.
XX DR N-PSDB; ADD51875.
XX CC New secreted and transmembrane PRO nucleic acids and polypeptides, useful
XX CC for detecting the presence of a tumor, stimulating the release of tumor
XX CC necrosis factor alpha from human blood and treating, e.g. organ failure.
XX PS Claim 12; Fig 474; 637pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The
XX CC invention also relates to an antibody which specifically binds to a PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
```





ADD02109

ID

ADD02109 standard; protein; 90 AA.

XX

ADD02109;

AC

XX

15-JAN-2004 (first entry)

DT

XX

Human PRO polypeptide #237.

DE

XX

Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW

XX

tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW

XX

cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;

KW

XX

liver; microvascular endothelial cell; glucose; FFA;

KW

XX

skeletal muscle cell; adipocyte cell; pericyte cell;

KW

XX

inner ear utricular supporting cell; T-lymphocyte cell;

KW

XX

endothelial cell tube formation; bone disorder; cartilage disorder;

KW

XX

sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW

XX

rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW

XX

immune system cell infiltration.

KW

XX

Homo sapiens.

OS

XX

US2003203430-A1.

PN

XX

30-OCT-2003.

PD

XX

23-APR-2002; 2002US-00128685.

PF

XX

11-AUG-1998; 98US-0096143P.

PR

XX

02-JUN-1999; 99WO-US012252.

PR

XX

30-MAR-2000; 2000US-00380137.

PR

XX

30-MAR-2000; 2000WO-US008439.

PR

XX

01-DEC-2000; 2000WO-US032678.

PR

XX

19-DEC-2001; 2001US-00028072.

PR

XX

(GETH ) GENENTECH INC.

PA

XX

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

PI

XX

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI

XX

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

PI

XX

WPI; 2003-875637/81.

DR

XX

N-PSDB; ADD02108.

DR

XX

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

PT

XX

PRO4978, useful in molecular biology, chromosome and gene mapping, in

PT

XX

generating antisense RNA and DNA, and in gene therapy.

PT

XX

Claim 12; Fig 474; 637pp; English.

PS

XX

The invention relates to isolated human PRO polypeptides (secreted and

CC

XX

transmembrane polypeptides) and the polynucleotides encoding them. The

CC

XX

invention also relates to an antibody which specifically binds to a PRO

CC

XX

polypeptide, a method for stimulating the release of tumour necrosis

CC

XX

factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC

XX

proliferation or differentiation of chondrocyte cells and a method for

CC

XX

detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC

XX

colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC

XX

polynucleotides are useful in molecular biology, including uses as

CC

XX

hybridisation probes, in chromosome and gene mapping, in generating

CC

XX

antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC

XX

be used in preparing PRO polypeptides by recombinant techniques and in

CC

XX

generating either transgenic animals or knock-out animals which are

CC

XX

useful in the development and screening of therapeutically useful

CC

XX

reagents. The PRO polypeptides or antibodies are used in preparing a

CC

XX

medicament for treating a condition responsive to the polypeptides or

CC

XX

antibodies, such as tumours, for stimulating and inhibiting proliferation

CC

XX

of human microvascular endothelial cells, for modulating the uptake of

CC

XX

glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC

XX

stimulating differentiation of adipocyte cells, for stimulating

CC

XX

proliferation of or gene expression in pericyte cells, for stimulating

CC

XX

the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC

XX

cells, for inducing endothelial cell tube formation and for treating

CC

XX

CC various bone and/or cartilage disorders such as sports injuries and

CC

XX

arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC

XX

from cartilage are useful for treating sports-related joint problems,

CC

XX

articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC

XX

polypeptides are also useful for treating various mammalian haemoglobin-

CC

XX

associated disorders such as various thalassaemias and conditions which

CC

XX

may benefit from enhanced local immune system cell infiltration. This

CC

XX

sequence represents a human PRO polypeptide of the invention. Note: The

CC

XX

sequence data for this patent is also available in electronic format from

CC

XX

USPTO at seqdata.uspto.gov/sequence.html.

CC

XX

Sequence 90 AA;

SQ

XX

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLILLVCEALWRSNCSNTLENGYFLSRKNKHSQPTQSSLEDVPTTKAVKTT 60

DB 1 MTFFLSLILLVCEALWRSNCSNTLENGYFLSRKNKHSQPTQSSLEDVPTTKAVKTT 60

QY 61 GKGIKGRNLDGRGLILGAEAWGRGVKKNT 90

DB 61 GKGIKGRNLDGRGLILGAEAWGRGVKKNT 90

RESULT 165

ADD54291

ID ADD54291 standard; protein; 90 AA.

AC ADD54291;

DT 15-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW Glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW Gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

XX US2003203432-A1.

PN 30-OCT-2003.

PD 10-MAY-2002; 2002US-00142886.

XX 05-JUN-2000; 2000US-0209832P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-875639/81.

DR N-PSDB; ADD54290.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

PT PRO4978, useful in molecular biology, chromosome and gene mapping, in

generating antisense RNA and DNA, and in gene therapy.

XX Claim 12; SEQ ID NO 474; 637pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and

transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 90 AA;  
SQ

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSOPTQSSLEDSVTPTKAVKTT 60  
DB 1 MTFELSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSOPTQSSLEDSVTPTKAVKTT 60

QY 61 KGKIVKGNLSDRGHILGAEWGRGVKNT 90  
DB 61 KGKIVKGNLSDRGHILGAEWGRGVKNT 90

RESULT 166  
ADD54746  
ID ADD54746 standard; protein; 90 AA.  
XX  
AC ADD54746;  
XX  
DT 15-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #118.  
XX  
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell; insulin deficiency; diabetes mellitus; haemoglobin-associated disorder; thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour; antidiabetic; antianaemic; cytostatic; cardiant; vulnary; antinflammatory; anorectic.  
XX  
OS Homo sapiens.  
XX  
PN US2002132253-A1.  
XX  
PD 19-SEP-2002.  
XX  
PF 14-NOV-2001; 2001US-00991163.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.

24-NOV-1997; 97US-0066770P.  
25-FEB-1998; 98US-0075945P.  
20-MAR-1998; 98US-0078910P.  
28-APR-1998; 98US-0083322P.  
07-MAY-1998; 98US-0084600P.  
28-MAY-1998; 98US-0087106P.  
02-JUN-1998; 98US-0087607P.  
02-JUN-1998; 98US-0087603P.  
02-JUN-1998; 98US-0087753P.  
03-JUN-1998; 98US-0087827P.  
04-JUN-1998; 98US-0088021P.  
04-JUN-1998; 98US-0088025P.  
04-JUN-1998; 98US-0088026P.  
04-JUN-1998; 98US-0088028P.  
04-JUN-1998; 98US-0088029P.  
04-JUN-1998; 98US-0088030P.  
04-JUN-1998; 98US-0088033P.  
04-JUN-1998; 98US-0088326P.  
05-JUN-1998; 98US-0088167P.  
05-JUN-1998; 98US-0088202P.  
05-JUN-1998; 98US-0088212P.  
05-JUN-1998; 98US-0088217P.  
05-JUN-1998; 98US-0088655P.  
10-JUN-1998; 98US-0088734P.  
10-JUN-1998; 98US-0088738P.  
10-JUN-1998; 98US-0088742P.  
10-JUN-1998; 98US-0088810P.  
10-JUN-1998; 98US-0088824P.  
10-JUN-1998; 98US-0088826P.  
11-JUN-1998; 98US-0088858P.  
11-JUN-1998; 98US-0088861P.  
11-JUN-1998; 98US-0088876P.  
12-JUN-1998; 98US-0089105P.  
16-JUN-1998; 98US-0089440P.  
16-JUN-1998; 98US-0089512P.  
16-JUN-1998; 98US-0089514P.  
17-JUN-1998; 98US-0089532P.  
17-JUN-1998; 98US-0089538P.  
17-JUN-1998; 98US-0089598P.  
17-JUN-1998; 98US-0089599P.  
17-JUN-1998; 98US-0089600P.  
17-JUN-1998; 98US-0089653P.  
18-JUN-1998; 98US-0089801P.  
18-JUN-1998; 98US-0089907P.  
18-JUN-1998; 98US-0089908P.  
18-JUN-1998; 98US-0089908P.  
16-SEP-1998; 98WO-US019330.  
17-SEP-1998; 98WO-US019437.  
07-OCT-1998; 98WO-US021141.  
01-DEC-1998; 98WO-US025108.  
05-JAN-1999; 99WO-US000106.  
08-MAR-1999; 99WO-US005028.  
02-JUN-1999; 99WO-US012252.  
15-SEP-1999; 99WO-US021090.  
15-SEP-1999; 99WO-US021547.  
30-NOV-1999; 99WO-US028313.  
01-DEC-1999; 99WO-US028301.  
01-DEC-1999; 99WO-US028634.  
16-DEC-1999; 99WO-US030095.  
20-DEC-1999; 99WO-US030911.  
06-JAN-2000; 2000WO-US000219.  
06-JAN-2000; 2000WO-US000376.  
11-FEB-2000; 2000WO-US003565.  
18-FEB-2000; 2000WO-US004341.  
22-FEB-2000; 2000WO-US004414.  
24-FEB-2000; 2000WO-US004914.  
24-FEB-2000; 2000WO-US005004.  
02-MAR-2000; 2000WO-US005841.  
10-MAR-2000; 2000WO-US006319.  
15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
30-MAR-2000; 2000WO-US008439.  
15-MAY-2000; 2000WO-US013358.  
17-MAY-2000; 2000WO-US013705.

22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 09-JUL-2001; 2001WO-US021066.  
PR 29-JUN-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX XX (GETH ) GENENTECH INC.  
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PU;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WT;  
PI Zhang Z;  
XX WPI: 2003-695825/66.  
DR N-PSDB; ADD54745.  
XX New PRO polypeptides and nucleic acid molecules, useful in gene therapy,  
PT or in diagnosing or treating inflammatory diseases, diabetes, cancer,  
PT rheumatoid arthritis, ulcers, amyotrophic lateral sclerosis or septic  
PT shock.  
XX Claim 12; SEQ ID NO 377; 658pp; English.  
XX The invention relates to human PRO polypeptides and the polynucleotides  
CC encoding them. The sequences are useful for inducing differentiation of  
CC pancreatic beta-cell precursor cells into mature pancreatic beta-cells,  
CC and thus for treating various insulin deficient states in mammals,  
CC including diabetes mellitus. The sequences are also useful for treating  
CC mammalian haemoglobin-associated disorders e.g., various thalassaemias,  
CC renal dysplasia, polycystic kidney disease and renal tumours. The  
CC polypeptides are useful for tissue typing, as molecular weight markers  
CC for protein electrophoresis purposes, as therapeutic agents and as  
CC hybridisation probes for isolating PRO cDNA from a cDNA library. The  
CC polynucleotides are useful in gene therapy, as chromosome identification  
CC recombinantly expressing molecular weight markers, in chromosome and gene  
CC mapping, in the generation of anti-sense RNA and DNA and in preparation  
CC of PRO polypeptides by recombinant techniques. This sequence represents a  
CC human PRO polypeptide of the invention. Note: The sequence data for this  
CC patent is also available in electronic format from USPTO at  
CC seqdata.uspto.gov/sequence.html.  
XX SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MTFPLSLLLLVCAIWRNSGNTLENGYFLSRNKENHSOPTOSSEDSVTPPKAVKTT 60  
Db 1 MTFPLSLLLLVCAIWRNSGNTLENGYFLSRNKENHSOPTOSSEDSVTPPKAVKTT 60  
Qy 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90  
Db 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90  
RESULT 167  
ADD92608  
ID ADD92608 standard; protein; 90 AA.  
XX  
AC ADD92608;

29-JAN-2004 (first entry)  
Human PRO polypeptide #237.  
Human; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.  
XX Homo sapiens.  
XX US2003199030-A1.  
XX 23-OCT-2003.  
XX 28-MAY-2002; 2002US-00156841.  
XX 03-MAR-2000; 2000US-0187202P.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;  
XX WPI: 2003-900159/82.  
XX N-PSDB; ADD92607.  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
XX useful for treating pericyte-associated tumors, diabetes and various bone  
XX and/or cartilage disorders, e.g. arthritis.  
XX Claim 12; SEQ ID NO 474; 636pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX from cartilage are useful for treating sports-related joint problems,  
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
XX polypeptides are also useful for treating various mammalian haemoglobin-  
XX associated disorders such as various thalassaemias and conditions which  
XX may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQTSLSLDSVTPTKAVKIT 60

Db 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQTSLSLDSVTPTKAVKIT 60

QY 61 GKGIVKGRNLDGRGLILGAEANGRVKKN 90

Db 61 GKGIVKGRNLDGRGLILGAEANGRVKKN 90

RESULT 168

ADD91504  
ID ADD91504 standard; protein; 90 AA.

XX AC

XX DT

XX 29-JAN-2004 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003199055-A1.

XX 23-OCT-2003.

XX 12-APR-2002; 2002US-00121063.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018224.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 16-SEP-1998; 98WO-US019177.

XX 17-SEP-1998; 98WO-US019330.

XX 07-OCT-1998; 98WO-US019437.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 10-MAR-1999; 2000WO-US006319.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 03-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 19-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001US-00887879.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUL-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-900165/82.  
DR N-PSDB; ADD91503.  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX Claim 12; SEQ ID NO 474; 636pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for treating  
CC the proliferation of inner ear utricular supporting cells and for treating  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems. PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
XX Sequence 90 AA;  
SQ  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFEFLSLLLVCEAIWRNSGNTLENGYFTSRNKENHSQPTQSSLEDVPTKAVKTT 60  
DB 1 MTFEFLSLLLVCEAIWRNSGNTLENGYFTSRNKENHSQPTQSSLEDVPTKAVKTT 60  
QY 61 GKGVKGRNLDGRGLILGAFAWGRGVKQNT 90  
DB 61 GKGVKGRNLDGRGLILGAFAWGRGVKQNT 90  
RESULT 169  
AD804118  
ID ADE04118 standard; protein; 90 AA.  
XX  
AC ADE04118;  
XX  
DT 29-JAN-2004 (first entry)

XX Human PRO polypeptide #237.  
XX  
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
XX immune system cell infiltration.  
XX  
XX Homo sapiens.  
XX OS  
XX US2003199057-A1.  
XX  
XX 23-OCT-2003.  
XX  
XX 15-APR-2002; 2002US-00123213.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 16-SEP-1998; 98WO-US019177.  
PR 17-SEP-1998; 98WO-US019330.  
PR 07-OCT-1998; 98WO-US019437.  
PR 29-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 2000WO-US006319.  
PR 14-MAY-1999; 99WO-US008615.  
PR 02-JUN-1999; 99WO-US010733.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 05-OCT-1999; 99WO-US021547.  
PR 29-NOV-1999; 99WO-US023089.  
PR 30-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028403.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US00376.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.



PR	28-MAY-1998;	98US-0087106P.	PR	02-JUL-1998;	98US-0091673P.
PR	02-JUN-1998;	98US-0087607P.	PR	07-JUL-1998;	98US-0091978P.
PR	02-JUN-1998;	98US-0087609P.	PR	07-JUL-1998;	98US-0091982P.
PR	02-JUN-1998;	98US-0087759P.	PR	09-JUL-1998;	98US-0092182P.
PR	03-JUN-1998;	98US-0087827P.	PR	10-JUL-1998;	98US-0092472P.
PR	04-JUN-1998;	98US-0088021P.	PR	20-JUL-1998;	98US-0093339P.
PR	04-JUN-1998;	98US-0088025P.	PR	30-JUL-1998;	98US-0094651P.
PR	04-JUN-1998;	98US-0088026P.	PR	04-AUG-1998;	98US-0095282P.
PR	04-JUN-1998;	98US-0088028P.	PR	04-AUG-1998;	98US-0095285P.
PR	04-JUN-1998;	98US-0088029P.	PR	04-AUG-1998;	98US-0095301P.
PR	04-JUN-1998;	98US-0088030P.	PR	04-AUG-1998;	98US-0095302P.
PR	04-JUN-1998;	98US-0088033P.	PR	04-AUG-1998;	98US-0095318P.
PR	04-JUN-1998;	98US-0088326P.	PR	04-AUG-1998;	98US-0095321P.
PR	05-JUN-1998;	98US-0088167P.	PR	04-AUG-1998;	98US-0095325P.
PR	05-JUN-1998;	98US-0088202P.	PR	10-AUG-1998;	98US-0095916P.
PR	05-JUN-1998;	98US-0088212P.	PR	10-AUG-1998;	98US-0095929P.
PR	05-JUN-1998;	98US-0088217P.	PR	10-AUG-1998;	98US-0096012P.
PR	09-JUN-1998;	98US-0088655P.	PR	11-AUG-1998;	98US-0096143P.
PR	10-JUN-1998;	98US-0088734P.	PR	11-AUG-1998;	98US-0096146P.
PR	10-JUN-1998;	98US-0088738P.	PR	12-AUG-1998;	98US-0096329P.
PR	10-JUN-1998;	98US-0088742P.	PR	12-AUG-1998;	98US-0096757P.
PR	10-JUN-1998;	98US-0088810P.	PR	17-AUG-1998;	98US-0096766P.
PR	10-JUN-1998;	98US-0088826P.	PR	17-AUG-1998;	98US-0096768P.
PR	10-JUN-1998;	98US-0088826P.	PR	17-AUG-1998;	98US-0096773P.
PR	11-JUN-1998;	98US-0088858P.	PR	17-AUG-1998;	98US-0096791P.
PR	11-JUN-1998;	98US-0088861P.	PR	17-AUG-1998;	98US-0096867P.
PR	11-JUN-1998;	98US-0088876P.	PR	17-AUG-1998;	98US-0096891P.
PR	11-JUN-1998;	98US-0089105P.	PR	17-AUG-1998;	98US-0096894P.
PR	12-JUN-1998;	98US-0089440P.	PR	17-AUG-1998;	98US-0096895P.
PR	16-JUN-1998;	98US-0089512P.	PR	17-AUG-1998;	98US-0096897P.
PR	16-JUN-1998;	98US-0089514P.	PR	18-AUG-1998;	98US-0096949P.
PR	17-JUN-1998;	98US-0089532P.	PR	18-AUG-1998;	98US-0096950P.
PR	17-JUN-1998;	98US-0089538P.	PR	18-AUG-1998;	98US-0096959P.
PR	17-JUN-1998;	98US-0089598P.	PR	18-AUG-1998;	98US-0096960P.
PR	17-JUN-1998;	98US-0089599P.	PR	18-AUG-1998;	98US-0097022P.
PR	17-JUN-1998;	98US-0089600P.	PR	19-AUG-1998;	98US-0097141P.
PR	17-JUN-1998;	98US-0089653P.	PR	20-AUG-1998;	98US-0097218P.
PR	17-JUN-1998;	98US-0089901P.	PR	24-AUG-1998;	98US-0097661P.
PR	18-JUN-1998;	98US-0089907P.	PR	26-AUG-1998;	98US-0097952P.
PR	18-JUN-1998;	98US-0089948P.	PR	26-AUG-1998;	98US-0097954P.
PR	19-JUN-1998;	98US-0089952P.	PR	26-AUG-1998;	98US-0097955P.
PR	22-JUN-1998;	98US-0090246P.	PR	26-AUG-1998;	98US-0097971P.
PR	22-JUN-1998;	98US-0090252P.	PR	26-AUG-1998;	98US-0097974P.
PR	22-JUN-1998;	98US-0090254P.	PR	26-AUG-1998;	98US-0097978P.
PR	23-JUN-1998;	98US-0090349P.	PR	26-AUG-1998;	98US-0097979P.
PR	23-JUN-1998;	98US-0090355P.	PR	26-AUG-1998;	98US-0097986P.
PR	24-JUN-1998;	98US-0090429P.	PR	31-AUG-1998;	98US-0098014P.
PR	24-JUN-1998;	98US-0090431P.	PR	31-AUG-1998;	98US-0098525P.
PR	24-JUN-1998;	98US-0090435P.	PR	16-SEP-1998;	98US-0100634P.
PR	24-JUN-1998;	98US-0090444P.	PR	16-SEP-1998;	98US-0100634P.
PR	24-JUN-1998;	98US-0090445P.	PR	17-SEP-1998;	98US-0100658P.
PR	24-JUN-1998;	98US-0090447P.	PR	17-SEP-1998;	98US-0100658P.
PR	24-JUN-1998;	98US-0090472P.			



```

PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US0005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US015964.
PR 02-JUN-2000; 2000US-0213637P.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSGTQSSLEDSVTPTKAVKTT 60
DB 1 MTFFLSLLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSGTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90
DB 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 171
ADE32415
ID ADE32415 standard; protein; 90 AA.
XX AC ADE32415;
XX AC ADE32415;
DT 29-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1159.
XX KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX KW Homo sapiens.
XX OS US2003194765-A1.
XX PN 16-OCT-2003.
XX PD 09-MAY-2002; 2002US-00142889.
XX PF 03-MAR-2000; 2000US-0187202P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2003-899784/82.
XX DR N-PSDB; ADE32414.
XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX PS Claim 12; SEQ ID NO 474; 636pp; English.
XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or TNF by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSGTQSSLEDSVTPTKAVKTT 60
DB 1 MTFFLSLLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSGTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90
DB 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 172
ADE22347
ID ADE22347 standard; protein; 90 AA.
XX AC ADE22347;
XX AC ADE22347;
DT 29-JAN-2004 (first entry)
XX DE Human PRO polypeptide #237.
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

```

KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	28-JUL-2000; 2000WO-US020710.	PR
KX	immune system cell infiltration.	11-AUG-2000; 2000WO-US022031.	PR
XX		23-AUG-2000; 2000WO-US023522.	PR
OS		24-AUG-2000; 2000WO-US023328.	PR
PN	Homo sapiens.	08-NOV-2000; 2000WO-US030952.	PR
XX		10-NOV-2000; 2000WO-US030873.	PR
XX	US2003199056-A1.	01-DEC-2000; 2000WO-US032678.	PR
XX		20-DEC-2000; 2000US-00747259.	PR
PD		20-DEC-2000; 2000WO-US034956.	PR
XX	23-OCT-2003.	28-FEB-2001; 2001US-00796498.	PR
PF		28-FEB-2001; 2001WO-US006520.	PR
XX	15-APR-2002; 2002US-00123212.	01-MAR-2001; 2001WO-US006666.	PR
XX		09-MAR-2001; 2001US-00802706.	PR
XX	31-MAR-1997; 97WO-US005230.	14-MAR-2001; 2001US-00806689.	PR
PR	12-JUN-1998; 98WO-US012456.	22-MAR-2001; 2001US-00816744.	PR
PR	14-JUL-1998; 98WO-US014552.	05-APR-2001; 2001US-00828366.	PR
PR	28-AUG-1998; 98WO-US017888.	10-MAY-2001; 2001US-00854208.	PR
PR	10-SEP-1998; 98WO-US018824.	10-MAY-2001; 2001US-00854280.	PR
PR	14-SEP-1998; 98WO-US019093.	18-MAY-2001; 2001US-00860216.	PR
PR	14-SEP-1998; 98WO-US019177.	25-MAY-2001; 2001US-00866028.	PR
PR	16-SEP-1998; 98WO-US019330.	25-MAY-2001; 2001US-00866034.	PR
PR	17-SEP-1998; 98WO-US019437.	25-MAY-2001; 2001WO-US017092.	PR
PR	17-SEP-1998; 98WO-US021141.	01-JUN-2001; 2001US-00872035.	PR
PR	07-OCT-1998; 98WO-US022991.	01-JUN-2001; 2001WO-US017800.	PR
PR	29-OCT-1998; 98WO-US022992.	05-JUN-2001; 2001US-00874503.	PR
PR	20-NOV-1998; 98WO-US024855.	14-JUN-2001; 2001US-00882636.	PR
PR	01-DEC-1998; 98WO-US025108.	19-JUN-2001; 2001US-00886342.	PR
PR	05-JAN-1999; 98WO-US00106.	20-JUN-2001; 2001WO-US019692.	PR
PR	08-MAR-1999; 98WO-US005028.	21-JUN-2001; 2001US-00887879.	PR
PR	10-MAR-1999; 98WO-US005190.	22-JUN-2001; 2001WO-US020116.	PR
PR	10-MAR-1999; 98WO-US006319.	29-JUN-2001; 2001WO-US021066.	PR
PR	20-APR-1999; 99WO-US008615.	09-JUL-2001; 2001WO-US021735.	PR
PR	14-MAY-1999; 99WO-US010733.	18-JUL-2001; 2001US-00908827.	PR
PR	02-JUN-1999; 99WO-US012252.	06-AUG-2001; 2001US-00924419.	PR
PR	01-SEP-1999; 99WO-US020111.	09-AUG-2001; 2001US-00927796.	PR
PR	08-SEP-1999; 99WO-US020594.	16-AUG-2001; 2001US-00931836.	PR
PR	13-SEP-1999; 99WO-US020944.	19-DEC-2001; 2001US-00028072.	PR
PR	15-SEP-1999; 99WO-US021090.	XX (GETH ) GENENTECH INC.	XX
PR	15-SEP-1999; 99WO-US021547.	XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;	XX
PR	05-OCT-1999; 99WO-US023089.	PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	PI
PR	29-NOV-1999; 99WO-US028214.	PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	PI
PR	30-NOV-1999; 99WO-US028313.	XX WPI: 2003-900166/82.	XX
PR	30-NOV-1999; 99WO-US028409.	DR N-PSDB; ADE22346.	DR
PR	01-DEC-1999; 99WO-US028301.	Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.	PT
PR	01-DEC-1999; 99WO-US028634.	Claim 12; Fig 474; 638pp; English.	XX
PR	02-DEC-1999; 99WO-US028551.	The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating	CC
PR	02-DEC-1999; 99WO-US028564.		CC
PR	02-DEC-1999; 99WO-US028565.		CC
PR	16-DEC-1999; 99WO-US030095.		CC
PR	20-DEC-1999; 99WO-US030911.		CC
PR	20-DEC-1999; 99WO-US030999.		CC
PR	22-DEC-1999; 99WO-US030720.		CC
PR	30-DEC-1999; 99WO-US031243.		CC
PR	30-DEC-1999; 99WO-US031274.		CC
PR	05-JAN-2000; 2000WO-US000219.		CC
PR	06-JAN-2000; 2000WO-US000277.		CC
PR	11-JAN-2000; 2000WO-US000376.		CC
PR	11-FEB-2000; 2000WO-US003565.		CC
PR	18-FEB-2000; 2000WO-US004341.		CC
PR	18-FEB-2000; 2000WO-US004342.		CC
PR	22-FEB-2000; 2000WO-US004414.		CC
PR	24-FEB-2000; 2000WO-US004914.		CC
PR	24-FEB-2000; 2000WO-US005004.		CC
PR	01-MAR-2000; 2000WO-US005601.		CC
PR	02-MAR-2000; 2000WO-US005746.		CC
PR	02-MAR-2000; 2000WO-US005941.		CC
PR	15-MAR-2000; 2000WO-US006884.		CC
PR	20-MAR-2000; 2000WO-US007377.		CC
PR	21-MAR-2000; 2000WO-US007532.		CC
PR	30-MAR-2000; 2000WO-US008439.		CC
PR	17-MAY-2000; 2000WO-US013705.		CC
PR	22-MAY-2000; 2000WO-US014042.		CC
PR	30-MAY-2000; 2000WO-US014941.		CC
PR	02-JUN-2000; 2000WO-US015264.		CC

CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
 |||||  
 Db 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90  
 |||||  
 Db 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 173

ADD79571  
 ID ADD79571 standard; protein; 90 AA.

XX AC ADD79571;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX XX US2003203428-A1.

XX XX 30-OCT-2003.

XX XX 22-APR-2002; 2002US-00127852.

XX XX 09-DEC-1999; 99US-0170262P.

XX XX 01-DEC-2000; 2000WO-US032678.

XX XX 19-DEC-2001; 2001US-00028072.

XX XX (GETH ) GENENTECH INC.

XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX XX WPI; 2003-875635/81.

XX XX N-PSDB; ADD79570.

XX XX New isolated, secreted and transmembrane PRO polypeptides and nucleic

XX XX acids, useful for the diagnosis, prevention and/or treatment of tumors,

PT

PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
 PT tumors.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
 |||||

Db 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

|||||

Db 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 174

ADE42107

ID ADE42107 standard; protein; 90 AA.

XX AC ADE42107;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

XX US2003194772-A1.

XX 16-OCT-2003.

XX 21-MAY-2002; 2002US-00152386.

XX 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-899788/82.

XX N-PSDB; ADE42106.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,

XX useful for treating pericyte-associated tumors, diabetes and various bone

XX and/or cartilage disorders, e.g. arthritis.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating differentiation of adipocyte cells, for stimulating  
proliferation of or gene expression in pericyte cells, for stimulating  
the proliferation of inner ear utricular supporting cells or T-lymphocyte  
cells, for inducing endothelial cell tube formation and for treating  
various bone and/or cartilage disorders such as sports injuries and  
arthritis. PRO polypeptides which stimulate the release of proteoglycans  
from cartilage are useful for treating sports-related joint problems.  
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
polypeptides are also useful for treating various mammalian haemoglobin-  
associated disorders such as various thalassaemias and conditions which  
may benefit from enhanced local immune system cell infiltration. This  
sequence represents a human PRO polypeptide of the invention. Note: The  
sequence data for this patent is also available in electronic format from  
USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 90 AA;

XX Query Match 100.0%; Score 462; DB 7; Length 90;

XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;

XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX 1 MTFFSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

XX 1 MTFFSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90

DB 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90

RESULT 175

ADE17924

ID ADE17924 standard; protein; 90 AA.

XX AC ADE17924;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.

XX Homo sapiens.

XX US2003199023-A1.

XX 23-OCT-2003.

XX 17-APR-2002; 2002US-00124821.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 07-SEP-1998; 98WO-US021437.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025103.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005199.

XX 20-APR-1999; 2000WO-US006319.

XX 14-MAY-1999; 99WO-US008615.

XX 02-JUN-1999; 99WO-US010733.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028584.

XX 02-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.



OS	Homo sapiens.	
XX	US2003199053-A1.	
XX	23-OCT-2003.	
XX	12-APR-2002; 2002US-00121053.	
XX	31-MAR-1997; 97WO-US005230.	24-AUG-2000; 2000WO-US023328.
PR	12-JUN-1998; 98WO-US012456.	08-NOV-2000; 2000WO-US030952.
PR	14-JUL-1998; 98WO-US014552.	10-NOV-2000; 2000WO-US030873.
PR	28-AUG-1998; 98WO-US017888.	01-DEC-2000; 2000WO-US032678.
PR	10-SEP-1998; 98WO-US018824.	20-DEC-2000; 2000US-00747259.
PR	14-SEP-1998; 98WO-US019093.	20-DEC-2000; 2000WO-US034956.
PR	14-SEP-1998; 98WO-US019094.	PR 28-FEB-2001; 2001US-00796498.
PR	14-SEP-1998; 98WO-US019177.	PR 28-FEB-2001; 2001WO-US006520.
PR	16-SEP-1998; 98WO-US019330.	PR 01-MAR-2001; 2001US-00802706.
PR	17-SEP-1998; 98WO-US019437.	PR 09-MAR-2001; 2001US-00808689.
PR	07-OCT-1998; 98WO-US021141.	PR 14-MAR-2001; 2001US-00816744.
PR	29-OCT-1998; 98WO-US022991.	PR 22-MAR-2001; 2001US-00816744.
PR	29-OCT-1998; 98WO-US022992.	PR 05-APR-2001; 2001US-00828366.
PR	20-NOV-1998; 98WO-US024855.	PR 10-MAY-2001; 2001US-00854208.
PR	01-DEC-1998; 98WO-US025108.	PR 10-MAY-2001; 2001US-00854280.
PR	05-JAN-1999; 98WO-US005028.	PR 18-MAY-2001; 2001US-00860216.
PR	08-MAR-1999; 98WO-US005190.	PR 25-MAY-2001; 2001US-00866028.
PR	10-MAR-1999; 2000WO-US006319.	PR 25-MAY-2001; 2001US-00866034.
PR	20-APR-1999; 99WO-US010733.	PR 25-MAY-2001; 2001WO-US017092.
PR	14-MAY-1999; 99WO-US012252.	PR 01-JUN-2001; 2001US-00872035.
PR	02-JUN-1999; 99WO-US020111.	PR 01-JUN-2001; 2001WO-US017800.
PR	08-SEP-1999; 99WO-US020594.	PR 05-JUN-2001; 2001US-00874503.
PR	13-SEP-1999; 99WO-US020944.	PR 14-JUN-2001; 2001US-00882636.
PR	15-SEP-1999; 99WO-US021090.	PR 19-JUN-2001; 2001US-00886342.
PR	05-SEP-1999; 99WO-US021547.	PR 20-JUN-2001; 2001WO-US019692.
PR	05-OCT-1999; 99WO-US023089.	PR 21-JUN-2001; 2001US-00887879.
PR	29-NOV-1999; 99WO-US028214.	PR 22-JUN-2001; 2001WO-US020116.
PR	30-NOV-1999; 99WO-US028313.	PR 29-JUN-2001; 2001WO-US021066.
PR	30-NOV-1999; 99WO-US028409.	PR 09-JUL-2001; 2001WO-US021735.
PR	01-DEC-1999; 99WO-US028301.	PR 18-JUL-2001; 2001US-00308827.
PR	01-DEC-1999; 99WO-US028634.	PR 06-AUG-2001; 2001US-00324419.
PR	02-DEC-1999; 99WO-US028551.	PR 09-AUG-2001; 2001US-00927795.
PR	02-DEC-1999; 99WO-US028564.	PR 16-AUG-2001; 2001US-00931836.
PR	16-DEC-1999; 99WO-US028565.	PR 19-DEC-2001; 2001US-00028072.
PR	20-DEC-1999; 99WO-US030095.	XX
PR	20-DEC-1999; 99WO-US030911.	PA (GETH ) GENENTECH INC.
PR	20-DEC-1999; 99WO-US030999.	XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PR	22-DEC-1999; 99WO-US030720.	PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PR	30-DEC-1999; 99WO-US031243.	PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PR	30-DEC-1999; 99WO-US031274.	XX WPI: 2003-900164/82.
PR	05-JAN-2000; 2000WO-US000219.	DR N-P8DB; ADD92055.
PR	06-JAN-2000; 2000WO-US000277.	XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, (secreted and
PR	06-JAN-2000; 2000WO-US000376.	CC transmembrane polypeptides) and the polynucleotides encoding them. The
PR	11-FEB-2000; 2000WO-US003565.	CC invention also relates to an antibody which specifically binds to a PRO
PR	18-FEB-2000; 2000WO-US004341.	CC polypeptide, a method for stimulating the release of tumour necrosis
PR	22-FEB-2000; 2000WO-US004342.	CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
PR	24-FEB-2000; 2000WO-US004914.	CC proliferation or differentiation of chondrocyte cells and a method for
PR	24-FEB-2000; 2000WO-US005004.	CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, The
PR	01-MAR-2000; 2000WO-US005601.	CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
PR	02-MAR-2000; 2000WO-US005746.	CC polynucleotides are useful in molecular biology, including uses as
PR	02-MAR-2000; 2000WO-US005841.	CC hybridisation probes, in chromosome and gene mapping, in generating
PR	15-MAR-2000; 2000WO-US006884.	CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
PR	20-MAR-2000; 2000WO-US007377.	CC be used in preparing PRO polypeptides by recombinant techniques and in
PR	21-MAR-2000; 2000WO-US007532.	CC generating either transgenic animals or knock-out animals which are
PR	30-MAR-2000; 2000WO-US014042.	CC useful in the development and screening of therapeutically useful
PR	02-JUN-2000; 2000WO-US014941.	CC reagents. The PRO polypeptides or antibodies are used in preparing a
PR	02-JUN-2000; 2000WO-US015264.	CC medicament for treating a condition responsive to the polypeptides or
PR	28-JUL-2000; 2000WO-US020710.	CC antibodies, such as tumours, for stimulating and inhibiting proliferation
PR	11-AUG-2000; 2000WO-US022031.	CC of human microvascular endothelial cells, for modulating the uptake of
PR	23-AUG-2000; 2000WO-US023522.	CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
		CC stimulating differentiation of adipocyte cells, for stimulating
		CC proliferation of or gene expression in pericyte cells, for stimulating
		CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
		CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX

XX SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90  
DB 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 177  
ADE33519  
ID ADE33519 standard; protein; 90 AA.  
AC ADE33519;  
XX  
XX 29-JAN-2004 (first entry)  
XX Novel human secreted and transmembrane protein PRO1159.  
XX Human; secreted and transmembrane protein; PRO;  
XX Tumour necrosis factor alpha release; TNF-alpha release;  
XX glucose uptake modulator; FFA uptake modulator;  
XX cell proliferation stimulator; cell differentiation stimulator;  
XX cell differentiation inhibitor; cytokine release stimulator; tumour;  
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;  
XX gene therapy; chromosome identification; chromosome marker.  
XX Homo sapiens.  
XX US2003194767-A1.  
XX 16-OCT-2003.  
XX 16-MAY-2002; 2002US-00147497.  
XX 26-AUG-1998; 98US-0097951P.  
XX 02-JUN-1999; 99WO-US012252.  
XX 25-AUG-1999; 99US-00380137.  
XX 30-MAR-2000; 2000WO-US008439.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-899786/82.  
XX N-ESDB; ADE33518.  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
XX useful for treating pericyte-associated tumors, diabetes and various bone  
XX and/or cartilage disorders, e.g. arthritis.

PS Claim 12; SEQ ID NO 474; 636pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells, for adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PBMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This is the amiro  
CC acid sequence of a novel human secreted and transmembrane PRO  
CC polypeptide.  
XX

XX SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90  
DB 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 178  
ADE34071  
ID ADE34071 standard; protein; 90 AA.  
XX  
XX ADE34071;  
XX 29-JAN-2004 (first entry)  
XX Novel human secreted and transmembrane protein PRO1159.  
XX Human; secreted and transmembrane protein; PRO;  
XX Tumour necrosis factor alpha release; TNF-alpha release;  
XX glucose uptake modulator; FFA uptake modulator;  
XX cell proliferation stimulator; cell differentiation stimulator;  
XX cell differentiation inhibitor; cytokine release stimulator; tumour;  
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;  
XX gene therapy; chromosome identification; chromosome marker.  
XX Homo sapiens.  
XX US2003194791-A1.  
XX 16-OCT-2003.  
XX 11-APR-2002; 2002US-00121046.

XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98WO-US005190.  
PR 10-MAR-1999; 2000WO-US006319.  
PR 20-APR-1999; 98WO-US008615.  
PR 14-MAY-1999; 98WO-US010733.  
PR 02-JUN-1999; 98WO-US012252.  
PR 01-SEP-1999; 98WO-US020111.  
PR 08-SEP-1999; 98WO-US020594.  
PR 13-SEP-1999; 98WO-US020944.  
PR 15-SEP-1999; 98WO-US021090.  
PR 15-SEP-1999; 98WO-US021547.  
PR 05-OCT-1999; 98WO-US023089.  
PR 29-NOV-1999; 98WO-US028214.  
PR 30-NOV-1999; 98WO-US028313.  
PR 30-NOV-1999; 98WO-US028409.  
PR 01-DEC-1999; 98WO-US028301.  
PR 01-DEC-1999; 98WO-US028634.  
PR 02-DEC-1999; 98WO-US028551.  
PR 02-DEC-1999; 98WO-US028564.  
PR 02-DEC-1999; 98WO-US028565.  
PR 16-DEC-1999; 98WO-US030095.  
PR 20-DEC-1999; 98WO-US030911.  
PR 20-DEC-1999; 98WO-US030999.  
PR 22-DEC-1999; 98WO-US030720.  
PR 30-DEC-1999; 98WO-US031243.  
PR 05-JAN-2000; 98WO-US031274.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 05-JUN-2001; 2001WO-US017800.  
PR 14-JUN-2001; 2001US-00874503.  
PR 19-JUN-2001; 2001US-00882636.  
PR 20-JUN-2001; 2001US-00886342.  
PR 21-JUN-2001; 2001WO-US019692.  
PR 22-JUN-2001; 2001US-00887879.  
PR 29-JUN-2001; 2001WO-US020116.  
PR 09-JUL-2001; 2001WO-US021066.  
PR 18-JUL-2001; 2001US-0021735.  
PR 06-AUG-2001; 2001US-00908827.  
PR 09-AUG-2001; 2001US-00924419.  
PR 16-AUG-2001; 2001US-00927796.  
PR 19-DEC-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
PR (GETH ) GENENTECH INC.  
PR Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;  
XX WPI; 2003-899790/82.  
DR N-PSDB; ADE34070.  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.  
PS Claim 12; SEQ ID NO 474; 636pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PMBC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.  
XX



(GETH ) GENENTECH INC.



Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTPKAVKT 60  
DB 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTPKAVKT 60

QY 61 GKGVGRNLDRLGLILGAEAWGRGVKNT 90  
DB 61 GKGVGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 181  
ADE19580  
ID ADE19580 standard; protein; 90 AA.  
XX  
AC ADE19580;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003199025-A1.  
XX  
PD 23-OCT-2003.  
XX  
PF 21-MAY-2002; 2002US-00152385.  
XX  
PR 03-MAR-2000; 2000US-0187202P.  
XX  
PR 10-NOV-2000; 2000WO-US030873.  
XX  
PR 01-DEC-2000; 2000WO-US032678.  
XX  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPT; 2003-900156/82.  
DR N-PSDB; ADE19579.  
XX  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
XX Claim 12; SEQ ID NO 474; 648pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-900157/82.  
DR N-PSDB; ADE19027.  
XX  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
XX  
PS Claim 12; SEQ ID NO 474; 636pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
XX Sequence 90 AA;  
SQ  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFEISLLILLYCEATWRNSGNTLNGCYFYSRNKENHSQPTOSLSDSVPTPKAVKT 60  
DB 1 MTFEISLLILLYCEATWRNSGNTLNGCYFYSRNKENHSQPTOSLSDSVPTPKAVKT 60  
QY 61 GKGVKGRNLDRLGLILGAEAWGRGVKNT 90  
DB 61 GKGVKGRNLDRLGLILGAEAWGRGVKNT 90  
RESULT 183  
AD843224  
ID ADE43224 standard; protein; 90 AA.  
XX  
AC ADE43224;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
XX Human PRO polypeptide #237.  
XX  
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
XX Homo sapiens.  
XX  
XX US2003199033-A1.  
XX  
PD 23-OCT-2003.  
XX  
PF 28-MAY-2002; 2002US-00156845.  
XX  
XX 05-JUN-2000; 2000US-0209832P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-900162/82.  
DR N-PSDB; ADE43223.  
XX  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
XX Claim 12; Fig 474; 636pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
XX Sequence 90 AA;  
SQ

Query Match	100.0%;	Score 462;	DB 7;	Length 90;
Best Local Similarity	100.0%;	Pred. No. 9.8e-49;		
Matches	90;	Conservative 0;	Mismatches 0;	Indels 0; Gaps 0

  

QY	1	MTFFLSLLLLLYCEAIWRSN	SGSNTLENGYFLSRN	KENHSOPTOSSLEDSVTPTKAVKTT	60
Db	1	MTFFLSLLLLLYCEAIWRSN	SGSNTLENGYFLSRN	KENHSOPTOSSLEDSVTPTKAVKTT	60
QY	61	GKGIIVKGRNLD	SGILGAEAWGRGV	KKNT 90	
Db	61	GKGIIVKGRNLD	SGILGAEAWGRGV	KKNT 90	

RESULT 184	
ADD96013	
ID	ADD96013 standard; protein; 90 AA.
XX	
AC	ADD96013;
XX	
DT	29-JAN-2004 (first entry)
XX	
DE	Human PRO polypeptide #237.
XX	
KW	Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW	liver; microvascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear utricular supporting cell; 1-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW	immune system cell infiltration.
XX	
OS	Homo sapiens.
XX	
PN	US2003199059-A1.
XX	
PD	23-OCT-2003.
XX	
PF	15-APR-2002; 2002US-00123322.
XX	
PR	31-MAR-1997; 97WO-US005230.
PR	12-JUN-1998; 98WO-US012456.
PR	14-JUL-1998; 98WO-US014552.
PR	28-AUG-1998; 98WO-US017888.
PR	10-SEP-1998; 98WO-US018624.
PR	14-SEP-1998; 98WO-US019093.
PR	14-SEP-1998; 98WO-US019093.
PR	14-SEP-1998; 98WO-US019177.
PR	16-SEP-1998; 98WO-US019330.
PR	17-SEP-1998; 98WO-US019437.
PR	07-OCT-1998; 98WO-US021141.
PR	29-OCT-1998; 98WO-US022991.
PR	29-OCT-1998; 98WO-US022992.
PR	20-NOV-1998; 98WO-US024855.
PR	01-DEC-1998; 98WO-US025108.
PR	05-JAN-1999; 98WO-US000106.
PR	08-MAR-1999; 98WO-US005028.
PR	10-MAR-1999; 98WO-US005190.
PR	10-MAR-1999; 2000WO-US006319.
PR	20-APR-1999; 98WO-US008615.
PR	14-MAY-1999; 98WO-US010733.
PR	02-JUN-1999; 98WO-US012252.
PR	01-SEP-1999; 98WO-US020111.
PR	08-SEP-1999; 98WO-US020594.
PR	13-SEP-1999; 98WO-US020944.
PR	15-SEP-1999; 98WO-US021090.
PR	15-SEP-1999; 98WO-US021547.
PR	03-OCT-1999; 98WO-US023089.
PR	29-NOV-1999; 98WO-US028214.
PR	30-NOV-1999; 98WO-US028313.
PR	30-NOV-1999; 98WO-US028409.

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-900168/82.  
DR N-PSDB; ADD96012.  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
XX Claim 12; Fig 474; 638pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems. PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at segdata.uspto.gov/sequence.html.  
XX  
XX Sequence 90 AA;  
SQ  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFFLSLLLLVCEATWRNSGNTLENGYFSLRNKENHSQPTQSSLEDSVPTKAVKTT 60  
Db 1 MTFFLSLLLLVCEATWRNSGNTLENGYFSLRNKENHSQPTQSSLEDSVPTKAVKTT 60  
QY 61 GKGIKGRNLDKRLGLILGAPAWGRVKKNT 90  
Db 61 GKGIKGRNLDKRLGLILGAPAWGRVKKNT 90  
RESULT 185  
ADE22899  
ID ADE22899 standard; protein; 90 AA.  
XX  
XX ADE22899;  
AC  
XX 29-JAN-2004 (first entry)  
DT  
XX Human PRO polypeptide #237.  
DE  
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW

KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
XX Homo sapiens.  
XX OS  
XX US2003199064-A1.  
XX 23-OCT-2003.  
XX  
XX 19-APR-2002; 2002US-00125932.  
31-MAR-1997; 97WO-US005230.  
12-JUN-1998; 98WO-US012456.  
14-JUL-1998; 98WO-US014552.  
28-AUG-1998; 98WO-US017888.  
10-SEP-1998; 98WO-US018824.  
14-SEP-1998; 98WO-US019093.  
14-SEP-1998; 98WO-US019094.  
14-SEP-1998; 98WO-US019177.  
16-SEP-1998; 98WO-US019330.  
17-SEP-1998; 98WO-US019437.  
07-OCT-1998; 98WO-US021141.  
29-OCT-1998; 98WO-US022991.  
29-OCT-1998; 98WO-US022992.  
20-NOV-1998; 98WO-US024855.  
01-DEC-1998; 98WO-US025108.  
05-JAN-1999; 99WO-US000106.  
08-MAR-1999; 99WO-US005028.  
10-MAR-1999; 99WO-US005190.  
10-MAR-1999; 2000WO-US006319.  
20-APR-1999; 99WO-US008615.  
14-MAY-1999; 99WO-US010733.  
02-JUN-1999; 99WO-US012252.  
01-SEP-1999; 99WO-US020111.  
08-SEP-1999; 99WO-US020594.  
13-SEP-1999; 99WO-US020944.  
15-SEP-1999; 99WO-US021090.  
15-SEP-1999; 99WO-US021547.  
05-OCT-1999; 99WO-US023089.  
29-NOV-1999; 99WO-US028214.  
30-NOV-1999; 99WO-US028313.  
30-NOV-1999; 99WO-US028409.  
01-DEC-1999; 99WO-US028301.  
01-DEC-1999; 99WO-US028634.  
02-DEC-1999; 99WO-US028551.  
02-DEC-1999; 99WO-US028584.  
02-DEC-1999; 99WO-US028565.  
16-DEC-1999; 99WO-US030095.  
20-DEC-1999; 99WO-US030911.  
20-DEC-1999; 99WO-US030999.  
22-DEC-1999; 99WO-US030720.  
30-DEC-1999; 99WO-US031243.  
30-DEC-1999; 99WO-US031274.  
05-JAN-2000; 2000WO-US000219.  
06-JAN-2000; 2000WO-US000277.  
11-FEB-2000; 2000WO-US003565.  
18-FEB-2000; 2000WO-US004341.  
22-FEB-2000; 2000WO-US004342.  
24-FEB-2000; 2000WO-US004914.  
24-FEB-2000; 2000WO-US005004.  
01-MAR-2000; 2000WO-US005601.  
02-MAR-2000; 2000WO-US005746.  
02-MAR-2000; 2000WO-US005841.  
15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
20-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015264.  
28-JUL-2000; 2000WO-US020710.  
11-AUG-2000; 2000WO-US022031.  
23-AUG-2000; 2000WO-US023522.  
24-AUG-2000; 2000WO-US023328.  
08-NOV-2000; 2000WO-US030952.  
10-NOV-2000; 2000WO-US030873.  
01-DEC-2000; 2000WO-US032678.  
20-DEC-2000; 2000US-00747259.  
20-DEC-2000; 2000WO-US034956.  
28-FEB-2001; 2001US-00796498.  
28-FEB-2001; 2001WO-US006520.  
01-MAR-2001; 2001WO-US008566.  
09-MAR-2001; 2001US-00802706.  
14-MAR-2001; 2001US-00808689.  
22-MAR-2001; 2001US-00816744.  
05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854208.  
18-MAY-2001; 2001US-00860216.  
25-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
01-JUN-2001; 2001WO-US017092.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00882636.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019692.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
23-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.  
(GETH ) GENENTECH INC.  
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
WPI; 2003-900169/82.  
N-PSDB; ADE22898.  
Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
useful for treating pericyte-associated tumors, diabetes and various bone  
and/or cartilage disorders, e.g. arthritis.  
Claim 12; Fig 474; 638pp; English.  
The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.  
XX  
SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNENHSQPTQSSLESVPTTKAVKT 60  
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNENHSQPTQSSLESVPTTKAVKT 60  
QY 61 GKGIKGRNLDGRGLTILGAEAWGRGVKNT 90  
Db 61 GKGIKGRNLDGRGLTILGAEAWGRGVKNT 90  
RESULT 186  
ADD79017  
ID ADD79017 standard; protein; 90 AA.  
XX  
AC ADD79017;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003023429-A1.  
XX  
PD 30-OCT-2003.  
XX  
PF 22-APR-2002; 2002US-00127900.  
XX  
PR 05-JUN-2000; 2000US-0209832P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
PI  
XX

DR WPI; 2003-875636/81.  
DR N-PSDB; ADD79016.  
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic  
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,  
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
PT tumors.  
XX  
XX  
PS Claim 12; Fig 474; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.  
XX  
SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDVPTKAVKTT 60  
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDVPTKAVKTT 60  
QY 61 GKGIKVRNLDLSGLILGAWGRGVKKNT 90  
Db 61 GKGIKVRNLDLSGLILGAWGRGVKKNT 90  
RESULT 187  
ADE26367  
ID ADE26367 standard; protein; 90 AA.  
XX  
AC ADE26367;  
DT 29-JAN-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1159.  
XX human; secreted and transmembrane protein; PRO; neotropic;  
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;  
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;  
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.

XX Homo sapiens.  
XX  
XX US2003087305-A1.  
XX  
PD 08-MAY-2003.  
XX  
PF 15-NOV-2001; 2001US-00997384.  
XX  
XX 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0085186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 28-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088328P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088555P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 19-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 23-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.



```
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 25-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091678P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095322P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 24-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0098014P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0101141P.
PR 01-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US014252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028113.
PR 01-DEC-1999; 99WO-US028101.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005034.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTFELSLLLLVCAIWRNSGNTLENGYFLSRKNHSHQPTOSSEDSVTPKAVKTT 60
Db 1 MTFELSLLLLVCAIWRNSGNTLENGYFLSRKNHSHQPTOSSEDSVTPKAVKTT 60
Qy 61 GKGVKGRNLDNRGLILGAEAWGRGVKNT 90
Db 61 GKGVKGRNLDNRGLILGAEAWGRGVKNT 90
RESULT 188
ADE32967
ID ADE32967 standard; protein; 90 AA.
XX ADE32967;
AC ADE32967;
XX
XX 29-JAN-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1159.
XX
XX Human; secreted and transmembrane protein; PRO;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX Glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
```

gene therapy; chromosome identification; chromosome marker.

Homo sapiens.

US2003194766-A1.

16-OCT-2003.

14-MAY-2002; 2002US-00145874.

05-JUN-2000; 2000US-0209832P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-899785/82. N-PSDB; ADE32966.

Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

Claim 12; SEQ ID NO 474; 636pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (II) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90; Best Local Similarity 100.0%; Pred. No. 9.8e-49; Mismatches 0; Indels 0; Gaps 0; Matches 90; Conservative 0;

1 MTFPLSLLLLVCAIWRNSGNTLNGVFLSRNKHNSOPTSSLEDSVTPFKVKT 60  
|||||  
1 MTFPLSLLLLVCAIWRNSGNTLNGVFLSRNKHNSOPTSSLEDSVTPFKVKT 60  
|||||  
61 GKGIVKGRNLDRLGILGAEAWGRVKNT 90  
|||||  
61 GKGIVKGRNLDRLGILGAEAWGRVKNT 90  
|||||

RESULT 189  
ADE42659  
ID ADE42659 standard; protein; 90 AA.  
XX  
AC ADE42659;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003199032-A1.  
XX  
PD 23-OCT-2003.  
XX  
PF 28-MAY-2002; 2002US-00156844.  
XX  
PR 03-MAR-2000; 2000US-0187202P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-900161/82.  
DR N-PSDB; ADE42658.  
XX  
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
PS Claim 12; Fig 474; 636pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX

SQ Sequence 90 AA;  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVPTTKAVKIT 60  
Dd 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVPTTKAVKIT 60  
QY 61 GKGIVKGRNLDGRGLILGAEAWGRGVKKNT 90  
Dd 61 GKGIVKGRNLDGRGLILGAEAWGRGVKKNT 90

RESULT 190  
ADD80675  
ID ADD80675 standard; protein; 90 AA.  
XX  
AC ADD80675;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
FN US2003207418-A1.  
XX  
PD 06-NOV-2003.  
XX  
PF 07-MAY-2002; 2002US-00140809.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022591.  
PR 20-NOV-1998; 98WO-US022992.  
PR 01-DEC-1998; 98WO-US024855.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 10-MAR-1999; 2000WO-US006319.

PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 16-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030939.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 09-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882536.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019632.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.

[illegible]

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 90 AA;  
  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49; Indels 0; Gaps 0;  
Matches 90; Conservative 0; Mismatches 0;  
  
QY 1 MTFLLSLLLVCFAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
DB 1 MTFLLSLLLVCFAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
  
QY 61 GKGIVKGRNLDGRGLIILGAEAWGRGVKNT 90  
DB 61 GKGIVKGRNLDGRGLIILGAEAWGRGVKNT 90  
  
RESULT 192  
ADE40987  
ID ADE40987 standard; protein; 90 AA.  
XX  
AC ADE40987;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
FN US2003199031-A1.  
XX  
PD 23-OCT-2003.  
  
28-MAY-2002; 2002US-00156842.  
PF  
XX  
XX 05-JUN-2000; 2000US-0209832P.  
PR  
XX 01-DEC-2000; 2000WO-US032678.  
PR  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-900160/82.  
DR  
XX N-PSDB; ADE40986.  
XX  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
XX useful for treating pericyte-associated tumors, diabetes and various bone  
XX and/or cartilage disorders, e.g. arthritis.  
XX  
XX Claim 12; Fig 474; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, biology, including uses as  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polypeptide of the invention. Note: The  
CC USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 90 AA;  
  
Query Match 100.0%; Score 462; DB 7; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49; Indels 0; Gaps 0;  
Matches 90; Conservative 0; Mismatches 0;  
  
QY 1 MTFLLSLLLVCFAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
DB 1 MTFLLSLLLVCFAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
  
QY 61 GKGIVKGRNLDGRGLIILGAEAWGRGVKNT 90  
DB 61 GKGIVKGRNLDGRGLIILGAEAWGRGVKNT 90  
  
RESULT 193  
ADE40786  
ID ADE40786 standard; protein; 90 AA.  
XX  
AC ADE40786;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human PRO polypeptide #237.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
FN US2003199034-A1.  
XX  
PD 23-OCT-2003.

XX PF 28-MAY-2001; 2001US-00156846.  
 XX PR 03-MAR-2000; 2000US-0187202P.  
 XX PR 01-DEC-2000; 2000WO-US032678.  
 XX PR 19-DEC-2001; 2001US-00028072.  
 XX PA (GETH ) GENENTECH INC.  
 XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX DR WPI; 2003-900163/82.  
 XX DR N-PSDB; ADE04785.  
 XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
 XX PT useful for treating pericyte-associated tumors, diabetes and various bone  
 XX PT and/or cartilage disorders, e.g. arthritis.  
 XX PS Claim 12; Fig 474; 637pp; English.  
 XX CC The invention relates to isolated human PRO polypeptides (secreted and  
 XX CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 XX CC invention also relates to an antibody which specifically binds to a PRO  
 XX CC polypeptide, a method for stimulating the release of tumour necrosis  
 XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 XX CC proliferation or differentiation of chondrocyte cells and a method for  
 XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 XX CC polynucleotides are useful in molecular biology, including uses as  
 XX CC hybridisation probes, in chromosome and gene mapping, in generating  
 XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 XX CC be used in preparing PRO polypeptides by recombinant techniques and in  
 XX CC generating either transgenic animals or knock-out animals which are  
 XX CC useful in the development and screening of therapeutically useful  
 XX CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 XX CC medicament for treating a condition responsive to the polypeptides or  
 XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 XX CC of human microvascular endothelial cells, for modulating the uptake of  
 XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 XX CC stimulating differentiation of adipocyte cells, for stimulating  
 XX CC the proliferation of or gene expression in pericyte cells, for stimulating  
 XX CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 XX CC cells, for inducing endothelial cell tube formation and for treating  
 XX CC various bone and/or cartilage disorders such as sports injuries and  
 XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 XX CC from cartilage are useful for treating sports-related joint problems,  
 XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 XX CC polypeptides are also useful for treating various mammalian haemoglobin-  
 XX CC associated disorders such as various thalassemias and conditions which  
 XX CC may benefit from enhanced local immune system cell infiltration. This  
 XX CC sequence represents a human PRO polypeptide of the invention. Note: The  
 XX CC sequence data for this patent is also available in electronic format from  
 XX CC USPTO at seqdata.uspto.gov/sequence.html.  
 XX SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 7; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFSLILLVCEATWRNSGNTLENGYFLSRNKNHNSQPTQSSLEDSVPTKAVKT 60  
 DB |||||  
 DB 1 MTFSLILLVCEATWRNSGNTLENGYFLSRNKNHNSQPTQSSLEDSVPTKAVKT 60  
 QY 61 GKGVKGRNLDRLGLILGAENRGVKNT 90  
 DB |||||  
 DB 61 GKGVKGRNLDRLGLILGAENRGVKNT 90  
 RESULT 194  
 ADC81211

ID XX ADC81211 standard; protein; 90 AA.  
 AC XX ADC81211;  
 DT 15-JAN-2004 (first entry)  
 XX DE Novel human secreted and transmembrane protein PRO1159.  
 XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
 KW cell differentiation; skeletal muscle cell; adipocyte cell;  
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
 KW immune system cell infiltration; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX OS Homo sapiens.  
 OS US2003092115-A1.  
 PN 15-MAY-2003.  
 PD 30-MAY-2002; 2002US-00158785.  
 XX PF 05-JUN-2000; 2000US-0209832P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX PA (GETH ) GENENTECH INC.  
 XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX DR WPI; 2004-020238/02.  
 XX DR N-PSDB; ADC81210.  
 XX PT New secreted and transmembrane nucleic acids and polypeptides, designated  
 XX PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
 XX PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
 XX PT cancer.  
 XX PS Claim 12; Fig 474; 637pp; English.  
 XX CC The invention relates to isolated human PRO polypeptides (secreted and  
 XX CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 XX CC invention also relates to an antibody which specifically binds to a PRO  
 XX CC polypeptide, a method for stimulating the release of tumour necrosis  
 XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 XX CC proliferation or differentiation of chondrocyte cells and a method for  
 XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 XX CC polynucleotides are useful in molecular biology, including uses as  
 XX CC hybridisation probes, in chromosome and gene mapping, in generating  
 XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 XX CC be used in preparing PRO polypeptides by recombinant techniques and in  
 XX CC generating either transgenic animals or knock-out animals which are  
 XX CC useful in the development and screening of therapeutically useful  
 XX CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 XX CC medicament for treating a condition responsive to the polypeptides or  
 XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 XX CC of human microvascular endothelial cells, for modulating the uptake of  
 XX CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
 XX CC cells, for stimulating differentiation of adipocyte cells, for  
 XX CC stimulating proliferation of or gene expression in pericyte cells, for  
 XX CC stimulating the proliferation of inner ear utricular supporting cells, for  
 XX CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
 XX CC treating various bone and/or cartilage disorders such as sports injuries

CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassaemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polypeptide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTFPLSLLLLVCAIRWSNSGNTLENGYFLSRNKENHSOPTQSSLEDSVTPKAVKTT 60  
Db 1 MTFPLSLLLLVCAIRWSNSGNTLENGYFLSRNKENHSOPTQSSLEDSVTPKAVKTT 60  
QY 61 KGKIVKGRNLDNRGLILGAEGWGRGVKNT 90  
Db 61 KGKIVKGRNLDNRGLILGAEGWGRGVKNT 90

RESULT 195

ADD76659  
ID ADD76659 standard; protein; 90 AA.

XX AC ADD76659;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; macrovascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003100087-A1.

XX PD 29-MAY-2003.

XX PF 16-APR-2002; 2002US-00123912.

XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 08-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 16-DEC-1999; 99WO-US028565.  
PR 20-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006319.  
PR 20-MAR-2000; 2000WO-US006884.  
PR 21-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001US-00796498.  
PR 01-MAR-2001; 2001WO-US006520.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 03-JUN-2001; 2001US-00871800.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.





CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVTPTKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVTPTKAVKTT 60

QY 61 KGKIVKGRNLDGRGLILGAEGAWGRGVKNT 90

Db 61 KGKIVKGRNLDGRGLILGAEGAWGRGVKNT 90

#### RESULT 197

ADD86427

ID ADD86427 standard; protein; 90 AA.

XX AC

XX AC ADD86427;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polypeptide #237.

XX DE

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

XX OS Homo sapiens.

XX OS

XX FN US2003203440-A1.

XX PD 30-OCT-2003.

XX PF 29-MAY-2002; 2002US-00157798.

XX PR 05-JUN-2000; 2000US-0209832P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH ) GENENTECH INC.

XX PA

XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX PI WPI; 2004-021363/02.

XX DR N-ESDB; ADD86426.

XX DR

XX PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

XX PT PRO4978, useful in molecular biology, chromosome and gene mapping, in

XX PT generating antisense RNA and DNA, and in gene therapy.

XX PS Claim 12; Fig 474; 637pp; English.

XX PS

XX CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC the proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVTPTKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVTPTKAVKTT 60

QY 61 KGKIVKGRNLDGRGLILGAEGAWGRGVKNT 90

Db 61 KGKIVKGRNLDGRGLILGAEGAWGRGVKNT 90

#### RESULT 198

ADE75875

ID ADE75875 standard; protein; 90 AA.

XX AC

XX AC ADE75875;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polypeptide #237.

XX DE

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX OS Homo sapiens.

XX OS

XX FN US2003211571-A1.

XX PD

PD 13-NOV-2003.

XX 20-MAY-2002; 2002US-00152405.

XX 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000MO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2004-051576/05.

DR N-PSDB; ADE75874.

XX New secreted and transmembrane PRO polypeptide and nucleic acid encoding

PT it, for use in gene therapy, as diagnostic markers for the presence of a

PT disease condition, or as therapeutic targets for treating tumors,

PT diabetes, or arthritis.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC the proliferation of or gene expression in pericyte cells, for stimulating

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polypeptide of the invention. Note: The

CC sequence data for this patent is also available in electronic format from

CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

XX Query Match 100.0%; Score 462; DB 8; Length 90;

XX Best Local Similarity 100.0%; Pred. No. 9,8e-49;

XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60

Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60

QY 61 GKGVKGRNLDRLGLILGAERWGVKNT 90

Db 61 GKGVKGRNLDRLGLILGAERWGVKNT 90

RESULT 199

ADE23451

ID ADE23451 standard; protein; 90 AA.

XX AC ADE23451;

XX 29-JAN-2004 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; FFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; T-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

XX Homo sapiens.

XX US2003092108-A1.

XX 15-MAY-2003.

XX 24-APR-2002; 2002US-00131835.

XX 01-DEC-2000; 2000MO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2004-020234/02.

XX N-PSDB; ADE23450.

XX New secreted and transmembrane nucleic acids and polypeptides, designated

XX as PRO, useful for treating inflammation, organ failure, atherosclerosis,

XX cardiac injury, infertility, birth defects, premature aging, AIDS, or

XX cancer.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX antibodies, such as tumours, for stimulating and inhibiting proliferation

XX of human microvascular endothelial cells, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX stimulating differentiation of adipocyte cells, for stimulating

XX the proliferation of or gene expression in pericyte cells, for stimulating

XX cells, for inducing endothelial cell tube formation and for treating

XX various bone and/or cartilage disorders such as sports injuries and

XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

XX from cartilage are useful for treating sports-related joint problems,

XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

XX polypeptides are also useful for treating various mammalian haemoglobin-

XX associated disorders such as various thalassaemias and conditions which

XX may benefit from enhanced local immune system cell infiltration. This

XX sequence represents a human PRO polypeptide of the invention. Note: The

XX sequence data for this patent is also available in electronic format from

XX USPTO at seqdata.uspto.gov/sequence.html.

CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 GKGIVKGRNLDGRGLGAEAWGRGVKNT 90  
DB 61 GKGIVKGRNLDGRGLGAEAWGRGVKNT 90

RESULT 200  
ADE24003  
ID ADE24003 standard; protein; 90 AA.

XX ADE24003;

DT 29-JAN-2004 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003092110-A1.

XX 15-MAY-2003.

XX 03-MAY-2002; 2002US-00137864.

XX 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2004-020235/02.

XX N-PSDB; ADE24002.

XX New secreted and transmembrane nucleic acids and polypeptides, designated  
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
XX cancer.

XX Claim 12; Fig 474; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60  
QY 61 GKGIVKGRNLDGRGLGAEAWGRGVKNT 90  
DB 61 GKGIVKGRNLDGRGLGAEAWGRGVKNT 90

RESULT 201

ADE24646

ID ADE24646 standard; protein; 90 AA.

XX ADE24646;

DT 29-JAN-2004 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003092111-A1.

XX PD 15-MAY-2003.  
XX PF 03-MAY-2002; 2002US-00137869.  
XX PR 03-MAR-2000; 2000US-0187202P.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX PA (GETH ) GENENTECH INC.  
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX DR WPI; 2004-020236/02.  
XX DR N-PSDB; ADE24645.  
XX PT New secreted and transmembrane nucleic acid useful for treating  
XX PT inflammation, organ failure, atherosclerosis, cardiac injury,  
XX PT infertility, birth defects, premature aging, acquired immunodeficiency  
XX PT syndrome, or cancer.  
XX PS Claim 12; Fig 474; 637pp; English.  
XX CC The invention relates to isolated human PRO polypeptides (secreted and  
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The  
XX CC invention also relates to an antibody which specifically binds to a PRO  
XX CC polypeptide, a method for stimulating the release of tumour necrosis  
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX CC proliferation or differentiation of chondrocyte cells and a method for  
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX CC polynucleotides are useful in molecular biology, including uses as  
XX CC hybridisation probes, in chromosome and gene mapping, in generating  
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX CC be used in preparing PRO polypeptides by recombinant techniques and in  
XX CC generating either transgenic animals or knock-out animals which are  
XX CC useful in the development and screening of therapeutically useful  
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a  
XX CC medicament for treating a condition responsive to the polypeptides or  
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX CC of human microvascular endothelial cells, for modulating the uptake of  
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX CC stimulating differentiation of adipocyte cells, for stimulating  
XX CC the proliferation of or gene expression in pericyte cells, for stimulating  
XX CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX CC cells, for inducing endothelial cell tube formation and for treating  
XX CC various bone and/or cartilage disorders such as sports injuries and  
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX CC from cartilage are useful for treating sports-related joint problems,  
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
XX CC polypeptides are also useful for treating various mammalian haemoglobin-  
XX CC associated disorders such as various thalassemias and conditions which  
XX CC may benefit from enhanced local immune system cell infiltration. This  
XX CC sequence represents a human PRO polypeptide of the invention. Note: The  
XX CC sequence data for this patent is also available in electronic format from  
XX CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).  
XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;  
Best Local Similarity 100.0%; Pred. No. 9.8e-49;  
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEALWRNSGNTLENGYFSLRNKENHSQPTQSSLEDSVPTTKAVKT 60  
Db 1 MTFFLSLLLLVCEALWRNSGNTLENGYFSLRNKENHSQPTQSSLEDSVPTTKAVKT 60  
QY 61 GKGIVKGRNLDGRGLILGAEMGRGVKNT 90  
Db 61 GKGIVKGRNLDGRGLILGAEMGRGVKNT 90

RESULT 202  
ADD87471  
ID ADD87471 standard; protein; 90 AA.  
XX AC ADD87471;  
XX DT 29-JAN-2004 (first entry)  
XX DE Human PRO polypeptide #237.  
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX OS Homo sapiens.  
XX PN US2003203439-A1.  
XX PD 30-OCT-2003.  
XX PF 17-MAY-2002; 2002US-00147499.  
XX PR 04-AUG-1998; 98US-0095301P.  
XX PR 02-JUN-1999; 99WO-US012252.  
XX PR 30-MAR-2000; 2000US-00380137.  
XX PR 30-MAR-2000; 2000WO-US008439.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX PA (GETH ) GENENTECH INC.  
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX DR WPI; 2004-021362/02.  
XX DR N-PSDB; ADD87470.  
XX PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
XX PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
XX PT generating antisense RNA and DNA, and in gene therapy.  
XX PS Claim 12; Fig 474; 648pp; English.  
XX CC The invention relates to isolated human PRO polypeptides (secreted and  
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The  
XX CC invention also relates to an antibody which specifically binds to a PRO  
XX CC polypeptide, a method for stimulating the release of tumour necrosis  
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX CC proliferation or differentiation of chondrocyte cells and a method for  
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX CC polynucleotides are useful in molecular biology, including uses as  
XX CC hybridisation probes, in chromosome and gene mapping, in generating  
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX CC be used in preparing PRO polypeptides by recombinant techniques and in  
XX CC generating either transgenic animals or knock-out animals which are  
XX CC useful in the development and screening of therapeutically useful  
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a  
XX CC medicament for treating a condition responsive to the polypeptides or  
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX CC of human microvascular endothelial cells, for modulating the uptake of  
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX CC stimulating differentiation of adipocyte cells, for stimulating  
XX CC the proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX USPTO at seqdata.uspto.gov/sequence.html.

QY Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 8; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-45;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCEAIWRNSGSSNTLENGYFLSRKKNHSQPTQSSLEDSVTPKAVKTT 60

Db 1 MTFLLSLLLVCEAIWRNSGSSNTLENGYFLSRKKNHSQPTQSSLEDSVTPKAVKTT 60

QY 61 GKGIVKGRNLDNRGLILGAERAWGRGVKNT 90

Db 61 GKGIVKGRNLDNRGLILGAERAWGRGVKNT 90

RESULT 203

ADE89337

ID ADE89337 standard; protein; 90 AA.

XX AC ADE89337;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; PFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003199062-A1.

XX PD 23-OCT-2003.

XX PF 17-APR-2002; 2002US-00124823.

XX PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-MAR-1999; 2000WO-US006319.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 11-FEB-2000; 2000WO-US000376.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006666.  
 PR 01-MAR-2001; 2001US-00802706.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2004-041360/04.  
 DR N-PSDB; ADE89336.  
 XX  
 XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or  
 PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
 PT attack, various coagulation disorders, tumors.  
 XX  
 XX Claim 12; SEQ ID NO 474; 638pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
 XX  
 SQ Sequence 90 AA;  
 Query Match 100.0%; Score 462; DB 8; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60  
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60  
 QY 61 GKGIVKGRNLDSEGLILGAEMGRGVKNT 90  
 Db 61 GKGIVKGRNLDSEGLILGAEMGRGVKNT 90

RESULT 204  
 ADE18476  
 ID ADE18476 standard; protein; 90 AA.  
 XX  
 AC ADE18476;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Human PRO polypeptide #237.  
 XX  
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003194794-A1.  
 XX  
 PD 16-OCT-2003.  
 XX  
 PF 17-APR-2002; 2002US-00125805.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019053.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 29-OCT-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 10-MAR-1999; 2000WO-US006319.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.

05-JAN-2000; 2000WO-US000219.  
 06-JAN-2000; 2000WO-US000277.  
 06-JAN-2000; 2000WO-US000376.  
 11-FEB-2000; 2000WO-US000365.  
 18-FEB-2000; 2000WO-US000431.  
 18-FEB-2000; 2000WO-US004342.  
 22-FEB-2000; 2000WO-US004414.  
 24-FEB-2000; 2000WO-US004914.  
 01-MAR-2000; 2000WO-US005004.  
 02-MAR-2000; 2000WO-US005601.  
 02-MAR-2000; 2000WO-US005746.  
 15-MAR-2000; 2000WO-US005841.  
 20-MAR-2000; 2000WO-US006884.  
 21-MAR-2000; 2000WO-US007377.  
 30-MAR-2000; 2000WO-US007532.  
 17-MAY-2000; 2000WO-US008439.  
 22-MAY-2000; 2000WO-US013705.  
 30-MAY-2000; 2000WO-US014042.  
 02-JUN-2000; 2000WO-US014941.  
 28-JUL-2000; 2000WO-US015264.  
 11-AUG-2000; 2000WO-US020710.  
 23-AUG-2000; 2000WO-US022031.  
 24-AUG-2000; 2000WO-US023522.  
 08-NOV-2000; 2000WO-US023328.  
 10-NOV-2000; 2000WO-US030952.  
 01-DEC-2000; 2000WO-US032678.  
 20-DEC-2000; 2000US-00747259.  
 20-DEC-2000; 2000WO-US034956.  
 28-FEB-2001; 2001US-00796498.  
 28-FEB-2001; 2001WO-US006520.  
 01-MAR-2001; 2001WO-US006666.  
 09-MAR-2001; 2001US-00802706.  
 14-MAR-2001; 2001US-00808689.  
 22-MAR-2001; 2001US-00816744.  
 05-APR-2001; 2001US-00828366.  
 10-MAY-2001; 2001US-00854208.  
 18-MAY-2001; 2001US-00854280.  
 25-MAY-2001; 2001US-00860216.  
 25-MAY-2001; 2001US-00866028.  
 25-MAY-2001; 2001US-00866034.  
 25-MAY-2001; 2001WO-US017092.  
 01-JUN-2001; 2001US-00872035.  
 01-JUN-2001; 2001WO-US017800.  
 05-JUN-2001; 2001US-00874503.  
 14-JUN-2001; 2001US-00882636.  
 19-JUN-2001; 2001US-00886342.  
 20-JUN-2001; 2001WO-US019692.  
 21-JUN-2001; 2001US-00887879.  
 22-JUN-2001; 2001WO-US020116.  
 29-JUN-2001; 2001WO-US021066.  
 09-JUL-2001; 2001WO-US021735.  
 18-JUL-2001; 2001US-00908827.  
 06-AUG-2001; 2001US-00924419.  
 09-AUG-2001; 2001US-00927796.  
 16-AUG-2001; 2001US-00931836.  
 19-DEC-2001; 2001US-00028072.  
 (GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI: 2004-021079/02.  
 N-FSDB; ADE18475.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
 PRO4978, for use in molecular biology, chromosome and gene mapping, in  
 generating antisense RNA and DNA, and in gene therapy.

Claim 12; SEQ ID NO 474; 638pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX  
 SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;  
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;  
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLLLLVCEAIWFSNGSNTLENGYFLSRKNKHNHSQPTQSSLEDSVTPKAVKTT 60  
 DB 1 MTFELSLLLLVCEAIWFSNGSNTLENGYFLSRKNKHNHSQPTQSSLEDSVTPKAVKTT 60  
 QY 61 KGIVKGRNLDNRGLILGAEGWGRGVKNT 90  
 DB 61 KGIVKGRNLDNRGLILGAEGWGRGVKNT 90

RESULT 205

ADE88785  
 ID ADE88785 standard; protein; 90 AA.

XX  
 AC ADE88785;

XX  
 DT 29-JAN-2004 (first entry)

XX  
 DE Human PRO polypeptide #237.

XX  
 KW Human; PRO: secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

OS Homo sapiens.

XX  
 PN US2003199054-A1.

XX PD 23-OCT-2003.  
XX PF 12-APR-2002; 2002US-00121054.  
XX PR 31-MAR-1997; 97WO-US0005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US020141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 01-DEC-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 03-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US0005028.  
PR 10-MAR-1999; 99WO-US0005190.  
PR 20-APR-1999; 99WO-US0006319.  
PR 14-MAY-1999; 99WO-US0008615.  
PR 02-JUN-1999; 99WO-US010733.  
PR 01-SEP-1999; 99WO-US012252.  
PR 08-SEP-1999; 99WO-US020111.  
PR 13-SEP-1999; 99WO-US020594.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004344.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005745.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-0076498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2004-041356/04.  
DR N-PSDB; ADE88784.  
XX  
XX Novel secreted and transmembrane polypeptides, PRO useful for treating bone disorders, arthritis, heart attack, injuries, tumors, and stimulating release of TNF-alpha from human blood.  
PS Claim 12; SEQ ID NO 474; 638pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumors, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems,





